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PR OJECT S YNOPSIS 
Title PRIME STUDY –  Evaluating the impact of enhanced health facility-based care for malaria and febrile 
illnesses in children in Tororo, Uganda 
 
Objectives 1. To compare the impact of enhanced health facility-based care to current standard of care on 
key population-based indicators, including the prevalence of anemia in children under five.   
2. To compare the impact of enhanced health facility-based care to current standard of care on 
key longitud inal indicators, including antimalarial treatment incidence density, in a cohort of 
ch ildren under five. 
3. To compare impact of enhanced health facility-based care to current standard of care on key 
indicators of case management for malaria and other illnesses, includ ing the risk of 
inappropriate antimalarial treatment, in children under five treated at health facilities.  
Description Enhanced health  facility care will be compared to the current standard of care provided by lower 
level government-run health  facilities, supplemented by services provided through the private 
sector and community-based interventions, using a cluster-randomized design. Clusters will be 
defined as households located within a 2 km rad ius of the facilities. 
Participants 
and Sample 
Size 
1. Objective 1. Cross-sectional surveys in  400 children (200 under-fives + 200 aged 5-15 years) 
randomly selected from households in each cluster; 4000 children per study arm; 8000 tota l. 
Surveys will be conducted at baseline and then annually for 2 years.  New populations of 
ch ildren will be selected  for each survey.  
2. Objective 2. Cohort of children under five recruited from 25 randomly selected households in  
each  cluster; 250 households per study arm; 500 total. 
3. Objective 3. Interviews will be conducted with children under five and their caregivers visiting 
health  facilities on  days selected  for the exit interviews, including 10 patients per health 
facility. Exit interviews will be conducted every 6 months, for a tota l of four surveys; 200 
patients will be interviewed during each  survey; 800 total.  
Study site Tororo district, an area with very h igh malaria transmission intensity.  The five sub-counties of 
West Budama North Health Sub-district (Nagongera, Paya, Kirewa, Kisoko, and Petta), and two sub-
counties of West Budama South Health Sub-district (Mulanda and Rubongi) will be included. 
Study period The total duration of the study will be approximately 2.5 years. The health facility intervention will 
be scaled-up over 2 months and will run for approximately 2 years; the cross-sectional surveys will 
be conducted at baseline and then annually for 2 years; and each of the cohort study participants 
will be fo llowed for 2 years.   
Intervention 20 lower-level government-run health facilities in the area will be randomly assigned to one of two 
interventions:  (1) health  facility intervention (HFI), or (2) standard  care.  The HFI will focus on 
improving health  center management, information management, health worker tra ining, and 
ensuring adequate diagnostics and drug supplies.  
Primary 
outcome 
1. Objective 1. Prevalence of  anemia 
2. Objective 2. Antimalaria l treatment incidence density 
3. Objective 3. Inappropriate treatment of malaria 
Secondary 
outcomes 
1. Objective 1. Prevalence of parasitemia, prevalence of gametocytemia, a ll-cause mortality rate 
in ch ildren  under five 
2. Objective 2. Incidence of hosp italizations, illness, and febrile illness episodes, prompt effective 
treatment of fever, prompt effective treatment of malaria , incidence of serious adverse 
events, antibiotic treatment incidence density 
3. Objective 3. Appropriate treatment of malaria , patient satisfaction, patient attendance, gaps 
in staffing, drug stock outs, health worker knowledge questionnaire scores 
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1 B ACKGR OU ND 
1.1. INTRODUCTION 
Malaria remains one of the most serious global health problems.[1]  Of the estimated 400 to 900 
million episodes of fever that occur each year in African children, probably about half are due to 
malaria, resulting in over one million deaths.[2-4]  Uncomplicated malaria can progress rapidly to 
severe disease, and most malaria deaths in young children occur within 2-3 days of onset of 
illness.[5]  The first few days of illness present an important window of opportunity to reduce 
morbidity and mortality with early treatment. 
Early effective antimalarial treatment is  one of the key strategies for reducing the burden of 
malaria.[6]  In the Global Strategic Plan for 2005-2015, the Roll Back Malaria Partnership has set a 
target to ensure that 80% of malaria episodes are adequately treated within 24 hours of onset of 
symptoms.[6]   Despite increasing availability of effective artemisinin-based combination therapies 
(ACTs) and the emphasis on early antimalarial treatment, many patients with malaria do not benefit 
from this therapy. A recent UNICEF report of data collected between 2000 and 2006 estimated that 
35% of febrile children in sub-Saharan Africa were treated with antimalarial medicines.[7]  However, 
only 23% of these children were treated within 24 hours of onset of illness, and 60% of febrile 
children received chloroquine, rather than effective first-line therapies.   
1.2. MALARIA DIAGNOSIS AND TREATMENT 
1.2.1. Ba rriers  to  s ervice  in  the  f ormal healthcare sector  
Diagnosis and treatment of malaria is often challenged by limited health-care infrastructure, 
particularly in Africa.[8,9]  Substantial barriers to providing good quality health care exist, including 
logistical, cultural, and wider system barriers.  As a result, few malaria patients receive treatment in 
the formal healthcare sector; most are treated at home with drugs purchased from informal drug 
shops.[2,10]   Unfortunately, such treatment is  often inadequate, with ineffective or poor quality 
drugs given at incorrect doses.[10-12]   Community-based programs, such as home management of 
malaria (HMM), have been promoted by the World Health Organization (WHO) and others to extend 
care beyond the formal sector, and have been adopted in many African countries.[13-15]   
1.2.2. Un iver sal  d iagnos tic  test ing 
The WHO has recently released new guidelines for malaria treatment, recommending that suspected 
cases be confirmed by a parasitological test when possible.[16]  Specifically, the WHO guidelines 
state that prompt parasitological confirmation by microscopy or alternatively by rapid diagnostic 
tests (RDTs) is recommended in all patients suspected of malaria before treatment is  started; and 
that treatment solely on the basis of clinical suspicion should only be considered when a 
parasitological diagnosis is not accessible. The shift towards universal diagnostic testing for malaria is 
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very welcomed, but raises serious questions about the capacity for diagnosing malaria in  endemic 
areas.  
Currently, malaria diagnostics are generally only available in the formal healthcare sector, where a 
minority of antimalarial treatments are distributed. Even where diagnostic facilities are available,  
studies suggest that antimalarial treatment is  given to at least half of patients with a negative 
test.[17-20]  RDTs for malaria offer promise for extending diagnosis beyond hospitals and clinics, 
reaching the areas where many patients seek treatment. However, deployment of RDTs not 
straightforward, and introducing them into the periphery has several operational challenges.  When 
RDTs have been introduced into settings where microscopy is  available, studies suggest that 
providers often ignore negative results, misdiagnosing and overtreating malaria.[19,20]   
1.2.3. Tr ain ing hea lth  workers in  ma la ria  dia gnos is 
Limited training, supervision, and support for the shift from presumptive to diagnostic-driven 
treatment may be associated with poor provider adherence to test results. More recently, 
encouraging results have been seen in Uganda where a one-week integrated course for health 
workers at facilities with microscopy significantly decreased unnecessary ACT prescriptions.[21]  Also 
in Uganda, data from a study evaluating an RDT training course targeted to health workers in lower-
level public health centers, which included clear guidelines on management of positive and negative 
RDT results, dramatically decreased unnecessary antimalarial prescriptions while maintaining 
satisfactory patient outcomes [H Hopkins, unpublished data]. However, it remains to be seen 
whether these more intensive training programs can be taken to scale. One of the main challenges 
for the introduction of malaria diagnostics has been to concurrently enhance capacity to diagnose 
and treat alternative causes of fever.[22] The need to integrate training in case management of 
malaria with that of non-malaria febrile illnesses, and evidence that more supportive training 
packages increase effectiveness,[23-25] demonstrates the importance of integrating malaria 
programs with health services in general. A more comprehensive approach to health care that will 
attract more patients and manage multiple diseases effectively is  called for to produce tangible 
health benefits in the population as a whole.  
1.3. MALARIA IN UGANDA 
1.3.1. Overview 
Malaria is  one of the most important health problems in Uganda and the leading cause of morbidity 
and mortality in children, accounting for up to 40% of outpatient visits, 20% of hospital admissions, 
and 14% of inpatient deaths.[26]  Children in Uganda experience an estimated average of six 
episodes of malaria each year, resulting in between 70,000 and 110,000 deaths annually. Up to 90% 
of Uganda’s population lives in highly endemic areas with perennial malaria transmission, while 10% 
live in areas at risk for epidemics.[27]  The Ugandan Ministry of Health has developed a strategic 
plan for malaria control which focuses on intermittent presumptive treatment of pregnant women, 
vector control measures (including use of insecticide-treated bednets and indoor residual spraying), 
improved epidemic preparedness and response, and improved case management of malaria in 
health facilities and at home.[27]  Access to care remains a major challenge in Uganda; only 49% of 
households live within a 5km radius of a  public health facility.[28], and febrile children are frequently 
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treated outside of the formal sector.[29-32]  Additional barriers to appropriate health care in 
Uganda include high costs, poor attitude of health workers, and stock-outs of drugs.[33] 
1.3.2. Ant imalaria l dru g po licy   
Artemether-lumefantrine (AL) was adopted as the new first-line treatment for uncomplicated 
malaria in 2004, with artesunate + amodiaquine (AS+AQ) as an alternative if AL was not available.  
Studies suggest that AL is  highly effective for treating uncomplicated malaria in Uganda, with risk of 
recrudescence of 1% in Kampala and Tororo;[34-36] however, stock-outs of AL remain an 
issue.[33,37,38] A severe shortage of AL in Uganda has markedly limited the amount of drug 
available in  the country.[39] Many public health facilities have been left without AL for months, and 
health care workers have been forced to resort to ineffective or inappropriate drugs for treatment of 
malaria.  
In 2002, Uganda launched the national home-based management of fever (HBMF) program to 
address the challenge of poor access to antimalarial treatment, and to extend delivery of effective 
antimalarial drugs beyond the formal sector.[40]   The aim of Uganda’s HBMF program was to 
improve access to drugs and to treat all fevers in children under five within 24 hours of onset of 
symptoms by distributing antimalarials free of cost via volunteer community medicine distributors 
(CMDs). The program was scaled-up to country-wide coverage over approximately three years;[41] 
however, it was fully functional in only a few areas. Policy on community-based interventions in 
Uganda has recently changed expanding from malaria-only to integrated community case 
management (ICCM).  Community health workers (CHWs), participating in village health teams 
(VHTs) will be trained to evaluate and provide presumptive treatment of malaria, pneumonia, and 
diarrhea based on clin ical criteria. Community-based health care in  Uganda is  currently in transition; 
the HBMF program is being phased out and is  inactive in most areas, but ICCM has not yet been 
rolled out.  The anticipated launch date of the new ICCM policy is  July 2010. 
1.3.3. Af for dable  M edic in es  Fac ility –  ma lar ia 
Another program that may increase access to antimalarials in  Uganda is the Affordable Medicines 
Facility – malaria (AMFm), which is  a  new financing mechanism, intended to increase access to ACTs 
and reduce access to less effective antimalarial treatments, particularly artemisinin monotherapies 
(http://www.theglobalfund.org/en/amfm/). The AMFm is hosted by the Global Fund and is being 
piloted in 9 countries, beginning in June 2010, dependent upon agreements being signed between 
relevant parties. The mechanism of the AMFm is to make a co-payment towards the cost of ACTs 
with eligible first-line buyers in the public, private or not-for-profit sectors. This subsidy is intended 
to result in lower costs of ACTs being distributed through the different sectors. Alongside the 
subsidy, countries are required to implement ‘supporting interventions’ such as training providers 
and outreach to communities in order to improve malaria case management and to promote ACT 
use. Each country is responsible for the design and implementation of supporting interventions as 
well as for monitoring and evaluation activities over the period of the first phase of the pilot, lasting 
two years. Uganda ’s application to be a pilot AMFm country was accepted in November 2009 and 
the agreement for the contract with the Global Fund is in progress.  
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1.4. HEALTH FACILITY INTERVENTIONS 
1.4.1. What is  q ua li ty ca re  and  wha t are  the  pro blems? 
The Institute of Medicine definition of quality of care incorporates six aims, that it be safe, effective, 
patient-centered, timely, efficient and equitable.[42]  Evidence from increasing numbers of studies 
suggests quality of care by these measures is poor in many settings, including delivery of primary 
care in low-income countries. In terms of effectiveness and safety, direct observation studies of 
performance have identified severe deficiencies, particularly in history taking and examinations, 
diagnosis, and appropriate treatment choice and dosage.[43-48]  This has been linked to low 
motivation of staff as well as poor resource availability in the work place. In terms of patient-
centeredness and timeliness, meeting a population’s expectations of how they should be treated by 
providers, including patient expectations for health care, is now seen as central to performance.[49]  
It has been argued that poor quality services fail to earn the population’s trust, leading to clients 
seeking alternative sources of care,[50] or discontinuing care.[51]  In  contrast, the perception of 
good quality services, including inter-personal relationships, has been found to encourage patients 
to access care,[52] and demand for services.[53-55]  Satisfied patients may be more likely to comply 
with treatment and maintain a continuing relationship with the health worker,[56] and loyalty to a 
clinic.[57], thus enjoying a better medical prognosis (presuming good technical quality of care).[58]  
1.4.2. Ho w  can  qual it y o f  care b e  impro ved? 
Interventions to improve quality of care in low-resource settings have largely fallen into two 
categories: resource-based interventions and performance-based interventions. Resource-based 
interventions include the provision of equipment, infrastructure and drugs. Performance-based 
interventions have mostly been focused on clin ical training and dissemination of guidelines. Far 
fewer studies have assessed interventions to improve aspects of quality care outside of clinical care. 
1.4.2.1 . Resource -based interventions 
Resource-based interventions have shown that improved supplies together with guideline training 
can lead to improvements in quality of care,[59] and these improvements can be effective when 
solutions to resource needs are driven by local actors, for example using participatory research 
methods.[60]  When resources, such as equipment, are delivered in a top-down fashion according to 
perceived needs, they may not be appropriate and may not be used.[61]  In addition, resources such 
as RDTs for malaria need to be introduced in an appropriate manner, including generating local 
ownership and preparedness for change and providing troubleshooting and support in the longer 
term.[62]  Further research to identify principle components for introducing equipment and supplies 
to primary health centers is  needed to inform implementation across low-resource countries. 
1.4.2.2 . Performance-based interventions 
Systematic reviews of evaluations of training-based interventions to change clinical behavior have 
produced mixed results in  both developed,[63-67] and developing countries.[68]  A training 
intervention to improve medical assistants’ malaria prescribing practices in Ghana found initial 
improvements in practice deteriorated after twelve months, attributing the gap between knowledge 
and practice to socio-cultural factors including patient pressure, self-interested motivations and a 
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lack of supervision.[69]  An evaluation of training for CHWs in Kenya found no improvement in 
overall process quality during consultations with pediatric patients after increasing numbers of 
refresher training series attended.[70]  In fact, longitudinal analysis of this intervention showed that 
whilst initia l refresher training led to improved management for severely ill children, adherence to 
guidelines for non-severe cases worsened, and after second refresher training the overall adherence 
declined rapidly.[71]  
1.4.2.3 . Why does tr aining fail?  
The failure of many training based programs to improve clinical care reflects a wider 
acknowledgement of a gap between knowledge and practice of health workers.  Interpretation of 
the literature suggests that training can form the basis of effective strategies but only as long as 
other conditions are fulfilled. For example, the introduction of the integrated management of 
childhood illnesses (IMCI) scheme to primary health care facilities has had better results in  countries 
with stronger health systems, and where support for the scheme has been strong, in terms of 
political advocacy, trainer support, and integration into current practices.[72-77]  The importance of 
management is echoed in findings from Mexico where interactive education was combined with 
managerial interventions to improve prescribing practices for rhinopharyngitis at 18 primary health 
centers.[78]  Similarly, in Kenya, treatment of uncomplicated malaria was better at facilities where 
health workers had undertaken in-service malaria training and where guidelines, wall charts, and 
more frequent supervision were provided.[79]  However, evaluation of supervision and job aids for 
CHWs in Kenya found that these interventions did not improve adherence to guidelines for pediatric 
case management.[70]  The authors suggest this may have been due to the quality of these 
interventions: relatively little time was spent on supervising clinical practice (co-examination of 
children by supervisor and health worker) compared to administrative tasks; quality of feedback 
from the supervisors may have been poor; and guidelines provided in job aides may not have been 
clear. In  spite of the emphasis on training, clinical quality of care remains poor in many low-resource 
settings. Further research into how to support clinicians to improve performance, beyond didactic 
training, is urgently needed. 
1.4.2.4 . Patient-centere dness 
Performance-based interventions tend to favor traditional continuing medical education training 
programs and are less focused on patient-centeredness. However, there is some evidence that 
participatory workshop interventions conducted over an extended period can improve 
communication with patients in different settings.[80] Ensuring that interventional methods used 
are appropriate to the local setting, and that participants are able to tackle wider issues that affect 
their ability to communicate effectively, have been shown to be important.[81,82]  In high-resource 
settings, interventions targeted at provider communication have shown some success in  targeting 
three aspects of the interaction: giving time to talk,[83] providing emotional care,[84,85] and giving 
positive communication.[86,87]  Intervention methods to tackle these specific issues in patient-
centeredness are based on adult learning theory, following principles of learning through experience 
and reflection. Self-observation, or ‘mindfulness meditation ’ has formed an important part of some 
effective programs.[88]  Further research is needed to identify intervention components that 
successfully achieve improved levels of patient-centeredness in  a sustainable way that are replicable 
in low-resource settings.  
 
ACT PRIME Study protocol V1.1, 18 Sept 2010  17 
 
 
1.5. PHASE I RESULTS 
In the first phase of this project, we aimed to characterize the population and local health services in 
Tororo district by conducting a census survey, a survey of health services, and a qualitative study.  All 
households within West Budama North health sub-district in Tororo, including Nagongera, Paya, 
Kirewa, Kisoko, and Petta sub-counties, were enumerated and mapped to provide a sampling frame 
for the main trial.  To characterize the population, households were surveyed on basic demographic 
information, markers of socioeconomic status, vital statistics, and bednet practices.  We also 
characterized the local health services, focusing on the public health facilities and the existing HBMF 
program, by surveying health care workers and community medicine distributors. In addition, we 
conducted a series of focus group discussions with primary caregivers, heads of households, and 
health care workers.  
The initial field work was conducted from October 2009 to February 2010. Our census team 
consisted of surveyors paired with local research assistants who moved with the local leaders of 
each village to identify all households. The health services survey and qualitative study were 
conducted by a team of interviewers trained in social science and qualitative research.  
Additional Phase I work, including (1) a census survey of two sub-counties in West Budama South 
health sub-district, (2) a  brief survey of lower-level government-run health facilities in that area to 
evaluate their catchment areas, and (3) self-observational activities for health workers to increase 
their awareness about barriers to communicating with patients, will be conducted in August and 
September 2010.  
1.5.1. Census sur vey 
We enumerated 26,793 households in  five sub-counties in Tororo district, including 144,216 
residents and 26,905 children under five. Our results suggest that this area of Tororo is  very rural, 
with limited infrastructure and education. Very few households have electricity (1%), or own a 
television (2%). Ownership of mobile phones (31%) and radios (43%) is  a lso low. One-quarter of 
households have no toilet facilities, and only 30 households have a flush toilet.  Overall, heads of 
household are not well-educated; one-quarter have received no formal education, and only 21% 
have received any secondary or higher education.  Mortality in children under five was estimated to 
be 10.99%.  
Although over half (63%) of households reported that they owned a bednet, only 37% of residents 
reported that they had slept under a bednet the previous night. Only 15% of residents and 20% of 
children under five slept under an insecticide-treated bednet (ITN) during the previous night, which 
is far below the targets of > 80%.  
1.5.2. Pub lic  h ealth  fac ilit ies 
We interviewed 81 (88%) of 92 health workers stationed at the 17 functional government-run health 
facilities in West Budama North. Most health workers (56 [69%]) were trained in management of 
malaria with AL, but only 29 (26%) had received training in RDTs for malaria.  
Staffing shortages and absenteeism are a problem at most health centers; 16 (94%) reported that 
the number of staff working at the facility was insufficient. Drug stock-outs are also a major problem, 
particularly at HC IIs  and HC IIIs. Nearly all health centers (94%) reported that they experienced 
 
ACT PRIME Study protocol V1.1, 18 Sept 2010  18 
 
 
stock-outs. Only 29% of health centers reported that the supply of antimalarial drugs was adequate 
for treating their patients. Infrastructure at the health facilities in  this area is also limited.  Most lack 
electricity (88%) and running water (94%).   
Overall, the knowledge of health workers about malaria case management was surprisingly poor.  
Out of a possible 178 points, the mean score achieved by health workers on a knowledge 
questionnaire was 51.6 (29%), ranging from 15 to 110. The in-charges of health centers scored 
unexpectedly low with a mean score of 60.5 (34%).  When asked how to confirm the diagnosis of 
malaria, only eight (10%) health workers mentioned microscopy and two (2%) RDTs.  
The results of knowledge questionnaire identified areas to target in training include physical 
examination skills, identification of danger signs for severe malaria, malaria diagnostics, differential 
diagnosis of non-malarial febrile illnesses, and key elements of managing uncomplicated and severe 
malaria (including administration of medications).   
1.5.3. Community med ic ine  d is tributors 
We selected 100 community medicine distributors (CMDs) who had participated in the HBMF 
program using convenience sampling from five sub-counties in Tororo district.  Major gaps in CMD 
training, supervision, and knowledge were identified. Interviews also revealed that CMDs are 
involved in implementing multiple programs led by different stakeholders, which are not integrated. 
Only four CMDs reported receiving support supervision in the last six  months. Most CMDs (92%) said 
that they refer at least one patient each week, most commonly to a local HCIII. However, only 23% 
of CMDs said that they would refer the child after two days if no improvement was seen, suggesting 
that they refer sick children on initia l review, but do not provide follow-up of patients.   
Overall, CMDs scored poorly on the knowledge questionnaire (mean score 22%).  Only 74% CMDs 
correctly identified fever as the most common symptom of malaria in children, and recognition of 
danger signs of severe malaria was poor.  Although 61% of CMDs had received training on 
management of malaria with AL, few CMDs correctly described how AL should be administered. 
Recognition of non-malarial causes of fever in children was also poor.   
Our results suggest that CMDs knowledge of appropriate management of malaria is limited, despite 
training, and they may be overstretched by stakeholders attempting to deliver community-based 
interventions.  
1.5.4. Qual itative  study 
We conducted 69 in-depth interviews with health workers stationed at the 17 health facilities. In-
depth interviews were conducted with 100 CMDs. A total of six  FGDs, involving 65 participants, were 
conducted with health workers, representing all three health center levels (HC II, III, and IV) and 
higher and lower cadres of health workers. Five FGDs were conducted with 55 primary caregivers 
from the community, including two with caregivers under the age of 30 years, and three with older 
caregivers.  Participants from four of these FGDs lived in parishes that had a public health facility.  
Five FGDs were conducted with 58 heads of household from the community, including two with 
female heads, and three with males.  Participants from four of these FGDs lived in parishes that did 
not have a public health facility.   
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1.5.4.1 . De fining good quality health  care 
When asked, ‘what is good quality health care’, community members, health workers and CMDs 
described similar values involving three themes:  1) comprehensive therapeutic process which 
describes the clinical treatment given to patients and the relationship between patient and health 
worker; 2) management of health facilities which describes operational components including 
staffing and facilities as well as availability of drugs and equipment, and 3) expectations of 
responsiveness  which describes the provision of prompt and free services.  
1.5.4.2 . Atte ndance at public he alth centers 
Community members report various and complex treatment seeking behaviors and outcomes. Most 
community members have visited their local health facility, but were dissatisfied with their 
experience. Barriers faced by patients in  getting to health facilities were identified. In addition, we 
found that health facilities are not attractive to community members. Patients cannot get to health 
facilities because of logistical and cultural barriers, and are not attracted to health facilities because 
of poor management, poor interpersonal relationships with health workers, and local system 
failures.   
1.5.4.3 . Quality of care provided at health ce nters 
We found that aspirations for good quality care were similar amongst health workers, CMDs, and 
community members. The most frequently discussed values include those involving the 
comprehensive therapeutic process (good clinical care and treatment, welcome and orientation, 
good interpersonal interactions between health workers and patients, and advice), responsiveness 
of health workers and the public health system (prompt and fair treatment, treatment free-of-
charge), and management of health facilities (adequate staff, equipment, and infrastructure, 
availability of drugs, professional health workers).   
At health centers, immediate barriers to quality care included drug stock-outs and lack of 
equipment; high patient to staff ratio; use of volunteer health workers; language barrier between 
health workers and patients and discriminatory treatment of patients. Underlying these barriers 
were poor motivation of staff; poor management of the health center; lack of patient-centerd 
culture and poor relationship between health workers and communities.  
1.5.4.4 . Treatment seek ing behav ior 
Treatment seeking behavior of community members is largely driven by perceptions and 
understanding of illnesses and practical concerns, including accessibility, available resources, and 
prior experiences. In  this area, first-line treatment for most conditions was with a biomedical drug. 
Nearly all community members had visited their local health center, but dissatisfaction with care was 
high. Other sources of health care include CMDs (when operational), private clinics, and drug shops. 
Herbal medicine was frequently used and interestingly, community members also relied heavily on 
shrines, churches and prayers for treatment.  
Choice of health care was influenced by the following factors: (1) initia l perceptions and beliefs 
about etiology and severity of the illness that would, from experience, require a particular source of 
treatment. Often, experience showed health centers to be a poorer source of care than other 
providers for common illnesses; (2) accessibility of the preferred treatment, which relied on distance 
to the provider as well as opening hours, spousal support in  meeting costs, opportunity costs of 
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leaving the home and travelling to the provider, ability to negotiate the logistical and social rules of 
the provider’s institution, and availability of treatment at that provider; and (3) tria l and error in 
moving between treatment sources. 
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2 R ATI ONA LE 
2.1. PROBLEM STATEMENT 
The current approach to management of malaria and febrile illnesses in Ugandan children is 
inadequate. Given the barriers to accessing good quality care through the formal heathcare sector, 
substantial attention and resources have been focused on developing community-based 
interventions to deliver antimalarial treatment and comprehensive care.[13,14,89]  However, 
whether resources should be put into community-based programs or into improving the public 
health system is not clear; malaria case management could be strengthened by improving the 
quality and delivery of care in existing government-run health facilities.  Our study is designed to 
assess whether an intervention to build capacity and improve delivery of drugs and diagnostics at 
government-run health facilities improves the health of children and quality of care delivered, as 
compared to ‘standard care’ currently available at health facilities, supplemented by services 
provided through the private sector and community-based interventions.  
2.2. STUDY OVERVIEW 
We are proposing to evaluate enhanced health facility-based care for malaria and febrile illnesses in 
children in Tororo district using a cluster randomized design. The health facility intervention (HFI) 
will aim to address barriers to achieving good quality health care that were identified in our 
formative research. A focus of our intervention will be providing RDTs and training health workers in 
management of both malaria and non-malarial febrile illnesses. We aim to implement an 
intervention which is sustainable and reproducible by the MoH in Uganda, working within the 
existing government systems in conjunction with the MoH and district teams.  
Clusters, defined as health facilities and their catchment areas, will be randomized to the HFI or to 
standard care delivered from government-run health facilities, supplemented by services provided 
through the private sector and community-based interventions.  Outcomes will be measured in 
three distinct populations: (1) cross-sectional surveys of children under 15 years randomly selected 
from households within the clusters; (2) a  cohort of children under five randomly selected from 
households within the clusters and followed for 2 years; and (3) patients attending all government-
run health facilities, including children under five and their caregivers participating in exit interviews 
on selected days every six  months.  
The primary outcome of the study is  prevalence of anemia in children under five. We will test the 
primary hypothesis that the prevalence of anemia in children under five from clusters randomized to 
the HFI will be lower than in children randomized to the current standard of care. The study 
proposed here will benefit greatly from our formative research, prior longitudinal studies of 
antimalarial therapy conducted in Kampala, including two cohort studies evaluating health facility-
based care,[34,90,91] and one cohort study evaluating HBMF, [92] and ongoing surveillance 
conducted by the Uganda Malaria Surveillance Project. The prior and ongoing studies are expected 
to inform the design and conduct of the planned research.  
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2.3. STUDY POPULATION AND DESIGN 
In the cross-sectional surveys and cohort study, we plan to focus on children under five as young 
children bear the greatest burden of malaria in this endemic population.  However, in our cross-
sectional surveys we will also evaluate children aged 5-15 years, as this group contributes 
substantially to malaria transmission. 
We have opted for a cluster randomized design rather than a non-randomized approach, in which 
the HFI would be implemented in all facilities, to minimize confounding. It is  likely that other health-
related interventions will be implemented in Tororo district by the MoH or other stakeholders, such 
as bednet distribution or safe water campaigns, which could have an impact on the health of 
children in the study area.  If we relied on comparisons between measurements taken before and 
after implementation of the HFI, we could risk falsely attributing improvements to our intervention, 
when in fact the changes were due to factors outside of our study.   
We have chosen the health facility as the unit of randomization, defining the clusters as catchment 
areas of these facilities, including households within a 2km radius of the health center.  Only children 
from households within the clusters will be eligible for participation in the cross-sectional surveys 
and cohort study.  We have opted to restrict the study population to children from villages near to 
facilities rather than including the full population of the study area to minimize risk of contamination 
between the study arms. We recognize that distance to the health facility is  a major factor 
influencing utilization, which we will not be able to change with our intervention.  Children from 
villages in the periphery of the health facility catchment areas may or may not be able to access 
services because of distance.  If children who could not access the health facilities were included in 
the study population, we could risk underestimating the impact of the intervention, resulting in a 
Type II error in which we fail to identify a real difference between our HFI and standard care.  
We also recognize the possibility of contamination in the other direction; primary caregivers of 
children in clusters randomized to standard care may seek care from facilities randomized to the HFI.  
Again, distance to the health center is  likely to influence the likelihood of seeking care.  By restricting 
the study population to children residing in households within a 2km radius of the health facility, we 
hope to focus our evaluation on children who are most likely to receive care from that facility. In 
addition, we plan to capture information on treatment seeking behavior during the cross-sectional 
surveys, and information on patient attendance and village of residence from all health facilities, to 
track patterns in utilization of services from various sources. We recognize that restricting the study 
population to households nearby the health facilities will limit our ability to generalize our results to 
more remote populations without access to health facilities. However, we plan to evaluate location 
of residence and distance to health facilities as a covariate in our analysis. In addition, when 
assessing outcomes for the cross-sectional survey and cohort study, analyses will be conducted 
primarily on an intention-to-treat basis, where data collected will be analyzed according to the 
assigned cluster. To address potential contamination issues due to children attending health facilities 
other than the one that defines their cluster, i.e. the health facility they live closest to, we shall also 
analyse data on a per-protocol basis. For this analysis, data collected will be analysed according to 
the facility at which the child accesses healthcare.  
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3 S TUD Y OBJECTIVES 
1. To compare the impact of enhanced health facility-based care to current standard of care on 
key population-based indicators, including the prevalence of anemia in children under five, 
using a cluster randomized design.  We will test the primary hypothesis that the prevalence 
of anemia will be lower in children under five from clusters randomized to the health facility 
intervention (HFI) than in children randomized to standard care. Children receiving care from 
the health facilities participating in the HFI may be more likely to receive good quality health 
care and appropriate treatment for malaria and non-malaria illnesses, including anemia and 
helminth infections. We will also test the secondary hypothesis that the prevalence of 
parasitemia in children under five, and children aged 5-15 years, from clusters that are 
randomized to the HFI will be lower than in children randomized to standard care. 
 
2. To compare the impact of enhanced health facility-based care to current standard of care on 
key longitudinal indicators, including treatment incidence density, in a prospectively 
followed cohort of children under five. We will test the hypothesis that delivery of 
antimalarial treatment via current care will result in  over-treatment and a higher incidence 
of antimalarial treatment, than antimalarial treatment delivered from health facilities 
randomized to the HFI, which will be targeted to lab-confirmed cases of malaria.  
 
3. To compare impact of enhanced health facility-based care to current standard of care on key 
indicators of case management for malaria and other illnesses, including the risk of 
inappropriate antimalarial treatment, in children under five treated at health facilities. We 
will test the hypothesis that the health facility intervention decreases inappropriate 
treatment with ACTs, as measured by the proportion of children under five with suspected 
malaria and a negative RDT result that are inappropriately treated with an ACT plus the 
proportion of children under five with suspected malaria and a positive RDT result that are 
not prescribed an ACT, which we expect to be lower in the facilities randomized to the 
intervention than in those in the standard care group.  
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4 S TUD Y DESIG N  
4.1. OVERVIEW 
We propose to compare enhanced health facility care to the current standard of care using a cluster-
randomized design in Tororo, Uganda. A census survey of the study area has been conducted to 
enumerate and map households, which will be used to create the sampling frame for the trial. The 
lower-level government-run health facilities (20 HC IIs  and IIIs) in the area will be randomly assigned 
to one of two interventions: (1) health facility intervention (HFI), or (2) standard care. The HFI will 
focus on four components: (1) improving health center management, (2) improving information 
management, (3) providing health worker training, and (4) ensuring adequate malaria diagnostics 
and drug supplies. Standard care will include services provided by government-run facilities that are 
not randomized to the HFI.  In addition, services provided by the private sector and through 
community-based interventions (CBI) implemented by the Ministry of Health and other partners will 
contribute to the health care provided in all areas. Currently, CBIs in Uganda are transitioning from 
home-based management of fever (HBMF) to village health teams (VHTs) delivering integrated 
community case management (ICCM). In Tororo district, CBIs are currently inactive but will likely be 
reactivated and scaled-up in Tororo district in  a phased approach during the study period as follows: 
phase A: no CBI; phase B: malaria-only intervention; and phase C: VHT/ICCM.  
 
Figure 1. Overview of study design 
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Information on changes in CBI policy and activity in the study area will be captured. In addition, 
AMFm may be scaled up in Uganda during the period of the study, which could include supporting 
interventions to train drug shop workers in the private sector and community awareness programs 
around ACTs. If AMFm is adopted in Uganda, these activities will be tracked as well. 
Cross-sectional surveys will be conducted at baseline in 400 randomly selected children per cluster 
(8000 total per survey), and will be repeated annually. A sub-cohort of children will be recruited 
from 25 households randomly selected per cluster (500 total households) at the start of the 
intervention, and will closely followed for 2 years.  All health facilities in the area will be assessed to 
monitor and evaluate the impact of the intervention; patient exit interviews will be conducted every 
6 months in 10 patients from each health facility (200 total per survey).   
4.2. STUDY SITE 
The study will be conducted in Tororo district, an area with very high malaria transmission intensity 
The estimated entomologic inoculation rate (EIR) in Tororo is 562 infective bites per person-year, 
and the prevalence of parasitemia among children aged 5-9 years is 63.5%.[93,94] The five sub-
counties of West Budama North Health Sub-district (Nagongera, Paya, Kirewa, Kisoko, and Petta), 
and two sub-counties of West Budama South Health Sub-district (Mulanda and Rubongi) will be 
included in the study population (Figure 2).   
 Figure 2. Study area 
 
The results of our formative research suggest that this area is  very rural, with limited infrastructure 
and education. Very few households have electricity (1%) and one-quarter have no toilet facilities.  
One-quarter of the heads of household have received no formal education, and only 21% have 
received any secondary or higher education.   
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4.3. STUDY POPULATION 
Within the seven sub-counties, there are 22 lower-level government run health facilities, including 
17 level II health centers (HC), and 5 level III HCs; 20 will be included in the randomization scheme. 
Clusters will be defined as the catchment areas of the health centers, including households that are 
located within a 2 km radius of the facilities. Only households located within the clusters will be 
included in the sampling frame for the cross-sectional surveys and the cohort study.  The study 
population for each objective is listed in Table 1. 
Table 1. Study objectives and populations 
Objective Study population and sample size 
1. To compare the impact of enhanced health facility-
based care to current standard of care on key 
population-based indicators, including the prevalence 
of anemia in  children under five.   
Cross-sectional surveys in 400 children (200 under-
fives + 200 aged 5-15 years) randomly selected from 
households in each cluster (8000 children tota l); 
surveys will be conducted at baseline and then 
annually for 2 years (3 surveys in total) 
 
2. To compare the impact of enhanced health facility-
based care to current standard of care on key 
longitud inal indicators, including antimalarial 
treatment incidence density, in a cohort of children 
under five. 
 
Cohort of children under five recruited from 25 
households randomly selected  from each cluster (500 
total) and followed for two years; all children of 
appropriate age from each  household will be eligible 
to participate 
3. To compare impact of enhanced health facility-
based care to current standard of care on key 
indicators of case management for malaria and other 
illnesses, including the risk of inappropriate 
antimalarial treatment, in children  under five treated 
at health facilities.  
 
Patients attending lower-level government-run health  
facilities (20 HC IIs and IIIs) in the study area, 
including 10 patients per health facility sampled in  the 
exit interviews every six months (200 patients per 
survey, 4 surveys total) 
 
4.4. CLUSTER RANDOMISATION 
The lower-level government-run health facilities in  the study area will be the unit of randomization. 
Clusters will be defined as the catchment areas of the health centers, including households located 
within a 2km radius of the facilities (Figure 3). The clusters will be defined prior to randomization 
using the full census survey database. All households and health facilities in West Budama North 
have already been mapped.  The census survey and mapping of the two sub-counties in West 
Budama South (Mulanda and Rubongi) will be conducted in August and September 2010.  The 
distances between every household and every lower-level government-run health facility in the area 
will be calculated. Households will be excluded from our sampling frame if they are > 2km from any 
health facility. If a household is  within 2km of a single health facility, the household will be 
considered to be within its catchment area and will be assigned to the cluster of that health facility. 
If a household is  within 2km of more than one facility, the household will be assigned to the cluster 
of the closest health facility.  
A total of 22 facilities are currently active in the area, however, 2 pairs of health centers are within 
close proximity (Soni HC II and Kirewa Chawolo HC II; Pokongo HC II and Morkiswa HC II) and have 
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substantially overlapping catchment areas. Given this, one facility from each pair will be randomly 
excluded from the randomization scheme.   
 
Figure 3.  Map of health facilities and clusters in West Budama North (mapping completed) and 
West Budama South (mapping in progress) 
 
 
The randomization will be conducted by an investigator who is not directly involved in the project. 
Health facilities will be stratified by level (HC IIs  and HC IIIs). Because of the uneven numbers of HC 
IIs  and IIIs, one of the HC IIIs without a laboratory will be ‘demoted ’ and paired with a HC II to ensure 
even numbers. Restricted randomization will be employed to ensure balance on geographical 
location. Specifically, restrictions will be applied that exclude the allocation of all clusters originating 
from a single sub-county, or that are otherwise in close geographical proximity from being allocated 
to the same arm of the trial. 
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4.5. OUTCOME MEASURES 
The primary and secondary outcome measures for each study objective are listed below in Table 2.   
Table 2. Study objectives and outcome measures 
Outcomes Indicator 
Objective 1: C ross-sectional survey s 
Prevalence of  anemia Proportio n of Hb measurements < 11.0 g/dL . Anemia  will be c lassified acco rding to severity: 
mild (Hb 8.0 –  10.9), moderate (Hb 5.0 –  7.9), severe (Hb < 5.0).  
Prevalence of parasitemia Proportio n of thick blood smears that are po sitive for asexual parasites 
Prevalence of gametocytemia Proportio n of thick blood smears that are po sitive for gametocytes 
All-cause morta lity Probability of dying between birth and five years of age, expressed per 1,000 live births 
Objective 2: Cohort study  
Antimalaria l treatment 
inc idence density 
Number of antimalaria l treatments given for fever/malaria over the period of fo llow-up  
Inc idence o f hospita lizations Overnight admission to a  hospital o r c linic 
Inc idence o f illness episo des Episode o f illness as repo rted by primary caregiver  
Inc idence o f febrile episodes Episode o f illness associated with fever as repo rted by primary caregiver  
Prompt effective treatment 
of fever 
Proportio n of children with fever treated within 24 hours of onset of symptoms with an ACT 
Prompt effective treatment 
of malaria 
Proportio n of children with malaria  (confirmed by a parasitolo gica l test) treated within 24 
ho urs of onset o f sympto ms with an ACT 
Inc idence o f serious adverse 
events 
Any experience that results in death, life-threatening experience, ho spita lization, persistent or 
significant disability or incapacity, o r specific  medical or surgical interventio n to  prevent one of 
the o ther serious outcomes 
Antibio tic  treatment 
inc idence density 
Number of antibio tic treatments given for fever/bacterial illnesses over the period o f follow-up 
Objective 3: Health facilities  
Patient exit interv iews conducted every 6 months 
Inappropriate treatment of 
malaria 
Proportio n of children under five with suspected malaria and a negative RDT result who are 
inappropriately given an ACT + Proportion of children under five with suspected malaria  and a 
po sitive RDT result who are not prescribed an ACT 
Appropriate treatment of 
malaria 
Proportio n of children under five with suspected malaria and a positive RDT result who are 
appropriately given an ACT + Proportion o f children under five with suspected malaria  and a 
negative RDT result who  are no t prescribed an ACT 
Inappropriate treatment of 
malaria 
Proportio n of children under five with suspected malaria and a positive RDT result who are 
inappropriately given a non-ACT regimen 
Patient satisfactio n with 
health care 
Proportio n of patients indicating they were satisfied with care provided at the health center in 
exit interviews 
Health facility  surveillance conducted every  2 months  
Patient attendance To tal number of patients attending health facilities and their characteristics, inc luding age, sex, 
village of residence, and diagno sis 
Gaps in staffing requirements Required positions, as indicated by the MoH staffing no rms policy, which are unfilled for 
greater than one mo nth 
Stock-o uts of ACTs Days per month that AL supplied by N MS via  the distric t is not ava ilable 
Health worker knowledge questionnaires conducted annually  
Knowledge questionna ire 
scores 
Proportio n of questions answered correctly following training in fever case management 
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5 H EALTH FACILITY  I NTERV ENTION 
5.1. OVERVIEW 
The health facility intervention (HFI) will be comprised of four components: 1) health center 
management training, 2) information management and continuous quality improvement (CQI); 3) 
health worker training, and 4) supply of consumables, including malaria diagnostics and antimalarial 
drugs. The goal of these components is to address the barriers to providing good quality care 
identified in our formative research (Appendix A).  By addressing these barriers, we aim to provide 
good quality care as defined by health workers and community members in Tororo district, 
attracting them to health facilities and improving the case management of malaria and non-malarial 
febrile illnesses received when they attend facilities. The intervention package will be rolled out to 
all health centers randomized to the HFI over approximately 8-10 weeks (Table 3). Some activities 
will continue to be supported by the project for the duration of the study. We aim to implement an 
intervention which is sustainable and reproducible by the MoH in Uganda, working within the 
existing government systems in conjunction with the MoH and district teams. 
Table 3.  Health care intervention implementation plan 
 Month 1 Month 2 
 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 
1) Health center management  
HC  management tra ining          
2) Information management 
Co ntinuo us qua lity improvement          
3) Health worker training 
Case management and RDTs          
Patient-centered services          
4) Supply of consumables 
NMS drug distribution          
Support for AL stock-o uts          
RDTs for malaria          
 
Prior to the start of the study, investigators and key study personnel will meet with members of the 
MoH, the National Malaria Control Program, district and sub-county officials, and community 
representatives to inform them about the study objectives, plans for the intervention, and follow-up 
assessments. An information sheet will be used to describe the plans for the intervention to the in-
charges of health facilities randomized to the HFI (Appendix B).  
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5.2. HEALTH CENTER MANAGEMENT 
5.2.1. Overview 
All in-charges of health centers randomized to the HFI will be trained in health center management.  
The purpose of this training is to equip in-charges with the skills and tools required to effectively and 
efficiently manage their health center.  The training module will be based on the concepts presented 
in the Management Sciences (MSH) for Health guide, ‘Health Systems in Action: an eHandbook for 
leaders and managers ’ (http://www.msh.org/Documents/upload/msh_eHandbook_complete.pdf). The 
information provided in the MSH guide will be adapted as appropriate to our study setting and the 
individual health facilities.  The training will include three components (Table 4). 
Table 4. Proposed content of Health Center Management training 
Human resource management Financial management Supply management 
― Staffing and a llocation 
― Using volunteers 
 
― Financial reporting 
― Budgeting and accounting  
― Ordering and d istributing 
― Inventory management and 
stock control 
― Rational use and dispensing 
― Managing stock-outs 
 
 
Our study staff will conduct a series of half-day group training workshops with the in-charges every 
1-2 weeks. The sessions will be conducted using both formal classroom lecture sessions and informal 
practical methods with discussions, demonstrations, and role plays. The Health Center Management 
Training module will last approximately 8-10 weeks. Workshops will be held in convenient locations 
for the participants and all costs will be covered by the project. 
5.2.2. Human  res ource  manag ement 
Staffing needs and appropriate use of volunteers will be the focus of the human resource 
management component. Our formative research revealed that inadequate staffing at health 
centers had a major impact on provision of good quality care. In addition, health workers cited that 
irregular payment of salaries resulted in poor job motivation and prompted them to seek alternative 
sources of income, such as seeking other employment in place of attending their shifts at the health 
center.  In addition, we found that a significant number of health workers in  the area are actually 
untrained volunteers. These volunteers are engaged in various roles including dispensing 
medications, immunizing, delivering mothers, registering patients, and dressing wounds. We will 
work with in-charges to help finds ways to appropriately use volunteers and to address the current 
staffing gaps at their health centers, including methods of communicating with the district about 
staffing gaps and need for timely payment of salaries. The project team will work with the in-charges 
to determine the appropriate staffing requirements, using the MoH Staffing Norms policy as a guide 
(Appendix C), and with the Ministry and district officials to help meet staffing needs at the HFI 
centers. 
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5.2.3. F inancia l  mana gem ent 
This component will focus on financial management and accounting including documentation of 
financial transactions and audit trails, procurement, and management of funds.  In addition, the 
training will cover budgeting and accounting for the primary health care (PHC) funds.  In our 
formative research, we found that management of the health centers was challenged by insufficient 
PHC funds. These funds are meant to cover the costs of a variety of activities at the health centers, 
including support staff, cleaning materials, transportation of drugs, and photocopying documents. 
Health centers are allocated an amount set by the district, and expenditure appears to vary 
depending on the individual needs of the facilities.  As part of the HFI, we propose to train the in-
charges to account for the PHC funds using a tool (Appendix D) designed to assist with the 
quantification and prioritization of the PHC funds.  Information will be collected on the action or 
service required; expected benefit or consequence if action/service cannot be conducted; person 
responsible; cost; frequency; and total cost per month. The information collected using the tool will 
be used for accounting, planning and prioritizing, and justifying to the district and MoH the need for 
continued or increased PHC funding to the health centers. The sample tool provided in Appendix D 
will be piloted and adapted to each individual facility during the Health Center Management 
Training. 
5.2.4. Supp ly management 
Effective management of supplies is  a crucial aspect of providing high quality health care services. 
This component will focus on enhancing the understanding and operation of the drug distribution 
cycle including barriers in ordering, receiving, and issuing of drugs; forecasting of supply needs; 
maintaining a regular inventory to prevent stock-outs; and completing and maintaining stock cards.  
In-charges will be trained to use the one-page ACT Drug Distribution Assessment Tool (ADDAT), 
which aims to identify and resolve issues in drug distribution from districts to local health facilities 
(Appendix E).  The ADDAT is based on a literature review, in-depth interviews and focus group 
discussions (FGDs) with health workers and key informants, and the MoH ‘Medicines Management 
Manual: Medicines Logistics and Store Management procedures for Districts and Health Facilities ’.  
The ADDAT will be used monthly by in-charges or persons responsible for drug procurement and 
distribution at the health center.  The sample tool provided in Appendix E will be piloted prior to the 
Health Center Management Training, and revised as appropriate. 
5.3. HEALTH INFORMATION MANAGEMENT 
This component will focus on the importance of monitoring and evaluation and managing health 
information, building on our experience with UMSP surveillance and CQI and other work done 
elsewhere in Africa (http://hciproject.org/).  To make informed decisions, in-charges and health 
workers should have access to information about the health needs and priorities of the communities 
they serve; the quality and coverage of the services they offer; and available resources. In-charges 
will be trained to capture information on patients accessing their health facility, diagnoses made, 
and treatment provided, and how to utilize that information to generate reports, supervise staff, and 
provide feedback to the health facility team to ensure continuous quality improvement (CQI).  
Information will be captured using the patient, drug, and laboratory registers. In-charges will be 
taught to tally information at the end of each month and to complete a report (Appendix F) which 
will include data on 
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― Number of patients seen at the facility 
― Number of children under five 
― Number of patients with fever 
― Number of patients who had a RDT performed 
― Number of patients with a positive RDT 
― Number of patients prescribed an ACT 
― Number of patients diagnosed with malaria 
Copies of the reports will be given to study personnel during the surveillance visits to the health 
facilities (Chapter 8).  In  addition, study personnel will provide detailed reports of RDT utilization and 
rational prescribing of ACTs bi-monthly.  Training will be provided to a district-level employee, such 
as the malaria focal person, and the in-charges to help build capacity for report generation and how 
to utilize the data effectively to improve the quality of care provided at the facilities.  
 
5.4. HEALTH WORKER TRAINING 
5.4.1. Tr ain ing in  f ever  cas e  mana gement and  use  of RDTs  
All clinical staff will receive training in fever case management. Training will be based on the 
Integrated Malaria Management training package developed by the JUMP team,[21] and the RDT 
training guidelines which have been adopted and implemented by Uganda’s MoH ‘User’s manual: 
Use of Rapid Diagnostic Tests (RDTs) for malaria in fever case management in Uganda’ (Appendix K). 
The training package will include the following sessions: 
 
― Session 1: How to evaluate febrile patients and select patients for RDT testing 
― Session 2: Performing and reading an RDT 
― Session 3: Management of a patient with fever and a positive RDT 
― Session 4: Management of a patient with fever and a negative RDT 
― Session 5: Recognition and referral of patients with severe illness 
― Session 6: Patient education 
― Session 7: RDT storage and monitoring 
― Session 8: Infection prevention 
The training program will last one week; the first two days will focus on theory, and the remaining 3 
days will include practical aspects. The impact of training on knowledge will be assessed using a pre-
and post-training evaluation (Appendix H). The training will be conducted in Tororo at a local health 
facility by study personnel in collaboration with the JUMP training team. Health workers will be 
trained in two small groups to ensure that work at the health facilities continues alongside the 
training.   
5.4.2. Tr ain ing in  pat ient-centered  services 
The purpose of the Patient-Centered Services (PCS) training module is to identify and improve 
interpersonal interactions between health workers and patients.  The module builds on the results 
of our formative research which identified several barriers to proving good quality health care at 
health facilities, including poor interpersonal interactions between health workers and community 
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members resulting from poor communication skills, discriminatory behaviors of health workers, 
poor health worker motivation, and lack of patient-centered thinking. Through the PCS module, 
health workers will learn to recognize these challenges and develop skills for communicating and 
interacting with patients. 
The PCS module training will be implemented in a tiered approach to (1) a ll clinical staff, and (2) all 
health center support staff.  All clinical staff, including in-charges, will receive the full PCS training 
package which includes self-observation tasks and specific emphasis on clinical and patient 
interaction challenges.  Support staff including volunteers will receive a scaled-down PCS training 
package with specific emphasis on welcoming and guiding patients at the health facility.  All training 
activities and workshops will be lead by study personnel and trainers with experience in adult 
learning methodology.   
5.4.2.1 . PCS for  c linical staff 
The PCS module for all clinical staff starts with a series of four self-observation activities completed 
by health workers over a period of 8-12 weeks.  Health workers will conduct the self-observation 
exercises individually during their routine work at health facilities.  Most health workers will have 
conducted their self-observation activities during the formative research of this project. These 
observations serve three purposes: (1) to raise awareness of health workers about how their 
interactions with others affects their ability to work, (2) to begin to build a support network between 
colleagues, and (3) to help to identify issues directly relevant to the health workers in lower level 
health facilities.  Through the self-observation activities, health workers are asked to become aware 
of their behavior around a particular topic and write a short summary of how their behavior affected 
those around them and their subsequent ability to achieve work goals. Topics include the following: 
(1) ‘how you ask questions’, (2) ‘how you facilitate or hinder good communication’, (3) ‘what you do 
to relieve anxiety’; and (4) ‘how you manage anger and irritation’ (Appendices I & J).  On completion 
of each self-observation, participants join other health worker colleagues to discuss their own 
observations and give support about how to carry out the next observations.  The results of the 
observation activities are used to guide health workers through the one-week module. 
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Table  5: Clinical st aff PCS module the mes and competency aims 
PCS theme Competency aim 
Coaching In-charges will be able to: 
 Motivate and inspire others to work better 
 Facilitate meetings 
 Give constructive feedback 
 Feel empowered to bring about positive change 
Communication with 
patients 
Health workers (including in-charges) will be able to:  
 Identify their own motivations for work 
 Give patients time to talk 
 Show compassion 
 Communicate positively 
 Identify strategies to ensure equity of services 
Communication with 
colleagues 
Health workers (including in-charges) will be able to:  
 Develop self-awareness and respect for others in  the workplace 
 Contribute to a positive working environment 
 Manage stress 
Patient flow Health workers (including in-charges) will be able to:  
 Give a positive welcome to patients 
 Find strategies to ensure that shorter and more equitable waiting times 
for patients 
 Find strategies to improve patient navigation at the health center 
 
The PCS module consists of four half-day day themed workshops, which build on the self-
observation exercises. The four themes and competency aims are outlined in Table 5. The modules 
will use a combination of learning approaches including didactic material on each theme; 
appreciative enquiry exercises; role-plays or other participatory activities; and group discussions. The 
didactic component is  important for framing the central concepts and theories around each theme. 
Appreciative enquiry exercises will a llow participants to explore ways in which they successfully 
worked through difficult s ituations and identify what qualities they employed, using analysis and 
reinforcement of positive experiences to lead to behavior change, rather than focusing solely on 
negative experiences or deficiencies. Participants will work in small groups for these exercises.  The 
group discussion will explore reactions to the participatory activities and develop methods that can 
be employed to achieve successful outcomes related to the theme. Additional ice-breaker and 
group-building activities will be used to engage and motivate participants throughout the workshop.   
The half-day workshops will be approximately 3 hours in length and will be conducted over 2 weeks 
at a convenient location in the study area.  Health workers will be trained in two groups to ensure 
that work at the health facilities continues alongside the training.   
5.4.2.2 . PCS for  s upport s taff 
The PCS workshop for support staff will consist of two half-day themed modules using a combination 
of learning approaches. The modules are simplified versions of the clin ical staff PCS workshop and 
will include the presentation of didactic material on the theme; appreciative enquiry exercises; role-
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plays or other participatory activities; and group discussion.  The two themes linked to each self-
observation activity and learning outcomes are outlined in Table 6. 
The half-day workshops will be approximately 3 hours in length and will be conducted over 1 week 
at a convenient location in the study area.  Support staff will be trained in two groups to ensure that 
work at the health facilities continues alongside the training.   
Table  6: Support  staff PCS module  themes  and compet ency a ims 
PCS theme Competency aim 
Communication skills Support staff (including volunteers) will be able to:  
 Contribute to a positive working environment 
 Manage stress  
Patient flow Support staff (including volunteers) will be able to:  
 Give a positive welcome to patients 
 Find strategies to ensure that shorter and more equitable waiting times 
for patients 
 Find strategies to improve patient navigation at the health center 
 
5.5. CONSUMABL ES 
Results from the formative research indicate that drug shortages and stock-outs at health facilities 
are a major problem, especially for AL, the first-line treatment for uncomplicated malaria.  Both the 
quantitative and qualitative research show that these shortages have an impact on community 
members ’ perceptions of care provided at health centers and health workers’ ability to provide good 
quality care.  In addition, most health centers lack laboratory facilities and currently do not have the 
capacity to confirm the diagnosis of malaria.  A major aim of the HFI is  to ensure a continuous and 
adequate supply of drugs and RDTs for malaria.  
5.5.1. Dr ug d eliver y f rom  Na tio nal Med ical Sto res 
In Uganda, the National Medical Store (NMS) has recently adopted a new ‘modified push’ system for 
distributing drugs to lower-level health centers.  Districts are to make an annual procurement plan, 
and NMS will deliver the drugs every 2 months, based on that plan. If no additional requests are 
made by health facilities or the district, NMS will provide a standard delivery of drugs based on the 
procurement plan, regardless of health facility need or disease prevalence. Once the procurement 
plan is developed, and annual orders have been made, health facilities will have limited power to 
change the drug deliveries.  
As part of the HFI, the study team will work with the in-charges and the district health officer (DHO) 
to ensure the drug procurement system is working as planned including ordering, transporting, 
tracking, and storing of drugs.  The in-charges of the health facilities will be trained to use the ADDAT 
tool (Appendix E, section 5.2.5). When required, the team will work with key stakeholders to 
facilitate drug delivery to the health centers.   
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5.5.2. Supp ly ar temether -lumefan trine   
If the amount of AL provided to the health centers by NMS is not adequate to meet demand, or if 
the procurement of AL fails, the project will supply supplemental AL obtained from Joint Medical 
Stores in Uganda.  Batch numbers, expiry dates, date received, and date opened will be recorded for 
all AL supplied. 
5.5.3. RDTs  f or ma lar ia 
Most health centers do not have access to a laboratory or malaria diagnostic facilities. As part of the 
HFI package, we will ensure adequate supplies of RDTs at all health centers. One of the HRP2-based 
tests, are recommended in the most recent WHO / FIND Product Testing Report 
(http://www.wpro.who.int/sites/rdt/home.htm) and are approved by the Uganda National Drug 
Authority, will be used.  Batch numbers, expiry dates, date received, and date opened will be 
recorded for all RDTs supplied. RDTs may be introduced into lower-level health centers by the MoH.  
If so, we will track distribution and use of RDTs in a manner similar to that of drugs, as described 
above, and will supplement distribution of RDTs if needed.   
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6 S TAN DAR D CA RE 
6.1. OVERVIEW 
In this study, 10 health facilities will be randomly assigned to the standard care arm. Standard care 
will include services typically provided by government-run facilities.  
6.2. STAFFING AND PATIENT ATTENDANCE 
In our formative research, we interviewed 17 health workers, including the in-charges of health 
centers, to gain an understanding of the current situation at the local government-run health 
facilities. Not all health centres are open every day, depending on the availability of drugs and staff.  
The mean number of patients visiting the health centres each day is approximately 50-60, and 
staffing shortages are an issue at most health centers (Table 6.1). 
Table  6.1: Patient  att endance and  staffing, st rat ifie d b y level of health centr e 
 HC II 
N=12 
HC III 
N=3 
Patients visiting (mean, SD, range) 51.2 (20.4) 25-100 52.5 (15) 30-60 
Staff stationed (mean, SD, range) 2.08 (0.66) 1-3 9.75 (0.95) 9-11 
Staff available (mean, SD, range) 1.4 (0.51) 1-2 4.25 (0.96) 3-5 
 
6.3. INFRASTRUCTURE AND SUPPLIES 
Infrastructure at the health centres in this area is  limited; most lack electricity and running water. 
Drug stock-outs are a common problem at HC IIs  and IIIs.  Most centres, but not all, stock AL but few 
centres stock artesunate + amodiaquine, the alternative treatment for uncomplicated malaria.  
Stock-outs of both parenteral and oral quinine are also common. Malaria is diagnosed clinically, 
without laboratory confirmation at most health centres, even at the two HCIIIs with laboratories.   
6.4. STANDARD CARE 
Standard care will include services typically provided by government-run facilities; we will not 
provide any additional support to these facilities. Health care will be provided to patients attending 
these facilities according to the usual standards; in-charges will continue to manage the facilities 
using their standard approach, no additional training will be provided to the health workers 
stationed at these facilities; and no support for staffing or supplies will be provided beyond what is  
supplied by the district and MoH. 
 
ACT PRIME Study protocol V1.1, 18 Sept 2010  38 
 
 
7 CR OS S-S ECTIONA L SURV EYS 
7.1. OVERVIEW 
Cross-sectional surveys will be conducted in randomly selected children under fifteen years of age.  
We plan to sample 400 children from each cluster; 200 children under five and 200 children aged 5-
15 years. A total of 8000 children will be sampled in each survey. Surveys will be conducted at 
baseline and then annually for each year; new populations of children will be selected for each 
survey. The survey will include a structured questionnaire administered to the primary caregiver, 
and a clin ical and laboratory assessment of each child.  
7.2. DEFINITIONS  
Household: A household will be defined as any single permanent or semi-permanent dwelling 
structure acting as the primary residence for a person or group of people that generally cook and eat 
together.  Some households may include members who sleep in other dwelling structures within the 
same compound, if the members are still dependent on the head of household in the main 
household.    
Household resident: A resident within each household will be defined as a person who intends to 
have a sleeping place primarily at that location for a period of the next 6 months. This may include 
people who sleep in a separate house within the same compound, if they are still dependent on the 
head of household for decisions on finances and health care.   
7.3. ENROLLMENT  
7.3.1. Recruitment 
All households enumerated during the census will be assigned a unique number. A random sample 
of households with at least one child under fifteen years of age will be selected from each cluster to 
generate a list of households to be approached. Three separate lists will be generated prior to each 
survey from the original census list.  Study personnel will conduct door-to-door screening to identify 
those households with at least one child of appropriate age. Households without a child of 
appropriate age will be removed from the recruitment list. Residents not home during the initia l 
contact will be re-visited on at least three other occasions over a six-week period before eliminating 
them from our sample selection process.  
7.3.2. Screen ing 
When a household with at least one child of appropriate age is identified, study personnel will briefly 
describe the purpose of the study in the appropriate language (usually Japadhola, Luganda or 
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Swahili) with parent(s) or guardian(s), and proceed with screening (Appendix K). The inclusion 
criteria are: 1) age < 15 years, 2) agreement of parents or guardians to provide informed consent, 
and 3) agreement of a  child aged 8 years or older to provide assent.  The exclusion criterion is: 1) 
inability to locate the child.  One child under five and one child between the ages of 5-15 years from 
each household will be eligible for participation.  If more than one child of appropriate age resides in 
the household, study personnel will record the gender and ages of all children under five and all 
children between the ages of 5-15 years, and one child from each age category will be randomly 
selected for participation.  If only one child of appropriate age, or only one child in each age 
category, resides in the household they will be selected for participation. Previous participated in 
one of the cross-sectional surveys will not be an exclusion criterion; children who have previously 
participated in a survey will still be eligible to participate.   
7.3.3. Infor med Co nsent 
Study personnel will conduct the informed consent discussion with the parent(s) or guardian(s). 
Informed consent will be conducted in the appropriate language and a translator will be used if 
necessary. Consent forms will be available in English and the local languages (Appendices L & M). 
Following the informed consent discussion, parents/guardians will be asked by the study personnel 
to sign a written consent form for their child to participate in a research study and a second 
approved consent form for the future use of biological specimens obtained during the course of the 
study. If the parent/guardian is  unable to read or write, their fingerprint will substitute for a 
signature, and a signature from a witness to the informed consent procedures will be obtained. 
Written assent to participate in the study will a lso be obtained from children aged 8 years and older 
at the time of screening (Appendix N). 
7.3.4. En rol lment 
Children who fulfil the eligibility criteria will be assigned a study number and will undergo the survey 
procedures outlined below.  If a child selected to participate is not at home on the day of the initial 
visit, the household will be re-visited on at least three other occasions over a six-week period before 
excluding the child. 
7.4. SURVEY PROCEDURES 
7.4.1. Survey ques tionnaire 
Primary caregivers of selected children will be asked to complete a survey questionnaire to gather 
information about bednet use and management of child who was febrile within the last two weeks, 
including source of care, diagnostics test results, drug treatment, and actions taken for management 
of illnesses (Appendix O, Part 1).  Data will be collected about management of fever in any child 
under the primary caregiver’s care, and will not be restricted to children selected to participate in 
the survey. If more than one child has been febrile in the last two weeks, data will be collected on 
management of the most recent illness. If the primary caregiver is not available on the day of the 
initial visit, the household will be re-visited on at least three other occasions over a six-week period 
to administer the questionnaire. If the primary caregiver is not available after four visits, the survey 
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questionnaire will not be completed.  However, the child or children selected for the cross-sectional 
survey from that household will not be excluded, and all additional information collected will be 
utilized. In the last annual cross-sectional survey, a ll women of child-bearing age (13-49 years) in the 
household will be asked to provide birth histories, which will allow us to estimate all-cause mortality 
in children under five (Appendix O, Part 2).  
7.4.2. C lin ica l  and  labor ator y assessment 
Participating children will undergo a brief history and physical examination, including measurement 
of temperature, height, weight, mid-upper arm circumference, and spleen size (Appendix P). Blood 
will be collected by fingerprick for thick blood smear, hemoglobin, and for storage on filter paper for 
future molecular testing.  
7.4.3. Mana gemen t of  il l ch i ldr en 
Children enrolled in the survey who report fever in  the past 48 hours, or who have a temperature of 
> 38.0⁰C will have an RDT performed.  Febrile children will be treated with paracetamol as 
appropriate. Children with a positive RDT and no evidence of severe malaria will be treated with AL. 
Children with a positive RDT and evidence of danger signs of severe disease will be referred for 
further evaluation and treatment.  Children with a hemoglobin level of < 5.0 g/dL will be referred for 
further evaluation and transfusion. Any child with other concerning clinical symptoms will also be 
referred to an appropriate health care facility at the discretion of the study personnel. 
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8 COH OR T S TUD Y 
8.1. OVERVIEW 
A cohort of children under five will be enrolled from 25 households randomly selected from each 
cluster, for a total of 500 households. The cohort will be dynamic, in that all children within a 
household, who are under the age of five and who meet selection criteria, will be included. A 
household survey will be conducted at the start of the study. Children will undergo clin ical and 
laboratory assessments at baseline and then every six months. Primary caregivers will be asked to 
prospectively collect information on the clinical symptoms of participating children and expenditures 
for health care using pictorial d iaries.  Study personnel will vis it the households monthly to collect 
the diaries and administer a monthly questionnaire.  
8.2. ENROLLMENT 
8.2.1. Recruitment 
All households enumerated during the census will be assigned a unique number. A random sample 
of households with at least one child under five will be selected from each cluster prior to 
randomization to generate a list of households to be approached. Study personnel will conduct 
door-to-door screening to identify those households with at least one child of appropriate age. 
Households without a child of appropriate age will be removed from the recruitment list. Residents 
not home during the initial contact will be re-visited on at least three other occasions over a six-
week period before eliminating them from our sample selection process. When a household with at 
least one child of appropriate age is identified, study personnel will briefly describe the purpose of 
the study in the appropriate language (usually Japadhola, Luganda or Swahili) with parent(s) or 
guardian(s). If the parent(s)/guardian(s) are interested in the study, the study personnel will 
schedule an appointment date for screening. Residents not home during the initial contact will be re-
visited on at least 3 other occasions over a 6-week period before eliminating them from our sample 
selection process. All children of appropriate age from a single household will be eligible for 
evaluation for study enrollment. 
8.2.2. Screen ing 
Children will be screened at convenient sites within the community. Interviews will be conducted in 
the appropriate language with parents or guardians. Selection criteria are based on the goal of 
recruiting a representative sample of children from our target population (Appendix Q). The 
inclusion criteria are: 1) age < 5 years, and 2) agreement of parents or guardians to provide informed 
consent.  The exclusion criteria are: 1) intention to move during the follow-up period.  During the 
screening process, study personnel will assess for initial eligibility criteria through conversation with 
the parent/guardian (including age of the child, willingness of the parent/guardian to participate in 
the study and to provide informed consent, and intention to move from Tororo).  If the initial 
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screening criteria are met, the parent/guardian will be asked to provide informed consent for their 
child to participate in the study.  If parents/guardians are undecided about consenting for their child 
(or children) to participate in the study at the initia l screening visit, they will be allowed up to one 
week to make a final decision about study participation.  
8.2.3. Infor med Co nsent 
Study personnel will conduct the informed consent discussion with the parent(s) or guardian(s). 
Informed consent will be conducted in the appropriate language and a translator will be used if 
necessary. Consent forms will be available in English and the local languages (Appendices R & S). 
Following the informed consent discussion, parents (or guardians) will be asked by the study 
personnel to sign a written consent form approved by the IRBs for their child to participate in a 
research study and a second approved consent form for the future use of biological specimens 
obtained during the course of the study. If the parent or guardian is unable to read or write, their 
fingerprint will substitute for a signature, and a signature from a witness to the informed consent 
procedures will be obtained. 
8.2.4. En rol lment 
Children who meet the eligibility criteria will be assigned a study number, and will undergo a clinical 
and laboratory evaluation.  Height, weight, and temperature will be measured, and spleen size will 
be evaluated (Appendix T). Blood will be collected by finger prick for thick blood smear, hemoglobin, 
and for storage on filter paper for future molecular testing.  
8.2.5. Mana gemen t of  il l ch i ldr en  at enrol lment 
Children enrolled in the cohort study who report fever in the past 48 hours, or who have a 
temperature of > 38.0⁰C will have an RDT performed.  Febrile children will be treated with 
paracetamol as appropriate. Children with a positive RDT and no evidence of severe malaria will be 
treated with AL. Children with a positive RDT and evidence of danger signs of severe disease will be 
referred for further evaluation and treatment.  Children with a hemoglobin level of < 5.0 g/dL will be 
referred for further evaluation and transfusion. Any child with other concerning clinical symptoms 
will also be referred to an appropriate health care facility at the discretion of the study personnel. 
8.3. HOUSEHOLD SURVEYS 
Following enrollment, or within a 2 week period from the date of enrollment, a household survey 
will be performed at all participating households (Appendix U). Primary caregivers will be asked to 
complete a survey questionnaire to gather information about bednet use and management of a child 
who was febrile within the last two weeks, including source of care, diagnostics test results, drug 
treatment, and actions taken for management of illnesses. Data will be collected about management 
of fever in any child under the primary caregiver’s care, and will not be restricted to children 
selected to participate in the cohort study. If more than one child has been febrile in the last two 
weeks, data will be collected on management of the most recent illness. If the primary caregiver is 
not available on the day of the initial visit, the household will be re-visited on at least three other 
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occasions over a six-week period to administer the questionnaire. If the primary caregiver is  not 
available after four visits, the household survey questionnaire will not be completed.  However, the 
child or children selected for the cohort study from that household will not be excluded, and all 
additional information collected will be utilized. 
8.4. FOLL OW-UP 
8.4.1. Hous eho ld  d iaries  and  monthly vis its 
Primary caregivers will be asked to keep a diary of health of study participants for the duration of 
the study (Appendix V). The diaries will be based on instruments previously developed and validated 
in studies in Uganda and elsewhere in Africa.[92,95] The diaries have been developed by a Ugandan 
artist with input from the community, and will be adapted to the local setting if necessary.  The 
diaries will be used to collect information on clinical symptoms and health care expenditures. 
Households will be visited by study personnel every two weeks during the first two months, and 
then monthly, to collect completed diaries. At each monthly visit, questionnaires will a lso be 
administered to gather additional data on the health of the study participants, management of any 
illnesses, and health care expenditures (Appendix W). The information collected in the diaries and 
the questionnaires will be complementary.  Study personnel will review the diaries with the primary 
caregivers at each monthly visit and caregivers will be allowed to refer to the diaries while the 
questionnaire is administered to help prompt their memory. Small incentives (including sugar, soap, 
or washing powder) will be provided to each household during the monthly visit to encourage 
completion of the diaries. 
8.4.2.   Fo llow -up  eva luations   
Clinical and laboratory evaluations will be repeated every 6 months over the 2 years of study follow-
up in all cohort study participants (Table 7). At the end of study follow-up, all children will be given 
an insecticide-treated bednet.  
Table 7. Study objectives and outcome measures 
Evaluation Baseline Every 6 months 
Clinical evaluations 
     Height, weight 
     Temperature 
     Spleen size 
 
X 
X 
X 
 
X 
X 
X 
Laboratory evaluations 
     Thick blood smear 
     Hemoglobin 
     Filter paper sample 
 
X 
X 
X 
 
X 
X 
X 
Household evaluations 
     Household KAP survey 
     Pictorial diaries 
     Household questionnaires 
 
X 
― 
― 
 
― 
Monthly 
Monthly 
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8.4.3. Mana gemen t of  il l ch i ldr en  during fol low -u p 
At the follow-up assessments, children who report fever in the past 48 hours, or who have a 
temperature of > 38.0⁰C will have an RDT performed.  Febrile children will be treated with 
paracetamol as appropriate. Children will be managed as described above in section 7.2.5.  Any child 
with concerning clinical symptoms will be referred to an appropriate health care facility at the 
discretion of the study personnel.  
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9 M &E OF H EALTH  FACILI TY  INTER VENTION 
9.1. OVERVIEW 
We will conduct monitoring and evaluation (M&E) activities at all government-run health facilities in 
the study area, including those that are randomized to the intervention and those that are not.  
Patient exit interviews will be conducted every 6 months to gather information on rational use of 
ACTs and patient satisfaction.  In addition, standardized information will be captured from all 
facilities including data on patient attendance, drug stock-outs, and staffing shortages every two 
months. Additional, detailed information on RDT utilization and ACT prescribing practices will also be 
collected from HFI facilities. A knowledge questionnaire will be administered annually to consenting 
health workers at all facilities. M&E activities will begin one month after the roll-out period (lasting 
8-10 weeks) for the HFI has been completed.  
9.2. PATIENT EXIT INTERVIEWS 
9.2.1. Overview 
Every six months, exit interviews will be conducted with children under five and their caregivers at 
all health facilities. The purpose of the interviews is to evaluate for rational prescribing of ACTs, and 
to determine the level of satisfaction with the health facility visit.  For each survey, 10 patients will 
be selected by convenience sampling from each facility to participate in the interviews (200 total per 
survey).   
9.2.2. Recruitment 
As children and their caregivers are leaving the health facility, study personnel will ask the caregiver 
if their child is under five and if they would be willing to participate in an interview regarding the 
health care visit (Figure 4).  When a caregiver with a child of appropriate age is identified, study 
personnel will briefly describe the purpose of the study in the appropriate language (usually 
Japadhola, Luganda or Swahili) with parent(s) or guardian(s). The inclusion criteria are: 1) age < 5 
years, and 2) agreement of parents or guardians to provide informed consent (Appendix X). There 
are no exclusion criteria. If more than one child of appropriate age was seen at the health facility 
that day, all children will be eligible to participate.   
9.2.3. Infor med Co nsent 
Study personnel will conduct the informed consent discussion with the parent(s) or guardian(s). 
Informed consent will be conducted in the appropriate language and a translator will be used if 
necessary. Consent forms will be available in English and the local languages (Appendix Y). Following 
the informed consent discussion, parents/guardians will be asked by the study personnel to sign a 
written consent form for their child to participate in a research study. If the parent/guardian is 
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unable to read or write, their fingerprint will substitute for a signature, and a signature from a 
witness to the informed consent procedures will be obtained.  
Figure 4. Patient exit interview algorithm 
 
9.2.4. Int erview 
Children who fulfil the eligibility criteria will be assigned a study number and will undergo the survey 
procedures.  Caregivers of enrolled children will be interviewed using a standardized questionnaire 
(Appendix Z) to gather information about the purpose of the visit, presenting complaint, the child’s 
symptoms, whether a RDT or blood smear was done, the diagnosis given, medications prescribed, 
and medications received. Additional information about the satisfaction of the caregiver with the 
visit to the facility will also be obtained.  
9.2.5. RDT  results  
If a child has a temperature of >38.0⁰C or a history of fever in the past 48 hours, a fingerprick blood 
sample will be obtained to perform a RDT.  Febrile children will be treated with paracetamol as 
appropriate.  The results of the RDTs performed by the study personnel will be compared to the 
results of RDTs performed by health facility staff, where possible. Children with a positive RDT and 
no evidence of severe malaria, who have not been prescribed or received an ACT, will be given AL 
(Figure 4).  Children with a positive RDT and evidence of danger signs of severe disease will be 
• Approached by study personnel
Caregiver with child 
exiting health facility
• No → Exclude
• Yes → ProceedChild under five?
• No → Exclude
• Yes → Proceed
Willing to participate 
in study? 
• No → Do not perform RDT
• Yes → Perform RDT
Fever or history of 
fever in the last 48h? 
• Negative → No further action
• Positive → Review prescriptionsRDT result 
• ACT prescribed/received → No further action
• No ACT prescribed/received → Give AL Prescriptions 
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referred to an appropriate facility for further evaluation and treatment, regardless of the medicine 
prescribed.   
9.3. HEALTH FACILITY SURVEILLANCE 
9.3.1. Al l fa cil it ies 
We plan to conduct routine surveillance at all health facilities every month.  The purpose of the 
surveillance is to collect information about patient attendance, drug stocks, staffing gaps and health 
facility costs from all facilities. Study personnel will collect the information during a one-day visit to 
the health facilities.  The in-charge of the facility will be approached and informed about the 
surveillance activities.  An information sheet (Appendix AA) will be used to describe the purpose of 
the activities and verbal consent to collect information will be obtained from the in-charge.  The 
surveillance form (Appendix BB, Part 1) contains three sections: (1) data on patient attendance 
including date visited, village of residence, age, sex, and diagnoses collected from the patient 
registers; (2) drug stock data collected from the drug register; and (3) staffing allocation data 
collected from the in-charge.  The patient register and drug register are standard HMIS data 
collection tools, and are in place in all health facilities.  The surveillance form will be used to collect 
information on health facility costs (Appendix BB, Part 3) including 1) drugs & supplies, 2) overheads 
(utilities, capital equipment, space), and 3) staff allocation and activities.  Part 3 will only be 
conducted at baseline and annually for a total of three surveys.   
9.3.2. HFI fac i li ties 
Additional information on utilization of RDTs and use of ACTs will be collected at facilities 
randomized to the HFI and any other facilities where RDTs are available (Appendix BB, Part 2).  This 
information will be extracted from the patient, drug, and laboratory registers by study personnel.  
Study personnel will help the in-charges create the registers, to ensure that the appropriate 
information is captured.  The data collected will complement the information tallied by the in-
charges as part of the CQI activity in the health center management training module (section 5.2.6).  
Additional indicators evaluated in the health facility surveillance will include: 
― Number (proportion) of patients who had a RDT performed 
― Number (proportion) of patients with a positive RDT 
― Number (proportion) of patients diagnosed with malaria 
― Number (proportion) of patients diagnosed with malaria by RDT result 
― Number (proportion) of patients with a positive RDT prescribed an ACT 
― Number (proportion) of patients with a negative RDT prescribed an ACT 
― Number (proportion) of patients without a RDT done prescribed an ACT 
Reports of these indicators will be generated after each surveillance visit and will be provided to the 
in-charges of the facilities at the next visit as part of the ongoing CQI activities (section 5.2.6).  
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9.4. HEALTH WORKER KNOWLEDGE QUES TIONNAIRES 
Questionnaires will be administered to health workers at all health facilities annually to assess their 
knowledge about fever case management.  The first annual questionnaire will be administered after 
the intervention has been active for approximately one year. All available health workers will be 
approached to participate in the knowledge questionnaire.  Information sheets will be used to 
describe the purpose of the knowledge questionnaire and verbal consent will be obtained from the 
health care worker before conducting the questionnaire (Appendix CC).  The knowledge 
questionnaire includes structured questions allowing for open-ended answers to assess the health 
workers’ knowledge about malaria transmission, symptoms, diagnosis, and treatment, and etiology 
of non-malaria fevers (Appendix DD).   
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10 A DV ERS E EV ENT M ONITORIN G 
10.1. OVERVIEW 
Adverse event monitoring will be conducted in children enrolled into the cohort study.  Data on 
serious adverse events and suspected adverse drug reactions will be collected retrospectively during 
the monthly interviews. Serious adverse event reports and summary reports of suspected adverse 
drug reactions will be submitted to the IRBs, the Data and Safety Monitoring Board (DSMB), and the 
ACT Consortium Drug Safety Register (ACTcDSR) according to their guidelines.  
10.2. DEFINITIONS 
Serious adverse event (SAE): An experience that results in any of the following outcomes:  
― Death during the period of study follow-up 
― Life-threatening experience (one that puts a participant at immediate risk of death at the 
time of the event)  
― Inpatient hospitalization during the period of study follow-up 
― Persistent or significant disability or incapacity 
― Specific medical or surgical intervention to prevent one of the other serious outcomes listed 
in the definition. 
Adverse drug reaction (ADR): A response to a medicine which is noxious and unintended, and which 
occurs at doses normally used in man.  
10.3. IDENTIFICATION OF ADVERSE EVENTS  
At each monthly visit, study personnel will inquire about the occurrence of any SAEs and any 
suspected ADRs.  Two severity grading scales will be used to grade severity of events: 1) the WHO 
toxicity grading scale, which will be used by all projects involved in the ACT Consortium, and 2) a 
severity grading scale used previously in  clinical trials in Uganda, which is based on the WHO toxicity 
grading scale and the National Institutes of Health, Division of Microbiology and Infectious Diseases 
grading scales (Appendices EE & FF).   
10.4. REPORTING OF ADVERSE EVENTS 
For each SAE and suspected ADR identified, an adverse event report form will be completed 
(Appendix GG & HH).  The following information will be recorded for all experiences that are 
reported:  
― Description of the patient (ID number, age, sex, weight) 
― Description of the adverse event 
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― Date of event onset and date of resolution 
― Date event reported 
― Maximum severity of the event 
― Causality and expectedness  
― Whether the event was serious 
― Outcome of the event 
― Drug information (names, doses, dates administered for all drugs taken one month prior) 
― Past medical history 
― Known allergies and/or prior experience with drugs taken 
10.5. ACT CONSORTIUM DRUG SAFETY REGISTER 
10.5.1 . Overview 
Safety data collected in our study will be submitted to the central ACT Consortium Register within 
timescale agreed by the Consortium’s Steering Committee. The Steering Committee will ensure the 
timely dissemination of any early warnings of emerging patient safety information within the project 
to all parties in  the Consortium and to other relevant stakeholders. All individual patient data 
transferred to the ACT Consortium Register will be identifiable by study number only.  No names or 
addresses of individuals will be stored. The adverse event data will be coded centrally using industry-
standard MedDRA (Medical Dictionary of Drug Regulatory Authorities) coding systems.   
10.5.2 . Databas e 
The database will fully comply with ICH – E6 Guideline for Good Clinical Practice,[96] in  particular for 
the handling of electronic data (section 5.5.3), and will: 
― Ensure and document that the electronic data processing system(s) conform to the 
sponsor ’s established requirements for completeness, accuracy, reliability, and 
consistent intended performance (i.e. validation). 
― Maintain standard operation procedures for using these systems. 
― Ensure that the systems are designed to permit data changes in such a way that the data 
changes are documented and that there is  no deletion of entered data (i.e. maintain an 
audit trail, data trail, edit trail). 
― Maintain a security system that prevents unauthorized access to the data. 
― Maintain a list of the individuals who are authorized to make data changes  
― Maintain adequate backup of the data. 
― Safeguard the blinding, if any (e.g. maintain the blinding during data entry and 
processing).  
― The individual patient data transferred to the central pharmacovigilance team will be 
identifiable by study number only. No names and addresses of individuals will be stored. 
10.5.3 . M echa nis ms f or  data  handl in g/sha rin g: 
Each study will have ethical approval from all overseeing institutions, and sign an agreement 
regarding the data fields to be shared with the central database prior to the transfer of data to the 
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Liverpool School of Tropical Medicine (LSTM), who will manage the database. The agreement will be 
voluntary between the ACT Consortium study institution and the ACTc Pharmacovigilance database 
institution (LSTM).  The study institution will remain the owner of their data at all times and the data 
will be used for pharmacovigilance monitoring within the ACT Consortium. Any future requests for 
information from the central database will require the permission of the owners of the data to 
enable access to the collated dataset. 
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11 LA BORA TOR Y P ROCED UR ES 
11.1. MICROSCOPY 
Thick blood smears will be stained with 2% Giemsa for 30 minutes and read by experienced 
laboratory technologists who are not involved in direct participant care. Parasite densities will be 
calculated by counting the number of asexual parasites per 200 leukocytes (or per 500 leukocytes, if 
the count is <10 asexual parasites/200 leukocytes), assuming a leukocyte count of 8,000/l. A blood 
smear will be considered negative when the examination of 100 high power fields does not reveal 
asexual parasites. Gametocytemia will a lso be determined from thick smears. For quality control, all 
slides will be read by a second microscopist and a third reviewer will settle any discrepant readings.  
11.2. RAPID DIAGNOSTIC TESTS FOR MALARIA 
We will use RDTs when assessing febrile participants in the cross-sectional surveys, the cohort study, 
and in the patient exit interviews.  In addition, we plan to support the distribution of RDTs to the HFI 
facilities. If RDTs are not distributed by the MoH to lower-level health facilities, we will provide RDTs 
to all HFI facilities.  If RDTs are provided by the MoH, we will supply RDTs only when stock-outs 
occur. HRP2-based RDTs that have been approved by in the latest round of WHO / FIND product 
testing (http://www.wpro.who.int/sites/rdt/home.htm) will be used.   
Each RDT will be interpreted by a health worker, and the results will be recorded in the appropriate 
log book. An RDT result will be considered positive if both the control line and the test line are visible 
after the development time. A result will be considered negative if the control line is  visible, but no 
test line appears. The result will be considered invalid if no control line is visible, regardless of 
whether or not a test line appears.  
11.3. HEMOGL OBIN MEASUREMENT 
Hemoglobin will be measured from fingerprick blood samples using a portable spectrophotometer 
(HemoCue, Anglom, Sweden).  
 
11.4. MOLECULAR S TUDIES 
Each time a thick blood smear is obtained in the cross-sectional survey and cohort study blood will 
also be collected onto filter paper. Samples will be collected by fingerprick sampling. Blood will be 
placed onto filter paper in approximately 25 ul aliquots per blood spot (4 blood spots per sample). 
The samples will be labeled with study numbers and dates, air-dried, and stored in small, sealed 
sample bags at ambient temperature with desiccant. Parasite DNA will subsequently be removed 
from the filter paper and prepared for molecular analysis using a chelex extraction method. 
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Molecular studies may include analyses of polymorphisms in parasite and/or human genes for 
mutations that may impact on clinical malaria, and genotyping of malaria parasites. Molecular 
studies will be performed only for research purposes and will have no impact on the clin ical 
management of study participants.  
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12 S TATISTICA L  ISS UES 
12.1. SAMPLE SIZE CALCULATIONS 
12.1.1 . C luster rand omized  study   
We plan to sample 200 children under five, and 200 children aged 5-15 years from each cluster in  
each cross-sectional survey, for a total of 8,000 children sampled annually. The primary outcome for 
the cluster randomized study will be the prevalence of anemia (hemoglobin < 11.0 g/dL) in children 
under five as measured in the cross-sectional surveys, which is assumed to be 65% at baseline 
estimated from data collected in a household survey conducted Mulanda sub-county in West 
Budama South (Rachel Pullen, unpublished data). We plan to test the primary hypothesis that 
children under five randomized to the HFI will have a lower prevalence of anemia than children 
randomized to receive standard care.  With two study intervention arms, 10 clusters per 
intervention, a  coefficient of variation between clusters of 0.2, and allowing for the stratified design, 
200 children under five surveyed in each cluster will allow us to detect a difference in anemia 
prevalence between the two intervention arms of 17%, (or more) with power of 80% and 
significance of 5.  If we assume that the clusters are more homogeneous, with a coefficient of 
variation of 0.1, then a difference of about 10% (or more) can be detected.  As a secondary outcome, 
we will evaluate the prevalence of parasitemia in children under five, and in children aged 5-15 
years.  We will test the secondary hypothesis that children under five, and children aged 5-15 years, 
that are randomized to health facility-based care will have a lower prevalence of parasitemia than 
children randomized to receive standard care. In the older age group, the prevalence of parasitemia 
is estimated to be 60% at baseline based on data collected in Mulanda sub-county (Rachel Pullen, 
unpublished data).  Again, with two study intervention arms, 10 clusters per intervention, and a 
coefficient of variation between clusters of 0.2, 200 children aged 5-15 years will need to be 
surveyed in each cluster to detect a difference in parasitemia prevalence in the two intervention 
arms of 16%, with power of 80% and significance of 5%.   
 
12.1.2 . Coh ort study 
The primary outcome for the longitudinal cohort study will be treatment incidence density, which is 
assumed to be 2.5 treatments per year at baseline.  We plan to recruit 500 households into the 
longitudinal study (25 in each cluster), and estimate that the average number of children under five 
per household will be at least 1.5.  Given this, 250 households, and at least 375 children, will be 
available in  each intervention group.  Assuming 30% loss to follow-up over 2 years, 262 children can 
be followed for a total of 2 years, resulting in 524 child-years of follow-up in total; shared 
between 10 clusters, this results in  52.4 person-years per cluster on average. If the baseline group 
experience 2.5 treatments per year, resulting in 5 treatments per child over 2 years, then a 
difference of 2 treatments on average over 2 years can be detected between the two interventions 
(for example if the HFI group experiences 5 treatments over 2 years and the standard care group 
experiences 7 treatments per two years, or approximately 3.5 per year per child), assuming a 
coefficient of variation between clusters of 0.2, power of 80%, significance level of 5%, and allowing 
 
ACT PRIME Study protocol V1.1, 18 Sept 2010  55 
 
 
for the stratified design. This calculation does not include any partial follow-up data that are likely to 
be available from those that drop out over the course of the two years.  
12.1.3 . Pa tient exit  in terviews a t health  fac ilit ies 
The primary outcome for the patient exit interviews will be the proportion of children under five 
with suspected malaria and a negative rapid diagnostic test result that are inappropriately treated 
with an ACT. The hypothesis is that the proportion of children inappropriately treated with an ACT 
will be lower in the facilities randomized to the intervention arm compared to those in the standard 
care group. Assuming this proportion to be 50% in the standard care group, interviewing 10 children 
and their caregivers in  each of the 20 clusters will give 80% power to detect a difference in the 
proportion inappropriately treated for malaria between the two intervention arms of 24% (or more) 
at the 5% significance level, assuming a coefficient of variation between clusters of 0.2 and allowing 
for the stratified design. 
12.2. ANALYTICAL PLAN 
12.2.1 . Ana lyt ica l appro ach 
Since this is  a  cluster randomised trial, analysis will be conducted at both the cluster level using 
summary statistics from each cluster, and at the individual level. The primary analysis will be based 
on the cluster-level results as this is expected to be more robust when the number of clusters 
randomised is not large. A two-stage approach based on cluster summaries will be used to adjust for 
individual- and cluster-level covariates, where appropriate. 
Analysis will be conducted primarily on an intention to treat (ITT) basis, where data collected will be 
analysed according to the assigned cluster. To address potential contamination issues due to 
children attending health facilities other than the one that defines their cluster, i.e. the health facility 
they live closest to, we shall also analyse data on a per protocol (PP) basis. For this analysis, data 
collected will be analysed according to the facility at which the child accesses healthcare. 
12.2.2 . Ba seline  char acteristics  and  tr ial  prof ile 
Baseline demographic characteristics will be available from the census survey conducted in the first 
phase of the project, the baseline cross-sectional survey, and the household survey for the cohort 
study. Data from each source will be separately tabulated by trial arm and by stratum. A tria l profile 
will be produced. This will show, by trial arm, the numbers of households screened, eligible and 
enrolled for the cross-sectional surveys, plus numbers not enrolled (with reasons); the numbers of 
children within each age group (<5 years and 5-15 years) recruited for the cross-sectional surveys. 
For the cohort study, the trial profile will show the numbers of households and children screened, 
eligible and enrolled, plus numbers not enrolled (with reasons). The number of six-monthly visits at 
which clinical evaluations were conduced and the number of monthly visits at which household 
questionnaires were completed will be tabulated by study arm, both overall and separately for each 
time point.  
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12.2.3 . Cr oss -sectiona l sur vey outcomes 
The primary outcome for the cross-sectional surveys will be the prevalence of anemia (defined as 
hemoglobin < 11.0 g/dL). At each endpoint (one and two years after baseline), the crude prevalence 
of anemia will be tabulated for each cluster. There are equal numbers of clusters per intervention 
arm in each stratum and equal numbers of participants will be sampled from each cluster, so the 
simple mean prevalence across the 10 clusters per intervention arm will be used to calculate point 
estimates for overall prevalence of anemia in each intervention arm. A risk ratio for the effect of the 
intervention will then be calculated directly from these point estimates. If necessary, a  logarithmic 
transformation will be applied to normalize cluster-specific prevalences before analyzing the data. A 
stratified t-test will be used to compare the means of the cluster-specific proportions, where the 
within-stratum between-cluster variance will be estimated as the residual mean square from a two-
way analysis of variance of the log-prevalences on stratum and treatment arm, including an 
interaction term.  A 95% confidence interval (CI) for the risk ratio, adjusting for stratum, will be 
calculated from this variance using a t-statistic with 16 degrees of freedom. 
Adjusted analysis for the effect of the intervention on prevalence of anemia will also be performed 
to account for any baseline imbalances between groups. We will adjust for the cluster-specific 
prevalence of anemia collected at the baseline cross sectional survey. Additional a priori individual-
level factors to be adjusted for are age group, sex, use of insecticide treated nets, and distance to 
the health facility. Any other individual- or cluster-specific factors found to be unbalanced at 
baseline will also be adjusted for. Adjustment will be performed by fitting a logistic regression 
model, including terms for stratum and the covariates to be adjusted for, but no term for 
intervention arm, to data from all clusters. From this the predicted prevalence of anemia for each 
cluster will be available. The ratio between the observed and predicted prevalence will be calculated 
(risk ratio-residuals). A stratified t-test will then be conducted on the risk ratio-residuals and the 
covariate-adjusted risk ratio (and 95% CI) for the effect of the intervention will be calculated by 
applying the two-way analysis of variance method described above to the residuals. 
A secondary analysis of individual-level data will be implemented by fitting generalized estimating 
equation (GEE) models with an exchangeable correlation structure and robust standard errors, and 
including a fixed effect for stratum. Wald tests will be used to calculate p-values and 95% confidence 
intervals for the odds ratio for the effect of the intervention. Approaches based on individual-level 
data have been found to be less robust than the cluster-level approach, therefore results will be 
treated with caution. 
It is possible that community-based interventions (CBI) may be scaled up during the study period. If 
this scaling-up is  implemented approximately at the one year cross-sectional survey it will be 
possible to examine its impact by comparing outcomes from one to two years in the individual-level 
regression analysis described above, a lthough the study has not been powered for this comparison.  
Otherwise it will not be possible to quantify the impact of any scaling-up of these activities on cross-
sectionally collected outcomes.  
12.2.4 . Coh ort study outcomes 
The primary outcome for the cohort study will be antimalarial treatment incidence density, defined 
as the rate of antimalarial treatments administered to children in the cohort over the period of 
follow up. The number of events, child-years of follow-up and corresponding incidence rate will be 
tabulated by cluster. For each intervention arm, the cluster-specific rates will then be averaged to 
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give a point estimate of the rate for each intervention.  Rate ratios for the effect of the intervention 
on each outcome will then be calculated from these point estimates. The distribution of cluster-
specific rates is  likely to be skewed, therefore a logarithmic transformation will be applied to 
normalize rates before analysis. A test of the null hypothesis that the rate ratio is  equal to one will 
be conducted using a stratified t-test, where the within-stratum between-cluster variance will be 
estimated as the residual mean square from a two-way analysis of variance of the log-rates on 
stratum and treatment arm, including an interaction term.  A 95% confidence interval (CI) for the 
rate ratio will be calculated from this variance using a t-statistic with 16 degrees of freedom. 
Adjusted analysis will be performed to account for any baseline differences between groups. A priori 
individual-level factors to be adjusted for are baseline anemia, age group, sex, use of insecticide 
treated nets, and distance to the health facility. Any other individual- or cluster-specific factors 
found to be unbalanced between the intervention arms at baseline will also be adjusted for. 
Adjusted rate ratios will be calculated using a similar two-stage process as that described for the 
cross-sectional outcomes above, except Poisson regression will be used to calculate predicted rates 
and hence rate ratio residuals.  
For cohort study outcomes, it will be possible to allow for changes in underlying rates of these 
events due to scaling-up of CBIs in the study area. This will be done by splitting the follow-up time 
for each cluster into periods representing pre- and post-scale-up, and examining the effect of the 
intervention on event rates, stratified by time-period. 
12.2.5 . Ou tcomes  measur ed  a t h ea lth  faci lit ies 
The primary outcome collected at health facilities will be inappropriate treatment of malaria, as 
quantified by the proportion of children under five with suspected malaria and a negative RDT result 
that are inappropriately treated with an ACT plus the proportion of children under five with 
suspected malaria and a positive RDT result that are not treated with an ACT. These data will be 
collected every six  months at exit interviews from health facilities. 
For each time point, the proportion will be tabulated by cluster, and the cluster-specific mean 
proportions will be averaged to give a point estimate of proportion in appropriately treated with an 
ACT in each intervention arm. The risk ratio for the impact of the intervention will then be 
calculated. The two-way analysis of variance and stratified t-test approach described above for the 
cross-sectional survey prevalence outcomes will then be applied to test the null hypothesis that the 
risk ratio equals one and to derive a 95% CI for the risk ratio. Adjusted analyses will a lso be 
performed to account for any baseline differences between the study arms, using the same two-
stage approach described above. A priori individual-level factors to be adjusted for are age group 
and sex.  
Scaling-up of CBIs in the study area is unlikely to impact on outcomes measured at exit interviews 
from health facilities, therefore no further analysis is  planned to account for this.  
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13 D ATA  & S AFETY M ON ITORING  B OA R D 
13.1. OVERVIEW 
A data and safety monitoring board (DSMB) will be assembled in conjunction with the LSHTM and 
the ACT Consortium, consisting of a minimum of three members who are independent of the project 
and who have made no significant input into the project’s design. Members will include a chairman, 
a statistician, a  clinical monitor, and a local safety monitor, if needed.  The DSMB, investigators, and 
the sponsor will agree on the rules for reporting safety data during the course of the project, and the 
rules for recommending premature termination of the project on grounds of safety or efficacy. The 
DSMB will review the analytical plan and will agree to review the interim reported data at pre-
specified intervals. 
 
13.2. MONITORING PLAN 
We plan to prepare an interim report for review by the DSMB after approximately one half of the 
total projected follow-up time has been observed; specifically, after the HFI has been fully active for 
approximately one year, the first annual cross-sectional survey has been completed, and over 75% of 
the cohort study participants have been followed for one year. The interim report will contain 
information on study progress and data quality (including recruitment, follow-up, and protocol 
adherence), safety data (serious adverse events), and primary outcome data (prevalence of anemia, 
antimalarial treatment incidence density, inappropriate use of ACTs). A shell interim report will be 
prepared by project members in conjunction with our statisticians, and will be submitted to the 
DSMB for review prior to the start of the study.  
13.3. STOPPING GUIDELINES 
The DSMB will have the authority to recommend cessation of the project for reasons related to 
safety of trial subjects, and to notify the sponsor accordingly.  Interpretation of results and decisions 
about discontinuation of the study will be made by the members of the DSMB.  
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14 D ATA  M A NA GEM ENT 
14.1. DATA MANAGEMENT  
14.1.1 . Cr oss -sectiona l sur veys  
Screening forms, consent forms, survey questionnaires, and clinical case record forms will be 
completed by the field teams. Microscopy results will be recorded in a laboratory record book by lab 
technicians. All record forms will be reviewed by project coordinators for completeness and 
accuracy. Data entered onto paper record forms will be entered into a computerized database 
(Microsoft Access) by a data entry clerk and will be double-entered to verify accuracy. Electronic 
versions of the cross-sectional survey questionnaire will be created for personal digital assistants 
(PDAs) using appropriate software (Visual CE, Syware Inc).  Survey teams will move in pairs; one 
team member will administer the survey questionnaire and record answers on a PDA, while another 
team member will record answers on a paper questionnaire. Data captured on PDAs will be 
downloaded daily to a Microsoft Access database. Data captured on paper record forms will be used 
as back-up if synchronization of the PDA to the computerized database fails.  
14.1.2 . Coh ort study 
Screening forms, consent forms, household survey forms, clin ical case record forms, and monthly 
questionnaires will be completed by the field teams. Information recorded on the pictorial diaries by 
primary caregivers will be transferred onto standardized data extraction forms by study personnel. 
Microscopy results will be recorded in a laboratory record book by lab technicians. All record forms 
will be reviewed by project coordinators for completeness and accuracy. Data entered onto paper 
record forms and the data extraction forms will be entered into a computerized database (Microsoft 
Access) by a data entry clerk and will be double-entered to verify accuracy. Electronic versions of the 
household survey questionnaire and the monthly questionnaire will be created for the PDAs using 
appropriate software (Visual CE, Syware Inc).  Field teams will move in pairs; one team member will 
administer the appropriate questionnaire and record answers on a PDA, while another team 
member will record answers on a paper version of the questionnaire. Data captured on PDAs will be 
downloaded daily to a Microsoft Access database. Data captured on paper record forms will be used 
as back-up if synchronization of the PDA to the computerized database fails.  
14.1.3 . M &E  o f hea lth  fac ilit ies 
The patient exit interviews, health facility surveillance forms, and health worker knowledge 
questionnaires will be completed by field teams.  All record forms will be reviewed by project 
coordinators for completeness and accuracy. Data entered onto paper record forms and the data 
extraction forms will be entered into a computerized database (Microsoft Access) by a data entry 
clerk and will be double-entered to verify accuracy.  Electronic versions of the health facility 
surveillance forms will be created for the PDAs using appropriate software (Visual CE, Syware Inc).  
Data captured on PDAs will be downloaded daily to a Microsoft Access database. Data captured on 
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paper record forms will be used as back-up if synchronization of the PDA to the computerized 
database fails.  
14.2. QUALITY ASSURANCE AND QUAL ITY CONTROL   
All members of the study team will be trained in the project objectives, methods of effective 
communication with study participants, and collection of high quality data. Study team members will 
receive additional training specific to the tasks they will perform within the project including 
interviewing techniques, administration of surveys, completing questionnaires, and use of PDA 
devices. Standard Operating Procedures (SOPs) will be written for all project activities and booklets 
of all relevant documents will be provided to each member of the project team. Study group 
meetings will be conducted by the principal investigator to assess progress of the study, address any 
difficulties, and provide performance feedback to the members of the study group. Any corrections 
to data collection forms will be made by striking through the incorrect entry with a single line and 
entering the correct information adjacent to it, according to Good Clinical Practice guidelines.[96]  
The correction will be initia led and dated by the investigator.  The investigators will a llow all 
requested monitoring visits, audits or reviews. 
14.3. RECORDS AND STORAGE 
All study documents will be kept in secured filing cabinets in the Infectious Disease Research 
Collaboration offices. The principal investigator will be responsible for the security of a ll project 
documents.  Back-up files of databases will be stored onto the main project server after each data 
entry session. Participants will be identified by their study ID number, and participant names will not 
be entered into the computerised database.    
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15 P R OTECTION OF H UM A N PA R TI CIPA NTS 
15.1. INSTITUTIONAL REVIEW BOARDS 
This study will be reviewed by the following organizations: 
1. London School of Hygiene and Tropical Medicine Ethics Committee 
2. Makerere University Faculty Research and Ethical Committee 
3. Uganda National Council of Science and Technology 
4. University of California, San Francisco Committee for Human Research 
15.2. INFORMED CONSENT PROCESS 
Study personnel will conduct screening interviews and informed consent discussions with individual 
children and their parent/guardian during the screening process for the cross-sectional surveys and 
the cohort study. Informed consent will be conducted in the appropriate language (usually Luganda) 
and a translator will be used if necessary. Consent forms will be available in both English and 
Luganda. Following the informed consent discussion, parents (or guardians) will be asked by the 
study personnel to provide their written consent on the approved informed consent document for 
their child to participate in a research study and a second approved consent form for the future use 
of biological specimens obtained during the course of the study. If the parent or guardian is unable 
to read or write, their fingerprint will substitute for a signature, and a signature from a witness to 
the informed consent procedures will be obtained. Written assent to participate in the cross-
sectional surveys will also be obtained from children aged 8 years and older at the time of screening.  
15.3. CONFIDENTIALITY 
Parents and guardians will be informed that participation in a research study may involve a loss of 
privacy. All records will be kept as confidential as possible. Participants will be identified primarily by 
their study number and patient names will not be entered into the computerized database. No 
individual identities will be used in any reports or publications resulting from the study.  
15.4. RISKS AND DISCOMFORTS 
15.4.1 . Pr ivacy 
Care will be taken to protect the privacy of participants, as described in this protocol. However, 
there is  a risk that others may inadvertently see participants’ information, and thus their privacy 
compromised.  
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15.4.2 . Risks  of  r andomiz ation 
This will be a randomized tria l in which we propose to enhance the care provided at government-run 
health facilities. There is a risk that residents living in villages within clusters randomized to the 
standard care arm may receive health care that is inappropriate, ineffective, or delayed, given that 
care delivered from those facilities will not be enhanced. However, it is not clear if care provided by 
HFI facilities will improve the health of children or quality of care above care standardly available; 
this study is designed to answer that question.  
15.4.3 . F ingerprick  blood  dr aws 
Participants in the cross-sectional surveys and cohort study will have blood removed by fingerprick 
for laboratory evaluations, which has been associated with discomfort, bleeding, bruising, and rarely 
infection.   
15.4.4 . Risk  of ar temeth er-lumefan trine 
AL appears to be safe and well-tolerated,[97,98] which is supported by the results of studies in 
Uganda.[35,36,99,100] In one study, participants treated with AL were more likely to have elevated 
temperature than those treated with AQ+SP or AQ+AS, which may have been due to the known anti-
pyretic properties of amodiaquine, a  component of the other two study regimens.[100]  In addition, 
a higher risk of delayed diarrhea was observed in AL-treated patients, which has previously been 
reported.[101,102]  
 In  a review of the safety and tolerability of AL in 1869 patients (including 368 children aged < 5 
years), the most commonly reported adverse events that were possibly related to AL included 
gastrointestinal events (abdominal pain, anorexia, nausea, vomiting, and diarrhea), headache, and 
dizziness, while pruritis and rash occurred uncommonly.[102] Most events were of mild or moderate 
severity and were similar to symptoms associated with clinical malaria. The tolerability profile of AL 
compared favourably to other antimalarial drugs, including CQ, mefloquine, SP, and quinine.[102] In 
a systematic review including eight comparative clinical trials, AL was found to be associated with 
less vomiting (mild or moderate) than CQ, mefloquine, halofantrine, and AS + mefloquine.[103]  
The chemical structure of lumefantrine is similar to halofantrine, raising concern for possible cardiac 
toxicity with AL.  Treatment with halofantrine is associated with changes in cardiac conduction, 
particularly prolongation of the QT interval, which can produce arrhythmias.[104] However, no 
serious cardiac toxicity has been reported with AL.[103] A study of cardiac effects in healthy 
volunteers found a concentration-dependent prolongation of the QTc interval in all participants 
treated with halofantrine, but no change in the QTc interval after treatment with AL.[105] 
Electrocardiographic data from clinical trials evaluating AL are encouraging, indicating that the 
frequency of QTc prolongation with AL is similar to that observed with CQ, mefloquine, and AQ + 
mefloquine.[102,106,107] 
15.4.5 . RDTs  f or ma lar ia 
The accuracy of RDTs for diagnosing malaria has been well-studied.[108-112] In  Uganda, RDTs based 
on histidine-rich protein 2 (HRP2) and RDTs based on plasmodium lactate dehydrogenase (pLDH) 
were compared with expert microscopy and polymerase chain reaction (PCR)-corrected microscopy 
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for 7000 patients at sites of varying malaria transmission intensity across Uganda.[109] When all 
sites were considered, the sensitivity of the HRP2-based test was 97% when compared with 
microscopy and 98% when corrected by PCR; the sensitivity of the pLDH-based test was 88% when 
compared with microscopy and 77% when corrected by PCR. The speciﬁcity of the HRP2-based test 
was 71% when compared with microscopy and 88% when corrected by PCR; the speciﬁcity of the 
pLDH-based test was 92% when compared with microscopy and >98% when corrected by PCR. Based 
on Plasmodium falciparum PCR-corrected microscopy, the positive predictive value (PPV) of the 
HRP2-based test was high (93%) at all but the site with the lowest transmission rate; the pLDH-based 
test and expert microscopy offered excellent PPVs (98%) for all sites. The negative predictive value 
(NPV) of the HRP2-based test was consistently high (>97%); in contrast, the NPV for the pLDH-based 
test dropped signiﬁcantly (from 98% to 66%) as transmission intensity increased, and the NPV for 
expert microscopy decreased signiﬁcantly (99% to 54%) because of increasing failure to detect 
subpatent parasitemia 
15.4.6 . Compen sation   
Participants will not be paid for participating in this study.  Most assessments will be conducted at 
households or health facilities, which will eliminate the need for travel and minimize opportunity 
costs for the participants.  If cross-sectional survey or cohort study participants are referred by study 
personnel to a health facility for further assessment, transportation will either be provided by the 
study team, or the costs of transportation will be borne by the project.  Any other costs of 
transportation related to project activities will be reimbursed by the project.  Households 
participating in the cohort study will receive small incentives (soap, washing powder, or sugar) at 
monthly visits.  All children participating in the cohort study will be given an insecticide-treated 
bednet at the end of study follow-up.  
15.4.7 . Alter natives   
Children whose parents or guardians choose not to participate in this study will not be enrolled in 
the cross-sectional survey or cohort study. Children excluded from the study will still be eligible for 
standard care of medical problems as they arise at the government-run health facilities or other 
available health centers. 
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APPENDIX A: Intervention components, barriers, and outcomes 
 
Intervention Component Barriers intended to address Intended outcome 
1.  Health Centre Management 
Management training for in-
charges: 
 Human resource 
management (staffing) 
 Financia l management 
(budgeting and accounting) 
 Supply management (drug 
stocking)  
 
 Lack of in-charge skills to manage staff and HC  
 Low motivation of staff due to poor HC 
administration 
 Inappropriate use of volunteers 
 Under-utilization or lack of appropriate tools 
to appropriately mange health centres 
Good clin ical care 
Improved staff/patient ratio 
Appropriate use of 
volunteers 
Improved accounting of 
PHC funds 
Improved forecasting and 
stocking of needed supplies 
 
2.  Information Management 
Monitoring and evaluating 
information for continuous 
quality improvement 
 Low health  worker motivation and 
performance with patients (clinical and wider 
therapeutic process) 
 Lack of information to adequately manage 
the health facility and report to local and 
d istrict stakeholders 
Professional conduct 
Good clin ical care 
3.  Health Worker Training  
Training in  fever case 
management and use of RDTs 
 Poor knowledge of malaria case management 
 Inadequate/unavailable infrastructure or 
d iagnostic laboratory facilities 
Good clin ical care 
Improved HW-patient 
interactions 
Professional conduct  
Prompt and fair treatment 
Improved welcoming & 
guiding 
Improved HW-patient 
interactions 
 
 
Training in  Patient-Centered 
Services 
 Communication problems including language 
barrier 
 Lack of patient-centred thinking 
 Discrimination/preferentia l treatment of 
patients 
 Poor patient flow and management 
 Poor relationships between staff and 
communities 
4.  Supply of Consumables 
Drug delivery from NMS 
 Frequent stock-outs of drugs 
 Poor procurement system 
 Patients have to pay for drugs or services 
Good clin ical care 
Free services 
Availab ility of drugs 
Appropriate treatment of 
malaria 
 
Support supply artemether-
lumefantrine 
 Frequent stock-outs of first line antimalarial 
treatment  
RDTs for malaria 
 Inadequate/unavailable infrastructure or 
d iagnostic laboratory facilities 
 RDTs not available nationally 
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APPENDIX B. INFORMATION SHEET – Health facility intervention 
ACT PRIME Study 
 
Introduction 
Dr. Sarah Staedke and colleagues from the Uganda Malaria Surveillance Project / Infectious Diseases 
Research Collaboration are investigating delivery of health care services in Tororo District. We are doing a 
research study to see if we can improve the health of children in this area by improving services at 
government-run health facilities.  
 
What will be done in this study? 
Certain health centers in Tororo district will be selected to take part in the intervention to improve services, 
or to continue with their current services.  Assignment to the two groups has been determined by a lottery.  
The chance of being placed into either of the groups is the same.  Your health center has been selected to 
take part in the intervention.  
 
The health facility intervention will focus on 1) health center management training, 2) information 
management and quality improvement; 3) health worker training, and 4) supply of malaria diagnostics and 
antimalarial drugs. The intervention package will be introduced to all health centers selected to take part 
over approximately 8-10 weeks.  After this time, all health centers in the area will be assessed every two 
months to determine how well the intervention is working. Our study personnel will continue to support the 
intervention at the selected health centers for the full duration of the study. 
 
What will happen if my health center takes part in this study? 
The intervention will include three different training packages, which you and other members of staff at your 
facility will be asked to take part in: 
 
1) Health center management training. All in-charges of health centers assigned to the intervention will be 
trained in health center management.  The purpose of this training is to equip in-charges with the skills and 
tools required to effectively and efficiently manage their health center.  The training will include three 
components: human resource management, financial management, and supply management. Our study 
staff will carry out a series of half-day training workshops with the in-charges every 1-2 weeks, and the 
training module will last approximately 8-10 weeks. The in-charges will be taught how to collect data about 
patient attendance, primary health care (PHC) funds, and drug supplies during the training.  The in-charges 
will also be asked to continue to collect data and complete forms during the full period of the study.  
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2) Fever case management training. All clinical staff, including in-charges and other health workers, will 
receive training in fever case management. The training program will last 1 week.  
 
3) Patient-centered services (PCS) training. The purpose of this training is to identify and improve 
interpersonal interactions between health workers and patients.  All clinical staff, including in-charges, will 
receive the full PCS training package which will start with a series of 4 self-observation activities completed 
over a period of 8-12 weeks. This will be followed by a PCS workshop which will consist of 4 half-day 
modules, lasting about 3 hours, carried out over 2 weeks. The modules will focus on coaching, 
communication with patients and colleagues, and patient flow. Support staff, including volunteers will 
receive a scaled-down PCS training package with specific emphasis on communication skills and patient flow.  
The PCS workshop for support staff will consist of 2 half-day themed modules carried out over 1 week.  
Health workers and support staff will be trained in two groups to ensure that work at the health centers 
continues alongside the training.   
 
After beginning the intervention, we will collect information to see how well it is working. Every month, we 
will visit the health centers to gather information on patient attendance, drug stock-outs, staffing, and 
diagnosis and treatment of malaria. Every six months, we will interview patients as they are leaving the 
health center to learn more about their experience with the health center visit. Once a year, we will ask all 
health workers to take part in a survey about management of malaria and other fever illnesses to learn more 
about their knowledge and practices. 
 
How long will this study last? 
The intervention will be introduced over 2-3 months.  The total duration of the study will be about 2 ½ years. 
 
Can I stop being in the study? 
You can decide to stop participating at any time.  Just tell our study personnel right away if you wish to stop 
the activities. 
 
What risks can I expect from participating in the study? 
Participation in any research study may involve a loss of privacy.  Information you provide about your health 
center will be recorded, but your name will not be used in any reports of the information provided.  No 
quotes or other results arising from your participation in this study will be included in any reports, even 
anonymously, without your agreement. The information obtained from these study activities will only be 
used by the project researchers and will be locked up at our project offices. We will do our best to make sure 
that any personal information is kept private.   
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Are there benefits to taking part in the study? 
Through the intervention, we aim to improve the health of children in this area by improving services at the 
health centers. As part of the intervention, our project will provide training to in-charges and other health 
workers, which will benefit you directly, and help provide malaria drugs and tests for diagnosing malaria, 
which will benefit the health facilities and patients. The information that we gather in this study will help 
researchers and policy-makers understand how best to improve health services in this area.  
 
What other choices do I have if I do not take part in the study? 
You are free to choose not to take part in the study. If you decide not to take part, there will be no penalty to 
you.   
  
What are the costs of taking part in the study?  Will I be paid for taking part in the study? 
There are no costs to you for taking part in this study. You will not be paid for taking part in this study. The 
training activities will take place in convenient locations within Tororo district.  Any transport costs incurred 
by trainees will be reimbursed by the project.  
 
What are my rights if I take part in the study? 
Taking part in this study is your choice. You may choose either to take part or not to take part.  If you decide 
to take part in this study, you may change your mind at any time.  No matter what decision you take, there 
will be no penalty to you in any way. 
 
Who can answer my questions about the study? 
You can talk to the researchers about any questions or concerns you have about these study activities.  
Contact Dr. Sarah Staedke or other members of the Uganda Malaria Surveillance Project / Infectious Disease 
Research Collaboration on telephone number 0414-530692. If you have any questions, comments or 
concerns about taking part in these self-observation activities, first talk to the researchers.  If for any reason 
you do not wish to do this, or you still have concerns about doing so, you may contact Dr Charles Ibingira, 
Makerere University Faculty of Medicine Research and Ethical Committee at telephone number 0414-
530020. 
 
Giving verbal consent to take part in the study: 
You may keep this information sheet if you wish. Participation in these activities is voluntary.  You have the 
right to decline to take part in the activities, or to withdraw from them at any point without penalty.  If you 
do not wish to take part in the activities, you should inform the researcher now.  If you do wish to take part 
in these activities, you should tell the researcher now.  
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APPENDIX D: PRIMARY HEALTH CARE (PHC) FUND ACCOUNTING TOOL 
PART 1: Health Worker Information 
Health centre code 
 
[_____|_____] 
Health worker ID 
 
[_____|_____] 
Health worker position 
 
[_____|_____] 
P ick code from list below 
Reporting Month / Year 
 
 [_____|_____]/[_____|_____] 
month                               year 
1 = In-cha rge  
2 = Senior medical officer   
3 = Medical officer   
4  = Senior clinical officer    
5  = Clinical officer                                                                  
6  = Nursing officer 
7 = Enrolled nurse 
8 = Midwife
9 = Public health nurse 
10 =  Nursing a ide/assistant  
11 =  Labora tory technician 
12 =  Labora tory assistant 
13 = Hea lth a ssista nt 
14 = Hea lth educa tor 
15 = Other______________ 
The PHC Fund Tracking Tool should be completed monthly by the person responsible for managing the fund. 
 
PART 2: PHC Fund Accounting Tool 
Coding for Action or Service required 
1 = community outreach 
2 = slashing around the health centre 
3 = cleaning the health centre 
4 = health centre repairs 
5 = paying vo lunteers 
6 = paying staff 
7 = buying fuel 
 
8 = buying supplies 
9 = buying drugs 
10 = Other 
⑯ 
Action or Service required 
List code: [_____] 
Give details: 
 
Expected benefit or consequence if action/service cannot be conducted: 
 
Person responsible for completing the action/service: 
 
A Cost for action/service B Frequency required per month 
(hours or days) 
Cost per month 
(A x B) 
/=  /= per month 
⑯ 
Action or Service required 
List code: [_____] 
Give details: 
 
Expected benefit or consequence if action/service cannot be conducted: 
 
Person responsible for completing the action/service: 
 
A Cost for action/service B Frequency required per month 
(hours or days) 
Cost per month 
(A x B) 
/=  /= per month 
⑯ 
Action or Service required 
List code: [_____] 
Give details: 
 
Expected benefit or consequence if action/service cannot be conducted: 
 
Person responsible for completing the action/service: 
 
A Cost for action/service B Frequency required per month 
(hours or days) 
Cost per month 
(A x B) 
/=  /= per month 
 
Complete another Tracking Tool Sheet if there are additional services 
or actions required this month. 
Total monthly 
cost for all 
services/actions  
/= 
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APPENDIX E. ACT DRUG DISTRIBUTION ASSESSMENT TOOL (ADDAT) 
PART 1: HEALTH WORKER INFORMATION 
Health centre code 
 
[_____|_____] 
Health worker ID 
 
[_____|_____] 
Health worker position 
 
[_____|_____] 
P ick code from list below 
Reporting Month / Year 
 
 [_____|_____]/[_____|_____] 
month                               year 
1 = In-cha rge  
2 = Senior medical officer   
3 = Medical officer   
4  = Senior clinical officer    
5  = Clinical officer                                                                  
6  = Nursing officer 
7 = Enrolled nurse 
8 = Midwife
9 = Public health nurse 
10 =  Nursing a ide/assistant  
11 =  Labora tory technician 
12 =  Labora tory assistant 
13 = Hea lth a ssista nt 
14 = Hea lth educa tor 
15 = Other______________ 
The ADDAT should be completed monthly by the person responsible for drug procurement and distribution. 
 
PART 2: ADDAT 
Green:  The activity is on track. 
No intervention is required  to ensure 
this node is operational for distribution 
of ACTs. 
Yellow:  The activity is partially on tract or 
only a component is on track. 
Some intervention is required for this 
activity to become operational. 
Red:  The activity not is not on track. 
Sign ificant intervention is required for 
th is activity to  become operational. 
Drug delivery from NMS to DHO Date: Green  Yellow  Red  
Issue if status is ‘yellow’ or ‘red’: 
 
How the issue was resolved:  
 Date: 
Drug delivery to health center Date: Green  Yellow  Red  
Issue if status is ‘yellow’ or ‘red’: 
 
How the issue was resolved:  
 Date: 
Adequate storage for drugs Date: Green  Yellow  Red  
Issue if status is ‘yellow’ or ‘red’: 
 
How the issue was resolved:  
 Date: 
Adequate capacity for managing and 
distributing drugs 
Date: Green  Yellow  Red  
Issue if status is ‘yellow’ or ‘red’: 
 
How the issue was resolved:  
 Date: 
Request re-supply of drugs from DHI Date: Green  Yellow  Red  
Issue if status is ‘yellow’ or ‘red’: 
 
How the issue was resolved:  
 Date: 
Other activities this month Date: Green  Yellow  Red  
Describe action: 
 
Issue if status is ‘yellow’ or ‘red’: 
 
How the issue was resolved:  
 Date: 
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APPENDIX F: HEALTH FACILITY MONTHLY REPORT 
Section 1: Health Center Information 
Health centre code 
 
[_____|_____] 
Health worker ID 
 
[_____|_____] 
Date report completed 
 
[_____|_____]/[_____|_____]/[_____|_____] 
day                          month                           yea r 
START date of report 
 
[_____|_____]/[_____|_____]/[_____|_____] 
day                          month                           year 
STOP date of report 
 
[_____|_____]/[_____|_____]/[_____|_____] 
day                          month                           year 
 
Section 2: Clinical Report 
ALL PATIENTS  
Total number of patients visiting the health center th is month 
 
[______|______|______] 
Total number of patients who had fever 
 
[______|______|______] 
Total number of patients who had a rapid diagnostic test for malaria done 
 
[______|______|______] 
Total number of patients who had a positive rapid diagnostic test result 
 
[______|______|______] 
Total number of patients who had a negative rap id d iagnostic test resu lt 
 
[______|______|______] 
Total number of patients who were prescribed an ACT* to treat malaria 
 
[______|______|______] 
Total number of patients who were diagnosed with malaria 
 
[______|______|______] 
CHILDREN UNDER FIVE  
Total number of children under five years of age visiting the health  center th is month 
 
[______|______|______] 
Total number of children under five years of age who had fever 
 
[______|______|______] 
Total number of children under five who had a  rapid diagnostic test for malaria done 
 
[______|______|______] 
Total number of children under five who had a positive rap id  diagnostic test resu lt 
 
[______|______|______] 
Total number of children under five who had a negative rapid diagnostic test result 
 
[______|______|______] 
Total number of children under five who were prescribed an ACT* to treat malaria 
 
[______|______|______] 
Total number of children under five who were diagnosed with malaria 
 
[______|______|______] 
* ACT = artemisinin-based combination therapy for malaria. Examples include Coartem, Lumartem, Duocotexcin 
 
 
Section 3: Extra comments 
Describe  any situation tha t had an impact on patient ca re at your health center this month, such as drug stock-outs, staff shortages, or politica l instability.  
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TRAINING PROGRAMME 
Use of RDTs in fever case management in Uganda: 
INTRODUCTION 
Welcome to the training course on “Fever case management with RDTs.”  RDT 
stands for Rapid Diagnostic Test for malaria.  RDTs are diagnostic tools that can 
diagnose malaria using finger prick blood.  They are very accurate.  They are easy to 
use, and do not require electricity or special equipment.  They are very useful even in 
areas where there is no laboratory or trained laboratory staff. 
As a health worker, you likely see patients with fever every day.  Fever is a 
common and important sign of illness.  In Uganda and other parts of Africa, a patient 
with fever is often assumed to have malaria.  This is considered good clinical practice 
where no diagnostic tests are available.  However, now RDTs can provide accurate 
diagnosis.  
Although malaria is very common in many parts of Uganda, we know that not all 
fevers are caused by malaria.  Malaria is more common in some areas, and less 
common in others.  Look at the map on page 2 of this Introduction.  Let’s imagine a 
health centre in Apac district.  Apac is an example of an area in Uganda where 
malaria is very common.  If a health worker in Apac sees 50 patients with fever, 35 of 
those are likely to have malaria parasites in their blood.  As another example, let’s 
imagine a health centre in Kabale district.  Kabale is an example of an area in Uganda 
where malaria is not very common.  If a health worker there sees 50 patients with 
fever, only 2 are likely to have malaria parasites.  The patients with malaria should be 
treated promptly with antimalarial drugs.  But those without malaria should be given 
the correct treatment for their illness. 
It is important to give prompt antimalarial treatment to any patient who truly has 
malaria.  However, if we give antimalarial drugs to patients who do not have malaria 
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parasites in their blood, we have failed to give them the correct treatment.  If all 
patients with fever are given antimalarial drugs, it is clear that many will not receive 
the correct treatment for their illness.  This practice also wastes medicine, puts 
patients at risk of side effects, and increases drug stock-outs and health care costs. 
Therefore, we can provide better health care if we can confirm whether a patient 
truly has malaria, or another illness.   Most Health Centres II and III in Uganda do not 
have laboratories or microscopes or trained laboratory staff to perform blood smears.  
However, RDTs do not require these things.  RDTs are ideal for use in health centres 
where diagnostic tests were not available before. 
This training course will teach you how to perform and read RDTs, and how to 
use them to identify which patients have malaria and which do not have malaria. 
TRAINING SESSIONS: 
This course is made up of 7 sessions.  The information for each session is 
presented in a training guide, which we shall read together.  Each session will be 
followed by time to practice the knowledge and skills gained.  The sessions include: 
1) How to evaluate patients with fever and select patients for RDT testing 
2) Performing and reading an RDT 
3) Management of a patient with fever and a positive RDT 
4) Management of a patient with fever and a negative RDT 
5) Recognition and referral of patients with severe illness 
6) Patient education 
7) RDT storage and monitoring 
 
Let’s get started! 
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Malaria Endemicity Level
very high
medium- high
low
very low or no malaria
Arua
<5:  63%
5:  32%
Kanungu
<5:  47%
5:  25%
Tororo
<5:  59%
5:  13%
Kyenjojo
<5:  62%
5:  36%
Jinja
<5:  33%
5:  24%
Apac
<5:  85%
5:  49%
Kabale
<5:  4%
5:  4%
N
KAMPALA
blood smear data from Uganda Malaria Surveillance Project,
Hopkins et al, Journal of Infectious Diseases, 2008
 
 
This map shows us some important facts about malaria Uganda: 
1) Not all fever is malaria.  Expert laboratory technicians read blood smears from 
patients with fever in each of these areas of Uganda.  The number in each box shows 
the percentage of patients whose blood smear was positive.  The results are grouped by 
patient age:  <5 = children under 5 years old, and 5 = children 5 years and older and 
adults. 
2) Malaria risk is different in different parts of Uganda.  For example, in the mountain 
areas of Kabale, only 4% of patients with fever had malaria parasites.  However, in 
Apac, 85% of young children with fever had malaria parasites.  According to this 
map, how common is malaria in your area? 
3) Malaria risk is also different for older patients than for young children.  Older 
children and adults with fever are less likely to have malaria than young children.
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Use of RDTs in fever case management in Uganda: 
PRE- and POST-TEST 
Welcome to the pre-test for our training course in RDTs and fever case management.  There 
are 16 questions in the pre-test.  We will read each question together out loud.  After we read the 
question, you should mark your answer on your own sheet.  Don’t worry if you don’t know 
every answer.  The reason for this test is not really to see how much you already know.  The pre-
test is designed to raise your interest in RDTs and fever cases.  Each of these questions highlights 
an important learning point that we will cover during the course.  By the end of the course, you 
will have learned everything you need to answer these questions correctly.  On the last day of the 
course, we shall take this test again, and then discuss the answers as a group. 
 
Instructions:
1. Read each question carefully along with the group. 
2. Circle the letter in front of the answer you think is correct – for example   a) 
 
 
 
1. All cases of fever in Uganda are caused by malaria. 
a) True 
b) False 
 
 
2. RDT stands for Rapid Diagnostic Test for malaria.  Which of the following is NOT true 
about RDTs? 
a) If performed correctly, they are very accurate in diagnosing which patients have 
malaria and which do not. 
b) They can be performed in health centres that do not have power or laboratory 
equipment. 
c) They can detect typhoid fever and pneumonia as well as malaria. 
 
 
3. In order to perform an RDT, you will need to use finger prick blood.  After you prick a 
patient’s finger with a lancet, what should you do with the lancet? 
a) Save it to wash and use again later. 
b) Carefully put it immediately in the sharps container. 
c) Put it on the table beside you, to use for the next patient. 
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4. We will pass an RDT around the room.  Look carefully at it and read the result. 
a) Positive 
b) Negative 
c)  Invalid 
 
 
5. Here is another RDT.  Look carefully at it and read the result. 
a) Positive 
b) Negative 
c)  Invalid 
 
 
6. RDTs should be stored in a cool, dry place. 
a) True 
b) False 
 
 
7. You can use the same RDT for two different patients. 
a) True 
b) False 
 
 
8. You should always check the expiry date on the package of an RDT before using it. 
a) True 
b) False 
 
 
9. For which of the following patients should you perform an RDT for malaria? 
a) A 4-year-old boy with fever and mild cough 
b) An 8-month-old child with fever who refuses to breastfeed, is breathing rapidly and 
has very pale palms and sunken eyes 
c) A 20-year-old woman who is pregnant and has fever 
d) A 32-year-old man who is HIV-positive and has fever 
e) A 45-year-old man with fever and joint paints 
f) All of the above 
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10. A patient comes to your health centre with fever.  She has taken chloroquine for two days but 
the fever has persisted.  You perform an RDT and the result is positive.  What should you 
do? 
a) Tell the patient to complete the course of chloroquine. 
b) Prescribe a full course of Coartem. 
 
 
11.  A patient comes to your health centre with fever.  She took a complete, correct course of 
Coartem last week.  She did not vomit any of the doses.  You perform an RDT and the result 
is positive.  What should you do? 
a) Prescribe a full course of quinine. 
b) Prescribe a second full course of Coartem. 
c) Advise her to take Panadol and fluids only. 
 
 
12.  Which of the following is a symptom or sign of severe illness in a patient with fever? 
a) Convulsions currently or within the past 2 days 
b) Extreme weakness – patient is unable to sit or stand without support 
c) Severe anaemia – patient’s palms and conjunctivae are very pale 
d) Unable to drink or breastfeed 
e) All of the above 
 
 
13.  A 35-year-old man comes to your health centre.  He tells you that he has fever and muscle 
aches.  What should you do FIRST? 
a) Prescribe Coartem immediately. 
b) Prescribe chloroquine immediately – this regimen is best for adults. 
c) Prescribe Panadol only and tell the patient to go home and rest. 
d) Ask the patient how long he has had these symptoms, and ask if he has taken any 
drugs at home before coming to the health centre. 
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14.  A mother brings her 8-year-old daughter to your health centre.  Beginning yesterday, the girl 
has had fever and no appetite.  Her mother has given Panadol and fluids, but the symptoms 
continue.  There are no signs or symptoms of severe illness.  On physical examination, you 
find no obvious cause of her fever.  You perform an RDT, and the result is negative.  Which 
of the following is TRUE? 
a) This patient has a mild febrile illness, but the cause is not clear.  The mother should 
continue to provide fluids and Panadol.  You should advise her to bring the girl back 
to the health centre if the symptoms do not get better within 2 to 3 more days. 
b) You should prescribe a course of chloroquine.  Even though the RDT is negative, the 
girl may still have malaria, and chloroquine is appropriate for mild cases of malaria. 
c) You should prescribe Coartem.  Even though the RDT is negative, the girl may have 
malaria, and Coartem is the first-line regimen for malaria in Uganda. 
 
 
15.  A 10-year-old boy comes to your health centre with fever and joint pains.  He looks weak, 
but is able to sit up easily by himself.  After you take a history and do a physical 
examination, you perform an RDT.  The RDT is positive, and you plan to treat for 
uncomplicated malaria.  According to the Uganda Ministry of Health guidelines, which of 
the following is the BEST (first-line) treatment for this patient? 
a) Chloroquine 
b) Oral quinine 
c) Injectable quinine 
d) Coartem (artemether-lumefantrine) 
e) Chloroquine + Fansidar (Homapak) 
 
 
16.  A mother brings her 1-year-old son to your health centre.  She tells you he has not been 
feeding well.  The child’s body is hot to touch.  He is weak and cannot sit up by himself, and 
he is breathing very rapidly.  What should you do?  Be sure to read all the statements below 
before answering. 
a) Undress the child, and ask the mother to sponge him to help reduce the fever. 
b) Immediately prepare and inject a dose of quinine AND antibiotic. 
c) Perform an RDT and write the result on the referral note. 
d) Write a referral note and ensure that the child is referred to a Health Centre IV or 
Hospital as soon as possible. 
e) All of the above. 
 
You have finished the pre-test – congratulations! 
We hope these questions have raised your interest in RDTs and fever case management.  
Now, let’s move ahead with the first session of the training course.
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INTRODUCTION: 
Welcome to Session 1 on “How to evaluate patients with fever and select patients for 
RDT testing.”  An RDT can tell you whether or not a patient has malaria.  Therefore, when 
you are considering whether to test a patient with an RDT, the main question in your mind 
should be: 
Based on the patient’s symptoms, do I believe this patient may have malaria? 
If the answer to the question is yes, then you can use an RDT to help determine 
whether or not the patient the patient actually has malaria. 
Any time you are deciding whether a patient has malaria or another cause of fever, you 
can perform an RDT.  The RDT result, together with the information you get from talking 
with the patient and examining him or her, will help you to make the correct diagnosis and 
provide the best treatment. 
In this session, we will talk more about the symptoms of malaria, and the symptoms of 
other illnesses that may look like malaria.  One of the most common symptoms that patients 
report is fever.  Fever is an important signal that there is something wrong in the body.  Fever 
does not always require treatment, but a health worker should try to understand the cause and 
to provide treatment if appropriate. 
Frequently in Uganda, a patient with fever is assumed to have malaria.  Although malaria 
is very common in many parts of Uganda, we know that not all fevers are caused by malaria.  
Many other diseases also cause fever.  Therefore, it is important for you to be able to confirm 
whether a patient truly has malaria, or another illness.  In this session, we will discuss the key 
points in taking a history and examining a patient with fever.  
 
 
Session 1: HOW TO EVALUATE PATIENTS WITH FEVER 
AND SELECT PATIENTS FOR RDT TESTING  
 
Content: 
 Introduction 
 Learning objectives 
1  The importance of fever in selecting a patient for RDT testing 
2  Severe illness in a patient with fever 
3  Questions to ask when taking a history from a patient with fever  
4  Physical examination of a patient with fever 
5  Selecting a patient for RDT testing based on history and physical  
    examination 
 Summary 
 References 
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LEARNING OBJECTIVES: 
By the end of this session, you should be able to: 
1) Describe fever and explain how this symptom is important in selecting a patient for RDT 
testing  
2) List signs of severe illness in a patient with fever 
3) Outline important questions to ask when taking a history from a patient with fever 
4) Describe how to carry out a physical examination of a patient with fever 
5) Describe how to select a patient for RDT testing based on the history and physical 
examination 
 
 
1.1  THE IMPORTANCE OF FEVER IN SELECTING A PATIENT FOR 
RDT TESTING 
The main symptom that indicates that a patient may have malaria is fever.  If a patient has 
fever, you should consider testing him or her with an RDT. 
In our local languages, patients and their caregivers describe fever as a feeling that 
something is wrong in the body.  Some of the local terms are omusujja, kwaman lieth, 
omushwija and omutsusa.  These terms may describe body hotness, general body pain, or just 
feeling unwell.  It is the responsibility of the health worker to determine whether the patient 
actually has fever by carefully asking questions of the patient or caregiver. 
If you have a thermometer, you can measure the patient’s temperature.  Normal body 
temperature measured under the arm (axillary) is considered to be between 35.6°C to 37.0°C.  
Normal body temperature can vary over the course of the day in the same person, and can 
also vary from one person to the next. 
Fever is present if: 
- Axillary temperature is above 37°C 
- The patient or caregiver describes body hotness 
 
 
 
1.2 SEVERE ILLNESS IN A PATIENT WITH FEVER: 
Most patients come to the health centre with illness that is not severe.  However, some 
patients come with severe illness.  When you assess a patient, you should first look for signs 
of severe illness. 
If a patient has any of these symptoms or signs of severe illness, you should act quickly to 
give pre-referral treatment and refer the patient to a Health Centre IV or Hospital.  We 
shall discuss severe illness in more detail in Session 5. 
For now, let’s review the symptoms and signs of severe illness in the following box.  
These signs are listed in the Uganda Ministry of Health’s guidelines on “Management of 
Uncomplicated Malaria: A Practical Guide for Health Workers,” 3
rd
 edition, printed in 2005: 
Session 1:  How to evaluate fever and select for RDT testing 
11
 Danger signs of severe illness: 
 Convulsions or fits – now, or within the past 2 days 
 Not able to drink or breast feed 
 Vomiting everything – not able to keep down food, fluid, or drugs 
 Changes in mental state – patient is confused, very sleepy = lethargic 
or drowsy, or in a coma = unconscious 
 Extreme weakness (prostration) – patient is unable to sit or stand 
without support 
 Severe difficulty breathing = respiratory distress 
 Severe anaemia – pale palms, fingernails, eyelids 
 Severe dehydration – coated tongue, sunken eyes, skin pinch  
 
 
If the patient shows any of the danger signs listed in the box, follow the instructions in 
Session 5.  If the patient does not show danger signs, move on to take a history and perform a 
physical exam as below. 
 
 
1.3 QUESTIONS TO ASK WHEN TAKING A HISTORY FROM A 
PATIENT WITH FEVER: 
Your goal is to find clues in the patient’s history that suggest a specific diagnosis. You 
should ask the following questions: 
 
 Characteristics of the fever 
- When did the fever start?  
- How long has it lasted? 
A fever that has persisted for more than 7 days may be malaria, but in this case you 
should also consider another illness such as typhoid fever, tuberculosis and other infectious 
diseases. 
 
 Past medical history 
- Does the patient have any chronic diseases? 
- If the patient is a child, has he or she received the recommended schedule of 
immunizations? 
For example, patients with a chronic disease such as HIV are more likely to suffer from 
malaria, as well as other infections like pneumonia and TB.  Patients with sickle cell disease 
are also more in danger from malaria and other infections.  As another example, a child who 
has not received immunizations is more likely to get measles and certain respiratory 
infections.  
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 Prior treatment 
- What has been done to treat this illness before coming to your health centre today?  
- What other medications have been taken? 
- If medications were taken, was the dose complete, or partial? 
This information will help to guide your treatment decisions.  For example, if a patient 
has taken a full course of Septrin but has not improved, you should not prescribe Septrin 
again. 
As another example, a patient may come to the health centre after swallowing only part of 
a dose of Coartem.  (Note a complete course of Coartem requires 6 doses over 3 days.) 
 
 
 Other symptoms 
Many illnesses can cause fever.  Only malaria can be treated with antimalarials.  These 
other illnesses require other treatments.  Once you know that your patient has fever, you 
should also ask whether he or she has any of the following symptoms.  As we will see in 
Table 1 at the end of this session, these symptoms can be clues to help you diagnose the 
patient correctly. 
- Chills and rigors 
- Headache 
- General body weakness 
- General body aches and joint pains 
- Cough or flu 
- Sore throat and painful swallowing 
- Ear pain 
- Loss of appetite 
- Nausea, vomiting, abdominal pain, and diarrhoea 
- Pain when passing urine (dysuria) 
- Low abdominal pain 
- Bone pain in a specific area 
- Joint pain and/or swelling 
- Painful swellings in the skin 
- Skin rash 
 
Next we will discuss how to examine a patient with fever. 
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1.4 PHYSICAL EXAMINATION OF A PATIENT WITH FEVER:  
 
In the physical examination of a patient with fever look for the following: 
 
 Measure the temperature 
 
 
 Assess for danger signs 
– As we discussed above in section 1.2, and as we shall discuss in more detail in 
Session 5. 
 
 
 Measure the weight (if you have a scales) 
– You will need the body weight to give the correct dose of medication, especially in 
children. 
 
 
 Carefully examine the following systems  
 General 
– Look for pallor = paleness of the palms, soles, fingernails and conjunctiva.  Pallor 
indicates anaemia, which may be caused by malaria or other parasites. 
– Look for jaundice = abnormal yellow colour of the eyes.  Jaundice may indicate 
either liver disease such as hepatitis, or very severe anaemia from malaria.  
– With your fingers, feel for swollen or tender lymph nodes at the neck, armpits, 
and groin area.  Lymph nodes may be painful and swollen due to local bacterial 
infection or local TB infection. 
 
 
 Central Nervous System 
– Check for neck stiffness.  Meningitis often causes painful neck stiffness. 
– Check for a bulging fontanel in very young children.  This may also be caused by 
meningitis. 
 
 
 Ears / Nose / Throat (ENT) 
– Look for redness in the throat or tonsils.  This indicates throat infection = 
pharyngitis, or tonsil infection = tonsillitis. 
– Look for oral thrush = white coating on the tongue and inner cheeks.  Oral thrush 
may indicate immune suppression, such as HIV infection.  If a patient has HIV, he 
or she is more likely to suffer from other infections such as pneumonia or malaria. 
– Look for dryness of the tongue and mouth.  This may be a sign of dehydration. 
– Check ears for redness and discharge.  These may be signs of ear infection = 
otitis media. 
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 Respiratory 
– Count the number of breaths per minute.  Fast breathing in a patient with fever 
may be caused by severe pneumonia, severe malaria, or another serious infection.  
Fast breathing depends on the patient’s age: 
    - Younger than 2 months: 60 breaths per minute or more is fast breathing 
- 2 months to 12 months: 50 breaths per minute or more is fast breathing 
- 12 months to 5 years: 40 breaths per minute or more is fast breathing 
- 5 years or older: 20 or more breaths per minute is fast breathing 
 
– Look for signs of difficulty breathing: flaring of the nostrils, chest in-drawing.  
This may be caused by severe pneumonia or severe malaria. 
– If you know how to use a stethoscope, listen for any abnormal chest sounds such 
as rhonchi, wheezes, or crackling sounds = crepitations.  Abnormal chest sounds 
in a patient with fever may be caused by pneumonia or bronchitis, or by severe 
malaria. 
 
 
 Abdomen  
– Check for pain on pressure.  Pain over the liver may indicate hepatitis.  Lower 
abdominal pain may indicate urinary tract infection (UTI), or pelvic inflammatory 
disease (PID) in women. 
 
 
 Skin 
– Look for skin rashes.  Skin rash is not a sign of malaria.  Skin rash may occur in 
measles, HIV infection, and other infections. 
– Look for any painful swellings or abscesses.  These may indicate bacterial 
infection. 
– Examine any wounds:  Is there redness or pain to pressure around the wound?  Is 
there pus or discharge from the wound?  If so, the wound is likely infected with 
bacteria. 
Now we will look at Table 1 to see how the information from the history and physical 
examination can help us diagnose a patient with fever. 
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Table 1.  Clinical signs associated with common causes of fever 
Clinical sign Common diagnosis 
Chills and rigors 
Malaria 
Urinary tract infection (UTI) 
Bacterial infection, for example sepsis 
Headache 
Malaria 
Meningitis 
Sinus infection (sinusitis) 
Ear infection (otitis media) 
Dental problems 
General body weakness 
Malaria 
Other types of infection 
General body aches and joint pains 
Malaria 
Viral infections 
Cough, difficult breathing, rapid 
breathing 
Pneumonia 
Malaria 
Tuberculosis 
Measles 
Sore throat, painful swallowing 
Pharyngitis or tonsillitis 
Thrush (candidiasis) 
Ear pain Ear infection (otitis media) 
Loss of appetite, nausea, vomiting, 
abdominal pain, diarrhoea 
Malaria 
Gastro-enteritis 
Hepatitis 
Bloody diarrhoea  Dysentery – bacterial or amoebic 
Painful urination, frequent urination, 
flank pain 
Urinary tract infection (UTI) 
Kidney infection (pyelonephritis or severe UTI)
Low abdominal pain 
Urinary tract infection (UTI) 
Pelvic inflammatory disease (PID) 
(Table continues on next page…)
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Clinical sign Common diagnosis 
Bone pain, with increased pain if 
pressure is applied  
Osteomyelitis (bacterial bone infection) 
Joint pain and/or swelling, with pain 
on movement 
Bacterial infection of the joint 
Rheumatic fever 
Painful and swollen lymph nodes 
Bacterial abscess 
Tuberculosis (TB) 
Pain, swelling, hotness, and/or 
redness of the skin 
Bacterial skin infections (cellulitis) 
Abscess 
Skin rash 
Measles 
Chicken pox 
HIV sero-conversion 
Drug side effect or allergic reaction 
 
 
1.5 SELECTING A PATIENT FOR RDT TESTING BASED ON 
HISTORY AND PHYSICAL EXAMINATION 
As we have discussed, fever is an important symptom of malaria, but it is also a symptom 
of other illnesses.  There are many reasons why a patient may present with fever.  Therefore, 
it is important to carefully ask questions and examine any patient who presents with a fever. 
After you have taken a history and performed a physical examination, you should ask 
yourself this question: 
Based on the patient’s symptoms, do I believe this patient may have malaria? 
If the answer to the question is yes, then you can use an RDT to help determine 
whether or not the patient actually has malaria. 
 
**Any time you are deciding whether a patient has malaria or another cause of 
fever, you can perform an RDT.  The RDT result, together with the information you get 
from talking with the patient and examining him or her, will help you to make the 
correct diagnosis and provide the best treatment.** 
You can use Table 1, along with IMCI and other guidelines you may have, to consider 
non-malaria diagnoses in patients with a negative RDT.  Other diseases that are not listed in 
the table may also cause fever – but the diseases listed here are common and you should keep 
them in mind.  If you see a patient with a condition you do not recognize, you should 
consider REFERRING the patient to a Health Centre IV or Hospital. 
Session 1:  How to evaluate fever and select for RDT testing 
17
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keep the learning points from Session 1 in mind as we move on in this training course – 
we shall look back on this session when we discuss how to manage a patient with fever but a 
negative malaria RDT, in Session 4. 
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 SUMMARY 
 
We have come to the end of our session on “How to evaluate patients with 
fever and select patients for RDT testing.”  In this session we discussed fever 
and the usefulness of this symptom in determining whether to test a patient 
with an RDT.  We discussed important questions and physical examination 
findings in patients with fever.  We reviewed several common causes of fever. 
Any time you are deciding whether a patient’s fever is caused by malaria, 
or by another illness, you can perform an RDT.  Together with the 
information you get from the history and physical examination, the RDT 
result will help you to make the correct diagnosis and provide the best 
treatment for the patient. 
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INTRODUCTION: 
Welcome to Session 2 on “Preparing and reading an RDT.”  RDT stands for Rapid
Diagnostic Test for malaria.  RDTs are useful to test patients for malaria, especially in areas 
where blood smears and microscopes are not available.  RDTs detect the presence of malaria 
parasites in the blood. RDTs are called “rapid” because they give results within 15 minutes. 
RDTs have been studied and shown to be very accurate in areas around Uganda. 
This session will provide you with the knowledge and skills to correctly and safely use 
RDTs to test patients for malaria. 
 
LEARNING OBJECTIVES: 
By the end of this session, you should be able to: 
1. Describe an RDT and how it works 
2. Perform an RDT correctly and safely 
3. Read an RDT accurately and record the result as positive or negative 
4. List some important tips for using RDTs 
5. Describe safe handling of blood and sharps 
 
 
 
 
 
Session 2: PERFORMING AND READING AN RDT 
 
Content: 
 Introduction 
 Learning objectives 
1  Description of RDTs – How do they work? 
2  Performing an RDT (WHO picture guide) 
3  Reading an RDT (WHO picture guide) 
4  Important tips for using RDTs 
5  Safe handling of blood and sharps 
 Hands-on practice session 
 Summary 
 References 
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2.1 DESCRIPTION OF RDTs – HOW DO THEY WORK? 
RDTs are diagnostic tests that detect malaria in blood.  The presence of malaria parasites 
in a person’s blood is the cause of the fever and other symptoms we associate with malaria 
illness. 
What do RDTs detect? 
In the blood, malaria parasites make molecules called antigens.  It is these antigens that 
RDTs detect.  If a person is infected with malaria parasites, the parasites produce antigen in 
his or her blood, and the RDT result will be positive.  If there are no parasites in the blood, 
there is no antigen, and the RDT result will be negative. 
How do RDTS work? 
RDTs contain molecules called antibodies.  Antibodies fit together, or bind, with 
antigens.  If the malaria antigen is present in the blood, the antibodies in the RDT can bind to 
it. 
After we apply a drop of blood to the RDT, we add a special liquid called buffer.  Buffer 
carries the blood, along with any antigen, and the antibodies, along the length of the RDT. 
If antigen is present in the blood, and the antibodies in the RDT bind to it, the 
combination of antigen + antibody is trapped at the test line (position T) and forms a red or 
purple line.  This gives a positive RDT result. 
If there is no parasite antigen the antibodies have nothing to bind to, and they do not form 
a test line.  This gives a negative RDT result. 
The RDT also contains special molecules that are trapped at the control line (position C) 
if the buffer and blood have reached the end of the test strip.  The control line tells us whether 
the RDT has worked correctly.  All completed RDTs should show a red or purple control 
line.  If we do not see a control line, the RDT result is invalid.  In this case, we must repeat 
the patient’s test with a new RDT. 
 
Different types of RDTs are available. 
You may see RDTs detecting different antigens, and made by different companies.  Each 
brand or type of RDT has slightly different instructions for how to perform and read the tests.  
For now, let us focus on the RDT that will be used in this training. 
This RDT has been studied carefully in Uganda and shown to be very accurate in 
diagnosing malaria.  At this time it is the choice of the Malaria Control Program of the 
Uganda Ministry of Health. 
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2.2 PERFORMING AN RDT 
For this part of the session, we will use the WHO picture guide.  The picture guide has 
step-by-step instructions showing how to perform an RDT.  The steps are listed here, along 
with some additional tips for some of the steps: 
Before you begin, collect: 
a. NEW unopened test packet 
b. NEW unopened spirit swab (alcohol swab) 
c. NEW unopened lancet 
d. NEW pair of disposable gloves 
e. Buffer 
f. Timer or clock 
g. Sharps container 
Step 1: Check the expiry date on the test packet. 
Step 2:  Put on the gloves.  Use new gloves for each patient. 
Step 3:  Open the packet and remove: test, loop, and desiccant sachet. 
Extra tip for step 3:  Each RDT packet contains a “desiccant sachet,” which keeps 
the RDT dry until the packet is opened.  The desiccant in our RDT packets should be blue.  If 
the desiccant is purple, pink, or white, it means the test packet has been damaged.  If the 
desiccant is not blue, throw away the test and open a new RDT packet. 
Step 4:  Write the patient’s name on the cassette. 
Extra tip for step 4:  We will write the patient’s name and OPD number on the 
cassette.  Pencil works best for writing on the RDTs. 
Step 5:  Open the spirit swab (alcohol swab).  Grasp the patient’s ring finger.  Clean the 
finger with the spirit swab.  Allow the finger to dry before pricking. 
Extra tip for step 5: After cleaning the patient’s finger, allow it to air dry.  Do not 
blow on the finger or wipe it – these actions make the finger dirty again. 
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Step 6:  Open the lancet.  Prick patient’s finger to get a drop of blood. 
Extra tip for step 6:  When pricking the patient’s finger, squeeze the tip of the finger 
with your own fingers and prick the side of the fleshy part.  This is less painful than pricking 
in the middle or at the tip.  Prick hard enough so that a drop of blood quickly appears on the 
skin. 
Step 7:  Discard the lancet in the sharps box immediately after pricking finger.  Do not 
set down the lancet before discarding it. 
Step 8:  Use the loop to collect the drop of blood. 
Extra tip for step 8:  Touch the loop gently to the blood drop on the patient’s finger.  
The loop will fill with the correct amount of blood. 
Step 9:  Use the loop to put the drop of blood into the square hole at position A. 
Extra tip for step 9:  Hold the RDT flat on the table top with one hand.  With your 
other hand, carefully place the blood drop on the pad at position A.  It is important to work 
quickly enough that the blood does not clot, but carefully so that all of the blood is absorbed 
into the pad.  If most of the blood is accidentally wiped on the plastic edges of the well, the 
test will not work correctly. 
Step 10:  Immediately discard the loop in the sharps box. 
Step 11:  Put six (6) drops of buffer into the round hole at position B. 
Extra tip for step 11:  Check the time just after you add buffer to an RDT, and write 
the time on the RDT.  
Step 12:  Wait 15 minutes after adding buffer. 
Step 13:  Read test results.  Note:  Do not read the test sooner than 15 minutes after 
adding the buffer.  You may get false results. 
Extra tip for step 13:  Before you read the RDT, check the time again to be sure that 
at least 15 minutes have passed.  
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2.3 READING AN RDT 
For this part of the session, we will again use the WHO picture guide.  We shall also use 
example results in the WHO training photographs and quiz, and actual RDTs. 
See point 14 on the WHO picture guide: 
The RDT is positive if there is one red/purple line at position C and one red/purple 
line at position T.  This means the patient does have malaria.  The test is positive even if the 
red/purple line at position T is faint. 
The RDT is negative if there is one red/purple line at position C and NO red/purple 
line at position T.  This means the patient does not have malaria. 
The RDT is invalid if there is no line at position C.  This means the test is damaged.  
Even if there is a line at position T, if there is no line at position C it means the test is 
damaged.  The results are invalid (false). 
Immediately after you read the RDT, record the result on the outpatient form.  Use the 
following symbols, and write clearly: 
If the RDT is positive, write:    RDT pos 
If the RDT is negative, write:   RDT neg 
If the first test result is invalid, you should repeat with a new RDT.  Then record the new 
test result in the patient’s record.  We shall discuss the importance of each test result in more 
detail in Sessions 3 and 4. 
 
2.4 IMPORTANT TIPS FOR USING RDTs 
With attention and practice, you will soon be very skilled at preparing and reading RDTs.  
Here are some important points to keep in mind: 
 Always check the expiry date.  An expired RDT may give a false result. 
 Do not open an RDT packet until you are ready to use it for a patient.  If a packet has 
been open for some time before the RDT is used, the RDT may give a false result. 
 Do not put down the lancet or loop on the table after use.  Put the lancet and loop 
immediately into the sharps container.  If you put them on the table, you or 
someone else may accidentally be pricked.  Accidental pricks can spread HIV, 
hepatitis viruses, and other diseases. 
 Carefully collect the correct amount of blood and place it neatly on the pad at 
position A.  The RDT may not work properly if you use too little or too much blood, 
or if the blood is not absorbed into the pad.
 Hold the bottle of buffer vertically over position B and add exactly 6 drops of buffer.  
The RDT may not work properly if you use too little or too much buffer.
 Be sure to wait 15 minutes after adding buffer, before you read the RDT.  Reading 
the RDT too soon can give a false result.
 Remember to check for the control line.  If there is no control line, the RDT has not 
worked properly and the test result is invalid (false). 
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 SUMMARY: 
 
We have come to the end of session on “Performing and reading an RDT.”  We 
reviewed how RDTs detect malaria parasite antigen in the blood of infected patients. 
We learned and practiced the steps to perform and read RDTs correctly and safely. 
Remember:  Safe handling of blood and sharps is a very important part of the correct 
use of RDTs.  Always wear gloves when working with blood – and always put lancets 
and blood loops into the sharps box immediately after use. 
2.5 SAFE HANDLING OF BLOOD AND SHARPS 
Correct handling of blood and sharps is very important for your safety and for the safety 
of your co-workers and patients.  Safe handling involves protecting yourself and others from 
exposure to diseases that may be carried and transmitted by blood.  Remember: 
 Always wear gloves when working with blood, or with items that have touched 
blood.  (This includes used alcohol swabs and cotton swabs.) 
 Put the lancet into the sharps box immediately after using it.  If you put down the 
lancet after using it, you or someone else may accidentally be pricked with it.  Dirty 
lancets can spread HIV, hepatitis viruses, and other diseases. 
 Never use a lancet on more than one person.  Used lancets can spread HIV, 
hepatitis viruses, and other diseases.  Even if you wash or clean the lancet, it still may 
carry disease. 
 Never put the lancet into the regular waste container – only use the sharps box.  
If you put a used lancet with normal waste, anyone who handles the waste may be 
pricked and exposed to disease. 
 Put the blood loop into the sharps box immediately after the transfer of the 
blood to the test cassette.  The loop may also carry blood-borne diseases. 
 During this study, we will save all RDTs after use, for research purposes.  However, 
after the study has ended, you may discard used RDTs.  After they study has ended, 
after you have read an RDT and recorded the result in the patient’s record, put the 
RDT into the waste container.  The RDT should be disposed of with the rest of the 
medical waste from the health centre, including used gloves, used spirit swabs 
(alcohol swabs) and other items.  For example, many health centres discard waste in a 
garbage pit.  The pit should be in a place where children and animals cannot easily 
reach it. 
 
 
REFERENCES: 
1. WHO website “Malaria Rapid Diagnostic Tests,” www.wpro.who.int/sites/rdt 
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Session 3:  MANAGEMENT OF A PATIENT WITH FEVER  
AND A POSITIVE RDT  
 
Content: 
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1  Meaning of a positive RDT in a patient with fever 
2  How to treat a patient with fever and a positive RDT  
3  Supportive treatment 
 Summary 
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INTRODUCTION: 
Welcome to Session 3 on “Management of a patient with fever and a positive RDT.”  As 
we will discuss below in more detail, a patient with fever, a positive RDT, and no signs of 
severe illness should be treated for uncomplicated malaria.  In this session we will review 
Uganda Ministry of Health guidelines on treatment of patients with uncomplicated malaria.  
These guidelines are a review from the Ministry of Health’s booklet “Management of 
Uncomplicated Malaria: A Practical Guide for Health Workers,” 3
rd
 edition, printed in 2005.  
The goals of treating a patient with a positive RDT are to: 
- Cure the infection. 
- Prevent progression to severe disease. 
Correct treatment of patients with fever and a positive RDT also helps to reduce 
transmission of malaria infection to other people, and to prevent the spread of resistant  
malaria strains. 
 
 
 
LEARNING OBJECTIVES: 
By the end of this session, you should be able to: 
1) Explain the meaning of a positive RDT result in a patient with fever 
2) Describe how to treat a patient with fever and a positive RDT 
3) Outline supportive treatments for a patient with fever and positive RDT 
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  Review from the Ministry of Health’s booklet “Management of 
Uncomplicated Malaria: A Practical Guide for Health Workers,” 3
rd
 edition, 
printed in 2005:
Common symptoms and signs of malaria include: 
 Fever        Headache 
 Loss of appetite       Joint pains 
 Weakness       Muscle aches 
 Nausea or vomiting      Lethargy (tiredness   
3.1 MEANING OF A POSITIVE RDT IN A PATIENT WITH FEVER  
A patient with fever and a positive RDT is considered to have malaria.  The malaria may 
be uncomplicated or severe. 
Uncomplicated malaria is diagnosed when a patient has all of the following: 
1)  Symptoms of malaria (see box below). 
2)  Evidence of parasites in the blood – with a positive RDT (or blood smear). 
3)  No signs of severe illness.  (For more details on severe illness, see Sessions 1 and 5.) 
 
 
*Remember: To correctly diagnose a patient with uncomplicated malaria, you 
should see both symptoms AND a positive RDT. 
If a patient has symptoms as in the box above, NO signs of severe illness, AND a 
positive RDT, you should prescribe antimalarial treatment.* 
Now we shall review the recommended treatment for patients with uncomplicated malaria 
in Uganda. 
 
 
3.2 HOW TO TREAT A PATIENT WITH FEVER AND A POSITIVE RDT  
The Uganda national malaria treatment policy includes combination therapy.  A patient 
with fever and a positive RDT (and with no signs of severe illness) should be treated for 
uncomplicated malaria with combination therapy. 
Information on malaria and its treatment is presented in more detail in the Ministry of 
Health’s booklet ““Management of Uncomplicated Malaria: A Practical Guide for Health 
Workers,” 3
rd
 edition, printed in 2005.  Below, we will review some of the key points found 
in that booklet. 
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Combination therapy is the combination of two or more drugs given together to treat 
malaria.  The main reason to give combination therapy to treat malaria is that it is more 
effective than using just one antimalarial drug.  Think of an army is fighting an enemy – two 
soldiers are more effective than one. 
Over the past several years, the malaria parasite has developed resistance to the older 
commonly used drugs (for example, chloroquine).  Another important benefit of combination 
therapy is that it helps to prevent or delay the malaria parasite’s development of resistance to 
the new drugs.  For these reasons, the Uganda Ministry of Health now recommends 
combination therapy. 
 
3.2.1 Types of antimalarial combination therapy 
Currently, there are two types of antimalarial combination therapy: 
 Artemisinin-based combination therapy (ACT) 
The ACT regimens are based on drugs called artesunate, artemether, or 
dihydroartemisinin.  ACTs recommended by the Uganda MoH include: 
1) Artemether + lumefantrine = Coartem 
2) Amodiaquine + artesunate (AQ+AS)   
There are other ACTs available in Uganda.  The ACTs listed here are those recommended 
by the MoH. 
 Other antimalarial therapy 
Sometimes your health centre may not have ACTs in stock. In this case, you may be 
forced to recommend an older antimalarial therapy.  However, when available, ACT 
regimens are more effective, and are preferred. 
 
 
3.2.2 Specific treatment  
To treat a patient with uncomplicated malaria, you need to give specific treatment with 
effective antimalarials, which we shall discuss in this section.  You should also give 
supportive treatment, which we shall discuss in the following section (3.4). 
All of the information presented here is a review from the Ministry of Health’s booklet 
“Management of Uncomplicated Malaria: A Practical Guide for Health Workers.”   
The recommended first-line regimen for Uganda (and many other African 
countries) is artemether-lumefantrine = Coartem.   
 
 Artemether-lumefantrine (Coartem) 
Coartem is a co-formulated drug.  This means that two drugs are combined in each tablet. 
A complete treatment with Coartem requires 6 doses: one dose, given twice a day, over a 
period of 3 days. 
 
 Session 3:  Management of fever and positive RDT 
28
Table 1. Treatment schedule for artemether-lumefantrine (Coartem) 
Weight* 
in kg 
Age* Day 1 Day 2 Day 3 
Colour 
code 
5-14 
4 months to 
3 years 
1 tablet 
x 2  
12 hourly 
1 tablet 
x 2   
12 hourly 
1 tablet 
x 2 
12 hourly 
Yellow 
15-24 
3 years to  
7 years 
2 tablets 
x 2 
12 hourly 
2 tablets 
x 2 
12 hourly 
2 tablets 
x 2 
12 hourly 
Blue 
25-34 
7 years to 
12 years 
3 tablets 
x 2 
12 hourly 
3 tablets 
x 2 
12 hourly 
3 tablets 
x 2 
12 hourly 
Brown 
>35 
12 years 
and older 
4 tablets 
x 2 
12 hourly 
4 tablets 
x 2 
12 hourly 
4 tablets 
x 2 
12 hourly 
Green 
*If you have a scales, it is best to use the patient’s weight to determine the dose.  If you don’t 
have a scales, use the patient’s age. 
 
 
 
 Artesunate + amodiaquine 
The alternative first-line treatment for uncomplicated malaria in Uganda is artesunate 
(AS) + amodiaquine (AQ).  This combination can be used if Coartem is not available.  AS + 
AQ must be given as separate tablets, as in Table 2.  A complete treatment requires 3 doses of 
each drug: one dose of each, given once a day, over a period of 3 days. 
 
 
Table 2. Treatment schedule for Artesunate + Amodiaquine 
Dose in mg 
(Number of tablets) 
Artesunate = 50 mg tabs Amodiaquine = 153 mg tabs 
 
 
 
 
Age 
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 
5 months to 
11 months 
25 mg 
(1/2 tab) 
same as 
Day 1 
same as 
Day 1 
76 mg 
(1/2 tab) 
same as 
Day 1 
same as 
Day 1 
1 year to 
6 years 
50 mg 
(1 tab) 
same as 
Day 1 
same as 
Day 1 
153 mg 
(1 tab) 
same as 
Day 1 
same as 
Day 1 
7 years to 
13 years 
100 mg 
(2 tabs) 
same as 
Day 1 
same as 
Day 1 
306 mg 
(2 tabs) 
same as 
Day 1 
same as 
Day 1 
13 years 
and older 
200 mg 
(4 tabs) 
same as 
Day 1 
same as 
Day 1 
612 mg 
(4 tabs) 
same as 
Day 1 
same as 
Day 1 
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3.2.3 Contra-indications of ACTs 
Do not give an ACT medication to a patient who has had a bad reaction to the drug 
previously. 
Do not give ACT at the same time with quinine or with other antimalarial drugs. 
In addition, do not give ACT to: 
1. Women in the first 3 months of pregnancy 
2. Babies less than 4 months old 
3. Children who weigh less than 5 kg 
For patients in these 3 groups, you should give quinine. 
Coartem is safe and effective for pregnant women after the 3
rd
 month, for children older 
than 4 months, and for children weighing more than 5 kg. 
 
 
3.2.4 Treatment administration 
Treatment for uncomplicated malaria is taken orally (by mouth).  Remember that 
Coartem should be taken with food or fluids.  If possible the patient should take each dose of 
Coartem with milk or breast milk, or fatty or oily food (for example, meat or bean sauce 
made with cooking fat or oil, groundnut sauce, or odi).  This improves absorption of the drug 
from the gut. 
The first dose of any antimalarial treatment should be directly observed at the health 
centre.  If the patient vomits in less than 30 minutes, wait 10 minutes and then give a second 
dose.  If the second dose is vomited, change to injectable quinine or artemether. 
 
 
 
3.3 SUPPORTIVE TREATMENT 
Supportive treatment helps to relieve symptoms and improve recovery.  Supportive 
treatment includes relief of fever, relief of pain (headache, body and joint pains), and 
attention to the patient’s fluid and nutritional intake. 
 
 Use of antipyretics (drugs to decrease fever and pain) 
The following antipyretics are commonly used for patients with fever or malaria: 
- paracetamol (Panadol) 10 mg/kg every 6 hours 
- ibuprofen (Brufen) 5 mg/kg every 8 hours 
- aspirin (*Note: do not give aspirin to patients younger than 8 years, as it can cause a 
serious side effect called Reye’s syndrome) 
 
 Other measures: 
Other measures to relieve fever include tepid sponging, fanning and encouraging fluid 
intake. 
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REVIEW: Correct practices in treatment of uncomplicated malaria  
- Start antimalarial therapy as soon as possible after diagnosing the patient. 
- Give antimalarial combination therapy according to current guidelines. 
- Ensure the patient has the correct antimalarial dose for his or her weight or age. 
- Ensure the patient has a complete antimalarial dose and understands the importance 
of completing the full treatment. 
- Give advice on supportive treatment to relieve symptoms and speed recovery. 
- Watch for signs of severe malaria, give pre-referral treatment and REFER any 
patient with severe disease to a higher level facility immediately. 
 
You can use the flow chart on the following page to manage a patient with a positive 
RDT result: 
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FLOW CHART:  Management of patient with symptoms of uncomplicated 
malaria, no signs of severe illness, and a positive RDT for malaria 
 
Yes No 
Has the patient used ACT 
within the past 14 days? 
Did the patient take a 
complete, correct dose? 
Give first-line 
antimalarial treatment 
(ACT) 
Patient with fever, 
no signs of severe illness, 
and positive RDT  
Give quinine 
Did the patient vomit 
the doses? 
Yes No 
No Yes 
 Session 3:  Management of fever and positive RDT 
32
 
 
 
 
 
 
 
 
 
REFERENCES: 
1. Uganda Ministry of Health, “Management of Uncomplicated Malaria: A Practical Guide 
for Health Workers,” 3
rd
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 SUMMARY: 
We have come to the end of our discussion on “Management of a patient with fever and 
positive RDT.”  In this session we defined uncomplicated malaria, discussed antimalarial 
combination therapy, and reviewed the current guidelines for treatment of uncomplicated 
malaria in Uganda. 
Remember: To correctly diagnose a patient with uncomplicated malaria, you should see 
symptoms including fever, NO signs of severe illness, AND a positive RDT. 
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INTRODUCTION: 
Welcome to session 4 on “Management of a patient with fever but a negative RDT.”  Up to 
now, in many smaller health centres in Uganda, no diagnostic testing was available – so health 
workers gave antimalarial treatment based on symptoms and signs.  This was recommended 
when older, safe and less expensive drugs like chloroquine (CQ) were effective against 
malaria. 
However, now that artemisinin-based combination therapy (ACT) is required to effectively 
treat most true malaria cases, giving antimalarials without a using a diagnostic test is less 
accepted. 
Giving antimalarial drugs to patients who do not have malaria leads to: 
- Missing the opportunity to treat the true cause of a patient’s illness 
- Increased risk of drug stock-outs 
- Increased risk of side effects 
- Increased risk for development of drug resistant parasites 
 
 
LEARNING OBJECTIVES: 
By the end of this session, you should be able to: 
1. Outline the benefits of treating patients on the basis of RDT results 
2. Explain the meaning of a negative RDT in a patient with fever 
3. Describe the management of a patient with fever but a negative RDT  
4. List and describe the management of some common non-malaria febrile illnesses 
 
 
 
Session 4: MANAGEMENT OF A PATIENT WITH FEVER 
BUT A NEGATIVE RDT 
 
Content: 
 Introduction 
 Learning objectives 
1  Benefits of treating on the basis of a RDT results 
2  Meaning of a negative RDT in a patient with fever 
3  Management of a patient with fever but a negative RDT 
4  Management of some common non-malaria febrile illnesses 
 Summary 
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4.1 BENEFITS OF TREATING ON THE BASIS OF RDT RESULTS 
There are a number of possible benefits if you do not recommend antimalarial treatment 
for patients with negative RDTs.  These include: 
- You are more likely to focus on the true cause of fever. 
- You may treat the true cause of fever in a timely manner. 
- You can reduce the risk of antimalarial stock-outs in your health centre. 
- You can help to limit the development and spread of drug resistance. 
- You may reduce the patient’s risk of side effects (drug reactions) due to 
unnecessary antimalarial treatments.  A common example of a drug reaction is 
ringing in the ears after taking quinine. 
 
 
 
4.2 MEANING OF A NEGATIVE RDT IN A PATIENT WITH FEVER 
Let us begin this discussion by asking an important question:  When caring for patients, 
why would we perform an RDT?  Your response to this question might be something like: 
“To confirm the diagnosis and guide treatment decisions.” 
Then what does a negative RDT mean?  If performed correctly, a negative RDT 
means that the patient does not have malaria.  The patient most likely has another 
disease that presents with similar symptoms as malaria. 
RDTs have been studied carefully in Uganda.  If performed and read correctly, they are 
very accurate at diagnosing malaria.  In different regions of Uganda, the RDT you have 
learned to use is able to detect Plasmodium falciparum infections even in patients with very 
low numbers of parasites in their blood.  This gives us confidence that if the RDT is 
performed correctly, and the result is negative, the patient does not have malaria. 
 
 
 
4.3 MANAGEMENT OF A PATIENT WITH FEVER BUT A NEGATIVE RDT 
If a patient has fever but the RDT is negative, you should reconsider the history and 
clinical signs. 
 If the patient has a negative RDT, you can use the flow chart on the following 
page to manage his or her illness: 
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FLOW CHART: Management of patient with a negative RDT for malaria 
Yes No 
Does the patient show signs     
of non-malaria illness? 
Refer to Session 1, Table 1;      
look carefully for other possible 
cause of fever 
Treat non-malaria illness: 
use IMCI, Uganda 
Clinical Guidelines, and 
section 4.4 in this manual
Patient with fever     
and negative RDT 
Give supportive treatment for symptoms            
and ask patient to return in 1-2 days if symptoms 
continue or worsen 
 Give paracetamol 
 Counsel patient and be sure he or she 
understands the importance of returning to the 
health centre if symptoms worsen or do not resolve 
within 1-2 days 
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4.4 MANAGEMENT OF COMMON NON-MALARIA FEBRILE ILLNESSES 
Let’s return to Session 1, and review at the tables at the end of the session.  As we 
discussed, the diseases listed in the tables include some of the most common causes of fever 
in children and adults.  These are important diseases to consider when you are managing a 
patient with fever and a negative RDT. 
In this section, we shall outline the management of some common non-malaria febrile 
illnesses: 
1) Common cold (mild cough, runny nose = flu) 
2) Pneumonia (lung infection) 
3) Upper respiratory tract infection with sore throat = pharyngitis 
4) Otitis media (ear infection) 
5) Urinary tract infections 
6) Typhoid 
7) Bacterial meningitis 
 
 
 
 
 
4.4.1 Common cold (flu) 
(Uganda Clinical Guidelines pages 67-68 and IMCI page 10) 
 History: 
A patient with common cold has flu (runny nose) with clear mucus, and mild cough. 
 Physical examination: 
Look for clear or pale mucus in nostrils.  If you have a stethoscope, listen to the patient’s 
chest – if you hear rhonchi or crepitations, consider pneumonia (section 4.4.2) rather than 
common cold. 
 Treatment of common cold: 
- Give supportive treatment to relieve symptoms: 
- Relieve cough with fluids: 
- Tea with honey and lemon 
- Juice 
- For babies, breast milk 
- Panadol for fever 
- No antibiotic is needed. 
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4.4.2 Pneumonia 
(Uganda Clinical Guidelines pages 77-87 and IMCI pages 8 + 11) 
Pneumonia is an inflammation of the lung tissue due to infection.  The risk factors for 
pneumonia include: 
- Age: young children are most in danger. 
- Underlying medical illnesses: patients with HIV infection, diabetes, malnutrition, and 
sickle cell disease are at increased risk. 
- Environmental conditions: smoke from wood or paraffin, especially in poorly 
ventilated dwellings may increase risk. 
- Social conditions: over-crowding, smoking, alcohol and drug abuse, refugee 
conditions may increase risk. 
 History:  
A patient with pneumonia typically presents with cough and fever.  The patient may or 
may not also have thick pus-like sputum, chest pain that is worse with breathing and 
coughing, and difficulty breathing. 
 Physical examination:  
- Examine for increased respiratory rate (i.e. fast breathing). 
- Watch for signs of increased effort of breathing, such as nasal flaring, chest in-
drawing, and use of neck and chest muscles. 
- If you have a stethoscope, listen for decreased breath sounds and/or abnormal sounds 
such as rhonchi, crepitations and wheezes. 
 
 Treatment of pneumonia:  
Before you prescribe any treatment for a patient with pneumonia, you should consider 
whether the patient needs oral or injectable treatment.  If the patient has severe illness, he or 
she will need injected drugs.  If your health centre does not have injectable drugs, you should 
refer the patient urgently to a Health Centre IV or Hospital. 
 
 
Table 4.1  Recommended antibiotic doses for treatment of pneumonia 
Antibiotics Adults Children 
 Amoxicillin 
500 mg 3 times a day (8 hourly) 
x 5 days 
15-25 mg / kg 3 times a day          
(8 hourly) x 5 days 
 Cotrimoxazole 
(Septrin) 
960 mg 2 times a day (12 hourly) 
x 5 days 
24 mg / kg 2 times a day            
(12 hourly) x 5 days 
 PPF 20,000 IU / kg IM daily x 5 days 50,000 IU / kg IM daily x 5 days 
 Chloramphenicol 
(oral or IV) 
1g 4 times a day (6 hourly)        
IV or IM then orally x 7 days 
25 mg / kg 4 times a day (6 hourly) 
IV or IM then orally x 7 days 
* IV = intravenous injection; IM = intramuscular injection 
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 Other considerations in pneumonia treatment: 
- Add vitamin A for children, if not received within the prior month. 
 For children aged 6-12 months, give 100,000 IU. 
 For children aged 1-5 years, give 200,000 IU. 
- If the respiratory illness does not respond to standard antibiotic treatment as 
above, consider tuberculosis.  If a patient’s respiratory illness is rapidly 
progressing, or does not respond to standard antibiotic therapy, REFER him 
or her to a higher level health facility promptly. 
- HIV-positive patients are at risk of a type of pneumonia called PCP.  PCP cannot 
be treated with standard antibiotics.  If you suspect a patient may have PCP, 
REFER him or her promptly to a higher level health facility for high-dose 
cotrimoxazole treatment. 
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4.4.3 Pharyngitis (upper respiratory infection with sore throat) 
(Uganda Clinical Guidelines pages 237-238) 
 History: 
Ask about throat pain, painful swallowing, and mild cough.  Patients may have a hoarse
voice or feel throat pain when talking. 
 Physical examination: 
Look for red throat and/or tonsils.  Patients may have a white coating over their throat 
and/or tonsils.  Feel the anterior sides of the neck for swollen and tender lymph nodes. 
 Treatment of pharyngitis (sore throat): 
1)  Give supportive treatment to relieve symptoms: 
- Relieve cough with fluids and/or linctus: 
- Tea with honey and lemon 
- Juice 
- Cough linctus 
- For babies, breast milk 
- Panadol for fever 
 
2)  If the patient has fever, swollen lymph nodes in the anterior neck, and white coating 
over the throat, the patient may have bacterial infection with streptococcal 
pharyngitis (strep throat).  If so, give one of the antibiotics in Table 4.2. 
 
 
Table 4.2  Antibiotic doses for treatment of streptococcal pharyngitis 
Antibiotics Adults Children 
 Benzathine penicillin
1.2 million units x 1 injected 
(intramuscular) dose 
If child weighs less than 30 kg:   
30,000 units / kg x 1 injected 
(intramuscular) dose 
 PPF 
20,000 IU / kg injected daily         
x 10 days 
20,000 IU / kg injected daily             
x 10 days 
 Phenoxymethyl- 
       penicillin 
500 mg 6 hourly x 10 days 12.5 mg / kg 6 hourly x 10 days 
 Erythromycin 
(if allergic to 
penicillin) 
500 mg 6 hourly x 10 days 12.5 mg / kg 6 hourly x 10 days 
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4.4.4 Otitis media (ear infection) 
(Uganda Clinical Guidelines pages 223-224 and IMCI pages 8 + 11) 
 History: 
Ask about ear pain, pulling on ears, pus discharge from ear, irritability, and fever. 
 Physical examination: 
If you have an otoscope, examine for bulging, irritated tympanic membrane, with or 
without pus discharge. 
 Treatment of ear infection: 
- Give either cotrimoxazole or amoxicillin antibiotic therapy as in the tables: 
 
Table 4.4  Cotrimoxazole (Septrin) doses for ear infection 
Age or weight 
Adult tablet 
80 mg trimethoprim +    
400 mg sulfamethoxazole
Pediatric tablet 
20 mg trimethoprim +    
100 mg sulfamethoxazole 
Syrup 
40 mg trimethroprim +    
200 mg sulfamethoxazole   
per 5 mL 
  2 to 12 months 
  (or 4 to 10 kg) 
½ tab 2 times a day 
(12 hourly) x 5 days     
2 tabs 2 times a day    
(12 hourly) x 5 days 
5 mL 2 times a day 
(12 hourly) x 5 days 
 1 year to 5 years 
 (or 10-19 kg) 
1 tab 2 times a day 
(12 hourly) x 5 days 
3 tabs 2 times a day     
(12 hourly) x 5 days 
7.5 mL 2 times a day 
(12 hourly) x 5 days 
 Patients weighing 
 more than 19 kg 
2 tabs 2 times a day 
(12 hourly) x 5 days 
--- --- 
 
 
Table 4.4  Amoxicillin doses for ear infection 
Age or weight 
Tablet 
250 mg 
Syrup 
125 mg per 5 mL 
2 to 12 months 
(or 4 to 10 kg) 
½ tab 3 times a day 
(8 hourly) x 5 days     
5 mL 3 times a day 
(8 hourly) x 5 days 
  1 year to 5 years  
  (or 10-19 kg) 
1 tab 3 times a day 
(8 hourly) x 5 days 
10 mL 3 times a day 
(8 hourly) x 5 days 
Patients weighing 
more than 19 kg 
2 tabs (500 mg) 3 times a day 
(8 hourly) x 5 days 
--- 
 
- Advise the caregiver to dry the ear by wicking 3 times daily:  Roll clean absorbent cloth 
or soft gauze into a wick.  Place the wick in the patient’s ear, and remove the wick when 
wet.  Replace the wick with a clean one.  Repeat these steps until the ear is dry. 
- If possible, follow up and reassess the patient in clinic in 5-7 days. 
- Refer the patient to a higher level health facility if the tympanic membrane is damaged, 
or if the patient returns repeatedly with signs of ear infection. 
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4.4.5 Urinary Tract Infection (UTI) 
(Uganda Clinical Guidelines pages 241-246) 
 History: 
A patient with UTI typically presents with dysuria (painful urination) and frequent 
urination.  He or she may also have haematuria (blood in the urine), and fever.  Note that 
UTI is more common in women and girls than in men or boys. 
 Physical examination:  
On examination, the patient typically has lower abdominal tenderness (pain on 
pressure over the urinary bladder).  Fever may or may not be present.  The patient may 
also have renal angle tenderness (pain with light pounding over the mid-back to either 
side of the spine), which may indicate a more advanced infection reaching the kidney 
(pyelonephritis). 
 Treatment:  
To treat a patient with a UTI, you should consider the patient’s age, and the severity of 
the disease. 
See Table 4.5 for antibiotic doses in UTI treatment. 
If possible, follow up the patient and reassess in 3-5 days. 
- If a patient with UTI does not respond to standard antibiotic therapy, REFER 
him or her promptly to a higher level health facility. 
- If you suspect pyelonephritis (advanced infection reaching the kidney as 
above) or urosepsis (severe infection indicated by high fever and chills), 
injectable antibiotics should be used.  REFER the patient promptly to a higher 
level health facility. 
 
 
Table 4.5  Recommended antibiotic doses for treatment of UTI 
Antibiotic Adults Children 
Amoxicillin 
500 mg 3 times a day       
(8 hourly) x 5-7 days 
15 mg / kg 3 times a day (8 hourly) x 7 days 
Cotrimoxazole 
(Septrin) 
960 mg 2 times a day  
(12 hourly) x 5-7 days 
By patient age: 
2 months to 12 months: 
240 mg 2 times a day (12 hourly) x 5 -7 days 
1 year to 5 years: 
480 mg 2 times a day (12 hourly) x 5 -7 days 
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4.4.6 Typhoid fever (also known as enteric fever) 
(Uganda Clinical Guidelines pages 25-26) 
 History: 
A patient with typhoid fever often reports fever of gradual onset, general body aches and 
pains, loss of appetite, abdominal pain or discomfort, headache, diarrhoea or constipation 
and dry cough. 
 
 Physical examination:  
The physical examination findings are often not specific, and depend on the duration and 
severity of the illness.  Patients usually have abdominal pain and tenderness. 
 
 Treatment:  
See Table 4.6 for treatment recommendations for typhoid fever. 
 
Table 4.6  Treatment of typhoid fever 
Antibiotic Adults Children 
Chloramphenicol 
1000 mg 4 times a day      
(6 hourly) x 14 days 
25 mg / kg 4 times a day           
(6 hourly) x 14 days 
Cotrimoxazole 
960 mg 2 times a day     
(12 hourly) x 14 days 
24 mg / kg 2 times a day    
(12 hourly) x 14 days 
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4.4.7 Bacterial meningitis  
(Uganda Clinical Guidelines pages 9-11) 
 History: 
A patient with bacterial meningitis typically presents with fever, headache, painful stiff
neck, photophobia (desire to avoid light due to eye pain), and sometimes vomiting and 
convulsions. In babies, failure to feed, or in an older patient, confusion, may be the only 
signs of meningitis. 
 Physical examination: 
On examination, the patient may have changed mental state and may be confused,
irritable, very sleepy, or unconscious.  In children a bulging anterior fontanel may be 
seen.  Patients with meningitis often have severe neck pain and neck stiffness so that the 
patient is unable to touch the chin to the chest. 
 Treatment:  
Bacterial meningitis is a very serious and dangerous disease.  Treatment must be 
started as soon as possible.  Delay in appropriate treatment could result in death or 
brain damage. 
The only effective treatment for bacterial meningitis is injectable antibiotics.  You 
should begin pre-referral treatment as in Table 4.7, and REFER the patient to a higher 
level facility IMMEDIATELY. 
 
 
Table 4.7  Treatment of bacterial meningitis 
Antibiotic Adults Children 
Chloramphenicol 
1000 mg 4 times a day (6 hourly)   
IV or IM then orally x 14 days 
25 mg / kg 4 times a day (6 hourly) 
IV or IM then orally x 14 days 
* IV = intravenous injection ; IM = intramuscular injection 
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 SUMMARY: 
 
We have come to the end of our discussion on “Management of a patient with fever 
but a negative RDT.”  In this session, we have learned that in the era of artemisinin-
based combination therapy (ACT), the best practice is to use a diagnostic test to 
determine whether a patient has malaria.  This allows us to avoid giving antimalarials to 
patients who do not have malaria.  We want to give antimalarial therapy to patients who 
truly have malaria, and avoid unnecessary antimalarial treatment of patients with a 
negative RDT.  
When managing a patient with a negative RDT, you can follow the flow chart 
provided in this handout.  You should always consider whether a non-malaria illness 
could be the cause of fever when taking history and examining a patient with fever. 
You can then treat or refer for non-malaria illness, as appropriate. Lastly, we 
emphasized that you should refer patients with fever and severe illness.  You should 
also refer patients whose illness is not cured with initial treatment. 
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INTRODUCTION: 
Welcome to Session 5 on “Recognition and referral of patients with severe illness.”  In 
this session we will discuss how to recognize that a patient has severe illness that may be 
caused by malaria or another serious infection.  We will also review guidelines on how to 
pre-treat and refer such patients to a higher level health care facility. 
The symptoms and signs of severe illness that we will discuss here may result from 
malaria, from other infections, or more rarely from non-infectious illnesses.  At lower level 
health centres, without laboratory diagnosis, it is often impossible to know the exact cause of 
such symptoms and signs.  However, even without a definite diagnosis, you can make an 
important difference in the patient’s outcome by recognizing severe illness and acting 
quickly to offer pre-treatment and prompt referral to a Health Centre IV or Hospital. 
 
 
LEARNING OBJECTIVES: 
By the end of this session, you should be able to: 
1) List danger symptoms and signs of severe illness 
2) Outline the steps to refer severely ill patients to higher level health facilities 
3) Describe pre-referral treatments that may be given to severely ill patients before 
transfer to a higher level health centre 
 
 
 
Session 5: RECOGNITION AND REFERRAL OF PATIENTS 
WITH SEVERE ILLNESS 
 
Content: 
 Introduction 
 Learning objectives 
1  Symptoms and signs of severe illness 
2  Appropriate referral of patients with severe illness 
3  Pre-referral treatments for patients with severe illness 
 Summary 
 References 
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5.1 SYMPTOMS AND SIGNS OF SEVERE ILLNESS 
The first step in helping patients with severe illness is to recognize the symptoms and 
signs that the patient is in danger.  You should be especially careful to look for signs of 
severe illness in patients who are more likely to have severe infections including malaria: 
children younger than 5 years, pregnant women, and patients of all ages whose immune 
system is weak (e.g. HIV-positive patients).  When evaluating a patient, you should ask about 
and watch for: 
General danger signs: 
1.  Convulsions currently or at any time within the past two days 
2.  Inability to drink or eat, or inability to breastfeed for small children 
3.  Vomiting everything so that the patient is unable to keep down food, fluids, and 
medications 
4.  Changed mental state – confusion, lethargy (sleepiness), or unconsciousness 
(coma): 
a.  In adults and older children, observe: 
- Confusion:  Is the patient interacting with you and other individuals 
appropriately, or does he or she appear confused? 
 - Lethargy (sleepiness):  Is the patient awake and attentive? 
 - Coma:  Can you wake the patient, or is he or she unconscious? 
b.  In young children, observe: 
- Confusion or lethargy (sleepiness):  Does the child look at the mother or 
caregiver?  Does the child follow an object moved in front of his or her 
eyes? 
- Coma:  Does the child react to loud noises?  If the child is sleeping, can you 
wake him or her with gentle shaking?  
Other signs of severe illness: 
5. Extreme weakness or prostration – unable to sit or stand without support 
6.  Difficulty breathing (respiratory distress): 
 a.  Is the patient breathing faster than normal for his or her age? 
    - Younger than 2 months: 60 breaths per minute or more 
- 2 months to 12 months: 50 breaths per minute or more 
- 12 months to 5 years: 40 breaths per minute or more 
- 5 years or older: 20 or more breaths per minute 
 b.  In young children, watch for chest in-drawing and nasal flaring. 
7.  Severe anaemia – look for very pale palms, fingernails, tongue, and conjunctivae 
8.  Severe dehydration – look for dry mouth and tongue, sunken eyes, inability to 
drink or to keep down fluids, tenting of the skin (skin pinch goes back very 
slowly) 
**If the patient shows any of the symptoms and signs listed above, you should 
consider the need for urgent treatment and referral to a higher level health facility.** 
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5.2 APPROPRIATE REFERRAL OF PATIENTS WITH SEVERE 
ILLNESS 
The best treatment for a patient with severe illness requires injectable drugs and 
inpatient monitoring.  If your health centre has facilities to administer injectable drugs 
and monitor patients in an inpatient setting, follow your usual practice to admit and 
treat the patient on the ward. 
If your health centre does not have the facilities to administer injectable drugs and 
monitor patients in an inpatient setting, you should act as quickly as possible to REFER 
the patient to a higher level health centre.  Follow the steps outlined here: 
1)  Provide pre-referral treatments as described in section 5.3 below. 
2)  Perform an RDT and write the result on the patient’s referral note as below.  Whether 
the RDT result is positive or negative, you should still give all pre-referral 
treatments as below.  
2)  Inform the patient and/or caregiver that the patient shows signs of severe illness, and 
requires urgent treatment including referral to a higher level facility. 
3)  Write a referral note stating: 
 - Patient’s name and age 
 - Date and time 
 - Symptoms and signs 
 - RDT result 
- The name of any treatments/drugs given by you and the time they are given 
 - Reason for referral 
 
 
5.3 PRE-REFERRAL TREATMENTS FOR PATIENTS WITH 
SEVERE ILLNESS 
It is often very difficult to determine the specific cause of illness in a patient with 
symptoms and signs of severe illness, as listed in section 5.1 above.  Further diagnostic tests 
will be done at a higher level facility.  However, you should consider that any patient with 
the symptoms and signs above may have severe malaria. 
5.3.1 Pre-referral treatment with injectable antimalarial 
Before referral, pre-treat the patient with injectable quinine as follows: 
1)  Obtain a 2 mL ampoule of quinine (600 mg total). 
2)  Add 4 mL sterile water to the ampoule.  You now have a total of 6 mL of solution 
containing 600 mg quinine = 100 mg quinine per 1 mL. 
3)  The correct dose is 0.1 mL x body weight in kg, 8 hourly until the patient can 
be referred or can take oral medicine.  See Table 5.1 for some examples of how to 
calculate the dose: 
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Table 5.1  Example doses of injectable quinine 
Patient weight Dose of quinine 
0.1 mL x 10 kg child 1 mL per injection 
0.1 mL x 25 kg child 2.5 mL per injection 
0.1 mL x 60 kg adult 6 mL per injection 
 
4)  Inject the dose into the anterior (front) part of the thigh.  If the total dose is 
more than 3 mL, split the volume in two and inject half the dose into each thigh.  
Do not inject into the buttock. 
5.3.2 Pre-referral treatment with injectable antibiotic 
In addition to quinine as above, you should give an injectable antibiotic to any 
patient with symptoms and signs of severe illness.   The antibiotic is given to treat a 
possible serious bacterial infection.  Give benzyl penicillin or chloramphenicol as described 
in Table 5.2 until the patient can be transferred to a higher-level health center. 
 
Table 5.2  Doses of pre-referral antibiotic 
Antibiotics Adults Children 
 Benzyl penicillin 2 mega units IV or IM 4 hourly 100,000 IU / kg IV or IM 4 hourly 
 Procaine penicillin --- 
4 to 10 kg (2 to 12 months): 
   400,000 units daily 
10 to 19 kg (1 to 5 years): 
   800,000 units daily 
 Chloramphenicol 1g IV or IM 6 hourly 
25 mg / kg (maximum 750 mg per 
dose) IV or IM 6 hourly 
* IV = intravenous injection; IM = intramuscular injection 
 
5.3.3 Pre-referral supportive treatment 
While waiting for transfer to a higher level facility, you should also provide supportive 
treatment: 
1)  Reduce the fever – undress the patient, perform tepid sponging, fan the patient, 
and give Panadol (paracetamol). 
2)  If the patient has convulsions, give diazepam.  Use solution with 10 mg / 2 mL, 
with a dose of 0.5 mg / kg as in Table 5.3.  Note: for patients older than 10 
years, give 10 mg  =  2 mL injection. 
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 SUMMARY: 
 
We have come to the end of our discussion on “Recognition and referral of patients 
with severe illness.”  In this session, we have learned the symptoms and signs of severe 
illness, and how to refer such patients.  We have also reviewed appropriate pre-referral 
treatment with quinine, and supportive treatments. 
Be sure to ask about and watch for symptoms and signs of severe illness when 
evaluating febrile patients.  Remember: severe illness is an emergency.  Begin pre-
referral treatment as soon as possible, and ensure referral to a higher level facility as 
soon as possible. 
Table 5.3  Doses of rectal diazepam (solution 10 mg / 2 mL) 
Patient weight (or age) Dose of quinine 
4 to 6 kg   (2 to 4 months) 0.25 mL 
6 to 8 kg   (4 to 12 months) 0.50 mL 
10 to 14 kg   (1 to 3 years) 0.50 mL 
14 to 19 kg   (3 to 5 years) 0.75 mL 
20 to 40 kg   (5 to 10 years) 1.5 mL 
 
3)  Prevent low blood sugar: give sugar solution orally if the patient is able (or ask the 
mother to breastfeed if the patient is a baby), or give sugar solution through an NG 
tube if the patient cannot drink. 
4)  If the patient is dehydrated (section 5.1), give fluids orally if the patient is able, or 
through an NG tube if the patient cannot drink. 
 
***For a patient with severe illness, every minute counts.  Remember: 
- Begin pre-referral treatment as soon as possible. 
- Ensure referral to a Health Centre IV or Hospital as soon as possible. 
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Session 6: PATIENT EDUCATION 
Content: 
 Introduction 
 Learning objectives 
1  Good communication skills 
2  Important messages to give a patient/caregiver to encourage 
 adherence to treatment 
3  Important messages to give a patient/caregiver on symptoms that 
 indicate a need to return for further care 
4  Messages on malaria prevention  
 Summary checklist of key messages to give to patients 
 Summary 
 
Our aim in patient education is to: 
 Improve adherence to treatment
 Improve patient follow-up care 
 Give preventive health messages 
 
INTRODUCTION: 
Welcome to Session 6 on “Patient education.”  Patient education is an exchange of 
information between the health worker and the patient and/or caregiver.  As a health worker, an 
important part of your role is to provide information so that the patient or caregiver understands 
the diagnosis and treatment plan.  A good health care provider shares information in a manner 
that is respectful and appropriate to the patient’s or caregiver’s level of understanding.  Good 
communication skills are an important part of the health care process. 
 
 
 
 
 
 
 
 
 
 
 
 
LEARNING OBJECTIVES: 
By the end of this session, you should be able to: 
1. List 5 good communication skills 
2. Outline important messages to give to a patient/caregiver to encourage adherence to 
treatment 
3. Outline important messages to give a patient/caregiver on symptoms that indicate a 
need to return to for further care 
4. Outline important messages to give a patient/caregiver on malaria prevention 
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6.1 GOOD COMMUNICATION SKILLS 
In practicing good communication in patient education, you should: 
1) Ask questions and listen carefully to answers given by the patient or caregiver.  
This ensures that you have as much information as possible to make a correct 
diagnosis and prescribe an effective treatment. 
2) Put the patient or caregiver at ease so that he or she feels comfortable giving 
you honest and complete information about the illness, and trusting you to give 
correct advice and appropriate treatment. 
3) Give advice that is appropriate to the needs of each patient or caregiver.  
Consider the messages below in sections 6.2, 6.3 and 6.4.  Give explanations for 
your advice.  If you need to correct the patient or caregiver, try not to criticize or 
to make him or her lose confidence. 
4) Use simple language that can easily be understood by the patient/caregiver. 
5) Check to be sure the patient/caregiver understands the diagnosis made and 
treatment prescribed.  Encourage the patient/caregiver to ask any question he or 
she may have.  You should also ask specific questions of the patient/caregiver to 
be sure he or she understands the treatment plan. 
 
 
 
6.2 IMPORTANT MESSAGES TO GIVE A PATIENT OR CAREGIVER 
ON ADHERENCE TO TREATMENT 
This section outlines the important messages you should give the patient or caregiver 
about the current episode of illness. These messages include the following: 
6.2.1 The cause of this episode of illness: 
- Based on your diagnosis, tell the patient or caregiver what the cause of the illness is – 
malaria, a viral illness, an ear infection, pneumonia, etc.  This helps the patient or 
caregiver to understand the illness, and increases his or her confidence in the 
treatment recommendations. 
- If the RDT result is positive, show the result to the patient/caregiver.  Explain that the 
patient has malaria, and that you will prescribe antimalarial treatment. 
- If the RDT result is negative, show the result to the patient/caregiver.  Explain that the 
patient does not have malaria.  Explain that not all fevers are caused by malaria.  Tell 
the patient/caregiver that you will prescribe the appropriate treatment for the illness. 
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6.2.2 The treatment you recommend for this illness: 
- The name of the specific treatment you are giving. 
- The correct way to dose the drugs: number of tabs per dose, number of doses per day, 
number of days to complete the treatment. 
- The correct way to take the drugs: for example, if you prescribe Coartem, tell the 
patient or caregiver to take each dose with milk (breastmilk for small children) or 
fatty or oily food (for example, meat or bean sauce made with cooking fat or oil, 
groundnut sauce, or odi) to improve absorption. 
- Tell the patient about possible side effects of the treatment. However, mention that 
everyone is different and may react to a drug differently.  
- Provide advice on storing medication: drugs should be stored in a clean and dry place, 
out of the reach of children. 
- For any patient with fever, ensure the patient or caregiver understands how to use 
supportive treatment: 
• antipyretics (e.g. Panadol, ibuprofen) 
• adequate fluid intake: water, juice, and weak tea for adults and children who can 
drink, and breast milk for babies 
• tepid sponging for children and babies 
 
6.2.3 Expected course of the illness: 
Ensure that the patient or caregiver understands the following information: 
- In order to be totally cured, the patient must take the full course of treatment.  
- Symptoms may not disappear immediately after taking the first dose.  Improvement 
may take up to two days.  
- If symptoms worsen, or if they persist beyond two days, the patient should consult a 
health worker immediately. 
- If the patient vomits the medicine within 30 minutes of taking the dose, he or she 
should take another dose. 
- The patient should not change treatment by himself/herself.  He or she should check 
first with a health worker. 
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6.3 IMPORTANT MESSAGES TO GIVE A PATIENT OR CAREGIVER 
ON SYMPTOMS THAT INDICATE A NEED TO RETURN FOR 
FURTHER CARE  
A patient’s condition may worsen even while he or she is on treatment. The patient 
should immediately go to a health facility if he or she has any of the following symptoms: 
- Convulsions 
- Persistent fever 
- Severe vomiting or diarrhoea 
- Becoming sicker 
- Developing any new problem 
6.3.1 How to tell that a child’s condition is getting worse 
You should advise the child’s caregiver about symptoms that indicate that the child 
should go immediately to a health centre.  Describe these symptoms in terms that the 
caregiver can understand so that she or he will recognize if the child requires urgent medical 
attention. 
- Fever does not go away after two days of treatment 
- Child develops convulsions 
- Child is unable to eat, drink or breast feed 
- Child becomes unconscious 
- Child develops difficulty in breathing 
- Vomiting begins or continues so that the child cannot keep down food, fluids and 
oral medications 
- Child develops new symptoms 
- Child becomes weaker or generally more ill 
- Child develops a new rash – this may indicate an adverse drug reaction 
6.3.2 How to tell that an adult’s condition is getting worse 
For an adult patient, you should advise him or her about symptoms that indicate a need to 
go to a health centre for further care: 
- Fever does not go away after two days of treatment 
- New symptoms occur 
- Patient develops convulsions 
- Patient is unable to drink or eat 
- Vomiting begins or continues so that the patient cannot keep down food, fluids 
and oral medications 
- Patient becomes weaker or generally more ill 
- Patient develops a new rash – this may indicate an adverse drug reaction 
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6.4 MESSAGES TO GIVE A PATIENT OR CAREGIVER 
ON PREVENTION OF MALARIA 
Your time with the patient or caregiver is an important opportunity to teach about 
ways to prevent malaria.  Even if a patient has already heard these messages, being 
reminded by you as a health worker can help to reinforce the messages, and to encourage 
the patient’s commitment to good prevention practices.  You should counsel the patient 
or caregiver on the following topics: 
- Explain the role of mosquitoes in malaria transmission (in particular, mosquitoes 
that spread malaria bite in the evening and night time) 
- Explain the benefit of specific preventive measures such as: 
– Sleeping under an insecticide treated net. 
– The use of intermittent presumptive treatment (IPT) in pregnant women 
– this prevention method involves treatment with one dose of sulfadoxine-
pyrimethamine (SP or Fansidar) in the second trimester, and one dose in the 
third trimester of pregnancy.  IPT can be obtained from health centres and 
antenatal clinics across Uganda. 
– The Ugandan government is conducting indoor residual spraying (IRS) 
programs in some areas of Uganda.  IRS sprays insecticide on the inside walls 
of a house to prevent and kill mosquitoes.  If an IRS program is to be carried 
out in your area, the government will provide radio spots and community 
education to explain details of the program. 
 
 
SUMMARY CHECKLIST OF KEY MESSAGES TO GIVE TO PATIENTS 
 The treatment you are recommending and how to take it 
 How to tell that a patient’s illness is getting worse 
 What to do if the patient’s illness gets worse or does not improve 
 Ways to prevent the illness from recurring 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SUMMARY  
 
We have come to the end of our session on “Patient education.”  In this session, we 
have reviewed important messages to give patients and caregivers.  These messages 
encourage adherence to treatment, tell patients when to seek follow-up care, and teach 
about malaria prevention.  Good communication skills are an essential part of fever case 
management, and of malaria prevention.  Good communication involves asking and 
listening, putting the patient/caregiver at ease, offering advice, using simple language, 
and being sure the patient/caregiver understands what you have told him or her. 
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Session 7: RDT STORAGE AND MONITORING 
Content: 
 Introduction 
 Learning objectives 
1  Proper storage conditions for RDTs 
2  Monitoring RDT expiry dates at the health centre 
3  Ordering RDTs and disposing of used RDTs 
 Summary 
 
INTRODUCTION: 
Welcome to Session 7 on “RDT storage and monitoring.”  In this short session, we will 
discuss the proper way to store and monitor RDTs at the health centre. 
 
LEARNING OBJECTIVES: 
By the end of this session, you should be able to: 
1. Describe the proper storage conditions for RDTs at your health centre 
2. Explain how to monitor RDT expiry dates with the “FEFO” principle 
 
 
7.1 PROPER STORAGE CONDITIONS FOR RDTS 
RDTs must be stored in a cool, dry place in order to keep their ability to accurately 
diagnose malaria.  Like drugs, RDTs’ quality can be affected by heat and dampness.  
Therefore, the store room at your health centre, where the medicines are kept, is likely the 
best place to store RDTs. 
RDT manufacturers recommend that the tests be stored between 4°C and 40°C.  Uganda 
is a warm country, so we do not need to worry about RDTs reaching 4°C and freezing.  It is 
more likely that RDTs could become too hot during transport or storage.  However, in studies 
of RDTs in Uganda, the temperatures in storage rooms at health centres almost never went 
above 30°C.  Therefore, the storage room at your health centre should provide a safe 
temperature for the RDTs. 
Do not place RDTs near windows, where the sun can shine on them.  Be sure that they are 
always kept as cool as possible in the storage room and in patient care areas.  
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7.2 MONITORING RDT EXPIRY DATES AT THE HEALTH CENTRE 
During the monthly inventory at the health centre, the expiry date on each RDT carton 
should be checked. 
Use the “FEFO” principle: First Expired, First Out.  Put the carton with the earliest 
expiry date at the front of the storage area so that it is used soon. 
If the expiry date on an RDT carton is past, do not use RDTs from the carton.  If any 
RDTs have already been removed from the carton for use in the health centre, be sure they 
are removed from the health centre and replaced in the carton.  Return the carton to Kampala. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SUMMARY  
 
We have come to the end of our session on “RDT storage and monitoring.”  In this 
session, we learned that RDTs should always be stored in a cool, dry place at the health 
centre.  The expiry date on each carton should be checked during monthly inventory, 
using the “FEFO” principle. 
Session 8: RDT LOGISTICS MANAGEMENT 
Content: 
 Introduction 
 Learning objectives 
1  Describe the purpose of a Laboratory Logistics System 
2  Outline the structure and flow of products/information for RDTs 
3  Describe some LMIS forms used in logistics management 
4  Perform stock status review 
5  Outline the procedure for ordering, receiving and storage of RDTs 
 Summary 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION: 
 Welcome to Session 8 on “RDT logistics management.”  In this session, we will discuss how to 
check RDT stocks at your health center, and how to order RDTs. 
 
LEARNING OBJECTIVES: 
By the end of this session you should be able to: 
 Describe the purpose of a Laboratory Logistics System 
 Outline the structure and flow of products/information for RDTs 
 Describe some LMIS forms used in logistics management 
 Perform stock status review 
 Outline the procedure for ordering, receiving and storage of RDTs. 
 
8.1 THE PURPOSE OF A LABORATORY LOGISTICS SYSTEM 
The purpose of a logistics system is to ensure that products or supplies are available to the clients 
who will need them. It aims to provide the Six Rights of logistics system. A good logistics system 
provides excellent client/customer service by delivering: 
 the right product
 in the right quantity
 in the right condition
 to the right place
 at the right time for the right cost 
 
8.2 STRUCTURE AND FLOW OF PRODUCTS AND RDT INFORMATION 
Flowchart for the flow of product and information 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note:  Malaria RDTs are for use in Health Centers II and III, plus higher level health 
facilities that lack microscope services. 
 
 
 
HC to Quantify RDT Needs every 3 months 
HC to forward orders to HSD 
along with Order Form 
HSD to  
 examine & approve order and 
makes summary  
DHO to  
1. examine and approve orders 
2. ensure that all HCs have placed orders 
3. in coordination with DLFP, forward 
orders to NMS at least one month 
before delivery date 
NMS to deliver marked 
consignments along 
with other lab reagents 
and supplies to the 
district/ HSD stores
 
DHO/HSD to deliver 
individually parked 
order to health 
facility 
 
Product flow 
 
Information flow 
8.3 TYPES OF LABORATORY MANAGEMENT INFORMATION SYSTEM 
(LMIS) RECORDS 
8.3.1 Stock keeping records  
These are records for noting information about all products kept in storage (e.g. stock cards, 
ledgers, etc.)
8.3.2 Management of stock keeping records 
A stock card is the basic record that is used to keep track of commodities that are found in 
storage or wherever commodities are kept. 
 
 
 
HMIS 015: STOCK CARD
          
Health Unit Name:   Financial Year___________  Page ______  of pages _____ 
Folio Number _________________              Card Number ____________ 
 
Description: 
 
Special Conditions: 
 
Strength/ Size Expiry Date(S)  
Issue
Unit:
AMC Maximum 
Stock:
Minimum
Stock:
Quantity
To Order: 
Date To or 
From
Voucher
Number 
Quantity
In
Quantity
Out
Losses and 
Adjustments 
Balance on 
Hand
Remarks / 
Batch Number 
  
 
      
  
 
      
  
 
      
8.3.3 Importance of stock card 
 To track stock at hand, losses and adjustments 
 To track quantity of RDTs issued (issue data) which may be used when calculating average 
monthly consumption  when actual user data (dispensed data) is not available 
 To keep continuous track of expiry dates 
  
8.3.4 How to fill in the card 
This should be demonstrated during the training. 
 
8.3.5 When to complete the stock card 
 At the time of physical count 
 When products are received 
 When products are issued 
Any other time there is a change in the status of the products in the store-room (example: 
A physical count is the process of counting by hand the total number of units of each commodity in 
your storeroom or health facility at any given time. 
 Do a physical count on a regular basis 
 Check that recorded balances match actual quantities on the shelves 
 Verify product quality 
 Identify and correct errors in the stock card 
 (other ideas given by the participants) 
 
8.3.7 The link between a physical count and Product Quality Assurance  
Conducting a physical count provides us an ideal opportunity to help ensure product quality 
 Ensure that products are arranged according to FEFO 
 Ensure that products do not show visible signs of damage 
 Verify the product packaging before products are issued for use 
 Read and record the room temperature if the thermometer is available 
 (Other ideas given by the participants.) 
8.3.8 Transaction records  
These are records for keeping information about products being moved (e.g. packing slip, receiving 
report, issue voucher and requisition and issue voucher).  Safe storage of all transaction records should 
be observed. 
8.3.9 Consumption records  
These are records for keeping information about products being consumed (daily consumption log, 
activity register etc.). Consumption refers to the quantities of RDTs used to perform tests over a given 
review period. 
 
8.3.10 Types of consumption data 
 Dispensed-to-user data: Information about the quantity of goods actually put in the hands of 
ultimate clients or end users (often shortened to “dispensed data”). 
 Issues data: Information about the quantity of goods shipped from one level of the system to 
another. 
Note: This may involve malaria RDTs and Pregnancy tests depending on level of integration) 
Name of health facility______________________________________________________________________________________
HSD  ____________________________________________________________________________________________________
District___________________________________________________________________________________________________
Daily Activity Register for  Malaria RDT, TB and Pregnancy test  
Date Lab No Name Age Sex Address Serology 
Malaria  RDT TB RDT Pregnancy Test 
Pos Neg Pos Neg Pos Neg
   
   
   
Totals for each test done 
 
8.4 REVIEWING STOCK STATUS, CALCULATING AVERAGE 
MONTHLY CONSUMPTION, AND ORDERING
Before ordering new stock, review the following;  
 How long is stock going to last? 
 When do you need to order more stocks? 
 What quantities of a particular item should be ordered? 
  
To determine the Average Monthly Consumption (AMC), add up the last three consecutive months’ 
usage of a particular product, then divide by three. Get this data from the stock card (issues data) or from 
the RDT register (dispensed-to-user data) 
 
Use the following formula to determine Average Monthly Consumption: 
A) AMC = sum of 3 previous month’s RDT usage = AMC 3
8.4.1  Reviewing stock status 
What is your stock status? 
When you review your stock status, you determine how much of each product you have available at 
your facility. You can review your stock status by counting the stock available, as you do during a 
physical inventory. When you finish, you will have an absolute quantity of stock available. But, when 
managing RDTs, it is much more important to know how long the stocks will last. We refer to this as 
months of stock.  
 
What is “Months of Stock”? 
 
Months of stock is the number of months a product will last based on the present consumption rate. 
The importance of Months of Stock inventory is: 
To determine whether your facility/unit is 
 Under stocked 
 Overstocked  
 Adequately stocked 
  
If you are under stocked, you may need to place an emergency order. If you are overstocked, you may 
need to redistribute the stock to other facilities. 
 
Use the following formula  
 
 _              Stock on Hand                    _          =          Months of Stock 
                     Average Monthly Consumption 
 
Example: 
 
If the health facility has 1,000 RDTs and the average consumption rate is 500 RDTs per month, the 
Months of Stock will be: 
                                            1,000          = 2 Months of Stock 
                                              500 
 
 
8.5     Ordering RDTS and Disposing of used RDTS 
 RDTs will be availed to the health centres through a push system until NMS finalizes plans for 
regular supplies. 

8.5.2  Receiving and storage of RDTs 
8.5.2.1  Coordinating receipt of RDTs and storage 
Maintaining proper storage conditions for laboratory commodities is vital to ensuring their 
quality. Product expiry dates are based on ideal storage conditions and protecting product quality 
until their expiration date. 
8.5.2.2 Procedures for receiving RDTs and other laboratory supplies
 Ensure that there is sufficient storage space available 
 Prepare and clean the area used for receiving and storing the products 
 Inspect the products for damage and expiry 
 Separate the damaged or expired products from the usable stock 
 Count the number of units for each product received and compares to issue voucher 
 Inspect for completeness of the kit 
 Record the date and quantity received on stock card, and bin card if applicable 
 Ensure the expiry date is clearly marked and visible 
 
 
 
 
National Medical Stores/Joint Medical Stores 
HSD Order Summary- Rapid Diagnostic Tests (RDTs) 
Facility Name:-______________________________________ 
Level of Health Facility_____________________________________ 
District___________________________________________________ 
In the table below, fill in the name and level for each health unit ordering. Enter the quantities of each of the respective Rapid Diagnostic 
Tests (RDTs) ordered by the facilities.
Quantity of RDTs ordered 
No. Name of Health Unit Level (II,III)  Malaria RDT 
TB 
RDTs 
Pregnancy 
test 
1     
2      
3      
4      
5      
6      
7      
8      
  Total RDTs    
 HSD in charge signature: Date: Phone No: 
 DHO Signature: 
Date:
Phone No: 
8.5.2.3 Summary guidelines for proper storage of laboratory reagents and other 
supplies 
These are the general storage procedures to be followed regardless of the size of facility. These rules 
can be adapted for each facility within reason. 
 Clean and disinfect storeroom regularly 
 Store lab supplies in a dry, well lit and well ventilated storeroom, out of direct light 
 Secure the storeroom from water/animal (rodents) penetration 
 Ensure that fire safety equipment is available and accessible and that personnel are trained to 
use it 
 Store latex away from electric motors and florescent lights 
 Maintain cooled storage for reagents which require cool chain e.g. some testing kits 
 Limit storage area access to authorized personnel and lock up controlled lab reagents 
 Store flammable reagents separately using appropriate safety precautions 
 Store laboratory supplies away from pesticides, chemicals, and other hazardous material 
 Arrange cartons/reagent bottles so that arrows are facing up, and ensure that identification 
labels, expiry dates, and manufacturing dates are visible 
 Store laboratory reagents and supplies in a manner accessible for FEFO, accounting and 
general management 
 Separate and dispose of damaged or expiry products 
 
8.5.3  Disposing of expired RDTs 
The RDT should be disposed of with the rest of the medical waste from the health centre, 
including used gloves, used spirit swabs (alcohol swabs) and other items.  For example, many health 
centres discard waste in a garbage pit.  The pit should be in a place where children and animals 
cannot easily reach it. 
 
 
 
Annex 1: Exercise for completing the stock card for RDTs 
Annex 2: Job Aid for completing logistic forms 
Annex 2: Exercise for completing the Daily Activity Register for RDTs 
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APPENDIX H: USE OF RDTS IN FEVER CASE MANAGEMENT  
PRE – POST TRAINING ASSESSMENT (1) 
HEALTH WORKER INFORMATION 
Cluster Number 
 
[____|____] 
Health Centre Code 
 
[____|____] 
Health Worker Study ID 
 
[____|____] 
Date 
 
[____|____]/ [____|____]/[____|____] 
day                      month                     yea r 
Health Worker Position 
 
[_____|_____] 
1 = In-cha rge  
2 = Senior medica l officer   
3 = Medical officer   
4 = Senior clinical officer    
5 = C linica l officer                                                                  
6 = Nursing officer 
7 = Enrolled nurse 
8 = Midwife 
9 = Public hea lth nurse 
10 = Nursing a ide/a ssistant 
11 = Laboratory technician 
12 = Laboratory assistant 
13 = Hea lth a ssista nt 
14 = Hea lth educa tor 
15 = Other___________________ 
 
PART 1: INTRODUCTION 
Welcome to the pre-test for our training course in RDTs and fever case management. There are 16 
questions in the pre-test.  
 
The reason for this test is not really to see how much you already know. The pretest is designed to raise 
your interest in RDTs and fever cases. Each of these questions highlights an important learning point that 
we will cover during the course. By the end of the course, you will have learned everything you need to 
answer these questions correctly. On the last day of the course, we shall take this test again, and then 
discuss the answers as a group. 
 
Instructions: 
1. Read each question carefully along with the group. 
2. Put the letter to the answer you think is correct in the space on the right, for example: [__b__] 
 
PART 2: QUESTIONS & ANSWERS 
Questions Answers 
⑯ 
 
All cases of fever in Uganda are caused by malaria. 
a)  True 
b)  False 
 
[____] 
⑯ RDT stands for Rapid Diagnostic Test for malaria. Which of the following is  NOT true about RDTs? 
a)  If performed correctly, they are very accurate in diagnosing which patients have 
malaria and which do not. 
b)  They can be performed in health centres that do not have power or laboratory 
equipment. 
c)  They can detect typhoid fever and pneumonia as well as malaria. 
 
[____] 
⑯ In order to perform an RDT, you will need to use finger prick blood. After you prick a patient’s 
finger with a lancet, what should you do with the lancet? 
a)  Save it to wash and use again later. 
b)  Carefully put it immediately in the sharps container. 
c)  Put it on the table beside you, to use for the next patient. 
 
[____] 
⑯ We will pass an RDT around the room. Look carefully at it and read the result. 
a)  Positive 
b)  Negative 
c)  Invalid 
 
[____] 
⑯ Here is another RDT. Look carefully at it and read the result. 
a)  Positive 
b)  Negative 
c)  Invalid 
 
[____] 
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PRE – POST TRAINING ASSESSMENT (2) 
HEALTH WORKER INFORMATION  
Cluster Number 
 
[____|____] 
Health Centre Code 
 
[____|____] 
Health Worker Study ID 
 
[____|____] 
Date 
 
[____|____]/ [____|____]/[____|____] 
day                      month                     yea r 
 
PART 2: QUESTIONS & ANSWERS CONTINUED 
⑯ RDTs should be stored in a cool, dry place. 
a)  True 
b)  False 
 
[____] 
⑯ You can use the same RDT for two different patients. 
a)  True 
b)  False 
 
[____] 
⑯ You should always check the expiry date on the package of an RDT before using it. 
a)  True 
b)  False 
 
[____] 
⑯ For which of the following patients should you perform an RDT for malaria? 
a)  A 4-year-old boy with fever and mild cough 
b)  An 8-month-old child with fever who refuses to breastfeed, is breathing rapidly and 
has very pale palms and sunken eyes 
c)  A 20-year-old woman who is pregnant and has fever 
d)  A 32-year-old man who is HIV-positive and has fever 
e)  A 45-year-old man with fever and joint paints 
f)  All of the above 
 
[____] 
⑯ A patient comes to your health centre with fever. She has taken chloroquine for two days but the 
fever has persisted. You perform an RDT and the result is positive. What should you do? 
a)  Tell the patient to complete the course of chloroquine. 
b)  Prescribe a full course of Coartem. 
 
[____] 
⑯ A patient comes to your health centre with fever. She took a complete, correct course of Coartem 
last week. She did not vomit any of the doses. You perform an RDT and the result is  positive. 
What should you do? 
a)  Prescribe a full course of quinine. 
b)  Prescribe a second full course of Coartem. 
c)  Advise her to take Panadol and fluids only. 
 
[____] 
⑯ Which of the following is a symptom or sign of severe illness in a patient with fever? 
a)  Convulsions currently or within the past 2 days 
b)  Extreme weakness – patient is  unable to sit or stand without support 
c)  Severe anaemia – patient’s palms and conjunctivae are very pale 
d)  Unable to drink or breastfeed 
e)  All of the above 
 
[____] 
⑯ A 35-year-old man comes to your health centre. He tells you that he has fever and muscle 
aches. What should you do FIRST? 
a)  Prescribe Coartem immediately. 
b)  Prescribe chloroquine immediately – this regimen is best for adults. 
c)  Prescribe Panadol only and tell the patient to go home and rest. 
d)  Ask the patient how long he has had these symptoms, and ask if he has taken 
any drugs at home before coming to the health centre. 
 
[____] 
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PRE – POST TRAINING ASSESSMENT (3) 
HEALTH WORKER INFORMATION 
Cluster Number 
 
[____|____] 
Health Centre Code 
 
[____|____] 
Health Worker Study ID 
 
[____|____] 
Date 
 
[____|____]/ [____|____]/[____|____] 
day                      month                     yea r 
 
PART 2: QUESTIONS & ANSWERS CONTINUED 
⑯ A mother brings her 8-year-old daughter to your health centre. Beginning yesterday, the 
girl has had fever and no appetite. Her mother has given Panadol and fluids, but the 
symptoms continue. There are no signs or symptoms of severe illness. On physical 
examination, you find no obvious cause of her fever. You perform an RDT, and the result 
is negative. Which of the following is TRUE? 
 
a)  This patient has a mild febrile illness, but the cause is not clear. The mother 
should continue to provide fluids and Panadol. You should advise her to 
bring the girl back to the health centre if the symptoms do not get better 
within 2 to 3 more days. 
b)  You should prescribe a course of chloroquine. Even though the RDT is negative, 
the girl may still have malaria, and chloroquine is appropriate for mild 
cases of malaria. 
c)  You should prescribe Coartem. Even though the RDT is negative, the girl may 
have malaria, and Coartem is the first-line regimen for malaria in Uganda. 
 
[____] 
⑯ A 10-year-old boy comes to your health centre with fever and joint pains. He looks weak, 
but is able to sit up easily by himself. After you take a history and do a physical 
examination, you perform an RDT. The RDT is positive, and you plan to treat for 
uncomplicated malaria. According to the Uganda Ministry of Health guidelines, which of 
the following is the BEST (first-line) treatment for this patient? 
 
a)  Chloroquine 
b)  Oral quinine 
c)  Injectable quinine 
d)  Coartem (artemether-lumefantrine) 
e)  Chloroquine + Fansidar (Homapak) 
 
[____] 
⑯ A mother brings her 1-year-old son to your health centre. She tells you he has not been 
feeding well. The child’s body is hot to touch. He is weak and cannot sit up by himself, and 
he is breathing very rapidly. What should you do? Be sure to read all the statements 
below before answering. 
 
a)  Undress the child, and ask the mother to sponge him to help reduce the fever. 
b)  Immediately prepare and inject a dose of quinine AND antibiotic. 
c)  Perform an RDT and write the result on the referral note. 
d)  Write a referral note and ensure that the child is referred to a Health Centre IV 
or Hospital as soon as possible. 
e)  All of the above. 
 
[____] 
 
Thank you! 
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APPENDIX I. INFORMATION SHEET 
Health worker self-observation activities 
ACT PRIME Study 
 
Introduction 
Dr. Sarah Staedke and colleagues from the Uganda Malaria Surveillance Project / Infectious Diseases 
Research Collaboration are investigating the provision of health care services in Tororo District. We are doing 
a research study to see if we can improve the health of children in this area by improving services at 
government-run health facilities. Certain health centers in Tororo district will be selected to take part in the 
intervention to improve services, or to continue with their current services.  Assignment to the two groups 
has been determined by a lottery.  The chance of being placed into either of the groups is the same.  
 
Why are these self-observation activities being done? 
We would like to know more about the interaction between health workers and patients in this area. To do 
this, we are asking health workers to take part in a series of self-observation activities about their behaviors 
and experiences interacting with patients.  This information will help us to plan future training activities and 
health care studies in Tororo District.  
 
What will happen if I take part in these self-observation activities? 
We would like your participation in a series of self-observation activities in which you will reflect on your 
interpersonal behaviors and how you interact with patients.  We will start with a two-hour introduction to 
the planned activities.  You will then be asked to complete a series of tasks over a period of 8-12 weeks. The 
activities involve becoming aware of your behavior and writing a short summary of how your behavior 
affects those around you and your ability to achieve work goals.  On completion of each task, you will be 
invited to join other health workers to discuss your observations and give support to each other.  Over the 8-
12 week period, we will carry out four meetings lasting approximately two hours each.  We will ask you to 
give your written summaries to the workshop trainers.  The summaries will be typed and stored 
electronically.  We plan to use the summaries to help plan training activities for the future.  All information 
gathered will be treated as confidential by the study personnel, and records of the interviews will be kept 
securely in locked filing cabinets and offices.  No personal identification information such as names will be 
used in any reports arising out of this research. 
 
How long will these self-observation activities last? 
The introduction to the self-observation activities will last about 2 hours.  Over the 8-12 week period, you 
will carry out four self-observation tasks and there will be four colleague meetings lasting approximately two 
hours each. 
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Can I stop being in the self-observation activities? 
You can decide to stop participating at any time. Just tell the project researcher right away if you wish to 
stop the activities. 
 
What risks can I expect from participating in the self-observation activities? 
Participation in any research study may involve a loss of privacy.  Information you provide about your 
experiences and opinions will be recorded, but your name will not be used in any reports of the information 
provided.  No quotes or other results arising from your participation in this study will be included in any 
reports, even anonymously, without your agreement. The information obtained from these self-observation 
activities will only be used by the project researchers and will be locked at our project offices. We will do our 
best to make sure that the personal information gathered for this survey is kept private.   
 
Are there benefits to taking part in these self-observation activities? 
While we do not anticipate any immediate benefits to you, the self-observation activities may help you to 
develop an awareness of your interpersonal interactions with your colleagues and patients.  Additionally, the 
information that you provide will help researchers plan for future training activities and health care studies 
in this area. 
 
What other choices do I have if I do not take part in the self-observation activities? 
You are free to choose not to take part in the self-observation activities. If you decide not to take part, there 
will be no penalty to you.   
  
What are the costs of taking part in these self-observation activities?  Will I be paid for taking part in these 
self-observation activities? 
There are no costs to you for taking part in this survey. You will not be paid for taking part in this survey.  
 
What are my rights if I take part in these self-observation activities? 
Taking part in these self-observation activities is your choice. You may choose either to take part or not to 
take part.  If you decide to take part in these self-observation activities, you may change your mind at any 
time.  No matter what decision you take, there will be no penalty to you in any way. 
 
Who can answer my questions about the self-observation activities? 
You can talk to the researchers about any questions or concerns you have about these self-observation 
activities.  Contact Dr. Sarah Staedke or other members of the Uganda Malaria Surveillance Project / 
Infectious Diseases Research Collaboration on telephone number 0414-530692. If you have any questions, 
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comments or concerns about taking part in these self-observation activities, first talk to the researchers.  If 
for any reason you do not wish to do this, or you still have concerns about doing so, you may contact Dr 
Charles Ibingira, Makerere University Faculty of Medicine Research and Ethical Committee at telephone 
number 0414-530020. 
 
Giving verbal consent to take part in the self-observation activities: 
You may keep this information sheet if you wish. Participation in these activities is voluntary.  You have the 
right to decline to take part in the activities, or to withdraw from them at any point without penalty.  If you 
do not wish to take part in the activities, you should inform the researcher now.  If you do wish to take part 
in these activities, you should tell the researcher now, and the introduction session will begin shortly. If you 
do not agree to quotes or other results arising from your participation in the study being included, even 
anonymously, in any reports about the study, please tell the researcher now.  
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APPENDIX J. EXAMPLE HEALTH WORKER 
SELF-OBSERVATION TASK SHEET #1 
Tororo District Survey Project 
 
Observation Task 1: How you ask questions 
 
Notes to the participant 
Our personal communication style is an important factor in how we interact with others, whether 
we are consulting with patients, interacting with colleagues, or simply having a conversation. 
Developing awareness about how we communicate, and how our communication affects the 
person(s) we are communicating with, is a very important task in becoming a good health care 
worker. Understanding how we function, and what works well (and not so well) is the first step to 
understanding others. By paying conscious attention to how you communicate, you will become a 
better communicator.  
 
Thus, you are invited to observe your own communication practices. An important key to making 
effective observations is focus: If you look for one or a few things, you will be able to see the 
pattern in what you are doing, and become aware of what you need to learn more about – and 
what you do well, and can help others learn from. If you look at too much at the same time, you 
will not see the patterns.  Thus, you should follow the schedule proposed – look at one issue at a 
time for one week until you meet the facilitator again.  
 
Looking at not only what you are saying or doing, but also at how you say and do it, is very 
important. The effect of what you say and do on others is also crucial. Start looking at this, and at 
the feelings you have – and at what you cause in the other person. Understanding the effect of 
feelings on communication outcome is key in this learning. 
 
Tips for carrying out your observations: 
 Carry this page of instructions in a notebook.  
 When you plan your day, plot in one or two times or situations when you are know you will 
be interacting with patients or others in your workplace when you plan to observe yourself. 
 Before the consultation/meeting, read the instructions again to remind yourself what you 
are looking for.  
 Try to be aware during the meeting or conversation how you behave regarding the habit 
you are observing. 
 After the meeting/event, reflect on what you have observed in your own behaviour, and 
make a few notes in your notebook. 
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If you do this once or twice a day, you will start to see a pattern. And – discuss with your colleagues 
about how they do their observation, and may be what they have found out. This may help you to 
get used to doing this task.  
 
Please observe the following when you interact with others: 
1. When you ask questions of patients, do you usually: 
 Ask open-ended questions to allow the patient to tell their story in their own words? 
 Ask the patient a series of close-ended questions to get answers about specific 
symptoms? 
 Ask probing questions to find out more about what is troubling the patient if you 
feel that they haven’t told you everything? 
 Listen patiently while the patient is speaking?  
 Tend to feel pressured by time, and become impatient if the patient is telling a long 
story or asking many questions?  
 Wait until the patient has completed their story, and you have asked any additional 
questions, before making a decision about the patient’s likely diagnosis?   
 Often formulate your decision about a patient’s diagnosis before you have finished 
taking the complete history, because you already know the problem?  
 Try to understand the patient’s perspective and what their needs are while you take 
the history? 
 Do you notice any other patterns to your behavior when asking questions of 
patients? (Describe) 
 
2. Observe in what type of situations you use the different methods, and what are the results or 
outcome (Do you feel good/bad/indifferent? Does the other person feel 
good/bad/indifferent?) 
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APPENDIX J. EXAMPLE HEALTH WORKER 
SELF-OBSERVATION TASK SHEET #2 
Tororo District Survey Project 
 
Observation Task 2: How you facilitate or hinder good communication 
 
Notes to the participant 
During the last self-observation task, you started to observe your personal communication style by 
observing how you ask questions and how you listen to others: Do you try to really listen to find 
out what their ideas are, or are you more concerned about getting the other person to listen to 
your opinion and ideas? Or do you do a bit of both, depending on the situation?  If both, you 
should be able to define situations for each habit and why. 
  
This week, you are invited to observe how you facilitate or encourage communication with others 
and how you prevent or block good communication.  You should pay attention to how your verbal 
and non-verbal actions affect your communication style and how you communicate with others.  
You can continue to pay attention to your listening habits as you start on this week’s task of 
observing your discussion habits.  
 
You will now be more comfortable with self-observation and understanding the feelings you have – 
and how they evoke feelings in another person. Understanding the effect of feelings on 
communication outcome is key in this learning. 
 
Remember these tips for carrying out your observation tasks: 
 Carry this page of instructions in a notebook.  
 When you plan your day, plot in one or two times or situations when you are know you will 
be interacting with patients or others in your workplace when you plan to observe yourself. 
 Before the consultation/meeting, read the instructions again to remind yourself what you 
are looking for.  
 Try to be aware during the meeting or conversation how you behave regarding the habit 
you are observing. 
 After the meeting/event, reflect on what you have observed in your own behaviour, and 
make a few notes in your notebook. 
 
If you do this once or twice per day, you will start to see a pattern.  Remember that the key to useful 
observation is to focus: concentrate on observing only one or two habits at a time.  Continue to 
discuss with your colleagues about how they do their observation, and may be what they have 
found out. This may help you understand more about yourself.   
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This week, observe how you facilitate or hinder good communication with others.   
 
1.  When you discuss with another person, do you usually: 
 Maintain eye contact? 
 Sit and face the person squarely or turn away from the person? 
 Use simple terms or complex medical jargon? 
 Ask which language the person would prefer to use, if you see the person is having 
difficulty speaking English? 
 Use non-verbal cues such as head nodding and smiling to show that you are paying 
attention? 
 Respond to the person’s statements with your own opinions? 
 Ask questions to find out more what the other person is thinking? 
 Ask questions that lead to yes/no answers or to more descriptive answers?  
 Any other pattern? (Describe) 
 
2.  Observe in what type of situations you use the different methods, and what are the effects or 
results or outcome (Do you feel good/bad/indifferent? Does the other person feel 
good/bad/indifferent?).  Don’t forget to make notes! 
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APPENDIX J. EXAMPLE HEALTH WORKER 
SELF-OBSERVATION TASK SHEET #3 
Tororo District Survey Project 
 
Observation Task 3: What do you do to relieve work-related stress and anxiety? 
 
Notes to the participant 
During the last self-observation task, you started to observe how your discussion habits may 
facilitate or hinder good communication:  Do you use open and welcoming body language?  Do you 
use simple language or complex medical terms?  Do you practice active listening?  Do you ask 
questions for clarification or make your own assumptions about what people are trying to tell you? 
 
This week, you are invited to observe what you do to relieve work-related stress and anxiety.  You 
should pay attention to the type of situations that cause you to feel stressed or anxious.  Observe if 
you react in a way that has a positive or negative outcome on yourself and others around you.  You 
can continue to pay attention to your discussion habits as you start on this week’s task of observing 
your reactive emotions and behaviours. 
 
Remember these tips for carrying out your observation tasks: 
 Carry this page of instructions in a notebook.  
 When you plan your day, plot in one or two times or situations when you are know you will 
be interacting with patients or others in your workplace when you plan to observe yourself. 
 Before the consultation/meeting, read the instructions again to remind yourself what you 
are looking for.  
 Try to be aware during the meeting or conversation how you behave regarding the habit 
you are observing. 
 After the meeting/event, reflect on what you have observed in your own behaviour, and 
make a few notes in your notebook. 
 
If you do this once or twice per day, you will start to see a pattern.  Remember that the key to useful 
observation is to focus: concentrate on observing only one or two habits at a time.  Continue to 
discuss with your colleagues about how they do their observation, and may be what they have 
found out. This may help you understand more about how to interact with your colleagues.   
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This week, observe what you do to relieve work-related stress and anxiety. 
 
1.  List situations that trigger work-related stress or anxiety. These may be issues to do with your 
relationship with your colleagues/boss, your relationship with patients, or with your daily duties. 
 
2.  When faced with these situations, do you usually: 
 Avoid the situation or interaction that triggers the anxiety? 
 Pretend nothing is wrong and simply proceed hoping that the situation will resolve 
on its own? 
 Seek for an opportunity to openly address the problem? 
 Seek help from colleagues or other sources about how to handle the stressful 
situation? 
 Redirect your stress or anxiety, taking it out on colleagues, patients, or others? 
 Find and perform an activity that relaxes you and relieves the stress or anxiety? 
 Any other pattern? (Describe) 
 
3.  Observe in what type of situations you use the different methods, and what are the effects or 
results or outcome (Do you feel good/bad/indifferent? Does the other person feel 
good/bad/indifferent?)  Don’t forget to make notes! 
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APPENDIX J. HEALTH WORKER 
SELF-OBSERVATION TASK SHEET #4 
Tororo District Survey Project 
 
Observation Task 4: How do you handle anger and irritation? 
 
Notes to the participant 
During the last self-observation task, you started to observe how your reactive emotions and 
behaviours impacted on how you relieve work-related stress and anxiety: Do you avoid situations 
that trigger anxiety or seek advice on how to face them?  Do you find an activity that relaxes you?  
Do you avoid confrontation or establish open dialogue with colleague(s) involved in order to 
resolve the situation? Are you aware of how your stress and anxiety may interfere with your daily 
functions, job satisfaction as well as hinder good communication? 
 
This week, you are invited to observe how you handle anger and irritation at work.  You should pay 
attention to the difference between feelings of stress or anxiety and feelings of anger or irritation.  
These are two different types of emotions that can cause different types of reactions.  Observe if 
feelings of stress or anxiety are related to your own actions while feelings of anger or irritation are 
related to the actions of others around you.  Continue to pay attention to your reactive emotions 
and behaviours in these different situations. 
 
Remember these tips for carrying out your observation tasks: 
 Carry this page of instructions in a notebook.  
 When you plan your day, plot in one or two times or situations when you are know you will 
be interacting with patients or others in your workplace when you plan to observe yourself. 
 Before the consultation/meeting, read the instructions again to remind yourself what you 
are looking for.  
 Try to be aware during the meeting or conversation how you behave regarding the habit 
you are observing. 
 After the meeting/event, reflect on what you have observed in your own behaviour, and 
make a few notes in your notebook. 
 
If you do this once or twice per day, you will start to see a pattern.  Remember that the key to useful 
observation is to focus: concentrate on observing only one or two habits at a time.  Continue to 
discuss with your colleagues about how they do their observation, and may be what they have 
found out. This may help you understand more about yourself and your colleagues.   
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This week, observe what you in situations that cause anger and irritation. 
 
1.  List situations that may cause anger and irritation. These may be issues to do with your 
relationship with your colleagues/boss, your relationship with patients or simply your daily duties.  
Remember to try and differentiate between stress/anxiety and anger/irritation. 
 
2.  When faced with these situations, do you usually: 
 Express your anger by yelling? Or react to your feelings by crying?  
 Try to suppress your anger and bottle-up your feelings? 
 Try to understand the reasons the situation or person made you angry? 
 Try to understand what caused the situation, or the reasons for a person’s behavior 
that made you angry? 
 Avoid situations or people that might lead to conflict? Or do you work towards 
resolving conflict?  
 Look for an opportunity to openly address problems in a constructive way? 
 Find and perform an activity that relieves your anger or irritation? 
 Seek for help from someone else about how to handle the crisis? 
 Pretend nothing is wrong and simply proceed? 
 Any other pattern? (Describe) 
 
3.  Observe in what type of situations you use the different methods, and what are the effects or 
results or outcome (Do you feel good/bad/indifferent? Does the other person feel 
good/bad/indifferent?)  Don’t forget to make notes! 
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APPENDIX K: CROSS-SECTIONAL SURVEY SCREENING FORM 
PART 1: HOUSEHOLD & PARTICIPANT ID 
Subcounty ID 
 
Village ID 
 
Compound number 
 
Household number 
 
Cluster number 
[_____] [_____|_____] [_____|_____|_____|_____] [_____|_____] [_____|_____] 
Screening Date 
 
Screening ID 
 
[_____|_____]/[_____|_____]/[_____|_____] 
da y                              month                             year 
[_____|_____|_____|_____] 
Age If child is less than 1 
yea r, complete 
months, otherwise 
leave bla nk 
Gender 
 1 = Male 
2 = Female [_____|_____] / [_____|_____] 
yea rs                                  months 
[____]      
 
PART 2: SCREENING INTERVIEW with PARENTS/GUARDIANS 
Selection criteria Include Exclude  
1.  Appropriate age 
1 = Yes 2 = No [_____]      a.  Under five (aged 0 to less than 5 years) 
     b.  Aged 5 to  15 years      
2. Willingness of parent(s)/guardian(s) to  provide informed consent 1 = Yes 2 = No [_____]     
If any answers are ‘2’ from the EXCLUDE column, exclude from the study. If not, proceed to the next section. 
 
PART 3: AVAILABILITY OF CHILD 
 DATE APPROACHED: Child available to 
participate in survey? 
IF YES, go to Section 4. 
IF NO, GIVE REASON* 
DATE TO RETURN: 
 
1  Yes No   
2  Yes No   
3  Yes No   
4  Yes No  xxxxxxxxxxxxxxxxx 
* 1=No t Ho me, 2=Come back later, 3=Not interested, 4=Vacant, 77=Other (Please specify above) 
 
PART 4: SCREENING INTERVIEW with CHILD 
Selection criteria Include Exclude  
3. Able to  locate child 1 = Yes 2 = No [_____]     
4. Willingness of ch ild over 8 years to  provide assent to participate 1 = Yes 2 = No [_____]     
If any answers are ‘2’ from the EXCLUDE column, exclude from the study. If not, proceed to the next section. 
 
ASSIGN 
STUDY NUMBER 
 
[_____|_____|_____|_____] 
 
 
All criteria for study inclusion met?        
         1 = Yes      
         2 = No     If no, exclude from the study                                              
 
 
[_____]     
Date of enrollment (date  of survey) 
 
[______|______]/[______|______]/[______|______] 
day                              month                             yea r 
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APPENDIX L. CROSS-SECTIONAL SURVEY 
Research participant informed consent form 
  
Protocol Title:  ACT PRIME Study: Evaluating the impact of enhanced health facility-based care 
for malaria and febrile illnesses in children  
Site of Research:                Tororo, Uganda 
Principal Investigators: Dr. Sarah Staedke 
Date:    18 September 2010 
 
Introduction 
Dr. Sarah Staedke and colleagues from the Uganda Malaria Surveillance Project / Infectious Diseases 
Research Collaboration are investigating delivery of healthcare services in Tororo District. We are doing a 
research study to see if we can improve the health of children in this area by improving services at 
government-run health facilities.  
 
How is this survey being done? 
Certain health centers in Tororo district will be selected to either take part in the intervention to improve 
services, or to continue with their current services.  Assignment to the two groups has been determined by a 
lottery.  The chance of being placed into either of the groups is the same. To find out how well the 
intervention is working, we would like to review the health of children living near the health centers. We 
plan to carry out three surveys over about 2 years in children from households in this area.  We plan to 
sample 400 children from each area; 200 children under five and 200 children aged 5-15 years. A total of 
8000 children will be sampled in each survey.   
 
Households will be selected to participate by a lottery.  In each household, one child under five and one child 
aged 5-15 years will be eligible to take part.  If more than one child in the correct age group(s) lives in the 
house, we will select one child to take part by a lottery. For the survey, we would like to ask the primary 
caregiver some questions about bednets and treatment of fever in children. We would also like to examine 
your child and carry out some laboratory tests.  
 
What will happen if my child takes part in this survey? 
If you agree to let your child participate in this survey, the following will happen today: 
a) We will ask the primary caregiver some questions about him/herself, use of bednets to prevent 
malaria, and practices for treatment of fever in children. 
 
[_____]—[_____|_____]—[_____|_____|_____|_____]—[_____|_____]  [_____|_____|_____|_____] 
Household ID  CSS Study ID 
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b) We will collect information on your child’s general health.  
c) We will briefly examine your child.  
d)  A blood sample will be taken from your child's finger to examine for malaria parasites, to measure 
blood counts, and to store on filter paper for future research purposes that will not impact on the 
health care of your child.  
e) If your child has had a fever in the last 48 hours (2 days) or has a high temperature, we will do a rapid 
diagnostic test for malaria.  
f) If your child has a positive test for malaria, we will provide treatment with artemether-lumefantrine 
(including Coartem or Lumatem), which is the recommended treatment for simple malaria in Uganda.  
g) If your child has a negative test for malaria, has a low blood count, or has signs of severe malaria or 
another significant illness, we will refer you and your child to an appropriate health center or hospital 
for further care.  
 
How long will these activities last? 
Today the survey activities, including questions, examination, and blood tests will take about 1 hour.  
 
Can I stop my child from being in the survey? 
You can decide to stop participating at any time.  Just tell our study personnel right away if you wish to stop 
the activities. 
 
What risks can I expect if my child participates in the survey? 
We will obtain one blood sample by fingerprick from your child.  The risks of drawing blood from a 
fingerprick include temporary discomfort from the needle stick, bruising, and skin infection.  The amount of 
blood removed will be too small to affect your child’s health. 
 
Participation in any research study may involve a loss of privacy.  Information you provide will be recorded, 
but your name, and your child’s name, will not be used in any reports of the information provided.  The 
information obtained from these survey activities will only be used by the project researchers and will be 
locked at our project offices. We will do our best to make sure that any personal information is kept private.   
 
Are there benefits to letting my child take part in the survey? 
Through the intervention, we aim to improve the health of children in this area by improving services at the 
health centers. There will be no direct benefit to you from participating in this study.  However, the 
information that we gather in this survey will help researchers and policy-makers understand how best to 
improve health services in this area.  
 
What other choices do I have if I do not allow my child to take part in the survey? 
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You are free to choose not to participate in the survey. If you decide not to take part, there will be no 
penalty to you.   
  
What are the costs of taking part in the survey?  Will I be paid for letting my child take part in the survey? 
You and your child will not be charged for any of the treatments or procedures we perform today. However, 
if we refer your child for further evaluation and health care, you will be responsible for all costs for your 
child's health care.  You and your child will not be paid for participation in the survey.   
 
What are my rights if I allow my child to take part in the survey? 
Taking part in this survey is your choice. You may choose either to take part or not to take part.  If you decide 
to take part in this survey, you may change your mind at any time. If you decide to withdraw your child from 
the survey; your child will still be eligible for care at the local health facility and at Tororo District Hospital 
and at other local clinics. No matter what decision you take, there will be no penalty to you in any way. 
 
What if my child is injured as result of being in this survey?  
If your child is injured, or if you have questions about injuries as a result of being in the survey, please 
contact Dr. Sarah Staedke or other members of the Uganda Malaria Surveillance Project / Infectious Disease 
Research Collaboration on telephone number 0414-530692. The sponsoring organizations do not have a 
program to cover your costs if your child is hurt or has other bad results.   
 
Who can answer my questions about the survey? 
You can talk to the researchers about any questions or concerns you have about these survey activities.  
Contact Dr. Sarah Staedke or other members of the Uganda Malaria Surveillance Project / Infectious Disease 
Research Collaboration on telephone number 0414-530692. If you have any questions, comments or 
concerns about taking part in these activities, first talk to the researchers.  If for any reason you do not wish 
to do this, or you still have concerns about doing so, you may contact Dr Charles Ibingira, Makerere 
University Faculty of Medicine Research and Ethical Committee at telephone number 0414-530020. 
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WHAT YOUR SIGNATURE OR THUMBPRINT MEANS 
Your signature or thumbprint below means that you understand the information given to you in this consent 
form about your child’s participation in the survey and agree with the following statements: 
 
1. "I have read the consent form concerning this survey (or have understood the verbal explanation of 
the consent form) and I understand what will be required of me and what will happen to me and my 
child if we take part in it." 
 
2. "My questions concerning this survey have been answered by Dr. Staedke or the person who signed 
below." 
 
3. "I understand that at any time, I may withdraw my child from this survey without giving a reason and 
without affecting my child’s normal health care and management." 
 
4. "I agree that the child under my care will take part in this survey." 
 
You will also be asked to sign another informed consent form for the use of stored specimens. If you wish 
your child to participate in this survey, you should sign or place your thumbprint below.   
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WE WILL GIVE YOU A COPY OF THIS SIGNED AND DATED CONSENT FORM 
 
 
 
Name of Participant (printed) 
 
 
Name of Parent/Guardian     
 
 
Signature or Fingerprint * of Parent/Guardian      Date/Time 
 
 
Name of Investigator Administering Consent (printed)    Position/Title 
 
 
Signature of Investigator Administering Consent     Date/Time 
 
*If the parent or guardian is unable to read and/or write, an impartial witness should be present during the 
informed consent discussion.  After the written informed consent form is read and explained to the 
participant and parent or guardian, and after they have orally consented to their child’s participation in the 
trial, and have either signed the consent form or provided their fingerprint, the witness should sign and 
personally date the consent form.  By signing the consent form, the witness attests that the information in 
the consent form and any other written information was accurately explained to, and apparently understood 
by the parent or guardian, and that informed consent was freely given by the patient and parent or 
guardian. 
 
 
Name of Person Witnessing Consent (printed)    
 
 
Signature of Person Witnessing Consent      Date/Time  
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APPENDIX M. CROSS-SECTIONAL SURVEY 
Informed consent for future use of biological specimens 
  
Protocol Title:  ACT PRIME Study: Evaluating the impact of enhanced health facility-based care 
for malaria and febrile illnesses in children  
Site of Research:                Tororo, Uganda 
Principal Investigators: Dr. Sarah Staedke 
Date:    18 September 2010 
 
INTRODUCTION 
While your child is in this study, there may be blood samples taken from them that may be useful for future 
research.  These samples will be stored long-term at Makerere University Medical School and the London 
School of Hygiene and Tropical Medicine, and the University of California, San Francisco.  Samples may also 
be shared with investigators at other institutions.   
 
WHAT SAMPLES WILL BE USED FOR  
Your child’s blood and the malaria parasites in it will be used to study malaria and the response of this 
disease to treatment.  Results of these studies will not affect your child's care.   
1. These samples will be used for future research to learn more about malaria and other diseases. 
2. Your child’s samples will be used only for research and will not be sold or used for the production of 
commercial products.   
3. Genetic research may be performed on samples.  However, no genetic information obtained from 
this research will be placed in your child’s medical records.  These samples will be identified only by 
codes so that they cannot be readily identified with your child.    
 
LEVEL OF IDENTIFICATION 
Your child’s samples will be coded so that your child’s name cannot be readily identified.  Reports about 
research done with your child’s samples will not be put in their medical record and will be kept confidential 
to the best of our ability.  In the future, researchers studying your child’s samples may need to know more 
about your child, such as their age, gender, and race.  If this information is already available because of your 
child’s participation in a study, it may be provided to the researcher.  Your child’s name or anything that 
might identify them personally will not be provided.   You will not be asked to provide additional consent. 
 
 
[_____]—[_____|_____]—[_____|_____|_____|_____]—[_____|_____]  [_____|_____|_____|_____] 
Household ID  CSS Study ID 
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RISKS  
There are few risks to your child from future use of their samples.  A potential risk might be the release of 
information from your child’s health or study records.  Reports about research done with your child’s 
samples will not be put in their health record, but will be kept with the study records.  The study records will 
be kept confidential as far as possible.   
 
BENEFITS 
There will be no direct benefit to your child.  From studying your child’s samples we may learn more about 
malaria or other diseases: how to prevent them, how to treat them, how to cure them.   
 
RESEARCH RESULTS/MEDICAL RECORDS 
1. Results from future research using your child’s samples may be presented in publications and 
meetings but patient names will not be identified. 
2. Reports from future research done with your child’s samples will not be given to you or your child’s 
doctor.  These reports will not be put in your child’s medical record. 
 
QUESTIONS 
If you have any questions, comments or concerns about the future use of your child’s specimen’s, first talk to 
the researchers. You may also Contact Dr. Sarah Staedke or other members of the Uganda Malaria 
Surveillance Project on telephone number 0414-530692.  If for any reason you do not wish to do this, or you 
still have concerns about the future use of your child’s specimens, you may contact Dr Charles Ibingira, 
Makerere University Faculty of Medicine Research and Ethical Committee at telephone number 0414-
530020. 
 
FREEDOM TO REFUSE 
You can change your mind at any time about allowing your child’s samples to be used for future research.  If 
you do, contact Dr. Staedke or other members of the Uganda Malaria Surveillance Project at the numbers 
listed above.  Then your child’s samples will no longer be made available for research and will be destroyed. 
Whether or not you allow us to use your child’s samples in future research will not have any effect on your 
child’s participation in this study or future participation in other studies. 
 
WHAT YOUR SIGNATURE OR THUMBPRINT MEANS 
Your signature or thumbprint below means that you understand the information given to you in this consent 
form about your child’s specimens to be used for future research.  If you wish to allow your child’s 
specimens to be used for future research, you should sign or place your thumbprint below. 
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WE WILL GIVE YOU A COPY OF THIS SIGNED AND DATED CONSENT FORM 
 
 
 
Name of Participant (printed) 
 
 
Name of Parent/Guardian     
 
 
Signature or Fingerprint * of Parent/Guardian      Date/Time 
 
 
Name of Investigator Administering Consent (printed)    Position/Title 
 
 
Signature of Investigator Administering Consent     Date/Time 
 
*If the parent or guardian is unable to read and/or write, an impartial witness should be present during the 
informed consent discussion.  After the written informed consent form is read and explained to the 
participant and parent or guardian, and after they have orally consented to their child’s participation in the 
trial, and have either signed the consent form or provided their fingerprint, the witness should sign and 
personally date the consent form.  By signing the consent form, the witness attests that the information in 
the consent form and any other written information was accurately explained to, and apparently understood 
by the parent or guardian, and that informed consent was freely given by the patient and parent or 
guardian. 
 
 
Name of Person Witnessing Consent (printed)    
 
 
Signature of Person Witnessing Consent      Date/Time  
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APPENDIX N. CROSS-SECTIONAL SURVEY 
Research participant assent form for children 
  
Protocol Title:  ACT PRIME Study: Evaluating the impact of enhanced health facility-based care 
for malaria and febrile illnesses in children  
Site of Research:                Tororo, Uganda 
Principal Investigators: Dr. Sarah Staedke 
Date:    18 September 2010 
 
― I am being asked to decide if I want to be in this research study. 
― I know that I will have to see the survey field workers today.   
― The field workers will talk to me, ask me questions, and examine me. 
― I know I will have a few drops of blood drawn from my finger today.  
― I asked and got answers to my questions. I know that I can ask questions about this survey at any time. 
― I know that I can stop being in this survey at anytime without anyone being mad at me.  
 
Mark one box with X: 
 
I DO CONSENT:                       I hereby agree to take part in this survey 
 
I DO NOT CONSENT:               I do not wish to take part in this survey 
 
Name of child: 
                                                                             
Signature or 
fingerprint of child: 
                                                                             Date:
 
Witness: I hereby confirm that the study has been explained to the child. All questions (if any) have also been answered 
to his/her satisfaction, and he/she has, of his own free will, consented to take part in the survey. 
 
Name of witness: 
                                                                             
Signature of witness:                                                                              Date:
 
Name of person 
explaining study: 
 
Signature:                                                                              Date:
 
 
[_____]—[_____|_____]—[_____|_____|_____|_____]—[_____|_____]  [_____|_____|_____|_____] 
Household ID  CSS Study ID 
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APPENDIX O: CROSS-SECTIONAL SURVEY QUESTIONNAIRE (1) 
Subcounty ID 
 
[___] 
Village ID 
 
[___|___] 
Compound Number 
 
[___|___|___|___] 
Household Number 
 
[___|___] 
Date of visit 
 
[___|___]/ [___|___]/[___|___] 
da y                 month               yea r 
 
SECTION 1: DATES VISITING THIS HOUSEHOLD 
 DATE APPROACHED 
[dd/mm/yy] 
Primary caregiver able 
to participate in survey? 
1 = Yes      2 =  No 
IF YES, go to  Section  4. 
IF NO, give reason* 
(see below) 
DATE TO  RETURN 
[dd/mm/yy] 
1 [___ ___/___ ___/___ ___] [___] [___] ____________ [___ ___/___ ___/___ ___] 
2 [___ ___/___ ___/___ ___] [___] [___] ____________ [___ ___/___ ___/___ ___] 
3 [___ ___/___ ___/___ ___] [___] [___] ____________ [___ ___/___ ___/___ ___] 
4 [___ ___/___ ___/___ ___] [___] [___] ____________ [___ ___/___ ___/___ ___] 
* 1 = Not Home     2 = C ome ba ck la ter      3  = Not interested      4 = Vacant      77 = Other (Please specify a bove) 
 
SECTION 2: PRIMARY CAREGIVER 
1. “How old are you?” 
 
 
[____|____]years 
2. Gender 1 = Male 
2 = Female [____] 
3. What is the highest level of 
school you completed? 
0 = None 
1 = Primary (P1 — P4) 
2 = Primary (P5 — P7) 
3 = Secondary (S1 —  S4)  
4 = Secondary (S5 —  S6)  
10 = Certifica te/D iploma 
11 = University  
77 = Other 
88 = Don’t know 
99 = Refused to a nswer [____|____] 
4. "What is the main activity or job you do to earn 
income” OR “If you do not have regular employment, 
what other things do you do to earn income?"                            
1 = Peasant farmer 
2 = Commercial fa rmer 
3 = Brew a lcohol 
4 = Market vendor 
5 = Shop keeper 
6 = Transport(D river/rider) 
77 = Other 
88 = Don’t know 
99 = Refused to answer [____|____] 
  
SECTION 3: BEDNETS 
5. “Does your household have any  mosquito  nets?  
If no, go to Se ction 5: Treatment see king 
1 = Yes                 
2 = No 
88 =  D on ’t know 
99 =  Refused to answer [____|____] 
6. “How many  mosquito nets does your household  have?” 
List number [____|____] 
Net 1 Net 2 (if more  than 2 nets, go to extra bednet form) 
7a. “How many months ago d id  you  obtain the mosquito net?” 7b . “How many  months ago did you obtain  the mosquito net?” 
88 =  Don ’t know 
99 =  Refused to answer 
Insert number 
of months 
 
[____|____] 
88 = Don’t know 
99 = Refused to a nswer 
Insert number of 
months 
 
[____|____] 
8a. “From where d id you get the mosquito  
nets? [____|____] 
8b. “From where did you get the mosquito nets? 
[____|____] 
1 = Government health 
center 
2 = Government hospita l 
3 = Private hospita l/clinic 
4 = Private pharma cy 
5 = Shop 
6 = Open market 
7 = Ha wker 
8 = Project/NGO 
9 = Ca mpaign 
10 = Church 
77 = Other 
________________ 
88 = Don’t know 
99 = Refused 
1 = Government hea lth center 
2 = Government hospital 
3 = Private  hospital/clinic 
4 = Private  pha rmacy 
5 = Shop 
6 = O pen ma rket 
7 = Hawker 
8 = Project/NGO 
9 = Campaig n 
10 = Church 
77 = Other 
________________ 
88 = Don’t know 
99 = Refused 
9a. “May I have a look at the mosquito net?”     
(Observe  the net and re cord the  status)  
9b . “May  I have a look at the mosquito  net?”     
(Obse rve the  ne t and record the status)  
1 = Observed and inta ct   
2 = Observed and has visible  holes 
3 = Not a net 
4 = Not observed 
 
[____] 
1 = Observed a nd intact   
2 = Observed a nd ha s visible holes 
3 = Not a net 
4 = Not observed 
 
[____] 
10a. “What is the brand of the mosquito  net?”  (If net was observe d, 
re cord brand; if not, ask the respondent)  If 1, go to Section 5 
10b. “What is the brand  of the mosquito net?” (If ne t was obse rved, 
record brand; if not, ask the  re spondent)  If 1, go to Section 5 
1 = Long lasting net 
(Perma net, Smartnet, Olyset) 
2 = Factory net with 
insecticide kit (KO, Kooper, Ico, 
Sa fi) 
3 = Factory net with no 
insecticide (B52, Ba mboo, 
Century, Lucky, V ictoria ) 
4 = Home made net 
77 =  Other_________ 
 
[____] 
1 = Long la sting  net (Perma net, 
Smartnet, Olyset) 
2 = Fa ctory net with insecticide 
kit (KO, Kooper, Ico, Sa fi) 
3 = Factory net with no 
insecticide (B52, Ba mboo, 
Century, Lucky, V ictoria) 
4 = Home made net 
77 = Other_________ 
 
[____] 
11a. How many months ago was the mosquito net last soaked  or 
dipped in insecticide to  repel mosquitos? 
11b. How many  months ago  was the mosquito net last soaked or 
dipped in  insectic ide to repel mosquitos?  
1 = < 6 mo 
2 = > 6 mo 
3 = Never 
88 =  Don ’t know 
99 = Refused 
to a nswer 
 
[____|____] 
1 = < 6 mo 
2 = > 6 mo 
3 = Never 
88 =  D on ’t know 
99 = Refused 
to a nswer 
 
[____|____] 
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CROSS-SECTIONAL SURVEY QUESTIONNAIRE (2) 
Subcounty ID 
 
[___] 
Village ID 
 
[___|___] 
Compound Number 
 
[___|___|___|___] 
Household Number 
 
[___|___] 
Date of visit 
 
[___|___]/ [___|___]/[___|___] 
da y                 month               yea r 
 
SECTION 4: EXPERIENCE WITH ILLNESS DURING THE PAST TWO WEEKS 
14. "Did any of the children under your care have fever in the past 2 
weeks prior to this survey?"     
1 = Yes                   
2 = No 
88 =  D on ’t know 
99 =  Refused to 
a nswer 
 
[____|____] 
If NO, stop here. 
SECTION 4: PART 1: FIRST ACTION 
“Now we would like to get a detailed step by step description of everything you did to care for your child who fell sick the 
most recently.  There is no right or wrong answer to these questions.  We want you to be as open and honest as possible.” 
15. "What did you do FIRST (including tepid sponging and herbs)?" (choose only one action) 
 
[____|____] 
 1 = Nothing     
2  = Tepid sponging   
3  = Ga ve herbs kept at home   
4  = Ga ve medicines kept a t home 
5 = Boug ht medicines from duka 
6 = Boug ht medicines a t drug shop/pharma cy 
7 = Took to traditional healer            
8  = Took to clinic or hospital     
77 = Other _______________ 
88 = Don’t know 
99 = Refused to a nswer 
If clinic or hospital, go to #16,otherwise  skip to #17  
16. “If you took your child to clinic or hospital, where 
did you go?" 
1 = T ororo District Hospita l                
2 = Private hospital/clinic 
77 =  Other ________________ 
 
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
17. “How long had the child been ill when this FIRST 
action was taken?”               
1 = < 24 hrs   
2 = 1-3 da ys 
3 = 4-7 days 
4 = > 7 days  
77 = O ther  
_____________  
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
MEDICINES GIVEN AS FIRST TREATMENT 
“ If your child took medicine FIRST, what did he/she take?”  (Indicate all that were given as a first action) 
DRUG Number of times 
given per day 
Number of days 
given 
How long had the child been ill when the drug was started? 
1 = < 24 hrs   
2  = 1-3 days 
  
3 = 4-7 da ys 
4 = > 7 days     
 
77 = Other (list) 
88 = Don’t know 
99 = Refused to answer 
18. Panadol  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
19. Aspirin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
20. Chloroquine  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
21. Fansidar (SP) 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
22. CQ+SP  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
23. Amodiaquine  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
24. Quinine  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
25. Coartem  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
26. Septrin (Bactrim)   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
27. Amoxacillin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
28. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
29. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
30. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
31. Unknown [____|____] [____|____] 
 
[____|____]  _______________________ 
IF ILLNESS RESOLVED, skip to Section 5 on treatment outcome 
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CROSS-SECTIONAL SURVEY QUESTIONNAIRE (3) 
Subcounty ID 
 
[___] 
Village ID 
 
[___|___] 
Compound Number 
 
[___|___|___|___] 
Household Number 
 
[___|___] 
Date of visit 
 
[___|___]/ [___|___]/[___|___] 
da y                 month               yea r 
 
SECTION 4: PART 2: SECOND ACTION 
32. "What did you do SECOND (including tepid sponging and herbs)?" (choose only one action) 
 
[____|____] 
 1 = Nothing     
2  = Tepid sponging   
3  = Ga ve herbs kept at home   
4  = Ga ve medicines kept a t home 
5 = Boug ht medicines from duka 
6 = Boug ht medicines a t drug shop/pharma cy 
7 = Took to traditional healer            
8  = Took to clinic or hospital     
77 = Other _______________ 
88 = Don’t know 
99 = Refused to a nswer 
If clinic or hospital, go to #31,otherwise  skip to #32  
33. “If you took your child to clinic or hospital, where 
did you go?" 
1 = T ororo District Hospita l                
2 = Private hospital/clinic 
77 =  Other ________________ 
 
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
34. “How long had the child been ill when this SECOND 
action was taken?”               
1 = < 24 hrs   
2 = 1-3 da ys 
3 = 4-7 days 
4 = > 7 days  
77 = O ther  
_____________  
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
MEDICINES GIVEN AS SECOND TREATMENT 
“If your child took medicine SECOND, what did he/she take?”   (Indicate all that were given as a second action) 
DRUG Number of times 
given per day 
Number of days 
given 
How long had the child been ill when the drug was started? 
1 = < 24 hrs   
2  = 1-3 days 
  
3 = 4-7 da ys 
4 = > 7 days     
 
77 = Other (list) 
88 = Don’t know 
99 = Refused to answer 
35. Panadol 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
36. Aspirin 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
37. Chloroquine 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
38. Fansidar (SP)  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
39. CQ+SP   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
40. Amodiaquine   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
41. Quinine   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
42. Coartem  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
43. Septrin (Bactrim)   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
44. Amoxacillin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
45. Other 
________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
46. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
47. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
48. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
49. Unknown  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
 
IF ILLNESS RESOLVED, skip to Section 5 on treatment outcome 
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CROSS-SECTIONAL SURVEY QUESTIONNAIRE (4) 
Subcounty ID 
 
[___] 
Village ID 
 
[___|___] 
Compound Number 
 
[___|___|___|___] 
Household Number 
 
[___|___] 
Date of visit 
 
[___|___]/ [___|___]/[___|___] 
da y                 month               yea r 
 
SECTION 4: PART 3: THIRD ACTION 
50. "What did you do THIRD (including tepid sponging and herbs)?" (choose only one action) 
 
[____|____] 
 1 = Nothing     
2  = Tepid sponging   
3  = Ga ve herbs kept at home   
4  = Ga ve medicines kept a t home 
5 = Boug ht medicines from duka 
6 = Boug ht medicines a t drug shop/pharma cy 
7 = Took to traditional healer            
8  = Took to clinic or hospital     
77 = Other _______________ 
88 = Don’t know 
99 = Refused to a nswer 
If clinic or hospital, go to #46,otherwise  skip to #47  
33. “If you took your child to clinic or hospital, where 
did you go?" 
1 = T ororo District Hospita l                
2 = Private hospital/clinic 
77 =  Other ________________ 
 
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
34. “How long had the child been ill when this THIRD 
action was taken?”               
1 = < 24 hrs   
2 = 1-3 da ys 
3 = 4-7 days 
4 = > 7 days  
77 = O ther  
_____________  
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
MEDICINES GIVEN AS THIRD TREATMENT 
“If your child took medicine THIRD, what did he/she take?”   (Indicate all that were give n as a third action) 
DRUG Number of times 
given per day 
Number of days 
given 
How long had the child been ill when the drug was started? 
1 = < 24 hrs   
2  = 1-3 days 
  
3 = 4-7 da ys 
4 = > 7 days     
 
77 = Other (list) 
88 = Don’t know 
99 = Refused to answer 
53. Panadol 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
54. Aspirin 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
55. Chloroquine 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
56. Fansidar (SP)  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
57. CQ+SP   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
58. Amodiaquine   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
59. Quinine   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
60. Coartem  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
61. Septrin (Bactrim)   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
62. Amoxacillin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
63. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
64. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
65. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
66. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
67. Unknown  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
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CROSS-SECTIONAL SURVEY QUESTIONNAIRE (5) 
Subcounty ID 
 
[___] 
Village ID 
 
[___|___] 
Compound Number 
 
[___|___|___|___] 
Household Number 
 
[___|___] 
Date of visit 
 
[___|___]/ [___|___]/[___|___] 
da y                 month               yea r 
 
SECTION 5: TREATMENT OUTCOME 
68. "How long did the child's 
illness last?" 
1 = < 24 hrs   
2  = 1-3 days 
3 = 4-7 days     
4  = >7 da ys    
5 = Ongoing  a t time of interview 
77 =  Other________________________ 
88 =  Don ’t know                 
99 =  Refused to answer 
 
 
[____|____] 
69. "Did you experience any 
delays in treating your child's 
illness?"   
1 = Yes   
2  = No  
88 = D on ’t know                 
99 = Refused to answer 
 
[____|____] 
If no, skip to question #67 
70. "What were the reasons for 
the delays?" (list all that apply) 
1 =  No transport a va ila ble                           
2  = Not enough money 
a vailable                      
3  = Needed to find coverage 
for work 
 
4 = Needed to arra nge for child ca re   
5 = Wa iting  at the health facility 
88 =  Don ’t know 
99 =  Refused to answer 
 
[____|____] 
 
[____|____] 
 
[____|____] 
 
[____|____] 
 
[____|____] 
 
[____|____] 
71. "How much did you spend 
on management of this illness?"   
C ost of drugs                          
[____|____|____|____|____]Ush 
         
Fees (clinic, hospital, lab)      
[____|____|____|____|____]Ush 
 
                                       
T ransport                                
[____|____|____|____|____]Ush 
 
O ther                                      
[____|____|____|____|____]Ush 
 
TOTAL 
[____|____|____|____|____]Ush 
72. "Did caring for your child and managing his/her illness prevent 
you from doing your usual activities this month?"     
1 = Yes   
2  = No    
 
88 =  D on ’t know                 
99 =  Refused to answer 
 
[____|____] 
73. “If yes, how much time did you miss?” If < 1 day, indicate number of hours 
otherwise, record 00 
 
                    [____|____] hours 
                    [____|____] days 
 
Field worker 
initials         
 
[____|____] 
Initials of observers present  
at interview           [____|____]     [____|____]     [____|____] 
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APPENDIX P: CROSS-SECTIONAL SURVEY CLINICAL RECORD FORM (1) 
Subcounty ID 
 
[___] 
Village ID 
 
[___|___] 
Compound Number 
 
[___|___|___|___] 
Household Number 
 
[___|___] 
Date of visit 
 
[___|___]/ [___|___]/[___|___] 
day                 month               yea r 
Child’s initials 
[_____|_____] 
Study ID 
[_____|_____|_____|_____] 
Gender 
[_____] 
1 = Male 
2 = Female 
Age: [____|____]/[____|____] 
         years            months 
  
SECTION 1: BEDNETS 
1. “Does this child have (sleep under) a mosquito net? 
 
1 = Yes                 
2  = No 
88 =  D on ’t know 
99 =  Refused to answer [____|____] 
If no, go to Section 2: Case Record Form 
2. “ If yes, did the child sleep under the mosquito net last 
night?” 
1 = Yes                 
2  = No 
88 =  D on ’t know 
99 =  Refused to answer 
 
[____|____] 
3. “How many months ago did you obtain the mosquito net for 
the child?” 
88 = D on’t know 
99 = Refused to answer 
Insert the number 
of months 
 
 
[____|____] 
4. “From where did you get the 
mosquito net? 
1 = Government health center 
2 = Government hospital 
3  = Priva te hospita l/clinic 
4 = Priva te pharma cy 
5 = Shop 
6 = Open market 
7 = Ha wker  
8  = Project/NGO 
9 = Ca mpa ign 
10 =  Church 
77 =  O ther____________ 
88 =  D on ’t know 
99 =  Refused to answer  
[____|____] 
5. “May I have a look at the mosquito net?”     
(Observe the  net and record the status) 
1 = Observed a nd intact   
2 = Observed a nd ha s visible  
3  = Not a  net 
4 = Not observed 
 
[____|____] 
If observed go to #6, if not observed skip to #7 
6. “What is the brand of the mosquito net?”  
(If net was observed, record brand; if not, ask the 
respondent)   
If ‘1’, go to Section 2: Case Record Form 
1 = Long la sting  net (Perma net, Smartnet, Olyset) 
2 = Factory net with insecticide kit (KO net, Kooper net, Ico net, Safi net) 
3 = Factory net with no insecticide  (B52, Bamboo, Century, Lucky net, Victoria) 
4 = Home made net 
77 = Other___________________________________________ 
 
[____|____] 
7. How many months ago was the mosquito net last soaked or 
dipped with insecticide to repel mosquitos? 
1 = < 6months 
2 = > 6 months 
3 = Never 
88 =  D on ’t know 
99 =  Refused to answer 
 
[____|____] 
 
SECTION 2: CASE RECORD FORM 
10. Past medical history (list) ____________________ ____________________________________________ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
11. “Does the child have any drug allergies?” 1 = Yes                                                                                            
2  = No 
88 = Don’t know
99 = Refused to a nswer [____|____] 
12. If yes, to which drugs? (list) ___________________ _________________________________________ 
13. Current medications  
Drug 1 [____|____] 
1 = Panadol                             
2 = Aspirin      
7 = Quinine  
9 = Septrin  
5 = CQ+SP 
8 = Coartem 
 
3 = Chloroquine                     
4  = Fa nsida r (SP)                    
6  =  Amodia quine  
10 =  Amoxa cillin 
11 =  None 
12 =  O ther (list) 
____________________ 
Drug 2 [____|____] 
Drug 3 [____|____] 
Drug 4 [____|____] 
Drug 5 [____|____] 
14. History of fever in the last 48 hours?  1 = Yes                                                                                            
2  = No 
88 = Don’t know
99 = Refused to answer [____] 
15. Temperature (C), Severity* 
[____|____]•[____] 
Severity 
[____] 
16. Weight (kg) 
 [____|____] 
17. Height (cm) 
 [____|____|____] 
19. MUAC (mm) 
 
[____|____|____] 
19. Spleen size, Severity* 
[____] 
Severity 
[____] 
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CROSS-SECTIONAL SURVEY CLINICAL RECORD FORM (2) 
Subcounty ID 
 
[___] 
Village ID 
 
[___|___] 
Compound Number 
 
[___|___|___|___] 
Household Number 
 
[___|___] 
Date of visit 
 
[___|___]/ [___|___]/[___|___] 
day                 month               yea r 
Child’s initials 
[_____|_____] 
Study ID 
[_____|_____|_____|_____] 
 
SECTION 3: FEVER EPISODE 
Complete if there is a history of fever or documented temperature (≥ 38.0°C) 
20. Clinical Notes –  H istory of present illness 
 
 
 
 
 
 
 
 
 
21. Physical examination findings 
 
 
 
 
 
 
 
 
22. RDT result 1 = Positive                                                                                            
2 = Negative 
3 = Not performed
4 = Test failed [____] 
23. Diagnosis 1 = Uncomplicated malaria                                                                                           
2  = Severe ma la ria 
3 = Otitis media 
4 = Pharyngitis 
5  = Upper respiratory tract infection 
6 = Pneumonia 
7 = Gastroenteritis 
8  = Dia rrhea 
9 = D ysentery 
10 = Urina ry tract infection 
11 = Skin infection 
12 = Viral illness 
77 = Other 
88 = Unknown 
 
 [_____|_____] 
24. Was the child referred for additional care?  1  = Yes                                                                                            
2  = No [____] 
25. If yes, where? (specify)  
 
 
26. Medications prescribed  
Drug 1 [____|____] 
1 = Panadol                             
2 = Aspirin      
7 = Quinine  
9 = Septrin  
5 = CQ+SP 
8 = Coartem 
 
3 = Chloroquine                     
4  = Fa nsida r (SP)                    
6  =  Amodia quine  
10 =  Amoxa cillin 
11 =  None 
12 =  O ther (list) 
____________________ 
Drug 2 [____|____] 
Drug 3 [____|____] 
Drug 4 [____|____] 
Drug 5 [____|____] 
 
 
Initials:  [____|____] 
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APPENDIX Q: COHORT STUDY SCREENING FORM 
PART 1: HOUSEHOLD & PARTICIPANT ID 
Subcounty ID 
 
Village ID 
 
Compound number 
 
Household number 
 
Cluster number 
[_____] [_____|_____] [_____|_____|_____|_____] [_____|_____] [_____|_____] 
Screening Date 
 
Screening ID 
 
[_____|_____]/[_____|_____]/[_____|_____] 
da y                              month                             year 
[_____|_____|_____|_____] 
Age If child is less than 1 
year, complete  
months, otherwise 
leave blank 
Gender 
 1 = Male 
2 = Female [_____|_____] / [_____|_____] 
yea rs                                  months 
[_____]      
 
PART 2: SCREENING INTERVIEW with PARENTS/GUARDIANS 
Selection criteria Include Exclude  
1.  Appropriate age 1 = Yes 2 = No  
     —Under five (aged 0 to less than 5 years) [_____] 
2.  Intention to move from Tororo during the follow-up period 1 = No 2 = Yes [_____]     
If any answers are ‘2’ from the EXCLUDE column, exclude from the study. If not, proceed to the next section. 
 
PART 3: INFORMED CONSENT 
Selection criteria Include Exclude  
3. Willingness of parent(s)/guardian(s) to  provide informed consent 1 = Yes 2 = No [_____]     
If any answers are ‘2’ from the EXCLUDE column, exclude from the study. If not, proceed to the next section. 
 
ASSIGN 
STUDY NUMBER 
 
[_____|_____|_____|_____] 
 
 
All criteria for study inclusion met?        
         1  = Yes      
         2  = No     If no, exclude from the study                                              
 
 
[_____]     
Date of enrollment 
 
[______|______]/[______|______]/[______|______] 
day                              month                             yea r 
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APPENDIX R. COHORT STUDY 
Research participant informed consent form 
  
Protocol Title:  ACT PRIME Study: Evaluating the impact of enhanced health facility-based care 
for malaria and febrile illnesses in children  
Site of Research:                Tororo, Uganda 
Principal Investigators: Dr. Sarah Staedke 
Date:    18 September 2010 
 
Introduction 
Dr. Sarah Staedke and colleagues from the Uganda Malaria Surveillance Project / Infectious Diseases 
Research Collaboration are investigating delivery of healthcare services in Tororo District. We are doing a 
research study to see if we can improve the health of children in this area by improving services at 
government-run health facilities.  
 
Why is this study being done? 
Certain health centers in Tororo district will be selected to either take part in the intervention to improve 
services, or to continue with their current services.  Assignment to the two groups has been determined by a 
lottery.  The chance of being placed into either of the groups is the same. To find out how well the 
intervention is working, we would like to review the health of children living near the health centers. We 
plan to invite a group of children under five from 500 households near the health centers to take part in a 2-
year study.   
 
How is this study being done? 
Households will be selected to participate by a lottery.  In each household, all children under five will be 
eligible to take part.  If a new child is born into your household, we will include them.  When children reach 
the age of five, they will be taken out of the study.  A household survey will be conducted at the start of the 
study to learn more about your household and how you manage illnesses in children. We will examine 
children and do blood tests five times during the study.  We will ask members of your household to record 
information about the health of your children and how much you spend on their treatment using a diary 
with pictures. We will visit you once a month to collect the diaries and ask some questions about the health 
of your children.  
 
 
 
[_____]—[_____|_____]—[_____|_____|_____|_____]—[_____|_____]  [_____|_____|_____|_____] 
Household ID  Cohort Study ID 
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What will happen if my child takes part in this study? 
If you agree to let your child (or children) participate in this study, the following will happen today: 
a) We will collect information on your child’s general health and will briefly examine your child.  
b) A blood sample will be taken from your child's finger to examine for malaria parasites and to measure 
blood counts. 
c) We will also store a sample of blood on filter paper for future research purposes that will not impact 
on the health care of your child.  
d) If your child has had a fever in the last 48 hours (2 days) or has a high temperature, we will do a rapid 
diagnostic test for malaria.  
e) If your child has a positive test for malaria, we will provide treatment with artemether-lumefantrine 
(including Coartem or Lumatem), which is the recommended treatment for simple malaria in Uganda.  
f) If your child has a negative test for malaria, has a low blood count, or has signs of severe malaria or 
another significant illness, we will refer you and your child to an appropriate health center or hospital 
for further care.  
g) You will be asked to record information about the health of your child and certain problems using a 
diary with pictures.  You will also be asked to record how much money you spend on your child's 
health care.  We will give you pre-printed forms to help you record this information. You will be given 
instructions on how to complete the forms and will not be required to read in order to complete the 
forms. We will ask that you complete the forms for the duration of the study period (2 years).  A 
member of the study staff will visit you at home at least once a month to collect completed diary 
forms, to give you new forms, and to ask additional questions about the health of your child during 
the previous month.  
h) Either today or within the next two weeks, a member of the study staff will come to your home to ask 
you additional questions about your home and how members of your household manage malaria and 
other illnesses.  We will also answer any questions you might have about how to fill in the diary 
forms.   
 
Every six months for the next 2 years, we will schedule appointments for you and your child. At these 
appointments, the following will happen:   
a) We will examine your child.   
b) A blood sample will be taken from your child's finger to examine for malaria parasites and to 
measure blood counts.  
c) We will also store a sample of blood on filter paper for future research purposes that will not impact 
on the health care of your child.  
d) If your child has had a fever in the last 48 hours (2 days) or has a high temperature, we will do a 
rapid diagnostic test for malaria.  
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e) If your child has a positive test for malaria, we will provide treatment with artemether-lumefantrine 
(including Coartem or Lumatem), which is the recommended treatment for simple malaria in 
Uganda.  
f) If your child has a negative test for malaria, has a low blood count, or has signs of severe malaria or 
another significant illness, we will refer you and your child to an appropriate health center or 
hospital for further care.  
 
How long will these activities last? 
The study will last for 2 years.   
 
Can I stop my child from being in the study? 
You can decide to stop participating at any time.  Just tell our study personnel right away if you wish to stop 
the activities. 
 
What risks can I expect if my child participates in the study? 
We will obtain five blood samples by fingerprick from your child.  The risks of drawing blood from a 
fingerprick include temporary discomfort from the needle stick, bruising, and skin infection.  The amount of 
blood removed will be too small to affect your child’s health.  
 
Participation in any research study may involve a loss of privacy.  Information you provide will be recorded, 
but your name, and your child’s name, will not be used in any reports of the information provided.  The 
information obtained from these study activities will only be used by the project researchers and will be 
locked up at our project offices. We will do our best to make sure that all personal information is kept 
private.   
 
Are there benefits to letting my child take part in the study? 
Through the intervention, we aim to improve the health of children in this area by improving services at the 
health centers. There will be no direct benefit to you from participating in this study.  However, the 
information that we gather in this study will help researchers and policy-makers understand how best to 
improve health services in this area.  
 
What other choices do I have if I do not allow my child to take part in the study? 
You are free to choose not to participate in the study. If you decide not to take part, there will be no penalty 
to you.   
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What are the costs of taking part in the study?  Will I be paid for letting my child take part in the study? 
You and your child will not be charged for any of the treatments or procedures we perform today. However, 
if we refer your child for further evaluation and health care, you will be responsible for all costs for your 
child's health care.  You and your child will not be paid for participation in the study.   
 
What are my rights if I allow my child to take part in the study? 
Taking part in this study is your choice. You may choose either to take part or not to take part.  If you decide 
to take part in this study, you may change your mind at any time. If you decide to withdraw your child from 
the study; your child will still be eligible for care at the local health facility and at Tororo District Hospital and 
at other local clinics. No matter what decision you take, there will be no penalty to you in any way. 
 
What if my child is injured as result of being in this study?  
If your child is injured, or if you have questions about injuries as a result of being in the study, please contact 
Dr. Sarah Staedke or other members of the Uganda Malaria Surveillance Project / Infectious Disease 
Research Collaboration on telephone number 0414-530692. The sponsoring organizations do not have a 
program to cover your costs if your child is hurt or has other bad results.   
 
Who can answer my questions about the study? 
You can talk to the researchers about any questions or concerns you have about these study activities.  
Contact Dr. Sarah Staedke or other members of the Uganda Malaria Surveillance Project / Infectious Disease 
Research Collaboration on telephone number 0414-530692. If you have any questions, comments or 
concerns about taking part in these activities, first talk to the researchers.  If for any reason you do not wish 
to do this, or you still have concerns about doing so, you may contact Dr Charles Ibingira, Makerere 
University Faculty of Medicine Research and Ethical Committee at telephone number 0414-530020. 
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WHAT YOUR SIGNATURE OR THUMBPRINT MEANS 
Your signature or thumbprint below means that you understand the information given to you in this consent 
form about your child’s participation in the study and agree with the following statements: 
 
1. "I have read the consent form concerning this survey (or have understood the verbal explanation of 
the consent form) and I understand what will be required of me and what will happen to me and my 
child if we take part in it." 
 
2. "My questions concerning this survey have been answered by Dr. Staedke or the person who signed 
below." 
 
3. "I understand that at any time, I may withdraw my child from this survey without giving a reason and 
without affecting my child’s normal health care and management." 
 
4. "I agree that the child under my care will take part in this survey." 
 
You will also be asked to sign another informed consent form for the use of stored specimens. If you wish 
your child to participate in this study, you should sign or place your thumbprint below.    
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WE WILL GIVE YOU A COPY OF THIS SIGNED AND DATED CONSENT FORM 
 
 
 
Name of Participant (printed) 
 
 
Name of Parent/Guardian     
 
 
Signature or Fingerprint * of Parent/Guardian      Date/Time 
 
 
Name of Investigator Administering Consent (printed)    Position/Title 
 
 
Signature of Investigator Administering Consent     Date/Time 
 
*If the parent or guardian is unable to read and/or write, an impartial witness should be present during the 
informed consent discussion.  After the written informed consent form is read and explained to the 
participant and parent or guardian, and after they have orally consented to their child’s participation in the 
trial, and have either signed the consent form or provided their fingerprint, the witness should sign and 
personally date the consent form.  By signing the consent form, the witness attests that the information in 
the consent form and any other written information was accurately explained to, and apparently understood 
by the parent or guardian, and that informed consent was freely given by the patient and parent or 
guardian. 
 
 
Name of Person Witnessing Consent (printed)    
 
 
Signature of Person Witnessing Consent      Date/Time  
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APPENDIX S. COHORT STUDY 
Informed consent for future use of biological specimes 
  
Protocol Title:  ACT PRIME Study: Evaluating the impact of enhanced health facility-based care 
for malaria and febrile illnesses in children  
Site of Research:                Tororo, Uganda 
Principal Investigators: Dr. Sarah Staedke 
Date:    18 September 2010 
 
INTRODUCTION 
While your child is in this study, there may be blood samples taken from them that may be useful for future 
research.  These samples will be stored long-term at Makerere University Medical School and the London 
School of Hygiene and Tropical Medicine, and the University of California, San Francisco.  Samples may also 
be shared with investigators at other institutions.   
 
WHAT SAMPLES WILL BE USED FOR  
Your child’s blood and the malaria parasites in it will be used to study malaria and the response of this 
disease to treatment.  Results of these studies will not affect your child's care.   
1. These samples will be used for future research to learn more about malaria and other diseases. 
2. Your child’s samples will be used only for research and will not be sold or used for the production of 
commercial products.   
3. Genetic research may be performed on samples.  However, no genetic information obtained from 
this research will be placed in your child’s medical records.  These samples will be identified only by 
codes so that they cannot be readily identified with your child.    
 
LEVEL OF IDENTIFICATION 
Your child’s samples will be coded so that your child’s name cannot be readily identified.  Reports about 
research done with your child’s samples will not be put in their medical record and will be kept confidential 
to the best of our ability.  In the future, researchers studying your child’s samples may need to know more 
about your child, such as their age, gender, and race.  If this information is already available because of your 
child’s participation in a study, it may be provided to the researcher.  Your child’s name or anything that 
might identify them personally will not be provided.   You will not be asked to provide additional consent. 
 
 
 
[_____]—[_____|_____]—[_____|_____|_____|_____]—[_____|_____]  [_____|_____|_____|_____] 
Household ID  Cohort Study ID 
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RISKS  
There are few risks to your child from future use of their samples.  A potential risk might be the release of 
information from your child’s health or study records.  Reports about research done with your child’s 
samples will not be put in their health record, but will be kept with the study records.  The study records will 
be kept confidential as far as possible.   
 
BENEFITS 
There will be no direct benefit to your child.  From studying your child’s samples we may learn more about 
malaria or other diseases: how to prevent them, how to treat them, how to cure them.   
 
RESEARCH RESULTS/MEDICAL RECORDS 
1. Results from future research using your child’s samples may be presented in publications and 
meetings but patient names will not be identified. 
2. Reports from future research done with your child’s samples will not be given to you or your child’s 
doctor.  These reports will not be put in your child’s medical record. 
 
QUESTIONS 
If you have any questions, comments or concerns about the future use of your child’s specimen’s, first talk to 
the researchers. You may also Contact Dr. Sarah Staedke or other members of the Uganda Malaria 
Surveillance Project on telephone number 0414-530692.  If for any reason you do not wish to do this, or you 
still have concerns about the future use of your child’s specimens, you may contact Dr Charles Ibingira, 
Makerere University Faculty of Medicine Research and Ethical Committee at telephone number 0414-
530020. 
 
FREEDOM TO REFUSE 
You can change your mind at any time about allowing your child’s samples to be used for future research.  If 
you do, contact Dr. Staedke or other members of the Uganda Malaria Surveillance Project at the numbers 
listed above.  Then your child’s samples will no longer be made available for research and will be destroyed. 
Whether or not you allow us to use your child’s samples in future research will not have any effect on your 
child’s participation in this study or future participation in other studies. 
 
WHAT YOUR SIGNATURE OR THUMBPRINT MEANS 
Your signature or thumbprint below means that you understand the information given to you in this consent 
form about your child’s specimens to be used for future research.  If you wish to allow your child’s 
specimens to be used for future research, you should sign or place your thumbprint below. 
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WE WILL GIVE YOU A COPY OF THIS SIGNED AND DATED CONSENT FORM 
 
 
 
Name of Participant (printed) 
 
 
Name of Parent/Guardian     
 
 
Signature or Fingerprint * of Parent/Guardian      Date/Time 
 
 
Name of Investigator Administering Consent (printed)    Position/Title 
 
 
Signature of Investigator Administering Consent     Date/Time 
 
*If the parent or guardian is unable to read and/or write, an impartial witness should be present during the 
informed consent discussion.  After the written informed consent form is read and explained to the 
participant and parent or guardian, and after they have orally consented to their child’s participation in the 
trial, and have either signed the consent form or provided their fingerprint, the witness should sign and 
personally date the consent form.  By signing the consent form, the witness attests that the information in 
the consent form and any other written information was accurately explained to, and apparently understood 
by the parent or guardian, and that informed consent was freely given by the patient and parent or 
guardian. 
 
 
Name of Person Witnessing Consent (printed)    
 
 
Signature of Person Witnessing Consent      Date/Time  
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APPENDIX T: COHORT STUDY CASE RECORD FORM (1) 
Subcounty ID 
[____|____] 
Village ID 
[____|____] 
Compound # 
[____|____|____|____] 
Household # 
[____|____]  
Date ENROLLED: [____|____]/ [____|____]/[____|____] 
                           da y                      month                     yea r 
Study participant’s initials 
[____|____] 
Study ID 
[____|____|____|____] 
Gender 
[____] 
1 = Male 
2 = Female 
 
SECTION 1: BEDNETS 
1. “Does this child have (sleep under) a mosquito net? 
 
1 = Yes                 
2  = No 
88 =  D on’t know 
99 =  Refused to answer [____|____] 
If no, go to Section 2: Case Record Form 
2. “ If yes, did the child sleep under the mosquito net last night?” 1 = Yes                 
2  = No 
88 =  D on’t know 
99 =  Refused to answer 
 
[____|____] 
3. “How many months ago did you obtain the mosquito net for the child?” 88 =  D on ’t know 
99 =  Refused to answer 
Insert the  number of months 
 
 
[____|____] 
4. “From where did you get the mosquito net? 1 = Government hea lth center 
2 = Government hospital 
3  = Priva te  hospita l/clinic 
4  = Priva te  pharma cy 
5 = Shop 
6 = Open ma rket 
7 = Hawker  
8  = Project/NGO 
9 = Ca mpa ign 
10 =  Church 
77 =  O ther____________ 
88 =  D on’t know 
99 =  Refused to answer  
[____|____] 
5. “May I have a look at the mosquito net?”     
(Observe the  net and record the status) 
1 = Observed and intact   
2  = Observed and ha s visible   
3  = Not a  net 
4 = Not observed 
 
[____|____] 
 
6. “What is the brand of the mosquito net?”  (If net was observed, record brand; 
if not, ask the respondent)   
If ‘1’, go to Section 2: Case Record Form 
1 = Long la sting  net (Permanet, Sma rtnet, Olyset) 
2  = Fa ctory net with insecticide kit (KO  net, Kooper net, Ico net, Safi net) 
3  = Fa ctory net with no insecticide (B52, Ba mboo, Century, Lucky net, Victoria ) 
4  = Home ma de net 
77 = O ther___________________________________________ 
 
[____|____] 
7. How many months ago was the mosquito net last soaked or dipped with insecticide to repel 
mosquitos? 
1 = < 6months 
2 = > 6 months 
3 = Never 
88 =  D on’t know 
99 =  Refused to answer 
 
[____|____] 
 
 
 
 
  
    The A CT PRIME St udy 
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COHORT STUDY CASE RECORD FORM (2) 
Subcounty ID 
[____|____] 
Village ID 
[____|____] 
Compound # 
[____|____|____|____] 
Household # 
[____|____] 
Study ID 
[____|____|____|____] 
 
SECTION 2: CASE RECORD FROM 
10. Past medical history (list) _________________________________________________________________________________________________________________________________ 
 
11. “Does the child have any drug 
allergies?” 1 = Yes                                                                                            
2  = No 
88 = I don’t know
99 = Refused to answer                                                                            [___|___] 
12. If yes, to which drugs? (list) 
_________________________ __________________________________________________ 
 ENROLMENT 6 MONTHS 12 MONTHS 18 MONTHS 24 MO NTHS 
DATE 
 
[__ ___/__ ___/___ __] [__ ___/__ ___/___ __] [__ ___/__ ___/___ __] [__ ___/__ ___/___ __] [__ ___/__ ___/___ __] 
13. Current medications  
Drug 1 [___|___] Drug 1 [___|___] Drug 1 [___|___] Drug 1 [___|___] Drug 1 [___|___] 
1 = Panadol                            
2 = Aspirin      
7 = Quinine  
9 = Septrin  
5 = CQ+SP 
8 = Coartem 
 
 
 
3 = C hloroquine                    
4 = Fansidar (SP)                   
6 =  Amodia quine  
10 =  Amoxa cillin 
11 =  None 
12 =  Other (list) 
Drug 2 [___|___] Drug 2 [___|___] Drug 2 [___|___] Drug 2 [___|___] Drug 2 [___|___] 
Drug 3 [___|___] Drug 3 [___|___] Drug 3 [___|___] Drug 3 [___|___] Drug 3 [___|___] 
Drug 4 [___|___] Drug 4 [___|___] Drug 4 [___|___] Drug 4 [___|___] Drug 4 [___|___] 
Drug 5 [___|___] Drug 5 [___|___] Drug 5 [___|___] Drug 5 [___|___] Drug 5 [___|___] 
____________________ ____________________ ____________________ ____________________ ____________________ 
14. Fever in the past 48hrs? 
1 = Yes*     2 =  No      [___]           [___] [___] [___] [___] 
15. Temperature (C), 
Sev erity† 
 
[___|___].[___] 
Severity 
[___] 
 
[___|___].[___] 
Severity 
[___] 
 
[___|___].[___] 
Severity 
[___] 
 
[___|___].[___] 
Severity 
[___] 
 
[___|___].[___] 
Severity 
[___] 
16. Weight (kg) [___|___]  [___|___]  [___|___]  [___|___]  [___|___]  
17. Height (cm) [___|___|___]  [___|___|___]  [___|___|___]  [___|___|___]  [___|___|___]  
18. MUAC  (mm) [___|___|___] [___|___|___] [___|___|___] [___|___|___] [___|___|___] 
19. Sp leen  size, Severity† [____] 
Severity 
[___] [____] 
Severity 
[___] [____] 
Severity 
[___] [____] 
Severity 
[___] [____] 
Severity 
[___] 
* Fever = If child has fever or history of fever, complete Section 5, Fever Episode on page 4 
†Rank severity on scale of 0-5:        0 = Absent        1 = Mild         2 = Moderate        3 = Severe        4 = Life-threatening        5 = Unable to  assess 
  
    The A CT PRIME St udy 
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COHORT STUDY CASE RECORD FORM (3) 
Subcounty ID 
[____|____] 
Village ID 
[____|____] 
Compound # 
[____|____|____|____] 
Household # 
[____|____] 
Study ID 
[____|____|____|____] 
 
SECTION 3: LABORATORY RESULTS 
Rank severity on scale of 0-5: 0 = Absent 1 = Mild 2 = Moderate 3 = Severe 4 = Life-threatening 5 = Unable to assess 
 ENROLMENT 6 MONTHS 12 MO NTHS 18 MONTHS 24 MONTHS 
25. Hemoglobin (g/dL)** [___|___].[___] 
Severity 
[___] [___|___].[___] 
Severity 
[___] [___|___].[___] 
Severity 
[___] [___|___].[___] 
Severity 
[___] [___|___].[___] 
Severity 
[___] 
26. Parasite density (/ul) 
 
[__|__|__|__|__] 
 
[__|__|__|__|__] 
 
[__|__|__|__|__] 
 
[__|__|__|__|__] 
 
[__|__|__|__|__] 
27. Gametocytes  
1 = Yes    2 = No    3 = N/A 
 
[____] 
 
 [____] 
 
 [____] 
 
 [____] 
 
 [____] 
 
 
Hemoglobin  ** = If Hb is < 5.0 g/dL, refer to Tororo District Hospital 
 
SECTION 4: DATA ENTRY 
FIRST DATA ENTRY 
 
 
[__|__]/ [__|__]/[__|__] 
day           month          yea r 
 
[__|__]/ [__|__]/[__|__] 
day           month          yea r 
 
[__|__]/ [__|__]/[__|__] 
day           month          year 
 
[__|__]/ [__|__]/[__|__] 
day           month          year 
 
[__|__]/ [__|__]/[__|__] 
da y           month          year 
In itials:  [____|____] In itials:  [____|____] Initials:  [____|____] Initials:  [____|____] Initia ls:  [____|____] 
SEC OND DATA ENTRY 
 
 
[__|__]/ [__|__]/[__|__] 
day           month          yea r 
 
[__|__]/ [__|__]/[__|__] 
day           month          yea r 
 
[__|__]/ [__|__]/[__|__] 
day           month          year 
 
[__|__]/ [__|__]/[__|__] 
day           month          year 
 
[__|__]/ [__|__]/[__|__] 
da y           month          year 
In itials:  [____|____] In itials:  [____|____] Initials:  [____|____] Initials:  [____|____] Initia ls:  [____|____] 
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COHORT STUDY CASE RECORD FORM (4) 
Subcounty ID 
[____|____] 
Village ID 
[____|____] 
Compound # 
[____|____|____|____] 
Household # 
[____|____]  
Date of VISIT: [____|____]/ [____|____]/[____|____] 
                           da y                      month                     yea r 
Study ID 
[____|____|____|____] 
Visit type 
[____] 
1 = Enrolment 
2 = 6 months 
3 = 12 months 
4 = 18 months 
5 = 24 months 
 
 
SECTION 5: FEVER EPISODE 
Complete ONLY if there is a history of fever or documented temperature (≥ 38.0°C) 
28. Clinical Notes –  H istory of present illness 
 
 
 
29. Physical examination findings 
 
 
30. RDT result 1 = Positive                                                                                            
2 = Negative 
3 = Not performed
4 = Test failed [____] 
31. Diagnosis 1 = Uncomplicated mala ria                                                                                           
2  = Severe ma la ria 
3 = Otitis media 
4 = Pharyngitis 
5  = Upper respiratory tract infection 
6 = Pneumonia
7 = Gastroenteritis 
8 = Diarrhea 
9 = D ysentery 
10 = Urina ry tract infection 
 
11 = Skin infection 
12 = Viral illness 
77 = Other 
88 = Unknown 
 
 [_____|_____] 
32. Was the child referred for additional care?  1 = Yes                                                                                            
2 = No [____] 
33. If yes, where? (specify)  
 
34. Medications prescribed  
Drug 1 [____|____] 
1 = Panadol                             
2 = Aspirin      
7 = Quinine  
9 = Septrin  
5 = CQ+SP 
8 = Coartem 
 
3 = C hloroquine                     
4 = Fansidar (SP)                    
6 =  Amodiaquine  
10 = Amoxacillin 
11 = None 
12 = Other (list) 
____________________ 
Drug 2 [____|____] 
Drug 3 [____|____] 
Drug 4 [____|____] 
Drug 5 [____|____] 
 
Initials:  [____|____] 
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APPENDIX U: COHORT STUDY HOUSEHOLD SURVEY (1) 
Subcounty ID 
 
[___] 
Village ID 
 
[___|___] 
Compound Number 
 
[___|___|___|___] 
Household Number 
 
[___|___] 
Date of visit 
 
[___|___]/ [___|___]/[___|___] 
da y                 month               yea r 
 
SECTION 1: PRIMARY CAREGIVER 
1. “How old are you?” 
 
 
[____|____]years 
2. Gender 1 = Male 
2 = Female [____] 
3. "What is the highest level of school you completed?" 2 = Primary (P5 — P7) 
3 = Secondary (S1 —  S4)  
4 = Secondary (S5 —  S6)  
10 = Certifica te/D iploma  
11 = University  
77 = Other 
88 = Don’t know 
99 = Refused to a nswer [____|____] 
0 = None 
1 = Prima ry (P1 — P4) 
4. "What is the main activity or job you do to earn 
income” OR “If you do not have regular employment, 
what other things do you do to earn income?"                            
1 = Peasant farmer 
2 = Commercial fa rmer 
3 = Brew a lcohol 
4 = Market vendor 
5 = Shop keeper 
6 = Transport(D river/rider) 
77 = Other 
88 = Don’t know 
99 = Refused to answer [____|____] 
 
SECTION 2: HEAD OF HOUSEHOLD  
“Now I would like to ask you some questions about your household.” 
5. "Is the head of the household male or female?"  Skip to 
SECTION 3 if the primary care giver is  also the head of 
household 
1 = Male 
2 = Female  
[____] 
6. "How old is the 
head of household?"  [____|____] 
years 
7. "What is the highest level of school completed by the 
head of household?" 
0 = None 
1 = Primary (P1 — P4) 
2 = Primary (P5 — P7) 
3 = Secondary (S1 —  S4)  
4 = Secondary (S5 —  S6)  
10 =  Certificate/Diploma  
11 =  University  
77 =  O ther 
88 =  D on ’t know 
99 =  Refused to answer [____|____] 
8. "What is the main activity or job the head of 
household does to earn income” OR “ If he/she does not 
have regular employment, what other things does 
he/she do to earn income?"                             
1 = Peasant farmer 
2 = Commercial fa rmer 
3 = Brew a lcohol 
4 = Market vendor 
5 = Shop keeper 
6 = Tra nsport(Driver/rider)  
77 =  O ther 
88 =  D on ’t know 
99 =  Refused to answer [____|____] 
 
SECTION 3: TREATMENT SEEKING BEHAVIOR 
          Attendance of Public health facilities and satisfaction with health care provided  at Public Health facilities 
10. “Have you ever taken your child to a nearby 
public health facility for treatment?” 
1 = Yes                 
2 = No 
88 =  Don’t know 
99 =  Refused to a nswer [____|____] 
11. “If yes, how satisfied were you with the health 
care that your child received at the public health 
facility?” 
1 = Very dissatisfied 
2 = Dissatisfied 
3 = Uncertain 
 
4 = Satisfied 
5 = Very satisfied 
99 =  Refused to a nswer [____|____] 
12. “If dissatisfied or very dissatisfied what were the 
reasons for being dissatisfied?” (List all that apply) 
 
1  = Yes 
2 = No 
 
Long waiting time 
No trained pro fessiona ls 
No drugs were given  
No  lab tests done 
Rude HCW 
 
[____] 
[____] 
[____] 
[____] 
[____] 
 
Had to  pay fo r care  
Treatment was unsuccessful 
Other 
Refused to answer 
 
[____]  
[____] 
[____] 
[____] 
13. “What was the treatment outcome when you 
took your child to the public health facility for health 
care?” 
1= Recovered quickly 
2 = R ecovered slowly 
3 = Did not recover, and so I 
ha d to take child ba ck 
4 = Did not recover, so I soug ht 
ca re  elsewhere 
77 =  Other_________________ 
99 =  Refused to a nswer [____|____] 
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COHORT STUDY HOUSEHOLD SURVEY (2) 
Subcounty ID 
 
[___] 
Village ID 
 
[___|___] 
Compound Number 
 
[___|___|___|___] 
Household Number 
 
[___|___] 
Date of visit 
 
[___|___]/ [___|___]/[___|___] 
da y                 month               yea r 
 
 SECTION 4: BEDNETS 
14. “Does your household have any mosquito nets?  
If no, go to Se ction 5: Treatment see king 
1 = Yes                 
2 = No 
88 =  D on ’t know 
99 =  Refused to answer [____|____] 
15. “How many mosquito  nets does your household have?” 
List number [____|____] 
Net 1 Net 2 (if more  than 2 nets, go to extra bednet form) 
16a. “How many  months ago did you obtain the mosquito net?” 16b. “How many months ago did  you  obtain the mosquito  net?” 
88 =  Don ’t know 
99 =  Refused to answer 
Insert number 
of months 
 
[____|____] 
88 = Don’t know 
99 = Refused to a nswer 
Insert number of 
months 
 
[____|____] 
17a. “From where did you get the mosquito 
nets? [____|____] 
17b. “From where d id  you  get the mosquito nets? 
[____|____] 
1 = Government health 
center 
2 = Government hospita l 
3 = Private hospita l/clinic 
4 = Private pharma cy 
5 = Shop 
6 = Open market 
7 = Ha wker 
8 = Project/NGO 
9 = Ca mpaign 
10 = Church 
77 = Other 
________________ 
88 = Don’t know 
99 = Refused 
1 = Government hea lth center 
2 = Government hospital 
3 = Private  hospital/clinic 
4 = Private  pha rmacy 
5 = Shop 
6 = O pen ma rket 
7 = Hawker 
8 = Project/NGO 
9 = Campaig n 
10 = Church 
77 = Other 
________________ 
88 = Don’t know 
99 = Refused 
18a. “May  I have a look  at the mosquito  net?”     
(O bserve  the net and record the status) 
18b. “May I have a look  at the mosquito net?”    
(Observe the  net and record the status) 
1 = Observed and inta ct   
2 = Observed and has visible  holes 
3 = Not a net 
4 = Not observed 
 
[____] 
1 = Observed a nd intact   
2 = Observed a nd ha s visible holes 
3 = Not a net 
4 = Not observed 
 
[____] 
19a. “What is the brand of the mosquito  net?”  (If net was observed, 
record brand; if not, ask the  respondent)  If 1, go to Section 5 
19b. “What is the brand  of the mosquito net?” (If net was observed, 
record brand; if not, ask the respondent)  If 1, go to Section 5 
1 = Long lasting net 
(Perma net, Smartnet, Olyset) 
2 = Factory net with 
insecticide kit (KO, Kooper, Ico, 
Sa fi) 
3 = Factory net with no 
insecticide (B52, Ba mboo, 
Century, Lucky, V ictoria ) 
4 = Home made net 
77 =  Other_________ 
 
[____] 
1 = Long la sting  net (Perma net, 
Smartnet, Olyset) 
2 = Fa ctory net with insecticide 
kit (KO, Kooper, Ico, Sa fi) 
3 = Factory net with no 
insecticide (B52, Ba mboo, 
Century, Lucky, V ictoria) 
4 = Home made net 
77 = Other_________ 
 
[____] 
20a. How many months ago was the mosquito  net last soaked or 
dipped in insecticide to  repel mosquitos? 
20b. How many  months ago  was the mosquito net last soaked or 
dipped in  insectic ide to repel mosquitos?  
1 = < 6 mo 
2 = > 6 mo 
3 = Never 
88 =  Don ’t know 
99 = Refused 
to a nswer 
 
[____|____] 
1 = < 6 mo 
2 = > 6 mo 
3 = Never 
88 =  D on ’t know 
99 = Refused 
to a nswer 
 
[____|____] 
 
 
  
The A CT PRIM E Study 
 
 
ACT PRIME –  Version 1.1, 18 Sept 2010 
 
 
3 of 7 
COHORT STUDY HOUSEHOLD SURVEY (3) 
Subcounty ID 
 
[___] 
Village ID 
 
[___|___] 
Compound Number 
 
[___|___|___|___] 
Household Number 
 
[___|___] 
Date of visit 
 
[___|___]/ [___|___]/[___|___] 
da y                 month               yea r 
 
SECTION 5: EXPERIENCE WITH ILLNESS DURING THE PAST TWO WEEKS 
“Now I would like to  ask  you about your experiences with illness in this household and about what you do  when your child is sick.” 
22. "“Have any of the children under your care been 
sick  during the past two weeks?”  
1 = Yes                    
2 = No 
88 = Don’t know 
99 = Refused to a nswer 
 
[____|____] 
If no or unknown, skip to End. 
SECTION 6: FIRST  ACTION 
Now we would like to get a detailed step by step description of everything you did to care for your child during the most 
recent illness.  There is no right or wrong answer to these questions.  We need you to be as open and honest as possible.” 
23."Did your child have fever with this episode of illness?" 1=Yes 
2= No 
88= D on ’t know 
99= Refused to answer 
 
[____|____] 
24. "What did you do FIRST (including tepid sponging and herbs)?" (choose only one action) 
[____|____] 
 1 = Nothing     
2  = Tepid sponging   
3  = Ga ve herbs kept a t home   
4  = Ga ve medicines kept a t home 
5 = Boug ht medicines from duka  
6  = Boug ht medicines a t drug shop/pharma cy 
7 = Took to traditiona l hea ler            
8  = Took to clinic or hospital     
77 = Other _______________ 
88 = Don’t know 
99 = Refused to a nswer 
If clinic or hospital, go to #25,otherwise skip to Qn # 26  
16. “If you took your child to clinic or hospital, where 
did you go?" 
1 = T ororo D istrict Hospita l                
2 = Private hospital/clinic 
77 =  Other ________________ 
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
17. “How long had the child been ill when this FIRST 
action was taken?”               
1 = < 24 hrs   
2 = 1-3 da ys 
3 = 4-7 da ys 
4 = > 7 days  
77 =  O ther  
_____________  
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
MEDICINES GIVEN AS FIRST TREATMENT 
“ If your child took medicine FIRST, what did he/she take?”  (Indicate all that were given as a first action) 
DRUG Number of times 
given per day 
Number of days 
given 
How long had the child been ill when the drug was started? 
1 = < 24 hrs   
2  = 1-3 days 
  
3 = 4-7 da ys 
4 = > 7 days     
 
77 = Other (list) 
88 = D on’t know 
99 = Refused to answer 
27. Panadol  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
28. Aspirin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
29. Chloroquine  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
30. Fansidar (SP)  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
31. CQ+SP   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
32. Amodiaquine  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
33. Quinine  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
34. Coartem 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
35. Septrin (Bactrim)  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
36. Amoxacillin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
37. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
38. Unknown  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
IF ILLNESS RESOLVED, skip to Part 1: Section 9: Treatment outcome 
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COHORT STUDY HOUSEHOLD SURVEY (4) 
Subcounty ID 
 
[___] 
Village ID 
 
[___|___] 
Compound Number 
 
[___|___|___|___] 
Household Number 
 
[___|___] 
Date of visit 
 
[___|___]/ [___|___]/[___|___] 
da y                 month               yea r 
 
SECTION 7: SECOND ACTION 
39. "What did you do SECOND (including tepid sponging and herbs)?" (choose only one action) 
 
[____|____] 
 1 = Nothing     
2  = Tepid sponging   
3  = Ga ve herbs kept at home   
4  = Ga ve medicines kept a t home 
5 = Boug ht medicines from duka 
6 = Boug ht medicines a t drug shop/pharma cy 
7 = Took to traditional healer            
8  = Took to clinic or hospital     
77 = Other _______________ 
88 = Don’t know 
99 = Refused to a nswer 
If clinic or hospital, go to Qn.#40,otherwise skip to Qn # 41  
40. “If you took your child to clinic or hospital, where 
did you go?" 
1 = T ororo District Hospita l                
2 = Private hospital/clinic 
77 =  Other ________________ 
 
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
41. “How long had the child been ill when this SECOND 
action was taken?”               
1 = < 24 hrs   
2 = 1-3 da ys 
3 = 4-7 days 
4 = > 7 days  
77 = O ther  
_____________  
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
MEDICINES GIVEN AS SECOND TREATMENT 
“If your child took medicine SECOND, what did he/she take?”   (Indicate all that were given as a second action) 
DRUG Number of times 
given per day 
Number of days 
given 
How long had the child been ill when the drug was started? 
1 = < 24 hrs   
2  = 1-3 days 
  
3 = 4-7 da ys 
4 = > 7 days     
 
77 = Other (list) 
88 = Don’t know 
99 = Refused to answer 
42. Panadol 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
43. Aspirin 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
44. Chloroquine 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
45. Fansidar (SP)  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
46. CQ+SP   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
47. Amodiaquine   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
48. Quinine   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
49. Coartem  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
50. Septrin (Bactrim)   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
51. Amoxacillin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
52. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
53. Unknown 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
 
IF ILLNESS RESOLVED, skip to Part 1: Section 9: Treatment outcome 
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COHORT STUDY HOUSEHOLD SURVEY (5) 
Subcounty ID 
 
[___] 
Village ID 
 
[___|___] 
Compound Number 
 
[___|___|___|___] 
Household Number 
 
[___|___] 
Date of visit 
 
[___|___]/ [___|___]/[___|___] 
da y                 month               yea r 
 
SECTION 8: THIRD ACTION 
54. "What did you do THIRD (including tepid sponging and herbs)?" (choose only one action) 
 
[____|____] 
 1 = Nothing     
2  = Tepid sponging   
3  = Ga ve herbs kept at home   
4  = Ga ve medicines kept a t home 
5 = Boug ht medicines from duka 
6 = Boug ht medicines a t drug shop/pharma cy 
7 = Took to traditional healer            
8  = Took to clinic or hospital     
77 = Other _______________ 
88 = Don’t know 
99 = Refused to a nswer 
If clinic or hospital, go to Qn.#55,otherwise skip to Qn.#56  
55. “If you took your child to clinic or hospital, where 
did you go?" 
1 = T ororo District Hospita l                
2 = Private hospital/clinic 
77 =  Other ________________ 
 
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
56. “How long had the child been ill when this THIRD 
action was taken?”               
1 = < 24 hrs   
2 = 1-3 da ys 
3 = 4-7 days 
4 = > 7 days  
77 = O ther  
_____________  
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
MEDICINES GIVEN AS THIRD TREATMENT 
“If your child took medicine THIRD, what did he/she take?”   (Indicate all that were give n as a third action) 
DRUG Number of times 
given per day 
Number of days 
given 
How long had the child been ill when the drug was started? 
1 = < 24 hrs   
2  = 1-3 days 
  
3 = 4-7 da ys 
4 = > 7 days     
 
77 = Other (list) 
88 = Don’t know 
99 = Refused to answer 
57. Panadol 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
58. Aspirin 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
59. Chloroquine 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
60. Fansidar (SP)  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
61. CQ+SP   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
62. Amodiaquine   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
63. Quinine   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
64. Coartem  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
65. Septrin (Bactrim)   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
66. Amoxacillin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
67. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
68. Unknown 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
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COHORT STUDY HOUSEHOLD SURVEY (6) 
Subcounty ID 
 
[___] 
Village ID 
 
[___|___] 
Compound Number 
 
[___|___|___|___] 
Household Number 
 
[___|___] 
Date of visit 
 
[___|___]/ [___|___]/[___|___] 
da y                 month               yea r 
 
SECTION 9: TREATMENT OUTCOME 
69. "How long did the child's 
illness last?" 
1 = < 24 hrs   
2  = 1-3 days 
3 = 4-7 days     
4  = >7 da ys    
5 = Ongoing  a t time of interview 
77 =  Other________________________ 
88 =  Don ’t know                 
99 =  Refused to answer 
 
 
[____|____] 
70. "Did you experience any 
delays in treating your child's 
illness?"   
1 = Yes   
2  = No  
88 = D on ’t know                 
99 = Refused to answer 
 
[____|____] 
If no, skip to question #72 
71. "What were the reasons for 
the delays?" (list all that apply) 
1 =  No transport a va ila ble                           
2  = Not enough money 
a vailable                      
3  = Needed to find coverage 
for work 
 
4 = Needed to arra nge for child ca re   
5 = Wa iting  at the health facility 
88 =  Don ’t know 
99 =  Refused to answer 
 
[____|____] 
 
[____|____] 
 
[____|____] 
 
[____|____] 
 
[____|____] 
 
[____|____] 
72. "How much did you spend 
on management of this illness?"   
C ost of drugs                          
[____|____|____|____|____]Ush 
         
Fees (clinic, hospital, lab)      
[____|____|____|____|____]Ush 
 
                                       
T ransport                                
[____|____|____|____|____]Ush 
 
O ther                                      
[____|____|____|____|____]Ush 
 
TOTAL 
[____|____|____|____|____]Ush 
73. "Did caring for your child and managing his/her illness prevent 
you from doing your usual activities this month?"     
1 = Yes   
2  = No    
 
88 =  D on ’t know                 
99 =  Refused to answer 
 
[____|____] 
74. “If yes, how much time did you miss?” If < 1 day, indicate number of hours 
otherwise, record 00 
 
                    [____|____] hours 
                    [____|____] days 
 
 
Field worker 
initials         
 
[____|____] 
Initials of observers present  
at interview           [____|____]     [____|____]     [____|____] 
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COHORT STUDY HOUSEHOLD SURVEY (7) 
PART 2: WOMAN – BIRTH HISTORY 
PART 2 to be completed only on the last household survey interview. 
Subcounty ID 
 
[___] 
Village ID 
 
[___|___] 
Compound Number 
 
[___|___|___|___] 
Household Number 
 
[___|___] 
Date of visit 
 
[___|___]/ [___|___]/[___|___] 
da y                 month               yea r 
 
 “Now I would like to ask you about all the births you have had during your life.” 
75. “How many children have you given 
birth to in your life?”   [____|____] 
0 = None 
1 = O ne or more 
99 = Refused to answer 
 
If one or more, list total 
number of children 
76. Birthed: 
[____|____] 
77. Alive:  
[____|____] 
78. Died: 
[____|____] 
 Date of b irth 
Gender 
1 = Male 
2 = Female 
Is the ch ild 
aliv e now? 
1 = Yes 
2 = No 
If the ch ild has d ied, how o ld was the ch ild  
when s(he) died?   
(If <1 month a t dea th, enter 0 YEARS 0 MONTHs) 
79. Child 1 
 
Month  [___|___] Year  [___|___] [___] [___] Month  [___|___] Year  [___|___] 
80. Child 2 
 
Month  [___|___] Year  [___|___] [___] [___] Month  [___|___] Year  [___|___] 
81. Child 3 
 
Month  [___|___] Year  [___|___] [___] [___] Month  [___|___] Year  [___|___] 
82. Child 4 
 
Month  [___|___] Year  [___|___] [___] [___] Month  [___|___] Year  [___|___] 
83. Child 5 
 
Month  [___|___] Year  [___|___] [___] [___] Month  [___|___] Year  [___|___] 
84. Child 6 
 
Month  [___|___] Year  [___|___] [___] [___] Month  [___|___] Year  [___|___] 
85. Child 7 
 
Month  [___|___] Year  [___|___] [___] [___] Month  [___|___] Year  [___|___] 
86. Child 8 
 
Month  [___|___] Year  [___|___] [___] [___] Month  [___|___] Year  [___|___] 
87. Child 9 
 
Month  [___|___] Year  [___|___] [___] [___] Month  [___|___] Year  [___|___] 
 
If more than 9 children born to the 
respondent, please continue on page 5 
(supplement) 
Key for Child Births 
and Deaths 
If primary caregiver 
states: 
‘Beginning of the year’ For ‘Month’, enter:  2 fo r February 
‘Middle of the year’ For ‘Month’, enter:  6 fo r June 
‘End of year’ For ‘Month’, enter:  11 for November 
 
Home visitor        
 
[____|____] Observers present at interview           [____|____]     [____|____]     [____|____] 
 
 
A PPEN DIX V:  COHOR T STUDY PICTORI AL DIARIES 
 
[_____]—[_____|_____]—[_____|_____|_____|_____]—[_____|_____] [_____|_____|_____|_____]  [____|____]/ [____|____]/[____|____] 
Household ID Cohort S tudy  ID S tart date (day / month / year) 
 
SYMPTOMS 
1  
Monday 
Tich ach iel 
 
2   
Tuesday 
Tich aryo 
3 
Wed 
Tich ad ek 
4 
Thursday 
Tich angwen 
5 
Friday 
T ich  abich 
6  
Saturday 
Mukaaga 
7  
Sunday 
Sab iti 
1   
Monday 
T ich  achiel 
2   
Tu esday 
Tich aryo 
3 
Wed 
Tich adek 
4 
Thu rsday 
Tich ang wen 
5 
Friday 
Tich ab ich 
6  
Saturday 
M ukaaga 
7  
Sunday 
Sab iti 
DATE               
 
              
 
              
 
              
 
              
 
              
 
A PPEN DIX V:  COHOR T STUDY PICTORI AL DIARIES 
 
 
EXPENDITURES 
Health care fees 
1  
Monday 
Tich ach iel 
2   
Tuesday 
Tich aryo 
3 
Wed 
Tich ad ek 
4 
Thursday 
Tich angwen 
5 
Friday 
T ich  abich 
6  
Saturday 
Mukaaga 
7  
Sunday 
Sab iti 
1   
Monday 
T ich  achiel 
2   
Tu esday 
Tich aryo 
3 
Wed 
Tich adek 
4 
Thu rsday 
Tich ang wen 
5 
Friday 
Tich ab ich 
6  
Saturday 
M ukaaga 
7  
Sunday 
Sab iti 
DATE               
 
              
100 
              
200 
              
500 
              
 
1000 
              
 
2000 
              
 
5000 
              
 
10000 
              
A PPEN DIX V:  COHOR T STUDY PICTORI AL DIARIES 
 
 
EXPENDITURES 
Transport 
1  
Monday 
Tich ach iel 
2   
Tuesday 
Tich aryo 
3 
Wed 
Tich ad ek 
4 
Thursday 
Tich angwen 
5 
Friday 
T ich  abich 
6  
Saturday 
Mukaaga 
7  
Sunday 
Sab iti 
1   
Monday 
T ich  achiel 
2   
Tu esday 
Tich aryo 
3 
Wed 
Tich adek 
4 
Thu rsday 
Tich ang wen 
5 
Friday 
Tich ab ich 
6  
Saturday 
M ukaaga 
7  
Sunday 
Sab iti 
DATE               
 
  
          
100 
              
200 
              
500 
              
 
1000 
              
 
2000 
              
 
5000 
              
 
10000 
              
 
A PPEN DIX V:  COHOR T STUDY PICTORI AL DIARIES 
 
EXPENDITURES 
Medications 
1  
Monday 
Tich ach iel 
2   
Tuesday 
Tich aryo 
3 
Wed 
Tich ad ek 
4 
Thursday 
Tich angwen 
5 
Friday 
T ich  abich 
6  
Saturday 
Mukaaga 
7  
Sunday 
Sab iti 
1   
Monday 
T ich  achiel 
2   
Tu esday 
Tich aryo 
3 
Wed 
Tich adek 
4 
Thu rsday 
Tich ang wen 
5 
Friday 
Tich ab ich 
6  
Saturday 
M ukaaga 
7  
Sunday 
Sab iti 
DATE               
 
              
100 
              
200 
              
500 
              
 
1000 
              
 
2000 
              
 
5000 
              
 
10000 
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APPENDIX W: COHORT STUDY MONTHLY QUESTIONNAIRE (1) 
Subcounty ID 
[____|____] 
Village ID 
[____|____] 
Compound # 
[____|____|____|____] 
Household # 
[____|____] 
Study ID 
[____|____|____|____] 
Date of visit 
[___|___]/ [___|___]/[___|___] 
day                 month               year 
Visit # 
[____|____] 
 
PART 1: EXPERIENCE WITH ILLNESS DURING THE PAST MONTH 
1. “Has your child been sick since our last visit?” 1 = Yes 
2 = No 
88 =  Don’t know 
99 =  Refused to a nswer 
 
[____|____] 
2. “ If yes, how many episodes of illness did your child have since 
our last visit?” 
Insert number 
 
88 =  Don’t know 
99= Refused to answer 
 
[____|____] 
PART 1: SECTION 1: FIRST ACTION 
“No w we wou ld  lik e to get a  deta iled step by  step  description  of everything you d id  to care fo r your ch ild  du ring  each  illness ep isode during the past one 
month .  There is no  righ t o r wrong answer to these question s.  We need  you to be as open and honest as po ssible.” 
3."Did your child have fever with this episode of illness?" 1=Yes 
2= No 
88= D on ’t know 
99= Refused to answer 
 
[____|____] 
4. "What did you do FIRST (including tepid sponging and herbs)?" (choose only one action) 
 
[____|____] 
 1 = Nothing     
2  = Tepid sponging   
3  = Ga ve herbs kept at home   
4  = Ga ve medicines kept a t home 
5 = Boug ht medicines from duka 
6 = Boug ht medicines a t drug shop/pharma cy 
7 = Took to traditional healer            
8  = Took to clinic or hospital     
77 = Other _______________ 
88 = Don’t know 
99 = Refused to a nswer 
If clinic or hospital, go to Qn.# 5,otherwise skip to Qn # 6  
5. “ If you took your child to clinic or hospital, where 
did you go?" 
1 = T ororo D istrict Hospita l                
2 = Private hospital/clinic 
77 =  Other ________________ 
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
6. “How long had the child been ill when this FIRST 
action was taken?”               
1 = < 24 hrs   
2 = 1-3 da ys 
3 = 4-7 da ys 
4 = > 7 days  
77 =  O ther  
_____________  
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
MEDICINES GIVEN AS FIRST TREATMENT 
“ If your child took medicine FIRST, what did he/she take?”  (Indicate all that were given as a first action) 
DRUG Number of times 
given per day 
Number of days 
given 
How long had the child been ill when the drug was started? 
1 = < 24 hrs   
2  = 1-3 days 
  
3 = 4-7 da ys 
4 = > 7 days     
 
77 = Other (list) 
88 = D on’t know 
99 = Refused to answer 
7. Panadol  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
8. Aspirin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
9. Chloroquine  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
10. Fansidar (SP)  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
11. CQ+SP  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
12. Amodiaquine  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
13. Quinine  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
14. Coartem 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
15. Septrin (Bactrim)   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
16. Amoxacillin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
17. Other 
_______________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
18. Unknown  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
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COHORT STUDY MONTHLY QUESTIONNAIRE (2) 
Study ID 
[____|____|____|____] 
Date of visit 
[___|___]/ [___|___]/[___|___] 
day                 month               year 
Visit # 
[____|____] 
 
PART 1: SECTION 2: SECOND ACTION 
19. "What did you do SECOND (including tepid sponging and herbs)?" (choose only one action) 
 
[____|____] 
 1 = Nothing     
2  = Tepid sponging   
3  = Ga ve herbs kept at home   
4  = Ga ve medicines kept a t home 
5 = Boug ht medicines from duka 
6 = Boug ht medicines a t drug shop/pharma cy 
7 = Took to traditional healer            
8  = Took to clinic or hospital     
77 = Other _______________ 
88 = Don’t know 
99 = Refused to a nswer 
If clinic or hospital, go to Qn. # 20,otherwise skip to Qn. # 21  
20. “If you took your child to clinic or hospital, where 
did you go?" 
1 = T ororo District Hospita l                
2 = Private hospital/clinic 
77 =  Other ________________ 
 
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
21. “How long had the child been ill when this SECOND 
action was taken?”               
1 = < 24 hrs   
2 = 1-3 da ys 
3 = 4-7 days 
4 = > 7 days  
77 = O ther  
_____________  
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
MEDICINES GIVEN AS SECOND TREATMENT 
“If your child took medicine SECOND, what did he/she take?”   (Indicate all that were given as a second action) 
DRUG Number of times 
given per day 
Number of days 
given 
How long had the child been ill when the drug was started? 
1 = < 24 hrs   
2  = 1-3 days 
  
3 = 4-7 da ys 
4 = > 7 days     
 
77 = Other (list) 
88 = Don’t know 
99 = Refused to a nswer 
22. Panadol  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
23. Aspirin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
24. Chloroquine  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
25. Fansidar (SP)  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
26. CQ+SP   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
27. Amodiaquine   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
28. Quinine   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
29. Coartem 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
30. Septrin (Bactrim)  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
31. Amoxacillin 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
32. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
33. Unknown  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
IF ILLNESS RESOLVED, skip to Part 1: Section 4: Treatment outcome 
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COHORT STUDY MONTHLY QUESTIONNAIRE (3) 
Study ID 
[____|____|____|____] 
Date of visit 
[___|___]/ [___|___]/[___|___] 
day                 month               year 
Visit # 
[____|____] 
 
PART 1: SECTION 3: THIRD ACTION 
34. "What did you do THIRD (including tepid sponging and herbs)?" (choose only one action) 
 
[____|____] 
 1 = Nothing     
2  = Tepid sponging   
3  = Ga ve herbs kept at home   
4  = Ga ve medicines kept a t home 
5 = Boug ht medicines from duka 
6 = Boug ht medicines a t drug shop/pharma cy 
7 = Took to traditional healer            
8  = Took to clinic or hospital     
77 = Other _______________ 
88 = Don’t know 
99 = Refused to a nswer 
If clinic or hospital, go to Qn.#35,otherwise skip to Qn # 36  
35. “If you took your child to clinic or hospital, where 
did you go?" 
1 = T ororo District Hospita l                
2 = Private hospital/clinic 
77 =  Other ________________ 
 
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
36. “How long had the child been ill when this THIRD 
action was taken?”               
1 = < 24 hrs   
2 = 1-3 da ys 
3 = 4-7 days 
4 = > 7 days  
77 = O ther  
_____________  
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
MEDICINES GIVEN AS THIRD TREATMENT 
“If your child took medicine THIRD, what did he/she take?”   (Indicate all that were give n as a third action) 
DRUG Number of times 
given per day 
Number of days 
given 
How long had the child been ill when the drug was started? 
1 = < 24 hrs   
2  = 1-3 days 
  
3 = 4-7 da ys 
4 = > 7 days     
 
77 = Other (list) 
88 = Don’t know 
99 = Refused to answer 
37. Panadol  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
38. Aspirin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
39. Chloroquine  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
40. Fansidar (SP)  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
41. CQ+SP  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
42. Amodiaquine  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
43. Quinine  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
44. Coartem 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
45. Septrin (Bactrim)   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
46. Amoxacillin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
47. Other 
________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
48. Unknown  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
IF ILLNESS RESOLVED, go to Part 1: Section 4: Treatment outcome, otherwise continue sequence of events on 
MONTHLY QUESTIONNAIRE form (PART 2). 
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COHORT STUDY MONTHLY QUESTIONNAIRE (4) 
Study ID 
[____|____|____|____] 
Date of visit 
[___|___]/ [___|___]/[___|___] 
day                 month               year 
Visit # 
[____|____] 
 
PART 1: SECTION 4: TREATMENT OUTCOME 
49. "How long did the child's 
illness last?" 
1 = < 24 hrs   
2  = 1-3 days 
3 = 4-7 days     
4  = >7 da ys    
5 = Ongoing  a t time of interview 
77 =  Other________________________ 
88 =  Don ’t know                 
99 =  Refused to answer 
 
 
[____|____] 
50. "Did you experience any 
delays in treating your child's 
illness?"   
1 = Yes   
2  = No  
88 = D on ’t know                 
99 = Refused to answer 
 
[____|____] 
If no, skip to question #52 
51. "What were the reasons for 
the delays?" (list all that apply) 
1 =  No transport a va ila ble                           
2  = Not enough money 
a vailable                      
3  = Needed to find coverage 
for work 
 
4 = Needed to arra nge for child ca re   
5 = Wa iting  at the health facility 
88 =  Don ’t know 
99 =  Refused to answer 
 
[____|____] 
 
[____|____] 
 
[____|____] 
 
[____|____] 
 
[____|____] 
 
[____|____] 
52. "How much did you spend 
on management of this illness?"   
C ost of drugs                          
[____|____|____|____|____]Ush 
         
Fees (clinic, hospital, lab)      
[____|____|____|____|____]Ush 
 
                                       
T ransport                                
[____|____|____|____|____]Ush 
 
O ther                                      
[____|____|____|____|____]Ush 
 
TOTAL 
[____|____|____|____|____]Ush 
73. "Did caring for your child and managing his/her illness prevent 
you from doing your usual activities this month?"     
1 = Yes   
2  = No    
 
88 =  D on ’t know                 
99 =  Refused to answer 
 
[____|____] 
74. “If yes, how much time did you miss?” If < 1 day, indicate number of hours 
otherwise, record 00 
 
                    [____|____] hours 
                    [____|____] days 
 
 
Field worker 
initials         
 
[____|____] 
Initials of observers present  
at interview           [____|____]     [____|____]     [____|____] 
 
 
If the child experienced an additional episode of illness, go to Part 2 and complete the information for additional episodes. 
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COHORT STUDY MONTHLY QUESTIONNAIRE (5) 
Study ID 
[____|____|____|____] 
Date of visit 
[___|___]/ [___|___]/[___|___] 
day                 month               year 
Visit # 
[____|____] 
 
PART 2: EXPERIENCE WITH ILLNESS DURING THE PAST MONTH – Extra fever episodes 
PART 2: SECTION 1: FIRST ACTION 
“Now we would like to get a detailed step by step description of everything you did to care for your child during each illness 
episode during the past one month.  There is no right or wrong answer to these questions.  We nned you to be as open and 
honest as possible.” 
55."Did your child have fever with this episode of illness?" 
 
1=Yes 
2= No 
88= D on ’t know 
99= Refused to answer 
 
[____|____] 
56. "What did you do FIRST (including tepid sponging and herbs)?" (choose only one action) 
 
[____|____] 
 1 = Nothing     
2  = Tepid sponging   
3  = Ga ve herbs kept at home   
4  = Ga ve medicines kept a t home 
5 = Boug ht medicines from duka 
6 = Boug ht medicines a t drug shop/pharma cy 
7 = Took to traditional healer            
8  = Took to clinic or hospital     
77 = Other _______________ 
88 = Don’t know 
99 = Refused to a nswer 
If clinic or hospital, go to #57,otherwise  skip to Qn # 58 
57. “If you took your child to clinic or hospital, where 
did you go?" 
1 = T ororo D istrict Hospita l                
2 = Private hospital/clinic 
77 =  Other ________________ 
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
58. “How long had the child been ill when this FIRST 
action was taken?”               
1 = < 24 hrs   
2 = 1-3 da ys 
3 = 4-7 da ys 
4 = > 7 days  
77 =  O ther  
_____________  
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
MEDICINES GIVEN AS FIRST TREATMENT 
“ If your child took medicine FIRST, what did he/she take?”  (Indicate all that were given as a first action) 
DRUG Number of times 
given per day 
Number of days 
given 
How long had the child been ill when the drug was started? 
1 = < 24 hrs   
2  = 1-3 days 
  
3 = 4-7 da ys 
4 = > 7 days     
 
77 = Other (list) 
88 = D on’t know 
99 = Refused to answer 
59. Panadol  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
60. Aspirin 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
61. Chloroquine 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
62. Fansidar (SP) 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
63. CQ+SP  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
64. Amodiaquine   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
65. Quinine   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
66. Coartem  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
67. Septrin (Bactrim)   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
68. Amoxacillin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
69. Other 
_______________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
70. Unknown  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
IF ILLNESS RESOLVED, skip to Part 2: Section 4: Treatment outcome 
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COHORT STUDY MONTHLY QUESTIONNAIRE (6) 
Study ID 
[____|____|____|____] 
Date of visit 
[___|___]/ [___|___]/[___|___] 
day                 month               year 
Visit # 
[____|____] 
 
PART 2: SECTION 2: SECOND ACTION 
71. "What did you do SECOND (including tepid sponging and herbs)?" (choose only one action) 
 
[____|____] 
 1 = Nothing     
2  = Tepid sponging   
3  = Ga ve herbs kept at home   
4  = Ga ve medicines kept a t home 
5 = Boug ht medicines from duka 
6 = Boug ht medicines a t drug shop/pharma cy 
7 = Took to traditional healer            
8  = Took to clinic or hospital     
77 = Other _______________ 
88 = Don’t know 
99 = Refused to a nswer 
If clinic or hospital, go to #72,otherwise skip to Qn # 73  
72. “If you took your child to clinic or hospital, where 
did you go?" 
1 = T ororo District Hospita l                
2 = Private hospital/clinic 
77 =  Other ________________ 
 
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
73. “How long had the child been ill when this SECOND 
action was taken?”               
1 = < 24 hrs   
2 = 1-3 da ys 
3 = 4-7 days 
4 = > 7 days  
77 = O ther  
_____________  
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
74. Panadol  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
75. Aspirin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
76. Chloroquine  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
77. Fansidar (SP)  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
78. CQ+SP   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
79. Amodiaquine   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
80. Quinine  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
81. Coartem 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
82. Septrin (Bactrim)  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
83. Amoxacillin 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
84. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
85. Unknown  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
IF ILLNESS RESOLVED, skip to Part 2: Section 4: Treatment outcome 
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COHORT STUDY MONTHLY QUESTIONNAIRE (7) 
Study ID 
[____|____|____|____] 
Date of visit 
[___|___]/ [___|___]/[___|___] 
day                 month               year 
Visit # 
[____|____] 
 
PART 2: SECTION 3: THIRD ACTION 
86. "What did you do THIRD (including tepid sponging and herbs)?" (choose only one action) 
 
[____|____] 
 1 = Nothing     
2  = Tepid sponging   
3  = Ga ve herbs kept at home   
4  = Ga ve medicines kept a t home 
5 = Boug ht medicines from duka 
6 = Boug ht medicines a t drug shop/pharma cy 
7 = Took to traditional healer            
8  = Took to clinic or hospital     
77 = Other _______________ 
88 = Don’t know 
99 = Refused to a nswer 
If clinic or hospital, go to 87,otherwise  skip to Qn #88  
87. “If you took your child to clinic or hospital, where 
did you go?" 
1 = T ororo District Hospita l                
2 = Private hospital/clinic 
77 =  Other ________________ 
 
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
88. “How long had the child been ill when this THIRD 
action was taken?”               
1 = < 24 hrs   
2 = 1-3 da ys 
3 = 4-7 days 
4 = > 7 days  
77 = O ther  
_____________  
88 =  D on ’t know 
99 =  Refused to answer 
 
 
[____|____] 
MEDICINES GIVEN AS THIRD TREATMENT 
“If your child took medicine THIRD, what did he/she take?”   (Indicate all that were give n as a third action) 
DRUG Number of times 
given per day 
Number of days 
given 
How long had the child been ill when the drug was started? 
1 = < 24 hrs   
2  = 1-3 days 
  
3 = 4-7 da ys 
4 = > 7 days     
 
77 = Other (list) 
88 = Don’t know 
99 = Refused to a nswer 
89. Panadol  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
90. Aspirin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
91. Chloroquine  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
92. Fansidar (SP)  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
93. CQ+SP  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
94. Amodiaquine  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
95. Quinine  
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
96. Coartem 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
97. Septrin (Bactrim)   
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
98. Amoxacillin  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
99. Other 
_________________________ 
 
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
100. Unknown  
[____|____] 
 
[____|____] 
 
[____|____]  _______________________ 
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COHORT STUDY MONTHLY QUESTIONNAIRE (8) 
Study ID 
[____|____|____|____] 
Date of visit 
[___|___]/ [___|___]/[___|___] 
day                 month               year 
Visit # 
[____|____] 
 
PART 2: SECTION 4: TREATMENT OUTCOME 
101. "How long did the child's 
illness last?" 
1 = < 24 hrs   
2  = 1-3 days 
3 = 4-7 days     
4  = >7 da ys    
5 = Ongoing  a t time of interview 
77 =  Other________________________ 
88 =  Don ’t know                 
99 =  Refused to answer 
 
 
[____|____] 
102. "Did you experience any 
delays in treating your child's 
illness?"   
1 = Yes   
2  = No  
88 = D on ’t know                 
99 = Refused to answer 
 
[____|____] 
If no, skip to question #104 
103. "What were the reasons 
for the delays?" (list all that 
apply) 
1 =  No transport a va ila ble                           
2  = Not enough money 
a vailable                      
3  = Needed to find coverage 
for work 
 
4 = Needed to arra nge for child ca re   
5 = Wa iting  at the health facility 
88 =  Don ’t know 
99 =  Refused to answer 
 
[____|____] 
 
[____|____] 
 
[____|____] 
 
[____|____] 
 
[____|____] 
 
[____|____] 
104. "How much did you spend 
on management of this illness?"   
C ost of drugs                          
[____|____|____|____|____]Ush 
         
Fees (clinic, hospital, lab)      
[____|____|____|____|____]Ush 
 
                                       
T ransport                                
[____|____|____|____|____]Ush 
 
O ther                                      
[____|____|____|____|____]Ush 
 
TOTAL 
[____|____|____|____|____]Ush 
105. "Did caring for your child and managing his/her illness 
prevent you from doing your usual activities this month?"     
1 = Yes   
2  = No    
 
88 =  D on ’t know                 
99 =  Refused to answer 
 
[____|____] 
106. “If yes, how much time did you miss?” If < 1 day, indicate number of hours 
otherwise, record 00 
 
                    [____|____] hours 
                    [____|____] days 
 
 
Field worker 
initials         
 
[____|____] 
Initials of observers present  
at interview           [____|____]     [____|____]     [____|____] 
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APPENDIX X: EXIT INTERVIEW SCREENING FORM 
PART 1: PARTICIPANT INFORMATION 
Screening Date 
 
[______|______]/[______|______]/[______|______] 
da y                              month                             yea r 
Screening ID 
 
[______|______|______|______] 
Village 
name ___________________________________________ 
Sub-county ID 
 
[_____]      
Village ID 
 
[_____|_____] 
Child’s 
age 
 
[_____|_____] / [_____|_____] 
years                          months 
If child is less than 1 year, complete months, otherwise leave blank 
Gender 
 
 [_____]  
1 = Male 
2 = Female 
Was your child referred to 
another health centre today? 
[_____] 
1 = Yes 
2 = No 
88 = Don’t know 
 
If yes, exclude and allow caregiver to leave 
If the caregiver is not 
answering your questions, 
indicate why 
[_____|_____] 
1 = Refused to talk 
2 = Refused to wa it 
77 = O ther: list __________________________________________ 
 
SCREENING STAGE 1 – Appropriate age 
Selection criteria Include Exclude  
Is  the child the appropriate age 
     —Under five (aged 0 to less than 5 years) 1 = Yes 2 = No [_____] 
If the answer is ‘2’ from the EXCLUDE column, exclude from the study. If not, proceed to  the next section. 
 
INFORMATION ON STUDY 
Read the 
following to 
the caregiver: 
 
My name is ____________________________.  I work with the Uganda Malaria Surveillance Project which is 
part of the Infectious Disease Research Collaboration.  We would like to ask you some questions about your 
experience today at this health centre and briefly examine your child.  This should take about 30 minutes. 
Would you be able participate now? 
Does the caregiver agree to continue? 
Continue End interview 
[_____] 1 = Yes 2 = No 
If No, indicate reason 1 = R efused to talk 
2 = R efused to wa it 
77 = O ther: list 
  
[_____|_____] ________________________ 
Proceed with obtaining informed consent    
 
SCREENING STAGE 2 – Informed consent 
Selection criteria Include Exclude  
Is  the parent(s)/guardian(s) willing to  provide informed consent? 1 = Yes 2 = No [_____] 
If the answer is ‘2’ from the EXCLUDE column, exclude from the study. If not, proceed to  the next section. 
 
ASSIGN 
STUDY NUMBER 
 
[_____|_____|_____|_____] 
 
 
All criteria for study inclusion met?        
         1 = Yes      
         2 = No     If no, exclude from the study                                              
 
[_____] 
Date of enrollment 
 
[______|______]/[______|______]/[______|______] 
day                              month                             yea r 
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APPENDIX Y. PATIENT EXIT INTERVIEWS 
Research participant informed consent form 
  
Protocol Title:  ACT PRIME Study: Evaluating the impact of enhanced health facility-based care 
for malaria and febrile illnesses in children  
Site of Research:                Tororo, Uganda 
Principal Investigators: Dr. Sarah Staedke 
Date:    18 September 2010 
 
Introduction 
Dr. Sarah Staedke and colleagues from the Uganda Malaria Surveillance Project / Infectious Diseases 
Research Collaboration are investigating delivery of healthcare services in Tororo District. We are doing a 
research study to see if we can improve the health of children in this area by improving services at 
government-run health facilities.  
 
Why is this survey being done? 
Certain health centers in Tororo district will be selected to either take part in the intervention to improve 
services, or to continue with their current services.  Assignment to the two groups has been determined by a 
lottery.  The chance of being placed into either of the groups is the same. To find out how well the 
intervention is working, we would like to review the health of children under five who go to the health 
centers for care.  We would like to know if caregivers of children are satisfied with their visit to the health 
centers. We would also like to hear any suggestions on how to improve visits to these health centers. We 
would like to interview the caregivers of 10 children under five who have visited the health centers; 200 
children in total will be surveyed.  
 
What will happen if my child takes part in this survey? 
If you agree to let your child participate in this survey, the following will happen today: 
a) We will ask you some questions about your visit to the health center today including the purpose of 
the visit, your child’s symptoms, whether a test for malaria was done, and what treatment was given.  
We will also ask questions about whether you were satisfied with your visit or not.  
b) We will collect information on your child’s general health.  
c) We will briefly examine your child.  
d) If your child has had a fever in the last 48 hours (2 days) or has a high temperature, we will do a rapid 
diagnostic test for malaria.  
 
  [_____|_____|_____|_____] 
  Study ID 
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e) If your child has a positive test for malaria, and appropriate treatment for malaria has not been given, 
we will provide treatment with artemether-lumefantrine (including Coartem or Lumatem), which is 
the recommended treatment for simple malaria in Uganda.  
f) If your child has any signs of severe malaria or another significant illness, we will refer you and your 
child back to the health center or to the hospital for further care.  
 
After today, we will not ask you to do anything further.   
 
How long will this survey last? 
Today, the interview will last about 30 minutes. 
 
Can I stop my child from being in the survey? 
You can decide to stop participating at any time.  Just tell the project researcher right away if you wish to 
stop the activities. 
 
What risks can I expect if my child participates in the survey? 
We will obtain one blood sample by fingerprick from your child.  The risks of drawing blood from a 
fingerprick include temporary discomfort from the needle stick, bruising, and skin infection.  The amount of 
blood removed will be too small to affect your child’s health. 
 
Participation in any research study may involve a loss of privacy.  Information you provide about your health 
center will be recorded, but your name will not be used in any reports of the information provided.  The 
information obtained from these study activities will only be used by the project researchers and will be 
locked at our project offices. We will do our best to make sure that any personal information is kept private.   
 
Are there benefits if my child takes part in the survey? 
If we find that your child has malaria and has not been given appropriate treatment at the health center, we 
will give you medications and instructions on how to treat your child. Otherwise, there will be no direct 
benefit to you from participating in this study.  However, the information that you provide will help 
researchers and policy-makers understand who best to improve health services in this area.  
 
What other choices do I have if my child does not take part in the survey? 
You are free to choose not to participate in the study. If you decide not to let your child take part, there will 
be no penalty to you.   
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What are the costs of taking part in the survey?  Will my child be paid for taking part in the survey? 
There are no costs to you for taking part in this study. You and your child will not be paid for taking part in 
this study.  
 
 
 
What are my rights if I allow my child to take part in the survey? 
Taking part in this survey is your choice. You may choose either to take part or not to take part.  If you decide 
to take part in this survey, you may change your mind at any time. If you decide to withdraw your child from 
the survey; your child will still be eligible for care at the local health facility and at Tororo District Hospital 
and at other local clinics. No matter what decision you take, there will be no penalty to you in any way. 
 
What if my child is injured as result of being in this survey?  
If your child is injured, or if you have questions about injuries as a result of being in the survey, please 
contact Dr. Sarah Staedke or other members of the Uganda Malaria Surveillance Project / Infectious Disease 
Research Collaboration on telephone number 0414-530692. The sponsoring organizations do not have a 
program to cover your costs if your child is hurt or has other bad results.   
 
Who can answer my questions about the survey? 
You can talk to the researchers about any questions or concerns you have about these survey activities.  
Contact Dr. Sarah Staedke or other members of the Uganda Malaria Surveillance Project / Infectious Disease 
Research Collaboration on telephone number 0414-530692. If you have any questions, comments or 
concerns about taking part in these activities, first talk to the researchers.  If for any reason you do not wish 
to do this, or you still have concerns about doing so, you may contact Dr Charles Ibingira, Makerere 
University Faculty of Medicine Research and Ethical Committee at telephone number 0414-530020. 
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WHAT YOUR SIGNATURE OR THUMBPRINT MEANS 
Your signature or thumbprint below means that you understand the information given to you in this consent 
form about your child’s participation in the survey and agree with the following statements: 
 
1. "I have read the consent form concerning this survey (or have understood the verbal explanation of 
the consent form) and I understand what will be required of me and what will happen to me and my 
child if we take part in it." 
 
2. "My questions concerning this survey have been answered by Dr. Staedke or the person who signed 
below." 
 
3. "I understand that at any time, I may withdraw my child from this survey without giving a reason and 
without affecting my child’s normal health care and management." 
 
4. "I agree that the child under my care will take part in this survey." 
 
You will also be asked to sign another informed consent form for the use of stored specimens. If you wish 
your child to participate in this survey, you should sign or place your thumbprint below.   
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WE WILL GIVE YOU A COPY OF THIS SIGNED AND DATED CONSENT FORM 
 
 
Name of Participant (printed) 
 
 
Name of Parent/Guardian     
 
 
Signature or Fingerprint * of Parent/Guardian      Date/Time 
 
 
Name of Investigator Administering Consent (printed)    Position/Title 
 
 
Signature of Investigator Administering Consent     Date/Time 
 
*If the parent or guardian is unable to read and/or write, an impartial witness should be present during the 
informed consent discussion.  After the written informed consent form is read and explained to the 
participant and parent or guardian, and after they have orally consented to their child’s participation in the 
trial, and have either signed the consent form or provided their fingerprint, the witness should sign and 
personally date the consent form.  By signing the consent form, the witness attests that the information in 
the consent form and any other written information was accurately explained to, and apparently understood 
by the parent or guardian, and that informed consent was freely given by the patient and parent or 
guardian. 
 
 
Name of Person Witnessing Consent (printed)    
 
 
Signature of Person Witnessing Consent      Date/Time 
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APPENDIX Z: PATIENT EXIT INTERVIEW QUESTIONNAIRE (1) 
Section 1: Patient/Caregiver information 
Health centre code 
 
[_____|_____] 
Study ID 
 
[_____|_____|_____|_____] 
Date of interview 
 
[_____|_____]/[_____|_____]/[_____|_____] 
date                              month                               year 
Sub-county ID 
[_____]     
Village name 
 
_____________________________________________ 
Village ID 
[_____|_____|_____] 
CHILD 
 
If ch ild  is less than 1 
year, complete 
months, o therwise 
leave blank 
Age  
[______|______] / [______|______] 
years                                  months 
Gender 
  
[_____] 
1 = Male   
2  = Female                                                
CAREGIVER 
Age 
 
[______|______]years 
Gender  
 
[_____] 
1 = Male   
2  = Female                                                
 
SECTION 2: CLINICAL HISTORY 
1. What is the reason for your visit to the health center today? (Describe below) 
 
 
 
 
2. Did child have fever in the last 48 hours (2 days)? 
 
1 = Yes        88 = Do n’t know         
2 = No          99 = Refused  
 
[______|______]  
3. What other problems did the child have? (Describe below, and list 
all appropriate codes at right) 
 
 
 
1 = Co ugh 
2 = Flu 
3 = No t eating 
4 = Vo miting 
5 = Diarrhea 
6 = Weak (not playing) 
7 = Co nvulsions 
8 = Other 
77 = None 
 [______] 
[______] 
[______]  
4. Did your child have a diagnostic test for malaria done today? 
If no, skip to question 6. 
1 = Yes        88 = Do n’t know         
2 = No          99 = Refused  
 
[______|______]  
5. If yes, what was the result of the test?  
 
1 = Po sitive          88 = Don’t know        
2 = Negative        99 = Refused  
 
[______|______]  
6. Were you told what is causing your child’s illness? 
If no, skip to question 8. 
1 = Yes        88 = Do n’t know         
2 = No          99 = Refused  
 
[______|______]  
7. What diagnoses was your child given?   
 
 
 
 
1 = Malaria 
2 = Ear infectio n 
3 = Throat infection 
4 = Pneumonia 
5 = Gastro enteritis 
6 = Dysentery 
7 = Measles 
8 = Urine infection 
9 = Other 
88 = Do n’t know 
99 = Refused 
 
[______|______] 
 
[______|______]  
8. What treatment was prescribed for your child? 
 
 
 
 
 
 
1 = Panadol 
2 = AL  (Coartem, Lumartem) 
3 = DP (Duocotecxin) 
4 = Quinine 
5 = Chlo ro quine only 
6 = SP o nly (Fansidar) 
7 = CQ+SP combination 
8 = Amo diaquine (Camoquin) 
11 = Amoxacillin 
12 = Septrin 
13 = Iro n (Ferrous) 
14 = ORS 
15 = Vitamin A 
20 = Other 
88 = Do n’t know 
99 = Refused 
[______|______]  
 
[______|______] 
 
[______|______] 
 
[______|______] 
9. Did you receive the medications that were prescribed?   
If yes, skip to next section. 
1 = Yes        88 = Do n’t know         
2 = No          99 = Refused  
 
[______|______]  
10. If no, why?  
 
1 = Drug o ut of stock            
2 = Co uldn’t pay fo r drug     
3 = Other 
88 = Do n’t know 
99 = Refused         
 
 
[______|______]  
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PATIENT EXIT INTERVIEW QUESTIONNAIRE (2) 
Health centre code 
 
[_____|_____] 
Study ID 
 
[_____|_____|_____|_____] 
Date of interview 
 
[_____|_____]/[_____|_____]/[_____|_____] 
date                              month                               y ear 
 
 
Time of ARRIVAL to health center 
 
 [_____|_____]:[_____|_____] 
      hours                    minutes 
Time of DEPARTURE from health center 
 
 [_____|_____]:[_____|_____] 
  hours                    minutes 
SECTION 4: SUGGESTIONS 
What do you think can be done to improve services at this health center?  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SECTION 3: SATISFACTION WITH HEALTH CARE 
1 = very dissatisfied, 2 = dissatisfied, 3 = uncertain, 4 = satisfied, 5 = very satisfied 
1. How satisfied are you with the length of time you had to wait today? 1 2 3 4 5 
2. How satisfied are you with the waiting space available? 1 2 3 4 5 
3. How satisfied are you with the health center buildings and the consultation rooms?  1 2 3 4 5 
4. How satisfied are you with the directions provided at the health center? 1 2 3 4 5 
5. How satisfied are you with the attitude of health workers toward you? 1 2 3 4 5 
6. How satisfied are you with the consultation and examination of your child? 1 2 3 4 5 
7. How satisfied are you with the laboratory tests done? 1 2 3 4 5 
8. How satisfied are you with the treatment prescribed? 1 2 3 4 5 
9. How satisfied are you with the medications provided? 1 2 3 4 5 
10. How satisfied are you with the explanation of why your child is s ick?  1 2 3 4 5 
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PATIENT EXIT INTERVIEW QUESTIONNAIRE (3) 
Health centre code 
 
[_____|_____] 
Study ID 
 
[_____|_____|_____|_____] 
Date of interview 
 
[_____|_____]/[_____|_____]/[_____|_____] 
date                              month                               y ear 
 
SECTION 3: FEVER EPISODE 
Complete ONLY if there is a history of fever or documented temperature (≥ 38.0°C) 
1. C linical Notes – History of present illness 
 
 
 
 
 
 
 
2. Physical examination findings 
 
 
 
 
 
 
3. Temperature (⁰C)   
[____|____]•[____] 
4. PRIME RDT result                                          If ne gative, skip to Qn 6. 1 = Positive                                                                                             
2  = Nega tive 
3 = Not performed
4 = Test failed [____] 
5. If the RDT is positive, was the child prescribed appropriate treatment for malaria at 
the health center? 
1 = Yes                                                                                            
2 = No [____] 
6. Diagnosis made by PRIME 1 = Uncomplicated malaria                                                                                           
2  = Severe ma la ria 
3 = Otitis media 
4 = Pharyngitis 
5  = Upper respiratory tract infection 
6 = Pneumonia 
7 = Gastroenteritis 
8  = Dia rrhea 
9 = D ysentery 
10 = Urina ry tra ct infection 
11 = Skin infection 
12 = Viral illness 
77 = Other 
88 = Unknown 
 
 [_____|_____] 
8. Medications prescribed by PRIME  
Drug 1 [____|____] 
1 = Panadol                             
7 = Quinine  
8 = Coartem 
 
10 =  Amoxa cillin 
11 =  None 
12 =  O ther (list) 
____________________ 
____________________ 
 
 
Drug 2 [____|____] 
Drug 3 [____|____] 
Drug 4 [____|____] 
Drug 5 [____|____] 
9. Was the child referred for additional care by PRIME staff?  1 = Yes                                                                                            
2 = No [____] 
10. If yes, where? (specify)  
 
 
 
 
Initials:  [____|____] 
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APPENDIX AA. INFORMATION SHEET - Health facility surveillance 
ACT PRIME Study 
 
Introduction 
Dr. Sarah Staedke and colleagues from the Uganda Malaria Surveillance Project / Infectious Diseases 
Research Collaboration are investigating delivery of health care services in Tororo District. We are doing a 
research study to see if we can improve the health of children in this area by improving services at 
government-run health facilities. Certain health centers in Tororo district will be selected to participate in 
the intervention to improve services, or to continue with their current services.  Assignment to the two 
groups has been determined by a lottery.  The chance of being placed into either of the groups is the same.  
 
Why is this surveillance being done? 
As part of this study, we would like to know more about the types of patients seen, and the treatment 
provided, at lower-level health centers (HC IIs and HC IIIs) is this area.  We would also like to know more 
about drug supplies, staffing and costs at HC IIs and IIIs.  
 
What will happen if I take part in this surveillance? 
We will ask you, or another available health worker, to provide us with your registers, including the patient, 
drug, and laboratory (if applicable) registers. We will review the registers and enter the data into a 
questionnaire.  We estimate that it will take one day to enter the data.  We will also ask you some questions 
about staffing at the health center over the past two months, which should last about 15 minutes.  Once a 
year we will also ask you questions about routine costs at this health centre, which should last about 30-60 
minutes. 
 
How long will this surveillance last? 
We plan to conduct the surveillance over 2 years.  We will visit your health facility once every two months 
for a total of about 2 years.  
 
Can I stop being in the surveillance? 
You can decide to stop participating at any time.  Just tell our study personnel right away if you wish to stop 
the activities. 
 
What risks can I expect from participating in the surveillance? 
Participation in any research study may involve a loss of privacy.  Information you provide about your health 
center will be recorded, but your name will not be used in any reports of the information provided.  No 
quotes or other results arising from your participation in this study will be included in any reports, even 
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anonymously, without your agreement. The information obtained from these surveillance activities will only 
be used by the project researchers and will be locked at our project offices. We will do our best to make sure 
that any personal information is kept private.   
 
Are there benefits to taking part in the surveillance? 
There will be no direct benefit to you from participating in this study.  However, the information that you 
provide will help researchers and policy-makers understand who best to improve health services in this area.  
 
What other choices do I have if I do not take part in the surveillance? 
You are free to choose not to participate in the study. If you decide not to take part, there will be no penalty 
to you.   
  
What are the costs of taking part in the surveillance?  Will I be paid for taking part in the surveillance? 
There are no costs to you for taking part in this study. You will not be paid for taking part in this study.  
 
What are my rights if I take part in the surveillance? 
Taking part in this study is your choice. You may choose either to take part or not to take part.  If you decide 
to take part in this study, you may change your mind at any time.  No matter what decision you take, there 
will be no penalty to you in any way. 
 
Who can answer my questions about the surveillance? 
You can talk to the researchers about any questions or concerns you have about these surveillance activities.  
Contact Dr. Sarah Staedke or other members of the Uganda Malaria Surveillance Project / Infectious Disease 
Research Collaboration on telephone number 0414-530692. If you have any questions, comments or 
concerns about taking part in these activities, first talk to the researchers.  If for any reason you do not wish 
to do this, or you still have concerns about doing so, you may contact Dr Charles Ibingira, Makerere 
University Faculty of Medicine Research and Ethical Committee at telephone number 0414-530020. 
 
Giving verbal consent to participate in the surveillance: 
You may keep this information sheet if you wish. Participation in these activities is voluntary.  You have the 
right to decline to participate in the activities, or to withdraw from them at any point without penalty.  If you 
do not wish to participate in the activities, you should inform the researcher now.  If you do wish to 
participate in these activities, you should tell the researcher now, and the interview will begin shortly.  
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APPENDIX BB: HEALTH FACILITY SURVEILLANCE FORM (1) 
PART 1: Section 1: Health Center Information 
Health centre code 
 
[_____|_____] 
Health worker ID 
 
[_____|_____] 
Date Report Completed 
 
[_____|_____]/[_____|_____]/[_____|_____] 
day                          month                           yea r 
START date of report  
(this should be the STOP da te from the previous months’ report)  
 
[_____|_____]/[_____|_____]/[_____|_____] 
day                                month                                 yea r 
STOP date of report 
 
[_____|_____]/[_____|_____]/[_____|_____] 
da y                                month                                 year 
 
Section 2: Review of Record Books 
Assign each patient in the Patient Register a Patient Number and record into the PDA as much information as possible on 
each patient who attended the health facility since the date of the last visit using the Patient Register, Laboratory Log Book, 
and Dispensing Record. 
From Patient Register From Laboratory Log Book From Dispensing Record 
1. Date of visit 
2. Age of patient  
3. Gender of patient 
4. Village of residence 
5. Fever or history of fever 
6. Diagnosis  
(if hea lth fa cility has RDTs or a 
la bora tory, see the La bora tory Log 
B ook) 
7. Treatment prescribed 
1. RDT performed 
2. Result of RDT 
3. Laboratory tests performed 
4. Result of test 
1. Drug dispensed 
2. Amount 
 
Section 3: Drug Stock Report 
1. Was AL from NMS out-of-stock this month? 1 = Yes 
2 = No 
88 = Don’t know 
99 = Refused to a nswer 
 
[____|____] 
If No, skip to question 9 
2. List date when stock-out of AL 
began: 
3. Was AL re-stocked 
after this stock-out? 
4. If yes, who re-stocked your 
drugs? 
5. What date was AL re-
stocked? 
 1  = Yes 
2 = No 
88 = D on’t know 
99 = Refused to answer 
If N o, sk ip to question 9 
1 = NMS 
2 = ACT  PRIME study (us)  
3 = Used PHC or HF funds.  List a mount 
77 = Other: list 
88 = Don’t know 
99 = Refused to a nswer 
 
1st 
[__ ___/__ ___/___ __] 
da y           month           year 
[____|____] 
[____|____] 
amount:  UGX____________________  
Other: list:_______________________ 
[__ ___/__ ___/___ __] 
day           month           yea r 
2nd [__ ___/__ ___/___ __] 
da y           month           year 
[____|____] 
[____|____] 
amount:  UGX____________________  
Other: list:_______________________ 
[__ ___/__ ___/___ __] 
day           month           yea r 
3rd [__ ___/__ ___/___ __] 
da y           month           year 
[____|____] 
[____|____] 
amount:  UGX____________________  
Other: list:_______________________ 
[__ ___/__ ___/___ __] 
day           month           yea r 
9. If your supply of AL ran low, did 
you ration or keep some drugs 
aside?  
[_____] 
10. If yes, for what reasons did you ration or keep some drugs aside? List all that apply 
 
[_____|_____]     [_____|_____]    [_____|_____]     [_____|_____] 
1 = Yes                    
2 = No 
If no, skip to next 
section 
1  = To have drugs to treat children  
2  = To have drugs to treat severe cases of malaria 
3 = T o ha ve drug s a va ila ble if a politicia n visits 
77 =  Other, ________________________________ 
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HEALTH FACILITY SURVEILLANCE FORM (2) 
Health centre code 
 
[_____|_____] 
Health worker ID 
 
[_____|_____] 
Date Report Completed 
 
[_____|_____]/[_____|_____]/[_____|_____] 
day                          month                           yea r 
START date of report  
(this should be the STOP da te from the previous months’ report)  
 
[_____|_____]/[_____|_____]/[_____|_____] 
day                                month                                 yea r 
STOP date of report 
 
[_____|_____]/[_____|_____]/[_____|_____] 
da y                                month                                 year 
 
Section 4: Staff Availability 
Speak with the in-charge to determine the availability of each staff person assigned to the health facility 
1 = In-charge  
2 = Senior medical officer   
3 = Medical officer   
4 = Senior clinical officer    
5 = Clinical officer 
6 = Nursing officer 
7 = Enrolled nurse 
8 = Midwife 
9 = Public health  nurse 
10 = Nursing a ide/assistant 
11 = Laboratory technician 
12 = Laboratory assistant 
13 = Health assistant 
14 = Health educator 
15 = Other______________ 
16 = Other______________ 
 Position Total number of days 
available 
 Position Total number of days 
available 
1) [_____|_____] [_____|_____] 4) [_____|_____] [_____|_____] 
2) [_____|_____] [_____|_____] 5) [_____|_____] [_____|_____] 
3) [_____|_____] [_____|_____] 6) [_____|_____] [_____|_____] 
 
 
Section 5: Extra comments 
Describe  any situation tha t had an impact on patient care at your health center this month, such as drug stock-outs, staff shortages, or politica l instability.  
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HEALTH FACILITY SURVEILLANCE FORM – HEALTH CENTRE INDICATOR 
REPORTS (3) 
PART 2: Section 1: Health Center Information 
Health centre code 
 
[_____|_____] 
Health worker ID 
 
[_____|_____] 
Date Report Completed 
 
[_____|_____]/[_____|_____]/[_____|_____] 
day                          month                           yea r 
START date of report  
(this should be the STOP da te from the previous months’ report)  
 
[_____|_____]/[_____|_____]/[_____|_____] 
day                                month                                 yea r 
STOP date of report 
 
[_____|_____]/[_____|_____]/[_____|_____] 
da y                                month                                 year 
 
Section 2: Indicator report – ALL PATIENTS 
Total number of patients visiting the clinic this month 
 
[_____|_____|_____]  
Number (proportion) of patients who had fever 
 
[_____|_____|_____] 
 
[_____|_____] % 
Number (proportion) of febrile patients who had a RDT done 
 
[_____|_____|_____] 
 
[_____|_____] % 
Number (proportion) of patients who had a positive RDT result 
 
[_____|_____|_____] 
 
[_____|_____] % 
Number (proportion) of patients who had a negative RDT result 
 
[_____|_____|_____] 
 
[_____|_____] % 
Total number of patients who were diagnosed with malaria 
 
[_____|_____|_____]  
Number (proportion) of patients diagnosed with malaria  who had a 
positive RDT 
 
[_____|_____|_____] 
 
[_____|_____] % 
Number (proportion) of patients diagnosed with malaria  who had a 
negative RDT 
 
[_____|_____|_____] 
 
[_____|_____] % 
Total number of patients who were prescribed an ACT* to treat malaria 
 
[_____|_____|_____]  
Number (proportion) of patients who had a positive RDT result who 
were prescribed an  ACT* 
 
[_____|_____|_____] 
 
[_____|_____] % 
Number (proportion) of patients who had a negative RDT result who 
were prescribed an  ACT* 
 
[_____|_____|_____] 
 
[_____|_____] % 
Number (proportion) of patients without an RDT done who were 
prescribed an ACT* 
 
[_____|_____|_____] 
 
[_____|_____] % 
* ACT = artemisinin-based combination therapy for malaria. Examples include Coartem, Lumartem, Duocotexcin 
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HEALTH FACILITY SURVEILLANCE FORM – INDICATOR REPORTS (4) 
Health centre code 
 
[_____|_____] 
Health worker ID 
 
[_____|_____] 
Date Report Completed 
 
[_____|_____]/[_____|_____]/[_____|_____] 
day                          month                           yea r 
START date of report 
 
[_____|_____]/[_____|_____]/[_____|_____] 
day                          month                           year 
STOP date of report 
 
[_____|_____]/[_____|_____]/[_____|_____] 
day                          month                           year 
 
Section 3: Indicator report – CHILDREN UNDER FIVE 
Total number of children under five visiting the clinic this month 
 
[_____|_____|_____]  
Number (proportion) of children under five who had fever 
 
[_____|_____|_____] 
 
[_____|_____] % 
Number (proportion) of febrile children under five who had a RDT 
done 
 
[_____|_____|_____] 
 
[_____|_____] % 
Number (proportion) of children under five who had a positive RDT 
result 
 
[_____|_____|_____] 
 
[_____|_____] % 
Number (proportion) of children under five who had a negative RDT 
result 
 
[_____|_____|_____] 
 
[_____|_____] % 
Total number of children under five who were diagnosed with 
malaria 
 
[_____|_____|_____]  
Number (proportion) of children under five d iagnosed with malaria 
who had a positive RDT 
 
[_____|_____|_____] 
 
[_____|_____] % 
Number (proportion) of children under five d iagnosed with malaria 
who had a negative RDT 
 
[_____|_____|_____] 
 
[_____|_____] % 
Total number of children under five who were prescribed an ACT* 
to treat malaria 
 
[_____|_____|_____]  
Number (proportion) of children under five who had a positive RDT 
result who were prescribed an ACT* 
 
[_____|_____|_____] 
 
[_____|_____] % 
Number (proportion) of children under five who had a negative RDT 
result who were prescribed an ACT* 
 
[_____|_____|_____] 
 
[_____|_____] % 
Number (proportion) of children under five without an RDT done 
who were prescribed an ACT* 
 
[_____|_____|_____] 
 
[_____|_____] % 
* ACT = artemisinin-based combination therapy for malaria. Examples include Coartem, Lumartem, Duocotexcin 
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HEALTH FACILITY SURVEILLANCE FORM – COST COLLECTION (1) 
PART 3: Section 1: Health Center Information 
This section to be completed in all health facilities at baseline and then annually (3 surveys in total) 
Health centre code 
 
[_____|_____] 
Health worker ID 
 
[_____|_____] 
Date Report Completed 
 
[_____|_____]/[_____|_____]/[_____|_____] 
da y                          month                           year 
 
Section 2: DRUGS & SUPPLIES 
# Drugs Ever stocked? 
1 = Yes 
2 = No 
88 = Don’t know 
99 = Refused to a nswer 
Total number of 
units available on 
day of survey 
If 0 units available, 
how many days has 
this item been out of 
stock? 
Source of payment for item 
1 = Us, ACT  PR IME study 
2 = NGO/project 
3 = PHC Fund  
4 = Government 
77 =  Other, list 
88 =  Don ’t know 
99 =  Refused to answer 
1. 
Artemether-Lumefantrine – Coartem 
 
[_____|_____]  da ys 
 
[_____|_____]   ____________________ 
2. 
Artemether-Lumefantrine – Lumartem 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
3. 
Amodiaquine-Artesunate 
 
[_____|_____] 
 
da ys 
 
[_____|_____]  ____________________ 
4. 
Sulfadoxine-Pyrimethamine (Fansidar) 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
5. 
Chloroquine 150 base tab 
 
[_____|_____] 
 
da ys 
 
[_____|_____]  ____________________ 
6. 
Chloroquine 50mg base/5 Bottle 1000ml Syrup 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
7. 
Chloroquine 50mg base/5 Bottle 1000ml Syrup 
 
[_____|_____] 
 
da ys 
 
[_____|_____]  ____________________ 
8. 
Chloroquine inj 40 mg/ml; 39ml 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
9. 
Acetylsalicylic acid  300mg tab 
 
[_____|_____] 
 
da ys 
 
[_____|_____]  ____________________ 
10. 
Diazepam in j 5mg/ml 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
11. 
Ferrous su lphate tab. 200 + 0.25mg 
 
[_____|_____] 
 
da ys 
 
[_____|_____]  ____________________ 
12. 
Folic Acid 5mg 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
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HEALTH FACILITY SURVEILLANCE FORM – COST COLLECTION (2) 
Health centre code 
 
[_____|_____] 
Health worker ID 
 
[_____|_____] 
Date Report Completed 
 
[_____|_____]/[_____|_____]/[_____|_____] 
da y                          month                           year 
 
# DRUGS Ever stocked? 
1 = Yes 
2 = No 
88 = Don’t know 
99 = Refused to a nswer 
Total number of 
units available on 
day of survey 
If 0 units available, 
how many days has 
this item been out of 
stock? 
Source of payment for item 
1 = Us, ACT  PR IME study 
2 = NGO/project 
3 = PHC Fund  
4 = Government 
77 =  Other, list 
88 =  Don ’t know 
99 =  Refused to answer 
13. 
Oral Rehydration Salts 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
14. 
Paracetamol 120/5ml syrup 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
15. 
Paracetamol tab  500 mg 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
16. 
Quinine in j 300mg/ml 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
17. 
Quinine tab 300mg 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
18. 
Dextrose 5% 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
19. 
Dextrose 50% 
 
[_____|_____] 
 
da ys 
 
[_____|_____]  ____________________ 
20. 
Water for injection 10m 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
21. 
Other  _____________________________ 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
22. 
Other _____________________________ 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
23. 
Other _____________________________ 
 
[_____|_____] 
 
da ys 
 
[_____|_____]  ____________________ 
24. 
Other _____________________________ 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
25. 
Other _____________________________ 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
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HEALTH FACILITY SURVEILLANCE FORM – COST COLLECTION (3) 
Health centre code 
 
[_____|_____] 
Health worker ID 
 
[_____|_____] 
Date Report Completed 
 
[_____|_____]/[_____|_____]/[_____|_____] 
da y                          month                           year 
 
# SUPPLIES Ever stocked? 
1 = Yes 
2 = No 
88 = Don’t know 
99 = Refused to answer 
Total number of 
units available on 
day of survey 
If 0 units available, 
how many days has 
this item been out of 
stock? 
Source of payment for item 
1 = Us, ACT  PR IME study 
2 = NGO/project 
3 = PHC Fund  
4 = Government 
77 =  Other, list 
88 =  Don ’t know 
99 =  Refused to answer 
26. 
Syringe for needles 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
27. 
Cotton Wool 
 
[_____|_____] 
 
da ys 
 
[_____|_____]  ____________________ 
28. 
Plaster wound adhesive 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
29. 
Surgical gloves 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
30. 
Giving set 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
31. 
Cannula 
 
[_____|_____] 
 
da ys 
 
[_____|_____]  ____________________ 
32. 
Needle half circle 16 triangular 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
33. 
Other  _____________________________ 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
34. 
Other _____________________________ 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
35. 
Other _____________________________ 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
36. 
Other _____________________________ 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
37. 
Other _____________________________ 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
38. 
Other _____________________________ 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
39. 
Other _____________________________ 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
40. 
Other _____________________________ 
 
[_____|_____]  da ys 
 
[_____|_____]  ____________________ 
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HEALTH FACILITY SURVEILLANCE FORM – COST COLLECTION (4) 
Health centre code 
 
[_____|_____] 
Health worker ID 
 
[_____|_____] 
Date Report Completed 
 
[_____|_____]/[_____|_____]/[_____|_____] 
da y                          month                           year 
 
Section 3: OVERHEADS 
 UTILITIES Does this health 
facility have this 
utility? 
1 = Y es          2 = No 
88 =  Don ’t know 
99 =  Refused to a nswer 
Was this utility 
paid for this year? 
1 = Yes 
2 = No 
88 = D on’t know 
99 = Refused to answer 
Average price per 
month, in  UGX 
 
Average total price 
per year, in  UGX 
Source of payment for utility 
1 = NGO 
2 = PHC  Fund  
3 = Government 
 
77 =  Other, list 
88 =  Don ’t know 
99 =  Refused to a nswer 
41. 
Gas [___|___] [___|___] UGX UGX 
 
[___|___]  __________________________ 
42. 
Electricity [___|___] [___|___] UGX UGX 
 
[___|___]  __________________________ 
43. 
Water [___|___] [___|___] UGX UGX 
 
[___|___]  __________________________ 
44. 
Other _________________ [___|___] [___|___] UGX UGX 
 
[___|___]  __________________________ 
45. 
Other _________________ [___|___] [___|___] UGX UGX 
 
[___|___]  __________________________ 
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HEALTH FACILITY SURVEILLANCE FORM – COST COLLECTION (5) 
Health centre code 
 
[_____|_____] 
Health worker ID 
 
[_____|_____] 
Date Report Completed 
 
[_____|_____]/[_____|_____]/[_____|_____] 
da y                          month                           year 
 
 CAPITAL EQUIPMENT 
Vehicles, furniture, g enerator,  
Description 
Make/model 
# of units 
available 
Date purchased 
[Day/month/year] 
Cost, in  UGX Source of payment for item 
1 = NGO 
2 = PHC  Fund  
3 = Government, list department 
77 = Other, list 
88 = Don’t know 
99 = Refused to answer 
If this item is used 
in the treatment 
of malaria, 
indicate the % of 
time in a week the 
item is used to 
treat malaria. 
46.    [__ __/__ __/__ __] UGX [___|___] _______________ % 
47.    [__ __/__ __/__ __] UGX [___|___] _______________ % 
48.    [__ __/__ __/__ __] UGX [___|___] _______________ % 
49.    [__ __/__ __/__ __] UGX [___|___] _______________ % 
50.    [__ __/__ __/__ __] UGX [___|___] _______________ % 
51.    [__ __/__ __/__ __] UGX [___|___] _______________ % 
52.    [__ __/__ __/__ __] UGX [___|___] _______________ % 
53.    [__ __/__ __/__ __] UGX [___|___] _______________ % 
54.    [__ __/__ __/__ __] UGX [___|___] _______________ % 
55.    [__ __/__ __/__ __] UGX [___|___] _______________ % 
56.    [__ __/__ __/__ __] UGX [___|___] _______________ % 
57.    [__ __/__ __/__ __] UGX [___|___] _______________ % 
58.    [__ __/__ __/__ __] UGX [___|___] _______________ % 
59.    [__ __/__ __/__ __] UGX [___|___] _______________ % 
60.    [__ __/__ __/__ __] UGX [___|___] _______________ % 
 
  
The ACT PRI ME Study 
 
 
AC T PRIME  Study V1.1, 18 Sept 2010 
 
6 of 7 
HEALTH FACILITY SURVEILLANCE FORM – COST COLLECTION (6) 
Health centre code 
 
[_____|_____] 
Health worker ID 
 
[_____|_____] 
Date Report Completed 
 
[_____|_____]/[_____|_____]/[_____|_____] 
da y                          month                           year 
 
 SPACE - Description  Size, in square 
meters 
Price per square 
meter, in UGX 
Source of payment for space 
1 = NGO 
2 = PHC Fund  
3  = Government, list depa rtment 
77 =  O ther, list 
88 =  D on’t know 
99 =  Refused to answer 
If this space is used 
in the treatment of 
malaria, indicate the 
% of time in a week 
this space is used to 
treat malaria. 
1 = waiting  a rea 
2 = registration 
3 = examination room 
4 = dispensing room 
5 = la bora tory 
6 = kitchen 
7 = la undry 
8 = pha rmacy 
9 = storage 
10 =  corridor 
11 =  not in use 
77 =  other, list 
61. 
 
[____|____]  ____________________________ m2  UGX/m2 
 
[____|____]  _____________________ % 
62. 
 
[____|____]  ____________________________ m2  UGX/m2 
 
[____|____]  _____________________ % 
63. 
 
[____|____]  ____________________________ m2  UGX/m2 
 
[____|____]  _____________________ % 
64. 
 
[____|____]  ____________________________ m2  UGX/m2 
 
[____|____]  _____________________ % 
65. 
 
[____|____]  ____________________________ m2  UGX/m2 
 
[____|____]  _____________________ % 
66. 
 
[____|____]  ____________________________ m2  UGX/m2 
 
[____|____]  _____________________ % 
67. 
 
[____|____]  ____________________________ m2  UGX/m2 
 
[____|____]  _____________________ % 
68. 
 
[____|____]  ____________________________ m2  UGX/m2 
 
[____|____]  _____________________ % 
69. 
 
[____|____]  ____________________________ m2  UGX/m2 
 
[____|____]  _____________________ % 
70. 
 
[____|____]  ____________________________ m2  UGX/m2 
 
[____|____]  _____________________ % 
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HEALTH FACILITY SURVEILLANCE FORM – COST COLLECTION (7) 
Health centre code 
 
[_____|_____] 
Health worker ID 
 
[_____|_____] 
Date Report Completed 
 
[_____|_____]/[_____|_____]/[_____|_____] 
da y                          month                           year 
 
STAFF ALLOCATION & 
ACTIVITIES 
List all of the staff people present at the health  facility in an average week and then percentage of time in an average week they spend on  each activity.  
Indicate 0, if no  time is spent on an activity by a staff person.  Repeat for each staff person. 
1 = In-cha rge  
2 = Senior medical officer   
3 = Medical officer   
4 = Senior clinical officer    
5 = C linical officer                                                                  
6 = Nursing officer 
7 = Enrolled nurse 
8 = Midwife
9 = Public health nurse 
10 = Nursing  a ide/a ssista nt  
11 = Laboratory technician 
12 = Laboratory a ssistant 
13 =  Hea lth a ssista nt 
14 =  Hea lth educator 
15 =  O ther______________ 
Staff person 1: 
[___|___] 
Staff person 2: 
[___|___] 
Staff person 3: 
[___|___] 
Staff person 4: 
[___|___] 
Staff person 5: 
[___|___] 
Staff person 6: 
[___|___] 
Staff person 7: 
[___|___] 
Staff person 8: 
[___|___] 
Overhead activities         
Administration % % % % % % % % 
Accounting % % % % % % % % 
Compiling health in formation % % % % % % % % 
Cleaning health centre % % % % % % % % 
Laundry % % % % % % % % 
Other ________________ % % % % % % % % 
Other ________________ % % % % % % % % 
Support activities         
Dispensary activities % % % % % % % % 
Diagnostic services % % % % % % % % 
Other ________________ % % % % % % % % 
Other ________________ % % % % % % % % 
Service activities         
Out-patient - Malaria   % % % % % % % % 
Out-patient - Other illnesses % % % % % % % % 
Antenatal visits % % % % % % % % 
Postnatal care % % % % % % % % 
Vaccination % % % % % % % % 
Family planning % % % % % % % % 
Matern ity care % % % % % % % % 
Other ________________ % % % % % % % % 
Other ________________ % % % % % % % % 
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APPENDIX CC. INFORMATION SHEET 
Health worker knowledge questionnaire 
ACT PRIME Study 
 
Introduction 
Dr. Sarah Staedke and colleagues from the Uganda Malaria Surveillance Project / Infectious Diseases 
Research Collaboration are investigating the delivery of health care services in Tororo District. We are doing 
a research study to see if we can improve the health of children in this area by improving services at 
government-run health facilities. Certain health centers in Tororo district will be selected to either take part 
in the intervention to improve services, or to continue with their current services.  Assignment to the two 
groups has been determined by a lottery.  The chance of being placed into either of the groups is the same.  
 
Why is this study being done? 
As part of this study, we would like to assess health workers’ understanding of febrile illnesses, particularly 
malaria, including how it is transmitted, common symptoms, and approaches to management and 
treatment. We plan to carry out these surveys once a year for 2 years.  
 
What will happen if I take part in this study? 
Today, we would like to ask you some questions about fever and malaria using a questionnaire.  We will take 
notes of the discussion.  All information gathered will be treated as confidential by the study personnel, and 
records of the interviews will be kept securely in locked filing cabinets and offices.  No personal identification 
information such as names will be used in any reports arising out of this research. 
 
How long will the interview last? 
Today, the interview will last about 30 minutes. 
 
Can I stop being in the study? 
You can decide to stop participating at any time.  Just tell our study personnel right away if you wish to stop 
the activities. 
 
What risks can I expect from participating in the study? 
Participation in any research study may involve a loss of privacy.  Information you provide will be recorded, 
but your name will not be used in any reports of the information provided. The information obtained from 
these study activities will only be used by the project researchers and will be locked at our project offices. 
We will do our best to make sure that any personal information is kept private.   
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Are there benefits to taking part in the study? 
There will be no direct benefit to you from participating in this study.  However, the information that you 
provide will help researchers and policy-makers understand how best to improve health services in this area.  
 
What other choices do I have if I do not take part in the study? 
You are free to choose not to take part in the study. If you decide not to take part, there will be no penalty to 
you.   
  
What are the costs of taking part in the study?  Will I be paid for taking part in the study? 
There are no costs to you for taking part in this study. You will not be paid for taking part in this study.  
 
What are my rights if I take part in the study? 
Taking part in this study is your choice. You may choose either to take part or not to take part.  If you decide 
to take part in this study, you may change your mind at any time.  No matter what decision you take, there 
will be no penalty to you in any way. 
 
Who can answer my questions about the study? 
You can talk to the researchers about any questions or concerns you have about these study activities.  
Contact Dr. Sarah Staedke or other members of the Uganda Malaria Surveillance Project / Infectious Disease 
Research Collaboration on telephone number 0414-530692. If you have any questions, comments or 
concerns about taking part in these activities, first talk to the researchers.  If for any reason you do not wish 
to do this, or you still have concerns about doing so, you may contact Dr Charles Ibingira, Makerere 
University Faculty of Medicine Research and Ethical Committee at telephone number 0414-530020. 
 
Giving verbal consent to take part in the study: 
You may keep this information sheet if you wish. Participation in these activities is voluntary.  You have the 
right to decline to take part in the activities, or to withdraw from them at any point without penalty.  If you 
do not wish to take part in the activities, you should inform the researcher now.  If you do wish to take part 
in these activities, you should tell the researcher now, and the interview will begin shortly.  
 
    The A CT PRIME St udy 
 
 
ACT PRIME –  Version 1.1, 18 Sept 2010                      
 
1 of 4 
APPENDIX DD: HEALTH WORKER KNOWLEDGE QUESTIONNAIRE (1) 
 
Date: [____|____] / [____|____] / [____|____]  
                          da y                             month                              yea r 
Health worker position:      
1 = In-charge  
2  = Senior medical officer   
3  = Medica l officer   
4  = Senior clinical officer    
5  = Clinical officer    
6 = Nursing officer 
7 = Enrolled nurse 
8 = Midwife                                                   
9  = Public hea lth nurse 
10 = Nursing aide/assistant 
11 = Laboratory technician 
12 = Laboratory assistant 
13 = Hea lth a ssista nt 
14 = Hea lth educa tor 
15 = Volunteer 
16 = O ther____________________________ 
[____|____] Health center code HCW Study ID 
 
[_____|_____] 
 
[_____|_____] 
 
SECTION 1 
Administer questionnaire by asking the questions below, without prompting for 
answers. Record all of the health worker’s answers below during the interview. 
SECTION 2 
After the interview is fin ished, complete the questions 
in section 2 
SECTION 3 
Finally, score the questionnaire here in 
section  3 
1. "What is malaria?"   
       Record answer          
 
 
 
 
 
 
 
 
Did the respondent’s answer include: 1 = Yes 
2 = No 
Give 5 points for 
each Yes answer in 
SECTION 2. 
 
 
 
 
 
 
[____|____] 
  
[____] Fever or high temperature or hot body 
[____] Parasites 
2. “How does someone get malaria?"         
       Record answer          
 
 
 
 
 
 
 
 
Did the respondent’s answer include: 1 = Yes 
2 = No 
Give 5 points for 
each Yes answer in 
SECTION 2. 
 
 
 
 
 
 
[____|____] 
[____] Bite of a  mosquito 
[____] Female mosquito 
[____] Anopheles mosquito 
3. “What is the most common symptom of malaria in children?” 
       Record answer          
 
 
 
 
Did the respondent’s answer include: 1 = Yes 
2 = No 
Give 10 points for a  
Yes answer in 
SECTION 2. 
 
 
 
[____|____] 
 
[____] 
 
Fever or high temperature or hot body 
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HEALTH WORKER KNOWLEDGE QUESTIONNAIRE (2) 
 
Date: [____|____] / [____|____] / [____|____] 
            day                              month                               yea r 
Health center code: [____|____] HCW Study ID: [____|____] 
 
SECTION 1 
Administer questionnaire by asking the questions below, without prompting for 
answers. Record all of the health worker’s answers below during the interview. 
SECTION 2 
After the interview is fin ished, complete the questions 
in section 2 
SECTION 3 
Finally, score the questionnaire here in 
section  3 
4. “What are danger signs of severe malaria in children?” 
       Record answer          
Did the respondent’s answer include: 1 = Yes 
2 = No 
Give 2 points for 
each Yes answer in 
SECTION 2. 
 
 
 
 
 
 
 
 
[____|____] 
[____] Convulsions 
[____] Altered consciousness (co nfusion, coma) 
[____] Lethargy (prostration o r extreme weakness) 
[____] Unable to drink or breastfeed 
[____] Vomiting everything 
[____] Unable to sit/stand due to weakness 
[____] Severe anemia 
[____] Respiratory distress (labored breathing) 
[____] Jaundice (yellow coloring of eyes) 
5. “When you examine a child that you suspect has uncomplicated malaria, what 
signs do you look out for?"         
       Record answer          
 
 
 
 
 
Did the respondent’s answer include: 1 = Yes 
2 = No 
Give 5 points for 
each Yes answer in 
SECTION 2. 
 
 
 
[____|____] 
[____] Fever or high temperature or hot body 
[____] Evidence of anemia (pallor) 
[____] Enlargement of sp leen 
6. “When you examine a child that you suspect has severe malaria, what signs do 
you look out for?"         
       Record answer          
 
 
 
 
 
Did the respondent’s answer include: 1 = Yes 
2 = No 
Give 5 points for 
each Yes answer in 
SECTION 2. 
 
 
 
[____|____] 
[____] Mental status or level of consciousness 
[____] Evidence of severe anemia (pallor) 
[____] Dehydration  
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HEALTH WORKER KNOWLEDGE QUESTIONNAIRE (3) 
 
Date: [____|____] / [____|____] / [____|____] 
            day                              month                               yea r 
Health center code: [____|____] HCW Study ID: [____|____] 
 
SECTION 1 
Administer questionnaire by asking the questions below, without prompting for 
answers. Record the health worker’s answers below during the interview. 
SECTION 2 
After the interview is fin ished, complete the questions 
in section 2 
SECTION 3 
Finally, score the questionnaire here in 
section  3 
7. “What illnesses, other than malaria, commonly cause fever in children?” 
       Record answer          
Did the respondent’s answer include: 1 = Yes 
2 = No 
Give 2 points for 
each Yes answer in 
SECTION 2. 
 
 
 
 
 
 
 
 
[____|____] 
[____] Vira l infection  (common co ld, HIV/AIDS, etc) 
[____] Bacterial infection 
[____] Measles 
[____] Ear infection (otitis media  or externa) 
[____] Throat infection  (pharyngitis, tonsillitis) 
[____] Respiratory tract infection (pneumonia) 
[____] Urinary tract infection 
[____] Skin infection (abscess) 
[____] Typhoid  fever 
[____] Brucellosis 
8. "How can the diagnosis of malaria be confirmed?"   
       Record answer          
 
 
 
 
 
Did the respondent’s answer include: 1 = Yes 
2 = No 
Give 5 points for 
each Yes answer in 
SECTION 2. 
 
 
 
 
[____|____] 
[____] Positive blood slide for malaria parasites 
[____] Positive rapid diagnostic test 
9. “How should a child with uncomplicated malaria be treated?"         
       Record answer          
 
 
 
Did the respondent’s answer include: 1 = Yes 
2 = No 
Give 5 points for 
each Yes answer in 
SECTION 2. 
 
 
 
 
[____|____] 
[____] Coartem (artemether-lumefantrine) 
[____] Dose based on child ’s age or weight 
[____] Give Coartem tablets twice a day for 3 days 
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HEALTH WORKER KNOWLEDGE QUESTIONNAIRE (4) 
 
Date: [____|____] / [____|____] / [____|____] 
            day                              month                               yea r 
Health center code: [____|____] HCW Study ID: [____|____] 
 
SECTION 1 
Administer questionnaire by asking the questions below, without prompting for 
answers. Record the health worker’s answers below during the interview. 
SECTION 2 
After the interview is fin ished, complete the questions 
in section 2 
SECTION 3 
Finally, score the questionnaire here in 
section  3 
10. “What information should be given to the primary caregiver as part of the 
counseling when administering treatment for uncomplicated malaria?"         
       Record answer          
 
 
 
 
 
 
 
Did the respondent’s answer include: 1 = Yes 
2 = No 
Give 5 points for 
each Yes answer in 
SECTION 2. 
 
 
 
[____|____] 
[____] Give Coartem tablets twice a day for 3 days 
[____] Give Coartem with milk or meal if possible 
[____] What to  do if ch ild does not improve 
[____] Continue supportive treatment  
11. “If Coartem is not available, what other antimalarials can be used to treat 
uncomplicated malaria?” 
       Record answer          
 
 
 
 
 
Did the respondent’s answer include: 1 = Yes 
2 = No 
Give 10 points for a  
Yes answer in 
SECTION 2. 
 
[____|____] 
[____] Amodiaquine + artesunate 
12. “What medical treatment should be given to a child with severe malaria?"         
       Record answer          
 
 
 
 
 
 
Did the respondent’s answer include: 1 = Yes 
2 = No 
Give 5 points for 
each Yes answer in 
SECTION 2. 
 
 
 
[____|____] 
[____] Referral to a health center IV or hospital 
[____] Treatment with quinine  
[____] Quinine IV 10mg/kg every 8 hours 
[____] Give quinine for total of 7 days 
 
 
 
TOTAL SCORE [_____|_____|_____] 
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WHO Toxicity Grading Scale for Determining The Severity of Adverse Events 
 
 
 HEMATOLOGY 
 
 ITEM 
 
Grade 1 Toxicity 
 
Grade 2 Toxicity 
 
Grade 3 Toxicity 
 
Grade 4 Toxicity 
 
Hemoglobin 
 
9.5 - 10.5 gm/Dl 
 
8.0  - 9.4 gm/Dl 
 
 6.5 - 7.9 gm/Dl 
 
< 6.5 gm/Dl 
 
Absolute Neutrophil 
Count 
 
1000-1500/mm
3
 
 
750-999/mm
3
 
 
500-749/mm
3
 
 
<500/mm
3
 
 
Platelets 
 
75000-99000/mm
3
 
 
50000-74999/mm
3
 
 
20000-49000/mm
3
 
 
<20000/mm
3
 
 
Prothrombin  
Time (PT) 
 
1.01 - 1.25 x ULN 
 
1.26-1.5 x ULN 
 
1.51 -3.0 x ULN 
 
>3 x ULN 
 
Activated Partial 
Thromboplastin 
(APPT) 
 
1.01 -1.66 x ULN 
 
1.67 - 2.33 x ULN 
 
2.34 - 3 x ULN 
 
> 3 x ULN 
 
Fibrinogen 
 
0.75 - 0.99 X LLN 
 
0.50 - 0.74 x LLN 
 
0.25 - 0.49 x LLN 
 
< 0.25 x LLN 
 
Fibrin Split Product 
 
20-40 mcg/ml 
 
41-50 mcg/ml 
 
51-60 mcg/ml 
 
> 60 mcg/ml 
 
Methemoglobin 
 
5 - 9.9 % 
 
10.0 - 14.9 % 
 
15.0 - 19.9% 
 
> 20 % 
 
 LIVER ENZYMES 
 
AST (SGOT) 
 
1.25 - 2.5 x ULN 
 
2.6 - 5 x ULN 
 
5.1 - 10 x ULN 
 
> 10 x ULN 
 
ALT (SGPT) 
 
1.25 - 2.5 x ULN 
 
2.6 - 5 x ULN 
 
5.1 - 10 x ULN 
 
> 10 x ULN 
 
GGT 
 
1.25 -2.5 x ULN 
 
1.6 - 5 x ULN 
 
5.1 - 10 x ULN 
 
> 10 x ULN 
 
Alkaline Phosphatase 
 
1.25 - 2. 5 x ULN 
 
1.6 - 5 x ULN 
 
5.1 - 10 x ULN 
 
> 10 x ULN 
 
Amylase 
 
1.1 - 1.5 x ULN 
 
1.6 - 2.0 x ULN 
 
2.1 - 5.0 x ULN 
 
> 5.1 x ULN 
 
 CHEMISTRIES 
 
Hyponatremia 
 
130-135 mEq/L 
 
 123-129 mEq/L 
 
116-122 mEq/L 
 
< 116 or mental 
status changes or 
seizures 
 
Hypernatremia 
 
146-150 mEq/L 
 
151-157 mEq/L 
 
158-165 mEq/L 
 
> 165 mEq/L or 
mental status 
changes or seizures 
 
Hypokalemia 
 
3.0 - 3.4 mEq/L 
 
2.5 - 2.9 mEq/L 
 
2.0 - 2.4 mEq/L  
or intensive 
replacement Rx 
required or 
hospitalization 
required.  
 
< 2.0 mEq/L 
 or paresis or ileus 
or life-threatening 
arrhythmia 
 
Hyperkalemia 
 
5.6 - 6.0 mEq/L 
 
6.1 - 6.5 mEq/L 
 
6.6 - 7.0 mEq/l 
 
> 7.0 mEq/L 
or life-threatening 
arrhythmia 
 
Hypoglycemia 
 
55-64 mg/dL 
 
40-54 mg/dL 
 
30-39 mg/dL 
 
<30 mg/dL or 
mental status 
changes or coma 
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CHEMISTRIES (continued) 
 
Hyperglycemia 
(note if fasting) 
 
116 - 160 mg/dL 
 
161- 250 mg/dL 
 
251 - 500 mg/dL 
 
> 500 mg/dL 
or ketoacidosis 
 or seizures 
 
Hypocalcemia 
(corrected for albumin) 
 
8.4 - 7.8 mg/dL 
 
7.7 - 7.0 mg/dL 
 
6.9 - 6.1 mg/dL 
 
< 6.1 mg/dL 
or life threatening 
arrhythmia or tetany 
 
Hypercalcemia 
(correct for albumin) 
 
10.6 - 11.5 mg/dL 
 
11.6 - 12.5 mg/dL 
 
12.6 - 13.5 mg/dL 
 
> 13.5 mg/dL 
life-threatening 
arrhythmia 
 
Hypomagnesemia 
 
1.4 - 1.2 mEq/L 
 
1.1 - 0.9 mEq/L 
 
0.8 - 0.6 mEq/L 
 
< 0.6 mEq/L or life-
threatening 
arrhythmia 
 
Hypophosphatemia 
 
2.0 - 2.4 mg/dL 
 
1.5 -1.9 mg/dL or 
replacement Rx 
required 
 
1.0 -1.4 mg/dL  
intensive Rx or 
hospitalization 
required 
 
< 1.0 mg/dL or life-
threatening 
arrhythmia 
 
Hyperbilirubinemia 
 
1.1 - 1.5 x ULN 
 
1.6 - 2.5 x ULN 
 
2.6 - 5 x ULN 
 
> 5 x ULN 
 
BUN 
 
1.25 - 2.5 x ULN 
 
2.6 - 5 x ULN 
 
5.1 - 10 x ULN 
 
> 10 x ULN 
 
Creatinine 
 
1.1 x 1.5 x ULN  
 
1.6 - 3.0 x ULN 
 
3.1 - 6 x ULN 
 
> 6 x ULN or 
required dialysis 
 
 URINALYSIS 
 
Proteinuria 
 
1+ or < 0.3% or <3g/L 
or 200 mg - 1 gm 
loss/day 
 
2 -3 + or 0.3 - 1.0% or 
3-10 g/L 
1- 2 gm loss/day 
 
4+ or > 1.0% or > 10 
g/L  
2-3.5 gm loss/day 
 
nephrotic syndrome 
or > 3.5 gm loss/day 
 
Hematuria 
 
microscopic only 
 
gross, no clots 
 
gross+ clots 
 
obstructive or 
required transfusion 
 
CARDIAC DYSFUNCTION 
 
Cardiac Rhythm 
 
 
 
asymptomatic, 
transient signs, no 
Rx required 
 
recurrent/persistent; 
No Rx required 
 
requires treatment 
 
Hypertension 
 
transient inc. > 20 mm; 
no Rx 
 
recurrent, chronic, > 
20 mm, Rx required 
 
requires acute Rx; No 
hospitalization 
 
requires 
hospitalization 
 
Hypotension 
 
transient orthostatic 
hypotension, No Rx 
 
symptoms correctable 
with oral fluids Rx 
 
requires IV fluids; no 
hospitalization 
required 
 
requires 
hospitalization 
 
Pericarditis 
 
minimal effusion 
 
mild/moderate 
asymptomatic 
effusion, no Rx 
 
symptomatic effusion; 
pain; EKG changes 
 
tamponade; 
pericardiocentesis 
or surgery required 
 
Hemorrhage, Blood 
Loss 
 
microscopic/occult 
 
mild, no transfusion 
 
gross blood loss; 
1-2 units transfused 
 
massive blood loss; 
> 3 units transfused 
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 RESPIRATORY  
 
Cough  
 
transient- no Rx 
 
treatment associated 
cough 
local Rx 
 
uncontrolled 
 
 
 
Bronchospasm, Acute 
 
transient; no Rx 
< 80% - 70% FEV
1 
(or peak flow)
 
 
requires Rx 
normalizes with 
bronchodilator; 
FEV
1
 50% - 70% 
(or peak Flow) 
 
no normalization with 
bronchodilator; 
FEV
1
 25% - 50% 
(or peak flow 
retractions) 
 
cyanosis: FEV
1
 
< 25% 
(or peak flow) or 
intubated 
 
GASTROINTESTINAL 
 
Stomatitis 
 
mild discomfort; no 
limits on activity 
 
some limits on 
eating/drinking 
 
eating/talking very 
limited 
 
requires IV fluids 
 
Nausea 
 
mild discomfort; 
maintains reasonable 
intake 
 
moderate discomfort; 
intake decreased 
significantly; some 
activity limited 
 
severe discomfort; no 
significant intake; 
activities limited 
 
minimal fluid intake 
 
Vomiting 
 
transient emesis 
 
occasional/moderate 
vomiting 
 
orthostatic 
hypotension or IV 
fluids required 
 
hypotensive shock 
or hospitalization 
required for IV fluid 
therapy 
 
Constipation 
 
mild 
 
moderate 
 
severe 
 
distensions 
w/vomiting 
 
Diarrhea 
 
transient 3-4 loose 
stools/day 
 
5-7 loose stools/day 
 
orthostatic 
hypotension or 
> 7 loose stools/day or 
required IV fluids 
 
hypotensive shock 
or hospitalization 
for IV fluid therapy 
required 
 
NEURO & NEUROMUSCULAR 
 
Neuro-Cerebellar 
 
slight incoordination 
dysdiadochokinesis 
 
intention tremor, 
dysmetria, slurred 
speech; nystagmus 
 
locomotor ataxia 
 
incapacitated 
 
Mood 
 
mild anxiety or 
depression 
 
moderate anxiety or 
depression and 
therapy required 
 
severe anxiety or 
depression or mania; 
needs assistance 
 
acute psychosis; 
incapacitated, 
requires 
hospitalization 
 
Neuro Control 
(ADL = activities of 
daily living) 
 
mild difficulty 
concentrating; no Rx; 
mild 
confusion/agitation; 
ADL unaffected 
 
moderate 
confusion/agitation 
some limitation of 
ADL; minimal Rx 
 
severe 
confusion/agitation 
needs assistance for 
ADL; therapy 
required 
 
toxic psychosis; 
hospitalization 
 
Muscle Strength 
 
subjective weakness 
no objective symptoms/ 
signs 
 
mild objective  
signs/symptoms 
no decrease in 
function 
 
objective weakness 
function limited 
 
paralysis 
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OTHER PARAMETERS 
 
Fever: oral, > 12 hours 
 
37.7 - 38.5 C or  
100.0 - 101.5 F 
 
38.6 - 39.5 C or 
101.6 - 102.9 F 
 
39.6 - 40.5 C or 
103 - 105 F 
 
> 40 C or 
> 105 F 
 
Headache 
 
mild, no Rx therapy 
 
transient, moderate; 
Rx required 
 
severe; responds to 
initial narcotic therapy 
 
intractable; required 
repeated narcotic 
therapy 
 
Fatigue 
 
no decrease in ADL 
 
 normal activity 
decreased 25- 50% 
 
normal activity 
decreased > 50% can’t 
work 
 
unable to care for 
self 
 
Allergic Reaction 
 
pruritus without rash 
 
localized urticaria 
 
generalized urticaria; 
angioedema 
 
anaphylaxis 
 
Local Reaction 
 
tenderness or erythema 
 
induration < 10 cm or 
phlebitis or 
inflammation  
 
induration > 10 cm or 
ulceration 
 
necrosis 
 
Mucocutaneous 
 
erythema; pruritus 
 
diffuse, maculo 
papular rash, dry 
desquamation 
 
vesiculation, moist 
desquamation, or 
ulceration 
 
exfoliative 
dermatitis, mucous 
membrane 
involvement or 
erythema, 
multiforme or 
suspected Stevens-
Johnson or necrosis 
requiring surgery 
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APPENDIX FF. Guidelines for grading symptoms, signs and laboratory findings 
 
Table A. Guidelines for grading patient symptoms 
 Grade 1 
MILD 
Grade 2 
MODERATE 
Grade 3 
SEVERE 
Grade 4 
LIFE THREATENING 
Subjective fever 
in the past 24 h 
N/A Present (Yes) N/A N/A 
Weakness Mild decrease in activity; 
For children – weak, but 
still playing 
Moderate decrease in 
activity; For children – 
weak, and playing limited 
Not participating in usual 
activities; For children – 
not playing 
Prostration 
Muscle and/or 
joint aches* 
Mild and/or localized 
complaints 
Diffuse complaints Objective weakness; 
function limited 
N/A 
Headache* Mild, no treatment 
required 
Transient, moderate; 
treatment required 
Severe, constant; requires 
narcotic therapy 
Intractable; requires 
repeated narcotic therapy 
Anorexia Decreased appetite, but 
still taking solid food 
Decreased appetite, 
avoiding solid food but 
taking liquids 
Appetite very decreased; 
Refusing to breast feed, 
no solids or liquids taken 
(< 2 years < 12 hr; > 2 
years < 24 hr) 
Appetite very decreased; 
Refusing to breast feed, 
no solids or liquids taken 
(< 2 years > 12 hr; > 2 
years > 24 hr) 
Nausea* Mild, transient feeling of 
impending vomiting; 
maintains reasonable 
intake 
Moderate and/or 
constant feeling of 
impending vomiting; 
intake decreased  
Severe, constant feeling 
of impending emesis; 
intake decreased 
significantly  
N/A 
Vomiting 1 episode per day 2-3 episodes per day Orthostatic hypotension 
or IV fluids required 
Hypotensive shock or 
 nrolment ation required 
for IV fluid therapy 
Abdominal 
pain* 
Mild (1-3 on a scale of 1 
to 10) 
Moderate (4-6 on a scale 
of 1 to 10) 
Moderate to severe (> 7 
on a scale of 1 to 10) 
Severe –  nrolment at 
for treatment 
Diarrhea Transient 3-4 loose 
stools/day 
5-7 loose stools/day Orthostatic hypotension 
or > 7 loose stools/day or 
IV fluids required 
Hypotensive shock or 
 nrolment ation for IV 
fluid therapy required 
Cough Transient / intermittent Persistent / constant Uncontrolled Cyanosis, stridor, severe 
shortness of breath 
Pruritis Transient pruritis  Pruritis that disturbs 
sleep 
Severe, constant pruritis, 
sleep disturbed 
N/A 
Tinnitus* Mild, transient ringing or 
roaring sound 
Moderate, persistent 
ringing or roaring sound 
Severe ringing or roaring 
sound with associated 
hearing loss 
N/A 
Behavioural 
changes 
Mild difficulty 
concentrating; mild 
confusion or agitation; 
activities of daily living 
unaffected; no treatment 
Moderate confusion or 
agitation; some limitation 
of activities of daily living; 
minimal treatment 
Severe confusion or 
agitation; Needs 
assistance for activities of 
daily living; therapy 
required 
Toxic psychosis; 
 nrolment ation required 
“Flu”  
(viral URI) 
Mild nasal congestion, 
mild rhinorrhea 
Moderate nasal 
congestion, moderate 
rhinorrhea 
N/A  N/A  
Allergic 
reaction 
N/A N/A Urticaria Severe urticaria  
anaphylaxis, angioedema 
Convulsion N/A N/A Localized or generalized 
seizure 
Status epilepticus 
* Assess only in children > 3 years of age.  Answer N/A for younger children and those unable to answer. 
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Table B. Guidelines for physical examination 
 
Dehydration Assess skin touch and turgor, mucous membranes, eyes, crying, fontanelle, pulse, urine output 
 
Jaundice Assess for yellowing of the sclera.  Also evaluate the palpepral conjunctiva, lips, and skin. 
 
Chest Observe the rate, rhythm, depth, and effort of breathing.   Check the patient’s colour for cyanosis. 
 
The maximum acceptable respiratory rate by age: < 2 months = 60, 2-12 months = 50, 1-5 years = 40, 
above 5 years = 30. 
 
Inspect the neck for the position of the trachea, for supraclavicular retractions, and for contraction of 
the sternomastoid or other accessory muscles during inspiration.   
 
Auscultate the anterior and posterior chest for normal breath sounds and any adventitious sounds 
(crackles or rales, wheezes, and rhonchi).  Crackles are intermittent, non-musical, fine or coarse 
sounds that may be due to abnormalities of the lungs (pneumonia, fibrosis, early congestive heart 
failure) or airways (bronchitis or bronchiectasis).  Wheezes are high-pitched and result from narrowed 
airways.  Rhonchi are relatively low-pitched and suggest secretions in large airways.   
 
If abnormalities are identified, evaluate for transmitted voice sounds.  In addition, palpate the chest 
to assess for tactile fremitus, and percuss the chest to assess for areas of dullness.  Normal, air-filled 
lungs emit predominantly vesicular breath sounds, transmit voice sounds poorly with “ee” = “ee”, and 
have no tactile fremitus.  Airless lung, as in lobar pneumonia, emits bronchial breath sounds, 
transmits spoken words clearly with “ee” = “aay” (egophany), and has an increase in tactile fremitus. 
 
Abdomen Inspect and ausculate the abdomen.  Listen for bowel sounds in the abdomen before palpating it.  
Palpate the abdomen in all 4 quadrants lightly and then deeply.  Assess the size of the liver and 
spleen.  To assess for peritoneal inflammation, look for localised and rebound tenderness, and 
voluntary or involuntary rigidity.  
 
Skin Inspect the skin for colour, turgor, moisture, and lesions.  If lesions are present, note their location 
and distribution (diffuse or localised), arrangement (linear, clustered, annular, dermatomal), type 
(macules, papules, vesicles) and colour.   
 
Tablet test For children > 9 months of age, ask the patient to pick a tablet (or equivalent object) up off a flat 
surface using the thumb and index finger of their dominant hand.  This tests for co-ordination of the 
upper extremity assessing the function of the motor system, cerebellar system, vestibular system (for 
coordinating eye and body movements) and the sensory system, for position sense.  When testing 
small children, be aware that they will likely attempt to put the object into their mouth. 
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Table C.  Grading physical examination findings 
 
 Grade 1 
MILD 
Grade 2 
MODERATE 
Grade 3 
SEVERE 
Grade 4 
LIFE-THREATENING 
Temperature* 
(axillary) 
37.5-37.9C 38.0-39.5C > 39.5C Sustained fever, equal 
or greater than 40.0C 
for longer than 5 days 
Dehydration Less than 2 of the 
following: 
Restless, irritable 
Sunken eyes 
Drinks eagerly, thirsty 
Skin pinch goes back 
slowly 
2 of the following: 
Restless, irritable 
Sunken eyes 
Drinks eagerly, thirsty 
Skin pinch goes back 
slowly 
Two of the following: 
Lethargic or 
unconscious 
Sunken eyes 
Not able to drink or 
drinking poorly 
Skin pinch goes back 
very poorly 
Two of the following + 
shock: 
Lethargic or 
unconscious 
Sunken eyes 
Not able to drink or 
drinking poorly 
Skin pinch goes back 
very poorly 
Jaundice Slight yellowing of 
sclera and conjunctiva 
 
Moderate yellowing of 
sclera and conjunctiva, 
yellowing of mucous 
membranes 
Severe yellowing of 
sclera and conjunctiva, 
yellowing of skin 
N/A 
Chest Mildly increased RR 
(for age, temperature), 
transient or localised 
adventitious sounds 
 
Moderately increased 
RR, diffuse or 
persistent adventitious 
sounds 
Rapid RR (< 2 months > 
60, 2-12 months > 50, 
1-5 years > 40, adults > 
30)* nasal flaring, 
retractions 
Cyanosis 
Abdomen Normal bowel sounds, 
mild localised 
tenderness, and/or 
liver palpable 2-4 cm 
below the right costal 
margin (RCM), and/or 
spleen palpable, 
and/or umbilical 
hernia present 
Normal or mildly 
abnormal bowel 
sounds, moderate or 
diffuse tenderness; 
and/or mild to 
moderately enlarged 
liver (4-6 cm below the 
RCM) and/or spleen 
palpable up to half-
way between 
umbilicus and 
symphysis pubis 
Severely abnormal 
bowel sounds, severe 
tenderness to 
palpation.  Evidence of 
peritoneal irritation 
and/or significant 
enlargement of liver (> 
6 cm below the RCM) 
and/or spleen palpable 
beyond half-way 
between umbilicus and 
symphysis pubis 
Absent bowel sounds.  
Involuntary rigidity 
Skin† Localised rash, 
erythema, or pruritis 
Diffuse, maculopapular 
rash, dry 
desquamation 
Vesiculation, moist 
desquamation, or 
ulceration 
Exfoliative dermatitis, 
mucous membrane 
involvement or 
erythema multiforme 
or suspected Stevens-
Johnson or necrosis 
requiring surgery 
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Table C.  Grading physical examination findings (continued) 
 
 Grade 1 
MILD 
Grade 2 
MODERATE 
Grade 3 
SEVERE 
Grade 4 
LIFE-THREATENING 
Hearing < 4 years: N/A 
> 4 years: Decreased 
hearing in one ear 
< 4 years: N/A 
> 4 years: Decreased 
hearing in both ears or 
severe impairment in 
one ear 
< 4 years: Any evidence 
of hearing impairment 
> 4 years:  Severe 
impairment in both 
ears 
N/A 
Tablet test Difficulty grasping 
tablet but able to pick 
up 
Unable to pick up 
tablet without 
dropping 
Unable to grasp tablet N/A 
Clinical 
symptoms / 
sign (not 
otherwise 
specified) 
No treatment 
required; monitor 
condition 
Treatment required Requires treatment 
and possible 
hospitalisation 
Requires active 
medical intervention, 
hospitalisation, or 
hospice care 
 
 
 Reference – The Harriet Lane Handbook, 15th edition, 2000 
† Reference – WHO Toxicity Grading Scale for Determining the Severity of Adverse Events 
 
 
TABLE D.   Guidelines for grading of laboratory abnormalities 
 
 Grade 1 
MILD 
Grade 2 
MODERATE 
Grade 3 
SEVERE 
Grade 4 
LIFE-THREATENING 
Haemoglobin 
(g/dL) 
9.0 – 9.9 7.0 – 8.9 5.0 – 6.9 < 5.0 
 
Reference – The Harriet Lane Handbook, 15th edition, 2000†  
Reference – WHO Toxicity Grading Scale for Determining the Severity of Adverse Events 
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APPENDIX GG: SERIOUS ADVERSE EVENT FORM – INITIAL REPORT (1) 
Study ID 
 
[____|____|____|____] 
Date of SAE Onset 
 
[___|___]/  [___|___]/[___|___] 
day                 month               year 
Date of SAE Report 
 
[___|___]/  [___|___]/[___|___] 
day                 month               year 
SAE number 
 
[____|____]       
Gender 
 
[____]     
 
1  = Male 
2 = Female 
Age 
 
[____|____]    [____|____]      
                       years                     months (only if < 1 year) 
Weight 
 
[____|____] kg         
 
 
SECTION 1: EVENT INFORMATION 
 
Event description:_________________________________________________________________________________________ 
(symptom, sig n, or la boratory a bnorma lity) 
Indicate reason for serious AE:  
(list all that apply): 
1 = Yes 
2 = No 
 Maximum severity 
(WHO scale) 
1 = Mild 
2 = Mo derate 
3 = Severe 
4 = L ife-threatening [____]  Death [____] 
 
L ife-threatening [____] Maximum severity 
(Uganda scale) 
1 = Mild 
2 = Mo derate 
3 = Severe 
4 = L ife-threatening [____] 
 Resulted in or prolonged ho spitalizatio n [____] 
 Required medica l or surgica l intervention [____] 
 Resulted in significant or persistent disability [____] Was the event 
expected? 
1 = Yes 
2 = No 
[____]  Other _________________________________ [____] 
 
SECTION 2: EVENT SUMMARY 
EVENT SUMMARY (include details of event, associated signs and symptoms, possible alternative etiologies, relevant past 
medical h istory, and medical management): 
______________________________________________________________________________________ 
______________________________________________________________________________________ 
______________________________________________________________________________________ 
______________________________________________________________________________________ 
______________________________________________________________________________________ 
______________________________________________________________________________________ 
______________________________________________________________________________________ 
______________________________________________________________________________________ 
 
Study product name:    ARTEMETHER-LUMEFANTRINE Route of study product:  ORAL 
Dosing schedule at SAE onset:     
 
1 = 1 tab, 2x per day, for 3 days 
2 = 1 tabs, 2x per day, for 3 da ys 
3 = 3 tabs, 2x per day, for 3 da ys 
4 = 4 tabs, 2x per da y, for 3 da ys 
77 = Other ________________________________ 
88 = I don’t know 
 
 
[____|____] 
Date study product first started: 
 
[____|____]/[____|____]/[____|____] 
day                 month               year 
Date study product last taken prior to onset of SAE: 
 
[____|____]/[____|____]/[____|____] 
da y                 month               yea r 
Relationship to study product:  
 
 
 
 
[____] 
If not associated, is event related to: 
 
 
 
 
[____] 
 0 = None 
1 = Unlikely 
2 = Possible 
3 = Probable 
4 = Definite    
 
 1 = Study procedure 
2 = Other condition or illness 
3 = Other medica tion 
4 = Other (spe cify) 
___________________________________   
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SERIOUS ADVERSE 
EVENT FORM –  
INITIAL REPORT (2) 
Study ID 
 
[____|____|____|____] 
Date of SAE Report 
 
[___|___]/ [___|___]/[___|___] 
da y                 month               year 
 
Study product status: (list all that apply) 1 = Yes    2  = No 
 
Patient management: (list all that apply) 1 = Yes    2  = No 
No change in dose [____] Patient hospitalized [____] 
Study treatment held [____] Bloo d transfusion given [____] 
Study treatment disco ntinued permanently [____] Intravenous fluids given [____] 
Other_______________________________ 
 
 
[____] Parentera l quinine given [____] 
Other____________________________________ [____] 
Other____________________________________ [____] 
Other____________________________________ [____] 
RELEVANT LABORATORY TESTS 
Test Collection date 
[dd/mm/yy]  
Result 
Site normal 
range 
Most recent 
value prior to SAE 
Collection date 
[dd/mm/yy]  
 [          /          /          ]    [          /          /          ] 
 [          /          /          ]    [          /          /          ] 
 [          /          /          ]    [          /          /          ] 
RELEVANT DIAGNOSTIC TESTS 
Test Collection date 
[dd/mm/yy]  
Results/Comments 
 
[          /          /          ] 
 
 
[          /          /          ] 
 
 
[          /          /          ] 
 
CONCOMITANT MEDICATIONS  
(List relevant concomitant medications the subject was taking up to 1 month prior to SAE onset.) 
Medication Start date 
[dd/mm/yy]  
Stop date 
[dd/mm/yy]  
Total daily dose Indication 
Suspect 
for SAE 
1 = Yes 
2 = No 
 
[          /          /          ] [          /           /           ] 
  
[___] 
 
[          /          /          ] [          /           /           ] 
  
[___] 
 
[          /          /          ] [          /           /           ] 
  
[___] 
 
[          /          /          ] [          /           /           ] 
  
[___] 
 
[          /          /          ] [          /           /           ] 
  
[___] 
 
Outcome 
of event 
1 = Ongoing 
2 = Resolved without sequelae 
3 = Resolved with sequelae  
4 = Death [_____] 
If resolved or died, indicate date: 
 
[____|____]/[____|____]/[____|____] 
                             day                      month                     year 
Completed by (printed name): Date: 
 
[__|__]/[__|__]/[__|__] 
       day          month               year 
Investigator (printed name): Date: 
 
[__|__]/[__|__]/[__|__] 
       day          mo nth               year 
  
Signature: 
              
Signature:             
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APPENDIX GG: SERIOUS ADVERSE EVENT FORM – FOLLOW-UP REPORT (1) 
Study ID 
 
[____|____|____|____] 
Date of SAE Onset 
 
[___|___]/  [___|___]/[___|___] 
day                 month               year 
Date of SAE was first reported 
 
[___|___]/  [___|___]/[___|___] 
day                 month               year 
SAE number 
 
[____|____]       
Gender 
 
[____]     
 
1  = Male 
2 = Female 
Age 
 
[____|____]    [____|____]      
                       years                     months (only if < 1 year) 
Weight 
 
[____|____] kg         
 
 
Date of follow-up      
                                        [___|___]/ [___|___]/[___|___] 
                                                   day                  month               year 
Temperature 
 
[____|____]•[____]  ⁰C 
Progress note:  
 
 
 
 
 
 
 
 
 
Laboratory results:  
Date of follow-up      
                                        [___|___]/ [___|___]/[___|___] 
                                                   day                  month               year 
Temperature 
 
[____|____]•[____]  ⁰C 
Progress note:  
 
 
 
 
 
 
 
 
Laboratory results:  
Date of follow-up      
                                        [___|___]/ [___|___]/[___|___] 
                                                   day                  month               year 
Temperature 
 
[____|____]•[____]  ⁰C 
Progress note:  
 
 
 
 
 
 
 
 
Laboratory results:  
 
Outcome 
of event 
1 = Ongoing 
2 = Resolved without sequelae 
3 = Resolved with sequelae  
4 = Death [_____] 
If resolved or died, indicate date: 
 
[____|____]/[____|____]/[____|____] 
                             day                      month                     year 
Completed by (printed name): Date: 
 
[__|__]/[__|__]/[__|__] 
       day          month               year 
Investigator (printed name): Date: 
 
[__|__]/[__|__]/[__|__] 
       day          mo nth               year 
  
Signature: 
              
Signature:             
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APPENDIX HH. ADVERSE 
DRUG REACTION 
REPORT FORM 
Study ID 
 
[___|___|___|___] 
Age 
 
[____|____]    [____|____]      
                       years                     months (only if < 1 ye ar) 
Gender 
 
[____] 
 
1 = Male 
2 = Female 
 
Weight 
 
[____|____] kg        
 
 
 Complete on day first reported and update as appropriate Complete on final day 
Event description 
 
Date of event 
onset 
[dd/mm/yy] 
Date event 
reported 
[dd/mm/yy] 
Maximum 
severity 
(WHO)* 
Maximum 
severity  
(Uganda)* 
Relationship†  Expected‡ Serious**  Initials  Outcome ††  
Date event resolved 
[dd/mm/yy]  
1.           
2.           
3.           
4.           
5.           
6.           
7.           
8.           
9.           
10.           
11.           
12.           
 
 
* Severity:  Rank on scale of 1-4:   1 = mild;    2 = moderate;    3 = severe;    4 = life threatening 
† Relationsh ip :   Rank on scale of 0-4: 0 = none;    1 = unlikely;    2 = po ssible;    3 = probable;    4 = definite 
‡ Expectedness: Refer to  the Coartem package insert 
** Serious:  Indicate 1=Yes, 2=No C riteria  fo r SAE: (1) fatal, (2) life threatening, (3) results in or pro longs hospita lization, (4) results in significant or persistent disability or capac ity, (5) requires 
medica l / surgical interventio n to prevent serio us o utco me.   If serious, report to Kampala core facility staff immediately.   
††  Outcome:  Rank on scale of 1-5: 1 = reso lved witho ut sequelae;   2 = reso lved with sequelae;  3 = AE still present at study end/discontinuation, but improving;  4 = subject died;   5 = unkno wn 
 
